Zoek in alle tags
'gunstig hoog-risico' “one thousand HER2 patients” project (chemo)endocrine therapy [11C] docetaxel [18F]paclitaxel %FT 1-day multidisciplinary clinic 1-year versus shorter duration of adjuvant trastuzumab 10-year outcomes 10-year recurrence 15-hydroxyprostaglandinedehydrogenase 15-PGDH 16-gene POLAR molecular signature 16K PRIL 16q23 1703-studie 177-Lu-dotatate 177Lu-PSMA-617 plus maintenance pembrolizumab 18F-FDG opname 18F-FDG PET CT 18F-fluciclovine-PET CT 18F-PSMA-1007 PET CT versus multiparametric MRI 1975-2016 1980-2017 1988-2017 1990 to 2017 1990-2017 1997-2016 1999-2020 1p 19q co-deleted oligodendroglioma 1p 19q codeleted oligodendroglioma 1p 19q non-co-deleted anaplastic glioma 2 induction courses of bacillus Calmette-Guèrin 20-year follow-up 20-year mortality 2000-2014 2003-2007 versus 2013-2017 2006-2016 2006-2019 2008-2018 2010-2016 2010-2019 2010-2020 2018 FIGO stage IIIC SCC of the cervix 2020 UK post-polypectomy surveillance guidelines 2021 cancer mortality prediction in EU and UK 2022 cancer mortality predictions in EU and UK 21-gen recurrence score assay 21-gene assay 21-gene assay and breast cancer mortality 21-gene assay recurrence score 21-gene expression assay 21-gene recurrence score 21-gene recurrence score and BCSS 21-gene RS 21-gene RS and response to neoadjuvant chemotherapy 21-year follow-up 25-hydroxyvitamin D 25-OH-D 25-OH-D level at time of diagnosis 27-hydroxycholesterol 28-year risk of lung cancer 3 versus 1 year adjuvant imatinib 3 versus 6 cycles CEV chemotherapy 3 versus 6 months adjuvant chemotherapy 3 vs. 6 months oxaliplatin-based adjuvant chemotherapy 3-dose COVID-19 mRNA vaccination 321GO 3D brachytherapy 3D-conformal radiotherapy for breast cancer 3DCRT 4 Gy versus 24 Gy radiotherapy 45 and Up Study 4EVER trial 4L lymph node dissection 5-ARIs 5-fraction prone APB 5-fraction whole-breast radiotherapy 5-FU 5-gene peripheral blood signature 5-year final analysis 5-year follow-up 5α-reductase inhibitors 6-MP plus methotrexate 6.5-year outcomes 70-gene ST 70-GS 8-OHdG 8-year follow-up results of CheckMate 214 90-day outcomes 90101 CREATE-studie 90YIT 91-maands update van CALGB 100104-studie A M ESCC A M NSCLC A M STS A R EC A R endometrial cancer A U HER2-negative breast cancer A.R.R.O.W-studie A021501 trial A041202 study AA versus NHW patients AAC AACR AACR 2015 AACR Academy AACR Project GENIE AAML0531 trial AAML1031 phase III trial AAML1421 study AAP AAP for high-risk metastatic castration-sensitive prostate cancer AAP with or without cabazitaxel AAP with or without SBRT AB AB12005 study abatacept for prevention of acute GVHD ABBV-383 aBC aBC in young women ABC-06 trial ABCB1 genetic variants ABCD trial ABCD-study ABCSG 8A trial ABCSG-18 ABCSG-18 study abdominal and gluteofemoral size abdominal radiation for childhood cancer; subsequent risk of diabetes abdominopelvic RT for childhood cancer abemaciclib abemaciclib for MBC abemaciclib plus ET abemaciclib plus fulvestrant for MBC Abi Race studie abirateron abiraterone abiraterone acetate abiraterone acetate and prednisolone with or without enzalutamide abiraterone for prostate cancer abiraterone or enzalutamide abiraterone plus olaparib abivertinib ablatieve behandeling ablative radiation therapy ablative therapy after TACE for HCC abnormale peritoneale cytologie ABOUND.2L+ study ABP plus gemcitabine aBS abscopal effect ABSI ABSOLUTE absolute dense area absolute lymphocyte count absolute lymphocyte count at diagnosis absolute OPC risk absoluut neutrofielgetal ABT-199 ABTC ABVD ABVD versus BEACOPP-escalated AC after NAC and resection acalabrutinib acalabrutinib monotherapy acalabrutinib versus ibrutinib ACC accelerated cellular senescence after chemotherapy accelerated FDA approval cancer drugs accelerated partial breast irradiation accelerated partial breast irradiation versus whole breast irradiation ACCENT database analysis access to anticancer medicines for children and adolescents in Europe ACCorD trial accRCC accRCC after immunotherapy ACCRU study SC-1603 accrual accumulation of chronic disease ACE ACE inhibitors versus ARBs ACE study ACE-LY-004 studie acellular dermal matrix in immediate implant-based breast reconstruction ACES acetaminophen ACHIEVE study acid-suppressive medication ACIS study ACLD acne ACOSOG Z0011 ACOSOG Z11102 trial ACP statement acquired resistance to immune checkpoint inhibitors acquired resistance to osimertinib acraal melanoom ACRIN 6686-studie acromegaly aCSCC aCSCC in kidney transplant recipients AcSé Pembrolizumab trial AcSé phase 2 study AcSé study ACT ACT-2 trial Act.In.Sarc study aCTCL actieve surveillance ACTIM actinic keratosis actinisch carcinoom actinium-225-lintuzumab actinium-225-PSMA actionability activated osteoarthritis after immune checkpoint inhibitor treatment active cancer active melanoma brain metastases ACTIVE study active surveillance active surveillance for low-risk prostate cancer active surveillance for prostate cancer actively treated cancer patients activering immuunsysteem ACTs actual and surrogate Oncotype DX RS distribution acupuncture acupuncture for aromatase inhibitor-related joint pain acupuncture for hot flashes acute cancer-associated venous thromboembolism acute care use after initiation of systemic cancer therapy acute graft-versus-host disease acute GVHD acute kidney injury acute leukemia acute leukemie acute lymfoblastische leukemie acute lymphoblastic leukemia acute myeloid leukemia acute myeloïde leukemie acute promyelocytische leukemie acute promyeolcytische leukemie acute toxic effects of the skin acute toxicity AD AD-risico adagrasib adagrasib with or without cetuximab ADAM-studie ADAM8 ADAMTS-mutaties ADAPT-IT study ADAPT-studie adaptive immune resistance adaptive randomization ADAs ADAURA study ADAURA trial adavosertib ADC as response marker ADC versus SCC ADCs adding 6 months of ADT to PORT adding durvalumab and olaparib to chemotherapy adding gemcitabine to adjuvant chemotherapy adding immunotherapy to first-line chemotherapy adding MRI and biomarkers adding OFS to tamoxifen adding pertuzumab to first-line trastuzumab-docetaxel adding pertuzumab to trastuzumab and chemotherapy adding systemic to local therapy for stage I pT1aN0M0 breast cancer addition of adjuvant capecitabine to standard chemotherapy addition of ADT or PLNRT to PBRT addition of androgen deprivation therapy or brachytherapy boost addition of arsenic trioxide to frontline treatment addition of bortezomib to first-line dexamethasone-rituximab-cyclophosphamide addition of bortezomib to melphalan and dexamethasone addition of BV to chemotherapy addition of carboplatin to neoadjuvant chemotherapy addition of celecoxib to adjuvant FOLFOX for stage III colon cancer addition of chemotherapy to local therapy addition of chemotherapy to neoadjuvant radiotherapy addition of concurrent hypo-fractionated RT to failing anti-PD-1 therapy addition of COX inhibition to immune checkpoint blockade addition of daratumumab to lenalidomide plus dexamethasone addition of ibrutinib to first-line bendamustine-rituximab addition of ICIs to first-line chemotherapy addition of lenalidomide to R-CHOP addition of metastasis-directed therapy to systemic therapy addition of navitoclax to ruxolitinib addition of ramucirumab to docetaxel addition of ruxolitinib to neoadjuvant therapy addition of systemic therapy to definitive radiotherapy additional cytogenetic abnormalities additional immune modulators additional medical expenditures ADEBAR adebrelimab ademanalyse ademtest adenocarcinoma of the esophagus and esophagogastric junction adenocarcinoma of the small intestine adenocarcinoom adenoma detection rate ADH adherence adherence among cancer survivors adherence to healthy lifestyle adherene to adjuvant endocrine therapy adherentie adherentie AET adherentie orale chemotherapie ADI-PEG20 adipose tissue distribution adipositas adiposity and risk of YOBC subtypes adiposity and survival ADIUVO trial adjunctive ultrasonography adjuvant 3D-CRT versus image-guided IMRT for cervical cancer adjuvant abemaciclib plus endocrine therapy adjuvant abemaciclib plus endocrine treatment adjuvant AIs adjuvant alectinib versus chemotherapy adjuvant anastrazole for 10 or 5 years adjuvant and concurrent TMZ adjuvant anthracyclines adjuvant anti-PD-1 therapy adjuvant aromatase inhibitor adjuvant aspirin adjuvant aspirin for cancer adjuvant atezolizumab after adjuvant chemotherapy adjuvant atezolizumab plus bevacizumab adjuvant bevacizumab adjuvant capecitabine adjuvant capecitabine following concurrent chemoradiotherapy adjuvant carboplatin plus taxanes versus EC followed by taxanes adjuvant care adjuvant chemotherapy adjuvant chemotherapy after cytoreductive surgery adjuvant chemotherapy after pCR to neoadjuvant CRT adjuvant chemotherapy after RNU adjuvant chemotherapy for breast cancer adjuvant chemotherapy for breast cancer in older women adjuvant chemotherapy for prevention of colorectal liver metastasis adjuvant chemotherapy regimens adjuvant chemotherapy with or without radiotherapy adjuvant CRT adjuvant Cs-131 brachytherapy adjuvant CT after neoadjuvant ET adjuvant dabrafenib plus trametinib adjuvant dabrafenib plus trametinib for stage III melanoma adjuvant dabrafenib plus trametinib versus placebo for BRAF V600-mutated stage III melanoma adjuvant dabrafenib-trametinib versus anti-PD-1 adjuvant denosumab adjuvant docetaxel-based chemotherapy for early breast cancer adjuvant EGFR-TKIs adjuvant endocrine therapy adjuvant endocrine therapy in premenopausal breast cancer adjuvant enzalutamide adjuvant EP versus EC-P adjuvant erlotinib for early-stage NSCLC adjuvant erlotinib versus vinorelbine-cisplatin adjuvant ET ± CT adjuvant ET with or without abemaciclib adjuvant etoposide plus cisplatin adjuvant everolimus adjuvant exemestane with OFS in premenopausal breast cancer adjuvant fluoropyrimidine-oxaliplatin for early-onset CRC adjuvant FOLFIRINOX versus gemcitabine adjuvant FOLFOX FLOX adjuvant GC or CCRT adjuvant gefitinib versus chemotherapy adjuvant gemcitabine sensitivity of resectable PDAC adjuvant goserelin and tamoxifen adjuvant icotinib adjuvant icotinib versus chemotherapy adjuvant imatinib adjuvant ipilimumab adjuvant ipilimumab versus IFNα-2b adjuvant metronomic capecitabine adjuvant mitotane adjuvant multimodality therapy adjuvant nab-paclitaxel plus gemcitabine adjuvant neratinib adjuvant nivolumab adjuvant nivolumab after salvage resection adjuvant nivolumab plus ipilimumab versus placebo adjuvant nivolumab versus ipilimumab adjuvant nivolumab versus placebo adjuvant nivolumab vs ipilimumab adjuvant olaparib adjuvant olaparib for BRCA1 2-mutated breast cancer adjuvant osimertinib adjuvant paclitaxel and carboplatin versus CEF-T adjuvant palbociclib adjuvant pembrolizumab adjuvant pemetrexed plus cisplatin versus vinorelbine plus cisplatin adjuvant PemP versus NP adjuvant pertuzumab adjuvant phosphoinositide 3-kinase inhibitors adjuvant platinum-based chemotherapy adjuvant radiation adjuvant radiation therapy adjuvant radiotherapy adjuvant RT adjuvant RT for breast cancer adjuvant RT for EEC adjuvant S-1 adjuvant S-1 plus endocrine therapy adjuvant S-1 with or without docetaxel adjuvant SCRT versus CCRT or RT alone adjuvant sintilimab adjuvant sorafenib adjuvant TACE after hepatectomy adjuvant tamoxifen adherence adjuvant tamoxifen for HR-positive early breast cancer adjuvant tamoxifen or AI for breast cancer adjuvant therapies adjuvant therapy adjuvant TLPLDC vaccine adjuvant TMZ with or without IFNα adjuvant transarterial FOLFOX infusion adjuvant trastuzumab adjuvant trastuzumab duration adjuvant trastuzumab for HER2-positive breast cancer adjuvant trastuzumab with or without chemotherapy adjuvant treatment adjuvant treatment for breast cancer adjuvant treatment for stage III melanoma adjuvant treatments adjuvant versus early salvage radiotherapy adjuvant versus early salvage radiotherapy after prostatectomy for prostate cancer adjuvant versus salvage radiotherapy adjuvant weekly docetaxel plus radiotherapy adjuvant XT-XEC versus T-FEC ADJUVANT-studie adjuvante chemotherapie adjuvante CRT adjuvante HER2-remming adjuvante hormoontherapie adjuvante systemische therapie adjvant trastuzumab with or without chemotherapy adjvuant chemotherapy versus chemoradiotherapy ADMEC-O trial ADMIRAL study ADMIRAL trial ADNEX ado-trastuzumab emtansine adolescent and young adult adolescent and young adult cancer survivors adolescent and young adult HL adolescent overweigh or obesity adolescents and young adults adoptive T-cell therapy ADORE trial ADR ADR and postcolonoscopy CRC risk ADRD adrebrelimab adrenal metastases adrenocortical carcinoma adrenocortical carcinoma cohort ADRIATIC trial ADRRAD study ADRs ADT ADT for nmPCa ADT for prostate cancer ADT for prostate cancer in Canada ADT plus pelvic RT plus radium-223 ADT risk of depression ADT with or without docetaxel adult alternative donor HCT adult AML adult cancers adult childhood cancer survivors adult chilhood cancer survivors adult craniopharyngioma adult glioma adult glioma risk adult glioma with LM adult height adult osteosarcoma patients adult survivors of childhood ALL adult survivors of childhood cancer adult survivors of childhood cancer diagnosed between 1970 and 1999 adult survivors of neuroblastoma adult T-cell leukemia lymphoma adult type granulosa cell tumors of the ovary adult weight gain adults and children with cancer advance uterine leiomyosarcoma advanced acral melanoma advanced adrenocortical carcinoma advanced ALK-positive NSCLC advanced ALK-positive or ROS1-positive NSCLC advanced anal cancer advanced anal squamous cell carcinoma advanced anthracycline-naive sarcoma advanced B-cell malignancies advanced B-RAF- or K-RAS N-RAS-mutated solid tumors advanced BCC advanced biliary tract cancer advanced biliary tract cancers advanced BRAF V600-mutant melanoma advanced BRAF-mutant melanoma advanced BRAF-mutated melanoma advanced BRAF-V600 mutated melanoma advanced breast cancer advanced BTC advanced cancer advanced cancer patients advanced cancer-related chronic nausea and vomiting advanced cancers advanced carcinoid or pancreatic neuroendocrine tumor advanced ccRCC advanced cervical cancer advanced cHL advanced chondrosarcoma advanced chordoma advanced CLDN18.2 positive gastric cancer advanced clear cell RCC advanced colorectal liver metastases advanced colorectal neoplasms at least ten years after negative coloscopy advanced CRPC advanced cutaneous squamous cell carcinoma advanced dMMR solid tumors advanced EGA advanced EGFR T790M mutated non-small cell lung cancer advanced EGFR-mutant NSCLC advanced EGFR-mutated or ALK-rearranged NSCLC advanced EGFR-positive non-squamous NSCLC advanced endometrial cancer advanced endometrial carcinoma advanced ENKTL advanced epithelial ovarian cancer advanced epithelioid sarcoma with loss of INI1 SMARCB1 advanced ESCC advanced esophageal cancer advanced esophageal squamous cell carcinoma advanced esophagogastric cancer advanced extraskeletal myxoid chondrosarcoma advanced FL advanced G GEJ adenocarcinoma advanced G GEJ cancer advanced gastric cancer advanced gastric or colorectal cancer advanced gastric or gastroesophageal junction adenocarcinoma advanced gastric or gastroesophageal junction and other solid tumors advanced gastric or gastroesophageal junction cancer advanced gastroenteropancreatic neuroendocrine carcinoma advanced gastroesophageal cancer advanced gastrointestinal cancer advanced gastrointestinal stromal tumors advanced germ cell tumors advanced GIST advanced GIST with heterogenous KIT PDGFRA mutations advanced GIST with KIT or PDGFRA mutation advanced HCC advanced hepatocellu;ar carcinoma advanced hepatocellular carcinoma advanced hepatocellular carcinoma after progression on anti-PD-(L)1 advanced hepatocellular carcinoma in Asian patients advanced hepatocellular carcinoma with MET overexpression advanced HER2-negative breast cancer advanced HER2-negative breast cancer in germline BRCA-mutated patients advanced HER2-positive breast cancer advanced HL with large nodal mass advanced HN CSCC advanced HNSCC advanced Hodgkin lymphoma advanced HR-positive breast cancer advanced HR+ HER2- BC or TNBC advanced IDH1-mutant cholangiocarcinoma advanced indolent lymphoma advanced leiomyosarcoma advanced leiomyosarcoma liposarcoma advanced liposarcoma or leiomyosarcoma advanced liver cancer advanced lung adenocarcinoma advanced lung cancer advanced malignancy advanced malignant mesothelioma advanced MDS in elderly patients advanced melanoma advanced melanoma in patients not represented in phase 3 trials advanced Merkel cell carcinoma advanced metastatic esophageal squamous cell carcinoma advanced metastatic medullary thyroid carcinoma advanced microsatellite instability-high cancers advanced microsatellite stable colorectal cancer advanced MPM advanced mucosal melanoma advanced nccRCC advanced non-clear cell RCC advanced non-clear cell renal cell carcinoma advanced non-clear-cell RCC advanced non-small cell lung cancer advanced non-small cell lung cancer in older adults advanced non-small cell lung cancer with EGFR exon 20 insertion mutations advanced non-small cell lung cancer with PD-L1<50% in elderly patients advanced non-squamous non-small cell lung cancer advanced non-squamous NSCLC advanced noncolorectal gastrointestinal cancer advanced nonsquamous non-small cell lung cancer advanced nonsquamous NSCLC advanced nonsquamous NSCLC in elderly patients advanced NSCLC advanced NSCLC harboring EGFR exon 20 insertion mutations or common EGFR mutations advanced NSCLC harboring KRAS G12C mutation advanced NSCLC in special populations advanced NSCLC or CRC advanced NSCLC with EGFR ex19del or L858R alterations advanced NSCLC with high blood-based TMB advanced NSCLC with T790M mutated EGFR advanced or metaastatic colorectal cancer advanced or metastatic colorectal cancer advanced or metastatic CRC advanced or metastatic esophageal squamous cell carcinoma advanced or metastatic RCC advanced or metastatic thymic carcinoma advanced or metastatic urothelial carcinoma advanced or recurrent endometrial cancer advanced or recurrent endometrioid endometrial cancer advanced or refractory desmoid tumors advanced ovarian cancer advanced ovarian cancer in patients with BRCA-mutation advanced ovarian carcinoma advanced ovarian tubal-peritoneal cancer advanced ovarium neoplasms advanced pancreas cancer advanced pancreatic cancer advanced pancreatic neuroendocrine tumor advanced papillary renal cell carcinoma advanced PDAC advanced penile cancer advanced phyllodes tumor of the breast advanced prostate cancer advanced pulmonary sarcomatoid carcinoma advanced rare cancers advanced rare genitourinary malignancies advanced RCC advanced recurrent ovarian cancer advanced recurrent type B3 thymoma or thymic carcinoma advanced refractory biliary tract cancer advanced refractory CRC advanced refractory esophageal squamous cell carcinoma advanced renal cell carcinoma advanced renal-cell carcinoma advanced RET-mutant medullary thryoid cancer advanced ROS1 fusion-positive non-small cell lung cancer advanced salivary gland cancer advanced salivary gland carcinoma advanced sarcoma advanced soft tissue and bone sarcomas advanced soft-tissue sarcoma advanced solid cancer advanced solid cancer in trial-ineligible patients advanced solid cancers advanced solid HER2-positive tumors advanced solid KRAS G12C-mutated tumors advanced solid malignancies advanced solid tumors advanced solid tumors or tenosynovial giant cell tumor advanced solid tumors with KRAS-G12C mutation advanced squamous cell carcinoma of the anus advanced squamous non-small cell lung cancer advanced squamous non-small-cell lung cancer advanced squamous NSCLC advanced stage as end point advanced stage iNHL advanced stage mantle cell lymphoma advanced stage serous borderline ovarian tumor advanced STS advanced systemic mastocytosis advanced thymic carcinoma advanced thymoma advanced thyroid cancer advanced TNBC advanced triple-negative breast cancer advanced UC advanced urological cancers with pre-existing autoimmune disorders advanced urothelial cancer advanced urothelial carcinoma advanced urothelial carcinoma with FGFR1 3 expression advanced USC with HER2 overexpression advanced wild-type BRAF melanoma advanced-stage cancer advanced-stage Hodgkin lymphoma advanced-stage Hodgkin’s lymphoma advanced-stage melanoma advanced-stage orophryngeal squamous cell carcinoma Adventist cohort compared with a US Census popiulation adverse events adverse events of oral azicitidine adverse mental health outcomes adverse pediatric outcomes ADVL1412 study AEG AEGEAN trial AENEAS trial AERAS trial aerobe inspanning aerobic and muscle-strengthening activity combinations aerobic and resistance exercise aerobic exercise during chemotherapy aerobic physical activity and depression among cancer patients AET adherence Af afami-cel afatinib afatinib versus methotrexaat AFFIRM AFFIRM-studie aflibercept AFP AFT-01 AFUGEM GERCOR aG GEJ adenocarcinoma AG221-AML-005 trial AGC AGC with or without liver metastases age age at diagnosis age at diagnosis of colorectal cancer age at first breast cancer diagnosis age at initiation of breast cancer screening age at menarche age at onset of lung adenocarcinoma age at ovarian cancer onset age dependence of modern clinical risk groups age disparities age-related disease risks in youger versus older B-NHL survivors age-specific BMI agent orange Agent Orange exposure AGES-Reykjavik study aggressive lymphoma aggressive prostate cancer aggressive versus non-aggressive prostate cancer AGILE study AGITG MAX study AGO-OVAR 16-studie AGOC agressieve fibromatose agressive squamous cell carcinoma AGRICAN-studie aGVHD AH use aHCC aHCC in Japan aHCC refractory to hepatic arterial infusion chemotherapy AHELP study AHEP0731 study AHL2011 study aHNSCC AHOD1221 study AHOD1331 trial AI AI with or without palbociclib AI-induced arthralgia AI-therapie AIC AIM trial AIN3 AIO INTEGA trial AIO-FLOT3 studie air pollution and breast cancer incidence airport-related ultrafine particles AIs AIs for HR-positive breast cancer AIT for EBC in postmenopausal patients AJCC 8th edition stage III melanoma AJCC CSM-8 AJCC eighth edition staging AK treatments AK105-302 AL amyloidosis AL-amyloïdose ALBI albumin-bilirubin grade ALCANZA-studie ALCL aLCNEC alcohol alcohol and tobacco consumption alcohol consumption alcohol consumption and cancer risk in Australia alcohol intake alcoholconsumptie alcoholgebruik ALCYONE trial OS analysis ALCYONE-studie aldoxorubicine alectinib alectinib for crizotinib-resistant ALK-positive NSCLC alectinib versus crizotinib ALEX study ALEX study PRO analysis ALEX-studie ALFA-0701 trial ALFA0701 trial ALGONQUIN trial ALiCCS studie ALiCCS study ALiCCS-studie ALICE study ALINA trial alisertib alisertib plus induction chemotherapy alisertib with or without fulvestrant ALK inhibitors ALK inhibitors for NSCLC with ALK-rearrangement ALK positive advanced NSCLC ALK rearranged or ROS1 rearranged NSCLC ALK-positive advanced NSCLC ALK-positive ALCL ALK-positive ALCL in pediatric patients ALK-positive non-small cell lung cancer ALK-positive NSCLC ALK-rearranged nonlung solid tumors ALK-rearranged NSCLC ALK-remmer ALK(+) and ROS1(+) NSCLC ALK1 alkaline phosphatase ALKi alkylating chemotherapy alkylating CRT versus RT alkylerende chemotherapie ALL ALL in children ALL in children and AYAs all-cause and cancer-specific death all-cause and cancer-specific mortality all-cause and cardiovascular disease mortality all-cause mortality ALLCAR study Alliance A011502 Alliance A071401 trial Alliance A091401-studie Alliance N0572-studie ALLIVE-studie allo-BMT allo-HSCT allo-HST allogene hematopoïetische stamceltransplantatie allogene stamceltransplantatie allogeneic BCMA-targeting CAR T cells allogeneic blood or marrow transplantation allogeneic BMT in childhood allogeneic hematopietic cell transplantation allogeneic hematopoietic cell transplant allogeneic hematopoietic cell transplantation allogeneic hematopoietic cell transplantation outcomes allogeneic HSCT allogeneic stem cell transplantation allogeneic stem cell transplantation for AML or ALL allogeneic stem cell transplantion allogeneic transplantation allogeneic transplantation for myelodysplastic syndrome allogenic transplant for NHL alloHCT alloHCT after PD-1 blockade alloHCT for AML not in remission alloHCT for myelofibrosis alloHCT recipients alloHCT versus standard consolidation chemotherapy alloHCT with CB versus MMUD with PTCy alloHCT without first achieving complete remission alloHSCT alloHSCT for myelofibrosis alloHSCT for pediatric ALL alloHSCT in women alloHSCT recipients alloSCT allostatic load almonertinib aLMS ALND alopecie ALP and LDH prognostic potential ALPACA trial alpelisib alpelisib plus fulvestrant alpelisib plus nab-paclitaxel alpelisib plus olaparib alpelisib-associated hyperglycemia alpha-fetoprotein alpha-lipoic acid ALPINE trial ALTA-1L ALTA-1L second interim analysis ALTA-studie ALTER 01031 study ALTER 0303 study ALTER-H-003 trial ALTER-S006 trial alternative cisplatin schedule ALTERNATIVE study updated results ALTERNATIVE-studie ALTTO study sub-analysis ALUR-studie alveolar soft-part sarcoma alvleesklierkanker ALYCANTE trial AM Amara West AMAROS trial AMATERASU trial subgroup analysis AMBASSADOR trial ambient air pollution ambulatory function and mortality among cancer survivors aMCC amcenestrant AMD AMEERA-3 randomized phase 2 trial American Association for Cancer Research American Cancer Society nutriton and physical activity guidelines American Cancer Society richtljnen AMG 337 AMH amivantamab amivantamab plus lazertinib AML AML and ALL in AYAs AML in adult patients AML in elderly nonfit patients AML in elderly patients AML in first relapse AML in older adults AML in patients aged 70 years and older AML in remission AML MDS AML MDS in older patients AML or high-risk MDS AML or MDS AML survival AML with FLT3-ITD mutation AML with genomic evidence of residual disease AML with internal tandem duplication of Fms-like tyrosine kinase 3 AML-relapse after allo-HCT AML-risico AML17-studie AML19 trial AMLSG 09-09 study aMM AMPECT study AMPK variant AMPK-route AMPLCaRE study AMPLE-2 study amrubicine anal cancer analgesic use analgesics analgetica analyse AZURE-studie analyse binnen PICCOLO-studie analyse CheckMate 205-studie analyse COG AAML 1031 analyse CROSS-studie analyse fase 3-studie CALGB 40503 analyse fase 3-studie GeparQuinto analyse MA.27-studie analyse NORDIC-VII studie analyse STAMPEDE-studie Analyse van CheckMate 066 en CheckMate 067 analyse van fase 3-studie CAO ARO AIO-04 analyse van STAMPEDE-studie anamorelin anaplastic astrocytoma or glioblastoma anaplastic large-cell lymphoma anaplastic thyroid carcinoma anaplastisch grootcellig lymfoom anaplastisch schildkliercarcinoom anastrazole with or without fulvestrant anastrozol anastrozole anatomic locations of KCs anatomic stage and HIV infection and rituximab and time already survived and triennial mammography screening androgeendeprivatie androgeenreceptor androgeensuppressie androgen concentrations in prepubertal girls androgen deprivation for FIR versus UIR prostate cancer androgen deprivation therapy androgen deprivation therapy for prostate cancer androgen receptor expression androgen receptor signaling inhibitor androgen-ablative therapy for advanced prostate cancer aNENs anesthesia anesthesiologist volume anetumab ravtansine aneuploïdie ANG1005 angiogenese Angiome angiosarcoma angiosarcomen angiosarcoom angiotensin converting enzyme inhibitors angiotensin II receptor blockers ANGPT2 ANGPT2 and NOS3 polymorphisms ANHL12P1 trial animal and plant protein intake anlotinib anlotinib combined with PD-1 PD-L1 inhibitors anlotinib maintenance therapy anlotinib plus PD-1 inhibitor anlotinib plus temozolomide anlotinib plus TQB2450 anlotinib versus placebo as third- or further-line treatment anlotinib versus sunitinib ANNIE study ANNOUNCE trial anoikis-resistentie anorexia nervosa anorexie anosmin-1 ANS aNSCLC aNSCLC harboring c-Metex14 alterations aNSCLC in three countries aNSCLC with CNS metastases aNSCLC with EGFR exon 20 insertions aNSCLC with EGFR exon 20ins aNSCLC with KRAS G12C mutation aNSCLC with PD-L1 ≥ 1% aNSCLC with PD-L1 at least 50% aNSCLC with PD-L1 TPS ≥ 1% aNSLCL ansqNSCLC antacida anterior temporal lobotomy anthracycline chemotherapie anthracyclines anthracyclines for breast cancer anthracyclines for breast cancer or lymphoma anthracyclines for childhood cancer anthracylcines anthracyline-containing and taxane-containing chemotherapy anti GPRC5D CAR T cell therapy anti-angiogene middelen anti-angiogenese anti-angiogenic therapy anti-B-cell maturation antigen BiTE molecule AMG 420 anti-BCMA GPRC5D bispecific CAR T cell therapy anti-CD19 and anti-BCMA CAR T-cells anti-CD19 CAR T-cell therapy anti-CD19 CAR T-cells anti-CD22 CAR T-cells anti-CD30 CAR-T cell therapy anti-CD7 CAR T cells with anti-CD7 PEBL anti-CLL based CAR-T therapy anti-CTLA-4 plus anti-PD-1 blockade anti-diarrheal strategies anti-EGFR anti-EGFR rechallenge therapy anti-EGFR therapy for metastatic colorectal cancer anti-HER2 therapy anti-HER2 therapy for MBC anti-Hu anti-humaan T-lymfocyt immunoglobuline anti-inflammatory mouthwashes anti-PD-(L)1 for advanced NSCLC anti-PD-(L)1 monotherapy resistant metastatic melanoma anti-PD-(L)1 therapy anti-PD-(L)1 treatment for NSCLC anti-PD-(L)1 with or without chemotherapy anti-PD-1 anti-PD-1 antibodies plus RT anti-PD-1 consolidation anti-PD-1 immunotherapy for MSS solid tumors anti-PD-1 L1 anti-PD-1 monotherapy anti-PD-1 PD-L1 based regimes in advanced solid tumors anti-PD-1 plus CRT anti-PD-1 related pneumonitis anti-PD-1 resistant advanced melanoma anti-PD-1 therapy anti-PD-1 therapy for advanced melanoma anti-PD-1 therapy for solid tumors anti-PD-1 therapy with or without chemotherapy anti-PD-1 vs anti-PD-L1 for cancer anti-PD1 with or without anti-CTLA4 anti-programmed cell death 1 therapy Anti-T-lymfocten globuline anti-thymocyte globulin anti-TNF for steroid refractory toxicity anti-VEGF therapie anti-VGEF therapie antiangiogenese antibiotic use and risk of colorectal cancer antibiotics antibiotics before immune checkpoint inhibitors antibiotics use and subsequent risk of colorectal cancer antibodies antibody drug conjugate MRG003 antibody drug conjugates antibody-drug-conjugates anticancer immune checkpoint inhibitors anticoagulants and breast cancer survival anticoagulatie antidepressant use and mortality antihypertensive drugs antiogeneseresistentie antioxidant supplements antioxidanten antioxidants antithymocyte globulin antithymocytenglobuline antitumor-werkzaamheid van bisfosfonaten antiviral treatment anus squameus celcarcinoom anuscarcinoom anuskanker anxiety and depression symptoms AO AOA aOC aOC or aTNBC AOM AON AOTs APACT trial apalutamide apalutamide for nmCRPC apalutamide versus placebo for nmCRPC aPASC apatinib apatinib after failure of chemotherapy apatinib plus oral etoposide apatinib plus pemetrexed-platinum chemotherapy APBI versus WBI aPBSCT for HL aPC aPDAC aPDAC progressing on rucaparib APHINITY study post-hoc analysis APHINITY trial 6-year follow-up APHINITY-studie API-AI APICAL-RST trial apixaban apixaban versus aspirin APL APL in older patients aPM apocrine breast cancer APOLLO study APOLLO trial apoptose appendiceal adenocarcinoma appendiceal cancer appendiceal neuroendocrine tumors appendixcarcinoom appropriate use criteria for radiation therapy APPROVE trial aPRCC aprepitant APT trial APT trial 10-year analysis AR expression in breast cancer AR-expression AR-positive advanced breast cancer AR-positive triple-negative breast cancer AR-remming AR-V7 ARAMIS study ARANOTE trial ARASENS trial ARCAD ARCAD database individual patients analysis ARCAD-NADEGE cohort study ARCADIA trial ARCAGE-studie aRCC aRCC progressing after IO therapy aRCC with brain metastases ARCHER 1050 ARCHER 1050-studie ARCHES study ARCTIC study ARD in breast or head and neck cancer patients ARET0321 trial ARI0002h ARIC-studie ARIEL3-studie ARIEL4 study ARIES trial ARIs ARIs for prostate cancer Aristotle study ARMANI trial ARMD armodafinil for CRF aRMS aromatase inhibitor-resistant HR+ HER2- ABC aromatase inhibitors aromatase inhibitors versus tamoxifen aromatase inibitor-induced adverse effects aromataseremmer aromataseremmers ARON-1 study ARPIs array comparative genomic hybridization ARROW study ARROW trial ARRY-380 arseentrioxide arsenic trioxide plus ATRA arsenicum ARST1321 study ART ART versus ALND after positive SN biopsy ART-gerichte behandeling arterial chemotherapy versus sorafenib arterial thromboembolism preceding cancer diagnosis artificial intelligence artificial intelligence algorithms ARTIS study ARTIST 2 study ARTIST 2 trial ARTO trial artralgie ARTSCAN III study ARv567es AS for PCa AS04-adjuvanted HPV-16 18 vaccine ASAP trial ASCC ASCEMBL study ASCEND study ASCEND-2 ASCEND-3 final results ASCEND-5 ASCEND-5 studie ASCENT final results ASCENT study ASCENT trial ASCERTAIN trial asciminib asciminib versus bosutinib ascites ASCO ASCO 2016 ASCT ASCT versus maintenance chemotherapy consolidation ASH 2015 Ashkenazi Jewish ancestry Asian versus non-Asian patients ASILs asparaginase-associated pancreatitis ASPECCT AspECT study ASPEN study ASPIRE-studie aspirin aspirin NSAID use aspirin use aspirin use and CRC incidence according to lifestyle risk aspirin use and CRC risk in older adults aspirin use and ovarian cancer risk aspirine aspirine NSAIDs aspirineprofylaxe ASPREE study ASPREE trial ASPS asqNSCLC assessment of lung cancer risk assessment of screening mammograms Assisted reproduction assisted reproductive technologies after breast cancer assisted reproductive technology associatie diabetes en kanker association between age and survival trends after adoption of immunotherapy association between alcohol consumption and BTC risk association between Alzheimer disease and cancer association between meningioma and breast cancer association between PFS and QOL association between prediabetes and breast cancer association between previous infection and cancer risk association between weight change and breast cancer prognosis association of adjuvant chemotherapy with overall survival association of age with efficacy of immunotherapy association of age with TRAEs and survival association of BMI with efficacy of ICIs association of BMI with outcomes association of BMI with safety profile of nivolumab with or without ipilimumab association of breast cancer risk with type 2 diabetes and metformin use association of coffee intake and survival association of ctDNA and CTCs after NAC with disease recurrence association of cutaneous toxic effects with outcomes association of depression and anxiety with mortality association of diabetes with risk of SAEs during chemotherapy association of DM with first-line pembrolizumab efficacy association of endothelial dysfunction and thromboembolism association of ethnicity and prostate cancer after raised PSA test result association of extent of tumor resection and survival association of familial burden of cancer with outcomes of immunotherapy association of fatigue and outcomes in advanced cancer association of fiber intake and breast cancer incidence association of gut microbiome and response to anti-PD-1 therapy association of hearing impairment with neurocognition association of height and survival of resectable lung cancer association of HPV status with survival association of intensity and duration of alcohol use and risk of head and neck cancer association of intrinsic subtype with PFS association of marital status with cancer-specific survival association of measurable residual disease with DFS and OS association of MHT with breast cancer subtypes association of molecular characteristics with OS benefit association of multifocality with prognosis association of nativity with survival association of neoadjuvant chemotherapy with survival association of neuronal autoantibodies and cognitive impairment association of obesity with outcomes of breast cancer subtypes association of obesity with survival outcomes in patients with cancer association of obesity with toxicity association of pCR with outcomes in breast cancer association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors association of performance status with survival association of periodontal disease and edentulism with cancer mortality association of physical activity with cognitive function association of physical activity with survival Association of postmenopausal overweight obesitas and subtype-specific breast cancer risk association of PR status with RS and survival association of prediagnosis smoking cessation and overall survival association of preoperative chemosensitivity with survival association of procedure volume and in-house mortality association of race and socioeconomic factors with OS association of recent oncologic treatment with mortality association of residual DCIS after NAC with breast cancer recurrence association of response and event-free survival with overall survival association of RRSO with breast cancer risk association of sarcopenia with short-term outcomes association of sedentary behaviors with survival association of time-to-treatment initiation and survival association of tumor site with prognosis association of use of PET-CT with mortality association with breakthrough infections and complications in cancer patients association with cancer outcomes association with cancer risk association with hepatic malignancy association with long-term survival association with lung cancer risk association with management association with multiple diseases association with other cancers association with other types of tumors association with rate of treatment for recurrence association with relapse association with site-specific cancers association with survival association with type of treatment associations between circulating eosinophils and cancer risk associations of irAEs with clinical outcomes associations with mortality associations with outcomes associations with prostate cancer risk associations with season of birth AST astma ASTRO 2015 ASTRO 2016 ASTRRA trial ASTRUM-005 trial aSTS asunercept ASXL1 mutations asymptomatic brain metastases asymptomatic early-stage CLL asymptomatic mCRPC asymptomatic WM ASyMS AT RT ATBC Study ATC ATC of TILs ATE ATEMPT trial ATEMPT trial 5-year results atezo-bev atezo-bev for HCC Atezo-Brain trial atezolimuab plus bevacizumab atezolizumab atezolizumab for aHCC atezolizumab for NSCLC atezolizumab for urothelial carcinoma atezolizumab plus bevacizumab atezolizumab plus chemotherapy atezolizumab plus chemotherapy with or without bevacizumab atezolizumab plus nab-paclitaxel atezolizumab plus targeted therapy atezolizumab versus chemotherapy atezolizumab versus durvalumab atezolizumab versus nivolumab versus docetaxel atezolizumab with or without bevacizumab atezolizumab with or without CMB305 atezolizumab-bevacizumab for HCC atezolizumab-vemurafenib-cobimetinib AtezoTRIBE trial ATG ATHENA study ATHENA-MONO trial ATL ATLANTIC-studie ATLANTIS trial ATLAS trial ATM ATM gene PVs ATM mutations in cancer aTNBC ATOM study ATOM trial ATOMIC-Meso trial atopic dermatitis atopic eczema and cancer risk atopie ATR-blockers atrial fibrillation atriumfibrilleren ATRTs AtTEnd trial ATTRACTION-2 studie ATTRACTION-3 study ATTRACTION-4 trial attrition between lines of therapy atypical breast lesions atypical bronchopulmonary carcinoids atypical chronic myeloid leukemia atypical squamous cell of undetermined signifance atypical squamous cells of undetermined significance atypisch meningioom atypische ductale hyperplasie atypische hyperplasie Atypische teratoïde rhabdoïde tumor atypische teratoïde rhabdoïde tumoren aUC AUGMENT study AUGMENT-101 aumolertinib AURA AURA studies AURA-studie AURA-substudie AURA2 AURA3 AURA3 overall survival analysis AURA3 study AURA3-studie AURELIA AURELIA-studie AURELIA-substudie AURIGA study Aurora A aurora kinase A inhibition Australian Melanoma Family Study auto-immuunziekten autofagie autoHCT autoHSCT autoimmune disease autologe stamceltransplantatie autologous dendritic cell therapy autologous stem cell transplantation automated opt-out versus opt-in outreach strategy autoSCT after complete response to first-line treatment AVAglio avapritinib AVAST-M study AVAST-M trial AVAST-M trial analysis avastin avelumab avelumab maintenance avelumab plus axitinib avelumab plus cabozantinib avelumab versus chemotherapy avelumab versus chemotherapy maintenance avelumab-palbociclib-axitinib average risk B-ALL in children AVERT study AVERT trial avoidable cancer deaths by diagnosis prior to metastasis avoiding peg-filgrastim avoiding unnessecary surgery AvR-CHOP study axatilimab axi-cel axi-cel in the non-trial setting axicabtagene ciloleucel axillaire lymfeklierdissectie axillaire radiotherapie axillaire status axillaire ultrasound axillary dissection axillary lymph node dissection axillary response axillary soft tissue pathology axillary surgery and nodal irradiation axitinib axitinib plus avelumab axitinib plus pembrolizumab axitinib versus observation AYA cancer AYA cancer survivors AYA-maligniteiten AYAs AYAs at end of life AYAs versus older adults AYAs with cancer AZ9291 AZA-MDS-003 study azacitidine AZD4547 B-43 trial B-ALL in CAYAs B-ALL in patients aged 1-24 years B-ALL in pediatric and young adult patients B-cel activering B-cel lymfoom B-cel maligniteiten B-cel precursor-ALL B-cell ALL B-cell ALL in children and young adults B-cell ALL resistant to CD19 immunotherapy B-cell hematological malignancies B-cell infiltration B-cell lymphoma B-cell lymphomas after CD19-directed CAR T-cell therapy B-cell malignancies B-cell non-Hodgkin lymphoma B-cell precursor acute lymphoblastic leukemia B-cellymfoom B-F1RST trial B-precursos ALL B-progenitor acute lymphoblastic leukemia baarmoederhalskanker BACCI study BALLET-studie BAP1 pathogenic variant carriers bariatric surgery bariatric surgery after age 60 bariatric surgery and cancer risk in obese adults bariatric surgery in French obese patients bariatrische chirurgie Barrett esophagus Barrett slokdarm Barrett-slokdarm Barrett's esophagus Barrett's slokdarm Barrett’s oesophagus BArT study basaalcelcarcinoom basal-like mammacarcinoom base-edited CAR7 T cells Baselga baseline anxiety or depression baseline CTC count baseline factors associated with response baseline metabolic tumor volume as predictive and prognostic biomarker baseline QOL baseline tumor burden and overall survival baseline US and FDG-PET CT basline plasma tumor mutational burden bassi BAT BAY1436032 BAYOU trial bazedoxifene plus palbociclib bb2121 BBB BBD BBD-BC BC BC characteristics and outcomes related to race ethnicity in Canada BC risk BC survivors BC with three or more SLNs BC-LMD BCa BCBM BCC BCCs BCCSS BCG BCG vaccination in childhood BCG-unresponsive non-muscle-invasive bladder cancer BCIN+ BCIS Bcl-2 BCL2 expression BCLC B2 HCC BCMA-directed CAR-T BCMA-targeted CAR-T cell therapy for MM BCNU BCP-ALL BCR BCR after RT or RP BCRA-mutated advanced breast cancer BCRC trial 022 BCRL after ALND BCS BCS among women with intellectual disability BCS for N2 N3 disease BCS versus mastectomy after neoadjuvant chemotherapy BCS versus mastectomy for DCIS BCS with or without RT BCS with or without RT for large DCIS lesions BCT BCT versus mastectomie BCT versus mastectomy BCT vs MAST Be-Well Study BEACON CRC study BEACON-studie subgroep-analyse BEAT Cancer interventie BEATcc trial BEB trial BEBYP-studie Beckwith-Wiedemann syndrome BECOME randomized trial beeld-geleide brachytherapie beeldvorming beenmergevaluatie BEFLICO study beha belamaf belangenconflicten belantamab mafodotin belantamab mafodotin for advanced multiple myeloma belantamab mafodotin plus pomalidomide and dexamethasone BELIEVE trial belinostat BELIS study BELLE-2 studie BELLINI trial BELOB belotecan versus topotecan belumosudil belzutifan belzutifan plus cabozantinib bemarituzumab bempegaldesleukin plus nivolumab bendamustine bendamustine lymphodepletion before lisocabtagene maraleucel bendamustine plus dexamethasone benefit of healthy lifestyle benefits and harms of annual benign biopsy rate benign ovarian tumor benign ovarian tumors benign solid tumors benigne borstziekte benmelstobart benzeen benzodiazepine BEP berberine versus placebo for the prevention of recurrence of colorectal adenoma BERIL-1 BERT trial bestraling BET inhibitor RO6870810 beta-arrestin-1 beta-blocker use beta-blocker use at time of prostatectomy beta-blockers BETA-Text bètablokkers between-hospital variation BEV bevaciumzab bevacizumab bevacizumab and platinum-based combinations bevacizumab biosimilar bevacizumab plus chemotherapy bevacizumab plus CRT bevacizumab preconditionering voor chemotherapie bevacizumab versus cetuximab bevacizumab with or without reirradiation bevacizumab-etoposide-cisplatin before whole-brain radiotherapy bevacizumab-resistant high-grade glioma BEVERLY trial BEVZ92 BFAST cohort C BFAST trial BFM 2009 ALL trial BFORE trial 5 year follow-up BFORE-studie BFR14 trial BGJ398 bhatia BI-ALCL BIA ALCL biallelic pathogenic CHEK2 variants BIDOC-studie biennial BIG 1-01 BIG 1-98 BIG 1-98 trial analysis BIG 3-07 TROG 07.01 study BIG-RENAPE study bijnierschorscarcinoom bijniertumoren bijwerkingen bilateral and contralateral risk-reducing mastectomy bilateral breast cancer bilateral oophorectomy bilateral oophorectomy and all-cause mortality bilaterale risicoreducerende mastectomie BILCAP study BILCAP study long term outcomes BILCAP-studie biliary tract cancer BIND-014 Bing-Neel syndrome binimetinib binimetinib for NRAS-mutated cancers bintrafusp alfa biochemical recurrence of prostate cancer biochemically detected nonadherence to adjuvant tamoxifen biochemically recurrent prostate cancer biochemisch recidief BioItaLEE trial biologic subtype biological aging biological disease-modifying antirheumatic drugs biologische beschikbaarheid biomarker biomarker for response to MET inhibitors biomarker testing disparities biomarker voor respons op bevacizumab biomarker vs MRI-enhanced strategies for prostate cancer screening biomarker-driven therapies biomarkeranalyse ASPECCT-studie biomarkers biomarkers for detection biomarkers for nivolumab efficacy biomarkers for surveillance biomarkers of activity biomarkers of breast cancer risk biomarkers of response to adjuvant chemotherapy biomarkers of response to ICIs biomarkers of treatment benefit biomarkers predicting survival BioPER trial biopsie schildwachtklier biopsy preceding resection bipolar androgen therapy BIRC3 mutations BIRCH-studie birinapant birth defects birth order birth weight BIS versus circumference assesements bisfosfonaat bisfosfonaten bispecific CAR-T cell targeting both CD19 and CD22 bispecific CS1-BCMA CAR-T cells bisphosphonate use and breast cancer risk among women with DCIS bisphosphonates and risk of cancers bivalent HPV vaccination biweekly docetaxel plus ADT biweekly versus triweekly cabazitaxel BL-B01D1 blaascarcinoom blaaskanker black race Black versus non-Black patients black versus nonblack men Black versus White breast cancer patients black versus white patients black versus white women Black Women's Health Study Black Women’s Health Study bladder cancer bladder cancer in postmenopausal women bladder cancer progression bladder cancer risk bladder cancer VI-RADS score bladder-preserving trimodality treatment bladder-sparing TMT blast-phase CML blastic plasmacytoïd dendritic cell neoplasm BLC2001 study bleeding after ACS bleeding risk BLEND study bleomycin-related pulmonary toxicity bleomycine blinatumomab blinatumomab and POMP maintenance blinatumomab nonresponse blinded double reading bloedgluocse bloeding bloedkanker bloedlipiden bloedtest colorectaalcarcinoom blood arsenic levels blood cholesterol Blood ICT blood markers of oxidative stress blood or marrow transplant Blood or Marrow Transplant Survivor Study-2 blood pressure blood tests blood triglycerides blood tumor mutational burden blood-based genomic mutation signature blood-based test for the detection of multiple cancer types blood-based tests for multicancer early detection bloodstream infections bloodstream infections after curative-intent radiotherapy BLOOM study BLOSSOM trial BLU-667 BLV DNA BM BM from BC and NSCLC BM versus PB BMAs BMAs for bone loss in prostate cancer patients receiving androgen deprivation therapy BMBC bmCRPC without significant PSA response under enzalutamide BMD BMI BMI and molecular subtypes of premenopausal breast cancer BMI and outcomes of systemic therapy for metastatic melanoma BMI and prognosis BMI and T2D as determinants of response BMI during maintenance therapy BMI in early and middle adulthood BMI surgical treatment BMM BMs BMs from EGFR-mutant NSCLC BMS-986156 BMT BMT CTN 1501 study BMT survivor study BNT162b2 vaccination in patients undergoing treatment for cancer BO body composition body composition and cardiovascular events body composition features body composition phenotypes body fat body fat distribution body fat mass body fat percentage body mass index body mass index and risk of second cancer body shape trajectory Boekel BOLERO-1 BOLERO-2 bone loss in younger breast cancer patients bone marrow biopsy bone marrow donor registration bone marrow plasma cell level bone marrow versus blood stem cell graft bone metabolism bone metastases bone metastasis in stage IV NSCLC bone metastatic melanoma bone modifying agents bone sarcoma survivors bone-metastatic castration-resistant prostate cancer bone-only metastasis bone-targeted agents BONSAI trial BOOSTER trial borderline ovarian tumor borderline ovariumtumor borderline resectable or locally advanced unresectable pancreatic cancer borderline resectable pancreatic cancer borderline resectable PDAC Borealis-1 studie Borealis-2 studie borstbiopsie borstchirurgie borstdichtheid borstimplantaat borstkanker borstkanker bij mannen borstkankerpreventie borstkankerscreening borstkankerscreening oudere vrouwen borstkankersterfte borstparende chirurgie borstreconstructie borstreconstructie na mastectomie borstsparende chirurgie borsttomosynthese borstvoeding bortezomib bortezomib induction for NDMM bortezomib plus chemotherapy bortezomib plus rituximab maintenance BOS chordomas BOSS cohort BOSTON study bosutinib bosutinib for previously treated chronic myeloid leukemia bosutinib versus imatinib BOT bot-SPNs boteffect botensilimab plus balstilimab botmetastasen botmetastasen van mammacarcinoom botmetastasering botmicrometastasen botox botpijn botsarcoom bovenste-luchtwegkanker BP-RMS BPd versus PVd BPDCN bPFS BPH BPM BPs BR BR-ESCC BR.36 trial BRAC1 2-mutation brachytherapie brachytherapy for glioblastoma BRAF BRAF 594 en 596 mutaties BRAF 600 wild type melanoom BRAF HER2 MET RET-alterations BRAF mutated advanced solid tumors BRAF mutation BRAF non-V600-mutant mCRC BRAF plus MEK inhibition BRAF plus MEK inhibitors BRAF V600 mutated metastatic melanoma BRAF V600-mutated mNSCLC BRAF V600-mutated NSCLC BRAF V600-mutated pediatric LGG BRAF V600-mutated stage III melanoma BRAF V600E BRAF V600E mCRC BRAF V600E mutated CRC BRAF V600E-mutant mNSCLC BRAF V600E-mutated biliary tract cancer BRAF V600E-mutated CRC BRAF variants BRAF wild-type advanced melanoma BRAF-genfusies BRAF-mutant CRC BRAF-mutant mCRC BRAF-mutant melanoma BRAF-mutant mNSCLC BRAF-mutated aCRC BRAF-mutated malignancies BRAF-mutated melanoma BRAF-mutated metastatic melanoma BRAF-remmer BRAF-remmers BRAF-remming BRAF-V600 mutation-positive melanoma BRAF-V600 or BRAF-nonV600 mutated NSCLC BRAF-V600E BRAF-V600E mutant mCRC BRAF-V600E mutated tumors BRAF-V600E mutation BRAF-wt advanced melanoma BRAFV600-mutant melanoma BRAFV600-mutant stage III melanoma brain cancer brain imaging brain metastases brain metastases from melanoma brain metastases in older patients brain metastases nivolumab plus ipilimumab brain metastases of gastroesophageal adenocarcinoma brain metastases or leptomeningeal disease brain metastasis brain metastasis and survival outcomes brain metastasis outcomes brain radiotherapy plus pyrotinib and capecitabine brain tumors brain volume brain white matter microstructure brain-metastatic lung cancer brain-only mBC brainstem metastases BRCA BRCA mutation carriers BRCA mutation carriers with breast cancer BRCA mutational status BRCA PVs BRCA-defective tumors BRCA-mutatie BRCA-related cancer BRCA1 BRCA1 2 germline mutations BRCA1 2 mtuation. risk of contralateral disease BRCA1 2 mutation BRCA1 2 mutation carriers BRCA1 2 mutations BRCA1 2 mutations and endometrial cancer BRCA1 2 pathogenic variants BRCA1 2 pathogenic variants carriers BRCA1 2 pathogenic variants in women aged 50-75 years BRCA1 2 PV BRCA1 2 PV carriers BRCA1 2 PVs BRCA1 2 variants BRCA1 2-associated pT1 breast cancer BRCA1 2-mutatie BRCA1 2-mutaties BRCA1 2-mutations BRCA1 2-negative Chinese breast cancer patients BRCA1 and BRCA2 germline pathogenic variants BRCA1 and BRCA2 mutations BRCA1 mutation BRCA1- or BRCA2-mutated breast cancer BRCA1-mutatie BRCA1-versus BRCA2-altered mCRPC BRCA2 BRCA2-associated breast cancer BRCA2-mutaties BRCAAway trial BRCP BREACH study breakthrough COVID-19 infections in cancer patients breakthrough infections after COVID-19 vaccination in patients with cancer breakthrough SARS-CoV-2 infections in vaccinated patients with cancer breast and lung cancer mortality in women breast and prostate cancer breast angiosarcoma breast cancer breast cancer –related lymphedema breast cancer after radiotherapy for HL breast cancer and other cancers breast cancer bone metastasis breast cancer brain metastases breast cancer brain metastasis breast cancer central nervous system metastases breast cancer chemotherapy breast cancer chemotherapy dose reduction breast cancer CMs breast cancer conservation surgery breast cancer diagnosis breast cancer family history Breast Cancer Family Registry breast cancer in BRCA PV carriers breast cancer in childhood cancer survivors breast cancer in high-risk women breast cancer in HL survivors breast cancer in men breast cancer in older women breast cancer in sub-Saharan Africa breast cancer in women breast cancer in young women breast cancer incidence after a false-positive mammography result breast cancer incidence before age 40 Breast Cancer Index breast cancer leptomeningeal disease breast cancer lymph node metastases breast cancer metastases breast cancer metastatic recurrence breast cancer molecular subtypes breast cancer mortality breast cancer mortality by comorbidty and age breast cancer mortality rates in U.S. women breast cancer outcomes breast cancer ovarium cancer predisposition genes breast cancer patients breast cancer patients aged 35 years or younger breast cancer patients over age 50 breast cancer preventive effects of anastrozole breast cancer PRS breast cancer radiation therapy breast cancer radiotherapy planning CT scans breast cancer rate after oophorectomy in the general population breast cancer recurrence breast cancer risk breast cancer risk after age 60 breast cancer risk after bariatric surgery breast cancer risk before age 40 years breast cancer risk estimation model breast cancer risk in women ≥50 years breast cancer screening breast cancer screening among women with dense breasts breast cancer screening in average-risk women breast cancer screening interval breast cancer screening participation breast cancer second recurrences afte mastectomy breast cancer subtype breast cancer subtype incidence breast cancer subtypes breast cancer surgery breast cancer survival breast cancer survivors breast cancer survivorship breast cancer treated in neoadjuvant setting breast cancer treatment breast cancer treatment quality breast cancer treatments breast cancer with sentinel-node metastases breast cancer-related fatigue breast cancer-related lymphedema breast cancer-specific mortality breast cancer-specific survival breast compression breast conservation breast conservation vs mastectomy and reconstruction breast consevation versus mastectomy breast desmoid tumor management in France breast ductal carcinoma in situ breast feeding experiences breast intraepithelial neoplasia recurrence breast milk paclitaxel excretion breast MRI versus digital tomosynthesis breast non-invasive disease breast or ovarian cancer breast radiotherapy breast surgery after NAC breast symptoms breast tumors breast-conserving surgery breast-conserving surgery versus mastectomy for EBC breast-conserving therapy breast-conserving therapy in women over 70 breastfeeding BreastScreen Norway BRENDA-score brentuximab vedotin brentuximab vedotin and risk-adapted node radiation brentuximab verdotin brexu-cel as standard therapy brigatinib brigatinib after failure of BV BrighTNess study BRIM-3 studie BRIM7 study BRIM8-studie BRIs British Childhood Cancer Survivor Study BrMs Broad-based genomic sequencing BROCADE3 trial BROCADE3 trial exploratory analysis bronchopulmonary carcinoids BRPC BRRM BRUIN study BRUIN trial bruton's tyrosine kinase BTC BTC in patients aged ≥ 70 years BTC with ERBB2 3 alterations BTCRC-GU14-003 study BTCRC-LUN15-029 trial BTCs BTK BTK inhibition BTK inhibitor therapy bTMB as biomarker for atezolizumab activity bulky stage I-II cHL burden of pancreatic cancer in Europe between 1990 and 2019 Burkitt lymphoma Burkitt's lymfoom burnout in cancer care physicians busulfan plus fludarabine busulfan plus melphalan conditioning busulfan-fludarabine versus busulfan-cyclophosphamide BV BV plus AVD BV plus nivolumab BVd versus DVd BVD-523 BYLieve study cohort A BZD C reactive protein flare C SCANS studie C-144-01 study C-486 C-ALCL C-CAR066 C-ETACs as hallmarks of cancer C-ion RT c-Met protein-expressing NSCLC c-Met protein-overexpressing EGFR-wildtype NSCLC C-reactive protein C-reactive protein trajectories C-TASK FORCE studie CA 209-678 trial CA-125 CA-125 KELIM CA125 CA180-226 studie CA19-9 CA209-003 studie CA209-003 trial CA209-9JC trial CA301 study CABARET-studie CABASTY trial cabazitaxel cabazitaxel plus carboplatin cabazitaxel versus abiraterone or enzalutamide CABINET trial CABIR study CABONE study CABOSUN cabozantanib cabozantinb cabozantinib cabozantinib plus ADT cabozantinib plus atezolizumab cabozantinib plus atezolizumab versus sorafenib cabozantinib plus nivolumab cabozantinib plus nivolumab and ipilimumab cabozantinib plus nivolumab with or without ipilimumab cabozantinib versus everolimus cabozantinib with or without atezolizumab cabozantinib-nivolumab sequence cachexia CAD CADC CADM1 MAL-methylering cadmium and lead in erythrocytes cadonilimab cafeïne caffeïne CAG-repeat CAIRO3 CAIRO4 trial calcifications and cystic morphology on preoperative imaging calcitonin receptor-like calcium calcium and magnesium intake calcium supplementation calciuminname calculated tumor area CALGB 30160 RTOG 0538 CALGB 40601 follow-up CALGB 40903 study CALGB 50604 CALGB 50801 CALGB 80405 exploratory analysis CALGB 80803 CALGB 89803-studie CALGB Alliance 140503 CALGB SWOG 80405 CALGB SWOG 80405 study CALGB SWOG 80702 CALGB SWOG 80702 analysis CALGB SWOG 80702 post hoc analysis CALGB SWOG 80702 study CALLA trial CALM trial CALOR-studie caloric restriction CALYPSO trial CAM CameL study CameL trial Camel-sq trial camizestrant camrelizumab camrelizumab plus apatinib camrelizumab plus apatinib and fuzuloparib camrelizumab plus apatinib for advanced cervical cancer camrelizumab plus chemotherapy camrelizumab plus famitinib camrelizumab plus famitinib after PD-1 blockade camrelizumab plus gemcitabine plus oxaliplatin camrelizumab plus GEMOX camrelizumab plus GVD chemotherapy camrelizumab plus pemetrexed and carboplatin camrelizumab plus rivoceranib camrelizumab plus rivoceranib versus sorafenib camrelizumab with or without decitabine camrelizumab-apatinib-temozolomide CanAssist Breast test cancer Cancer and Aging Research Group score cancer and cardiovascular disease intensity an mortality cancer and cardiovascular risk with tofacitinib in rheumatoid arthritis cancer and risk of COVID-19 diagnosis and severity cancer burden in patients with sleep apnea cancer burden in the oldest-old in The Netherlands 1990 to 2019 cancer cachexia cancer case trends cancer cases attributable to modifiable lifestyle risk factors in Switzerland cancer chemotherapy during pregnancy cancer clinical trial participants cancer clinical trials cancer deaths due to delays in diagnosis in England cancer detection rate cancer diagnoses after recent weight loss cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible cancer diagnosis cancer diagnosis during adolescence cancer diagnosis in primary care cancer driver genes cancer drugs approved based on response rate cancer drugs receiving FDA accelerated approval cancer emergency presentation cancer history cancer immunotherapy cancer immunotherapy trials cancer in older adults cancer in solid organ transplantation recipients cancer in the prison population in England cancer incidence cancer incidence among children and young adults by single year of age cancer incidence and mortality cancer incidence and spectrum in children cancer incidence and survival in older adults cancer incidence in World Trade Center rescue and recovery workers Cancer Moonshot goal cancer mortality cancer mortality in Europe cancer of unknown primary Cancer of unknown rimary cancer outcomes cancer patients cancer patients aged 70 years or older cancer patients and matched norm population perceived care and well-being cancer patients treated with anticoagulation cancer patients undergoing systemic treatment cancer predisposition screening tool cancer prevalence cancer prevalence in medieval Cambridge (UK) cancer prevention cancer prevention recommendations Cancer READMIT Score cancer recurrence cancer risk cancer risk after hematuria diagnosis cancer risk in children cancer risk in children and adolescents cancer risk in individuals with major birth defects cancer risk in patients with bipolar disorder and unaffected siblings cancer risk in South Korean GERD patients cancer risk in women cancer risks cancer risks among men cancer screening cancer screening in people with mental illness cancer screening tests cancer spectrum cancer surgery in older adults cancer surgical procedures cancer survival in Germany cancer survivors cancer susceptibility genes cancer therapy approval timings in the US and Europe cancer trials cancer types and risk of delirium cancer-associated isolated DVT cancer-associated venous thromboembolism cancer-related cognitive impairment cancer-related fatigue cancer-specific mortality cancer-testis antigens cancers attributable to infections cancers of unknown primary origin cancers with MUC16-variants CANDOR study CANDOR study updated outcomes canine lung cancer detection cannabidiol for relief of symptoms in advanced cancer cannabigerol cannabinoids for symptom management cannabis cannabis use cannabis use and lung cancer susceptibilty CanSaRCC study CanSNET-studie CANTO prospective cohort study CANTO skin CANTO trial CANVAS trial CAO ARO AIO-04 study CAO ARO AIO-04 trial post hoc analysis CAO ARO AIO-12 trial long-term results CAP 01 study CAP 02 trial CAP 03 trial CAP trial CAP-BRAIN study CAP-studie CAPability-01 trial CAPAP-Lung trial capecitabine capecitabine maintenance after first-line induction chemotherapy capecitabine maintenance therapy capecitabine versus observation capecitabine-associated hand-foot syndrome CAPITAL study CAPItello-291 CAPItello-291 trial capivaserib for AKT1 E17K-mutated tumors capivasertib capivasertib for tumors with AKT mutations capmatinib capmatinib plus nivolumab CAPP-Seq CAPP2 study CAPRI trial CAPRI-GOIM CAPRICE CAPSTONE-1 trial CaPSURE trial CAPTAIN-1st study CAPTIVATE study MRD-cohort CAR T cell therapy CAR T cells and T-cell therapies for cancer CAR T cells and TCE CAR T-cell therapy CAR T-cell therapy for relapsed refractory large B-cell lymphoma CAR T-cellen voor solide tumoren CAR T-cells for B-cell lymphoma CAR T-celtherapie CAR-HEMATOTOX model CAR-T CAR-T celtherapie CAR-T for lymphomas CAR-T for pediatric ALL CAR-T therapy CAR-T-cell therapy in patients with advanced B-cell cancers and HBV-infection CAR-transduced natural killer cells CAR19 22 T-cell therapy Caravaggio study carbazitaxel carbon ion RT carbon nanoparticle suspension lymphografy guided distal gastrectomy carboplatin carboplatin dose capping carboplatin plus nab-paclitaxel carboplatin plus pemetrexed carboplatin with or without atezolizumab carboplatin with radiotherapy carboplatin-etoposide with or without atezolizumab carboplatin-paclitaxel with or without trastuzumab carboplatine carcinoïd tumoren CARD study cardiac dysfunction cardiac events cardiac impact of cytokine release syndrome cardiac outcomes cardiac safety cardiac substructure radiation dose and risk of late cardiac disease cardiale disfunctie cardiale toxiciteit cardiale veiligheid cardiometabolic risk factors cardiometabolic risk factors and survival after cancer cardiomyopathy in CCSs cardioprotective strategies cardiopulmonary complications cardiorespiratorische fitheid cardiorespiratory fitness cardiotoxiciteit cardiotoxiciteit anthracylines cardiotoxiciteit chemotherapie cardiotoxicity cardiotoxicity of doxorubicin cardiotoxicity with encorafenib and binimetinib cardiovasculair risico cardiovasculaire toxiciteit cardiovascular adverse events cardiovascular disease cardiovascular disease risk cardiovascular diseasse cardiovascular events cardiovascular events and chronic kidney disease cardiovascular fitness and muscular strength cardiovascular mortality cardiovascular outocmes cardiovascular risk cardiovascular risk factors cardiovascular surveillance cardiovascular toxicity CARE study CareMin650 CARES-310 carfilzomib carfilzomib for myeloma carfilzomib-bendamustine-dexamethasone carfilzomib-lenalidomide-dexamethasone followed by lenalidomide maintenance carfilzomib-lenalidomide-dexamethasone-daratumumab CARG tool CARMENA study CARMENA-studie carmustine Carolina Breast Cancer Study carotenoïden carpaal-tunnelsyndroom CARRIERS consortium CART-19 CART-SIE study CARTBCMA-HCB-01 trial CARTIFAN-1 study CARTITUDE-1 study CARTITUDE-1 trial CARTITUDE-4 trial CARTS study CARTTAS study cascade genetic testing case-control analysis within IBIS-II case-mix adjusted comparison of Dutch hospital perfomances CASPIAN study CASPIAN study follow-up CASPS study CASR CASSINI study CASSIOPEIA part 2 CASSIOPEIA study CASTOR and POLLUX age subgroup analysis CASTOR subgroup analysis castratieresistent prostaatcarcinoom castration-resistant AR-expressing salivary gland cancer castration-resistant prostate cancer CATCH CATCH program catch-up HPV-vaccination CATNON study CATNON trial post-hoc analysis CATNON-studie catumaxomab caudate lobe solitary HCC cause of death cause-specific mortality cause-specific mortality after initial chemotherapy causes of death causes of death after breast cancer diagnosis causes of death among Finnish women with breast cancer CAVE trial CBC CBC prediction CBC risk CBC-risico CBCSG010 study CBT-I CBTRUS CBTS cc mRCC CC-220-MM-001 trial CC-223 CC-486 CC-92480-MM-001 Study ccA and ccB molecular subtypes CCEC CCNE1 expression CCR7 ccRCC ccRCC brain metastases CCRT CCRT with or without nimotuzumab CCSS CCSS cohort CCTG BR.34 trial CCTG HE1 study CD103+ immune cells CD123 surface expression CD19 CAR-T cell therapy CD19 CAR-T cell therapy in children and young adults CD19 CAR-T for large B-cell lymphoma CD19-directed CAR T cell therapy CD19-directed CAR T-cell therapy CD19-positive lymphoid tumors CD20-positive diffuse large B-cell lymphoma CD22-directed CAR T-cell therapy CD4 CD4 CD8 ratio CD4+ percentage CD45-targeted antibody-radionuclide conjugate CD47 blockade plus rituximab CD8+ T cell infiltration CDG CDH1 mutation carriers CDK12-mutated prostate cancer CDK4 6 inhibition CDK4 6 inhibitor plus AI CDK4 6 inhibitor plus fulvestrant CDK4 6 inhibitors CDK4 6-inhibitors for breast cancer CDK4 6-remming CDKN2A alterations in solid tumors CDKN2A homozygous deletion CDKN2C CDS CDX-110 CDX2 CEA CEA-specifieke T-cel respons cediranib cediranib plus olaparib cediranib with or without lenalidomide CEGT celecoxib CELESTIAL trial celiac plexus radiosurgery cell nest size cell-free circulating tumor DNA variant allele frequency cell-free DNA multicancer early detection test cell-free Epstein-Barr virus DNA cell-free urine cellulaire immuuntherapie cellular immune activation CelTIL score CelTIL-score celvrij circulerend tumor DNA cemiplab versus investigator’s choice chemotherapy cemiplimab cemiplimab after HHIs cemiplimab plus chemotherapy cemiplimab Q4W central adiposity central adiposity and risk of subsequent breast cancer by menopause status centrale adipositas centrally located HCC ceralasertib (AZD6738) ceralasertib plus durvalumab cerebellopontine angle tumors cerebrospinal fluid microRNA signatures cerebrospinal fluid tumor DNA genotyping cerebrospinale vloeistof ceritinib cervical cancer cervical cancer and precancer risk cervical cancer incidence cervical cancer patients with or without mental disorder cervical cancer screening cervical cancer survivors cervical chordomas cervical conization cervical dysplasia after HPV vaccination cervical HPV-testing cervical neoplasia cervical screening cervicale glandulaire neoplasie cervicale intra-epitheliale neoplasie graad 3 cervicale intraepitheliale neoplasie cervicale-slokdarmkanker cervixcarcinoom cervixcarcinoomscreening cervixconisatie cervixkanker cervixkankerscreening cervixlaesies cesarean delivery cesium-131 brachytherapy CESM CeTeG NOA-09 study CETSA cetuximab cetuximab maintenance cetuximab plus nivolumab cetuximab-IRDye800 cetuximab-related infusion reactions cetuximab-resistant recurrent metastatic HNSCC cetuximab-resistentie CEVOREM trial CF-WBI cfDNA cfDNA blood-based test for CRC screening cfDNA genotyping cfDNA in CSF cfDNA methylation signatures CFS CGC CGT cGVHD cGVHD in pediatric patients ch CH and subsequent lung cancer risk CH and t-MN CH in long-term pediatric cancer survivors CHAARTED trial eight-year survival CHAARTED-analyse CHAARTED-studie CHANCE2201 study change in mammographic density change in PD-L1 expression change in serum uric acid level change in trust in US government health agencies change of breast cancer subtype during neoadjuvant chemotherapy changes from 1993-2015 changes in alcohol consumption changes in cancer diagnoses and stage distribution changes in length and complexity of oncology guidelines since 1996 changes in survival since 1995 changes in taste and smell of food changes in urological cancer surgical volume and length of stay changes in weight and waist circumference during menopause changes of body mass index or waist circumference changes of diet after cancer diagnosis characteristics and outcomes characteristics and prognosis characteristics and prognosis of luminal and basal subtypes characteristics in young versus old patients characteristics of high-volume lung segmentectomy hospitals Charlson-score CHART trial CHB ChcekMate 066 five-year results CHD CheckMate 012 CheckMate 016-studie CheckMate 017 and 057 trials CheckMate 017 en 057 CheckMate 017 en CheckMate 057 CheckMate 017-studie CheckMate 025 CheckMate 026-studie CheckMate 032 study CheckMate 037 CheckMate 040 CheckMate 040 cohort 6 CheckMate 040 five year follow-up CheckMate 040 study CheckMate 064 CheckMate 066 CheckMate 066 study CheckMate 067 CheckMate 067 five-year survival CheckMate 067 trial CheckMate 069 CheckMate 069 066 en 067 CheckMate 078 CheckMate 141 CheckMate 141-studie CheckMate 142 CheckMate 142 first-line therapy cohort CheckMate 143 study CheckMate 153 CheckMate 204 CheckMate 204 study CheckMate 205 study CheckMate 214 CheckMate 214 long-term follow-up CheckMate 214 study CheckMate 214 trial CheckMate 214 trial 42-months results CheckMate 227 CheckMate 227 part 1 three-year update CheckMate 227 study CheckMate 227-studie CheckMate 238 and EORTC 18071 CheckMate 238 five-year follow-up CheckMate 238 four-year results CheckMate 238-studie CheckMate 274 CheckMate 275 CheckMate 358 CheckMate 358 trial CheckMate 370-studie CheckMate 384 study CheckMate 401 CheckMate 436 study CheckMate 459 trial CheckMate 511 trial CheckMate 568 CheckMate 577 study CheckMate 648 CheckMate 648 study CheckMate 649 CheckMate 649 3-year follow-up CheckMate 649 HRQOL analysis CheckMate 743 trial CheckMate 76K trial CheckMate 77T CheckMate 816 study CheckMate 816 trial CheckMate 817 CheckMate 901 CheckMate 908 CheckMate 914 trial part A CheckMate 920 study CheckMate 9ER long-term follow-up analysis CheckMate 9ER study CheckMate 9ER trial CheckMate 9KD CheckMate 9LA study CheckMate studies CheckMate-032 study CheckMate-067 CheckMate-142 CheckPAC trial checkpoint blockade checkpoint blockade immunotherapy checkpoint inhibitor therapy checkpoint inhibitor-resistant metastatic melanoma checkpoint inhibitors for various types of melanoma checkpoint kinases CHEERS CHEK2 1100delC CHEK2 germline pathogenic variants CHEK2-mutaties CHEK2*1100delC chemerin plasma concentration chemobrain chemoimmunotherapy chemoimmunotherapy in patients with a poor performance status chemopreventie mammacarcinoom chemopreventie van mammacarcinoom chemoprevention of CRC chemoprevention of recurrence chemoprevention with low-dose aspirin chemoradiation plus durvalumab chemoradiotherapie chemoradiotherapy chemoradiotherapy versus radiotherapy chemoradiotherapy with proton versus photon therapy chemorefractory BTC chemorefractory metastatic colorectal cancer chemorefractory or relapsed gestational trophoblastic neoplasia chemoresection Chemoresistentie chemosensitizatie chemotherapie chemotherapie tijdens zwangerschap chemotherapie-geïnduceerd ovariumfalen chemotherapie-geïnduceerd POF chemotherapie-geïnduceerde febriele neutropenie chemotherapie-geïnduceerde misselijkheid en braken chemotherapy chemotherapy adherence chemotherapy after colorectal cancer liver metastasectomy chemotherapy after progression on EGFR-TKIs chemotherapy alone versus combined modality therapy chemotherapy and ICU admission in last phase of life chemotherapy and radiotherapy long-term adverse impact on dental health chemotherapy benefit chemotherapy demands chemotherapy for breast and prostate cancer chemotherapy for breast cancer chemotherapy for childhood cancer chemotherapy for CRC chemotherapy for early-stage breast cancer in older women chemotherapy for EBC chemotherapy for nonmetastatic breast cancer chemotherapy for pediatric AML chemotherapy free treatment chemotherapy plus atezolizumab for NSCLC chemotherapy plus immunotherapy chemotherapy plus pembrolizumab versus chemotherapy chemotherapy plus ponatinib chemotherapy regimens chemotherapy response chemotherapy response score chemotherapy timing in pregnancy chemotherapy use chemotherapy versus observation chemotherapy with bevacizumab or temsirolimus chemotherapy with or without cetuximab chemotherapy with or without pembrolizumab chemotherapy with versus without bevacizumab chemotherapy with versus without total hysterectomy chemotherapy-associated cognitive fatigue and evening physical fatigue chemotherapy-free treatment chemotherapy-induced alopecia chemotherapy-induced amenorrhea chemotherapy-induced anemia chemotherapy-induced cardiotoxicity chemotherapy-induced nausea and vomiting chemotherapy-induced neutropenia in adult NSCLC-patients chemotherapy-induced ovarian dysfunction in breast cancer patients chemotherapy-induced peripheral neuropathy chemotherapy-induced thrombocytopenia chemotherapy-induced toxicities chemotherapy-ineligible HL patients chemotherapy-naïve non-squamous NSCLC chemotherapy-related amenorrhea chemotherapy-related cognitive impairment chemotherapy-related hematological toxicity chemotherapy-related toxicities chemotherapy-related vomiting in children and adolescents chest CT plus x-ray versus x-ray follow-up chest radiation for childhood cancer chest-irradiated cancer survivors CHF CHHiP-studie chiauranib child and adolescent survivors of malignancies child self-report versus caregiver report Child-Pugh class B childbearing potential childbirth childhood ALL childhood ALL survivors childhood AML childhood and adolescent ALL in The Netherlands 1990-2015 childhood and AYA cancer survivors childhood and young adult ALL childhood B-ALL childhood B-cell ALL childhood brain tumors childhood cancer childhood cancer survival in immigrants Childhood Cancer Survivor Study childhood cancer survivors childhood central nervous system tumors childhood leukemia childhood leukemia among offspring childhood leukemia and lymphoma survivors childhood leukemia risk childhood leukemia; maternal hormonal contraception use childhood medulloblastoma survivors childhood nasopharyngeal carcinoma childhood ovarian non-seminomatous germ cell tumors children children and adolescents with cancer children and AYAs with cancer children with cancer children with cancer at home children with FA or AT Children’s Oncology Group Children’s Oncology Group AALL0434 study Children’s Oncology Group study Children’s Oncology Group Study AALL03N1 chimeric antigen receptor China Kadoorie Biobank cohort Chinese Alliance for Research in Thymomas database CHIP CHIPOR trial chirurgie cHL cHL after PD-1 blockade monotherapy cHL in young patients cHL survivors CHM choice between first-line endocrine versus chemotherapy CHOICE-01 trial cholangiocarcinoma cholangiocarcinoom cholecystitis cholesterol lowering drug use and breast cancer survival chondrosarcoma chondrosarcoom CHOP CHOP with or without alemtuzumab chordoma chordoom chromische lymfocytische leukemie chromocolonoscopy versus white-light colonoscopy chromosoom 21 chromosoominstabiliteit chromothripisis chronic comorbidities chronic fatigue in long-term survivors chronic health conditions chronic hepatitis B chronic irAEs chronic liver disease mortality chronic lymphocytic leukemia chronic musculosketal pain in cancer survivors chronic myeloid leukemia chronic myeloid leukemia in chronic phase chronic myelomonocytic leukemia chronic neutrophilic leukemia chronic pain chronic phase CML chronic radiation-induced xerostomia chronical medical conditions and late effects in survivors chronisch graft-versus-host disease chronische fase CML Chronische fase-CML chronische lymfatische leukemie chronische lymfocytische leukemie chronische lymfoide leukemie chronische myelomonocytische leukemie CHRONOS trial Chronos-1 CHRONOS-1 study two-year follow-up CHRONOS-3 study CHRYSALIS cohort E CHRYSALIS study chubb chyleuze ascites chylothorax and chylous ascites CI versus CE CIA cigarette type CIK therapy cilengitide cilta-cel cilta-cel for RRMM in Chinese patients ciltacabtagene autoleucel CIMBA cimetropium bromide CIMP CIN CIN 3 CIN2 3 CIN2 3 spontaneous regression CIN2+ detection CINP cinrebafusp alfa CINV CIO CIOD CIP CIPN CIPN in breast cancer survivors cirAEs circadiaan ritme CIRCULATE-Japan GALAXY circulating AR-status and resistance to Lu-177-PSMA-617 circulating biomarkers circulating breast cancer risk factors in normal weight postmenopausal women circulating cytokines circulating DNA circulating estradiol level circulating HPV DNA circulating immune cells circulating immune markers circulating levels of specific lipid groups circulating lipids and breast cancer prognosis circulating protein biomarkers for CRC risk circulating proteins circulating sex hormone levels circulating tumor cell-count driven therapy circulating tumor cells circulating tumor DNA circulating tumor DNA analysis circulating tumor DNA kinetics predict outcomes circulerend DNA circulerend tumor-DNA circulerende tumorcellen circulerende tumorcellen; detectie nieuwe mutaties circulerende vetzuren CIRT CIRT for unresectable pelvic bone sarcoma CIRT versus en bloc resection CISIG cisplatin cisplatin and fluorouracil versus carboplatin and paclitaxel cisplatin for cancer in children cisplatin-induced hearing loss in children and AYAs cisplatin-ineligible operable high-risk UC cisplatin-related hearing loss and tinnitus cisplatin-unfit NSCLC patients cisplatine cisplatine plus gemcitabine and IMRT CITADEL-203 CITN-10 study citrusfruit CITYSCAPE trial cixutumumab CL versus cBCS cladribine cladribine and low-dose cytarabine-based regimens CLAP study ClarIDHy study ClarIDHy trial CLARITY study CLASS-01 trial CLASS02 trial classic and variant hairy cell leukemia classic Hodgkin lymphoma classic or endemic KS classical Kaposi sarcoma CLASSICAL-Lung clinical trial claudine 18.2 CLDN18.2-positive gastric or gastroesophageal adenocarcinoma CLDN18.2-redirected CAR T cells for gastrointestinal cancers CLEAR clear cell renal cell carcinoma CLEAR study CLEAR trial CLEOPATRA study final results Clevers clinical actionability of cancers clinical and genetic risk factors clinical and genomic risk clinical and lifestyle characteristics clinical and molecular features clinical and molecular predictors of very late recurrence clinical benefit and regulatory outcomes clinical benefit of genomicprofiling clinical calculator for prediction of recurrence clinical characteristics clinical characteristics and outcomes clinical features clinical features and outcomes clinical features for prediction of survival clinical impact of tumor burden clinical management clinical meaningful outcomes clinical models to predict response and survival clinical outcomes clinical outcomes and prognostic factors clinical prognostic stage group system clinical significance of adult T-cell leukemia lymphoma clinical stage I gastric cancer clinical stage I nonseminoma clinical stage I NSCLC clinical stage I seminoma Clinical Treatment Score at 5 years clinical trial effect clinical trial enrollment clinical trial evidence clinical trial participation clinical trials clinical utility of qPCR plasma EGFR mutation detection in advanced lung cancer clinical value clinically N2 non-small cell lung cancer clinically node-positive breast cancer clinically node-positive breast cancer with downstaging to ypN0 after NACT clinician-level knowledge clinicogenomic classifier clinicopathologic characteristics clinicopathologic features clinicopathologic phenotype clinicopathological characteristics clinicopathological features and prognosis after RO resection clinicopathological predictors of outcomes CLL CLL 2007 SA-studie CLL in patients intolerant to BTK inhibitor or PI3K inhibitor CLL in younger patients CLL resistant to venetoclax CLL SLL CLL therapies after venetoclax discontinuation CLL therapy guided by MRD CLL with coexisting conditions CLL with comorbidities CLL with TP53 aberrations CLL-IPI CLL10 CLL14 study CLL14 trial CLL2-BAG study CLLM1-studie CLM CLND clofarabine clofarabine plus total body irradiation conditioning CLOG1302-studie CLOLE clomid clomifeen clomifeencitraat clonal hematopoiesis of indeterminate potential Clozel CLUE II cohort CME CML CML after ABL kinase inhibitor failure CML in chronic phase CML in chronic phase in older patients CML with T351I mutation CML without MMR after 2 years of TKI CML-BP CML-CP CML-CP after 2 or more TKIs CML-studie IV CMM CMML CMML and sAML CMS risk CMSs CMV CMV viremia after hematopoietic stem cell transplant CMV-viremie CN-AML cN+ M0 BCa CNAs CNBSS CNF CNS disease CNS disease control with cranial radiotherapy and ICIs versus chemotherapy CNS efficacy CNS efficacy analysis CNS lymphoma CNS metastases CNS metastases of breast ancer CNS metastasis CNS NGGCTs CNS relapsed or refractory B-ALL CNS response CNS tumors CNS tumors in children CNS tumors in young adult patients CNS-DLBCL CNS-lymfoom CNS-metastasen CNS-recidief HER2-tumoren CNS-tumoren CNS-tumoren; impact van behandelcentrum CNSL CNV signature co-occuring MET amplification co-occuring NOTCH and HR mutations CO.26 study coadministration of CD19- and CD22-directed CAR T-cell therapy cobas cobimetinib cobimetinib plus vemurafenib COBRA KAI Study COBRA study COBRA-score coBRIM-studie cochlear radiation dose CodeBreaK 101 substudy CodeBreaK 200 CodeBreaK 200 trial CodeBreaK100 trial codon 12 13 versus codon 61 mutation coffee intake COG AALL0232 study COG AALL0434 COG AALL0622-studie COG AALL0932 study COG AALL1231 trial COG AALL1331 study COG AALL1621 COG AAML0631-studie COG AAML1331 trial COG AEWS0031 trial COG ARAR0331 study COG AREN0533-studie COG trial ACNS0333 COG-studie AAML0531 COG-studie AREN0532 cognitief functioneren cognitieve disfunctie cognitieve klachten cognitieve veranderingen na chemotherapie cognition cognition after endocrine versus chemoendocrine therapy cognitive and behavioral development of 9-year-old children cognitive and functional toxicities cognitive and neurobehavioral impairment cognitive decline cognitive functioning cognitive performance cohabitation and breast cancer risk COIN colorectal trial colectomie colitis-associated CRC risk prediction collider stratification bias COLOFOL-studie Cologuard colon and rectal cancer colon cancer colon cancer drug metabolism Colon Cancer Family Registry colon cancer peritoneal recurrence colon cancer risk colon cancer surgery colon surgery colon-NET coloncarcinogenese coloncarcinoom colonkanker colonoscopic diagnosis of early-onset versus average-onset CRC colonoscopie colonoscopy after positive FIT colonoscopy bowel preparation colonoscopy in individuals older than 75 years colonoscopy screening colonoscopy screening intervals colonoscopy-based CRC screening COLOPEC trial colorectaakanker colorectaaladenomen colorectaaladenoom colorectaalcarcinoom colorectaalkanker colorectaalkankerscreening colorectaalneoplasie colorectaalpoliepen colorectal colorectal adenomas colorectal cancer colorectal cancer incidence in Americans approaching screening age colorectal cancer lever metastasis colorectal cancer molecular subtypes colorectal cancer mortality colorectal cancer precursors colorectal cancer risk colorectal cancer screening colorectal cancer survival models colorectal carcinogenesis colorectal liver metastases colorectal neoplastic polyps colorectal peritoneal metastasis colorectale chirurgie colorectale levermetastasen colorectale neoplasie coloscopie COLUMBA study COLUMBUS trial COLUMBUS trial 5-year update COMBI-AD COMBI-AD studie COMBI-AD study COMBI-d studie COMBI-MB studie COMBI-v CombiDT combination antiemetics combination of genetic and environmental risk scores combination of HAI and systemic chemotherapy combination of HDAC and mTOR inhibition combination of ICI and TKI combination of ICIs combination of osimertinib and bevacizumab combination strategy combined analysis of N9831 and NSABP B-31 combined BRAF- and MEK-inhibition plus PD-1 blockade combined CTLA-4 and PD-1 inhibition combined effect of breast density and BMI combined inhibition of PD-1 and BRAF and MEK combined lifestyle factors combined modality treatment combined nivolumab and bevacizumab combined PD-1 blockade and VEGF inhibition combined risk factors score combined surgical approach combined-modality therapy COMFORT-studies COMMAND study TP53-mutated AML COMMANDS trial commercial gene expression tests commercial tisagenlecleucel common cancers common medications CoMMpass study community jury comorbid depression comorbiditeiten comorbidities comorbidity prevalence in cancer comparative safety of ICIs comparison between men and women comparison Hong Kong and USA comparison of 5-aza and HSCT comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing HSCT comparison of black and white patients comparison of CBT and MRDT comparison of clinical studies and real-world outcomes comparison of early-onset and average-onset colorectal cancers comparison of first-line treatments comparison of five guidlelines comparison of outcomes across neoadjuvant and adjuvant treatments comparison of PD-L1 protein expression between primary and metastic lesions comparison of survival by treatment type comparison of systemic treatments comparison of three MIBG regimens comparison of two induction therapies comparison of two RT fractionation schedules COMPASS study COMPASS trial COMPASSION-03 trial COMPASSION-04 trial COMPASSION-16 trial CompLEEment-1 trial subgroup analysis complementaire en alternatieve behandelingen complementary and alternative medications complementary medicine complete mesocolic excision complete remission with vismodegib complete response to neoadjuvant CRT COMPLETE study completion of chemotherapy for breast cancer complex cancer surgery complex gastrointestinal cancer surgery complex karyotype complication rate and outcomes complication risk complications after surgery for colorectal cancer complications of axillary surgery COMPOSE-studies composite GRFS and CRFS outcomes compromised immune microenvironment computationele pathologie computed tomography screening computer-assisted colorectal adenoma detection Computer-geassisteerde chirurgie CONCERTO trial CONCERVE Study conclusions of publcations concomitant discontinuation of adjuvant hormone therapy and cardiovascular therapy concomitant mutations concomitant PPIs concomitant PPIs and CDK4 6 inhibitors concomitant use CONCORD-2 CONCORD-3 CONCORD-3 study concurrent capecitabine and stereotactic radiation concurrent cetuximab and nivolumab concurrent chemoradiotherapy concurrent chemoradiotherapy with IMRT versus IMPT concurrent CRT followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil concurrent intrathecal and intravenous nivolumab concurrent olaparib and radiotherapy concurrent tissue and ctDNA profiling in a multicancer cohort concurrent use of anticoagulants and ibrutinib conditional cancer-specific survival conditional immune toxicity rate conditional local recurrence risk conditional recurrence-free survival conditional relative survival conditional risks of BF and PCSD conditional survival conditional survival after five recurrence-free years conditional survival after resection conditionele ziektevrije overleving conditioning after autoHCT conditioning with G-CSF and decitabine CONDOR trial CONFIRM trial congenital heart disease congenital tooth agenesis congestive heart failure conjunctival melanoma CONKO-004 connexine 30 consecutive mammography screening examinations consensus definitions consensus molecular subtypes consequences of negative confirmatory trials conservative management CONSIGN consistent physical activity CONSOLE study consolidation radiotherapy consolidation with WBRT or stem-cell transplantation consoliderende radiotherapie Consomic Xenograft Model constitutional mismatch repair deficiency syndrome CONTACT-01 trial CONTACT-03 trial contemporary hormonal contraception contemporary immuno-oncology combination therapy contemporary lenalidomide-based regimens contemporary radiation therapy for ESFHL CONTESSA 2 study continuation of lorlatinib beyond progressive disease continuation of screening after age 70 years continuous growth model continuous lenalidomide maintenance for MM continuous tumor-size-based end points continuous versus 1-year nivolumab continuous versus intermittent dosing of dabrafenb-trametinib CONTINUUM trial CONTINUUM-studie contralateraal mammacarcinoom contralateral breast cancer contralaterale borstkanker contralaterale mastectomie contralaterale profylactische mastectomie convalescent plasma therapy conventional versus hypofractionation conventional versus moderate hypofractionated RT conversion surgery CONVERT-studie CONVINCE-studie coopERA Breast Cancer trial copanlisib copanlisib for tumors with PIK3CA mutations copanlisib plus gemcitabine COPD COPD and lung cancer copy number alteration screening copy number loss CORE-001 trial coronary artery calcifications corpus uteri cancer correlation between RFS and OS after resection of CLM correlation between surrogate end points and overall survival correlation of CTCs or DTCs with Oncotype DX recurrence score correlation with overall survival corticosteroid refractory ICI-induced enterocolitis corticosteroïden corticosteroids corticosteroids for immune-related adverse events cosibelimab COSMIC-021 cohort 6 COSMIC-021 study COSMIC-311 study COSMIC-312 trial COSMIC-313 COSMIC-313 trial COSMOS trial cost-effective global care for cancer in children cost-effectiveness cost-effectiveness of CAR T-cell therapy cost-effectiveness of intraoperative MRI cost-effectiveness of lung cancer screening cost-effectiveness of nivolumab-ipilimumab combination therapy cost-effectiveness of prostate RT cost-effectiveness of surveillance Costa RIca Costa Rica HPV Vaccine Trial cotinine COVID-19 COVID-19 after CAR T-cell therapy for B-cell malignancies COVID-19 among US cancer survivors COVID-19 and rates of cancer diagnosis in the US COVID-19 first wave COVID-19 hospitalized patients Covid-19 hospitalized patients with lymphoma COVID-19 in patients with hematological malignancies COVID-19 in patients with thoracic malignancies COVID-19 incidence and mortality COVID-19 lockdown COVID-19 mortality in patients with various cancers COVID-19 mortality risk COVID-19 mRNA vaccine COVID-19 outcomes COVID-19 pandemic COVID-19 sequelae COVID-19 severity and outcomes in patients with cancer COVID-19 vaccination COVID-19 vaccine COVID-19-infected cancer patients COVIDSurg Collaborative COX-2 inhibition coxibs CP-B uHCC CP-CML CP-genen CPA use CpG-B CPI-613 CPIs CPM CPPT CPRC5D-targeted CAR T cells CPX-351 CR after LRT plus IO CR24 CRA craniopharyngioma craniopharyngioma in adults craniotomie CRB-401 phase 1 trial CRBSI crc CRC and precursor lesions in adults younger than 50 years CRC detection CRC diagnosis CRC in Taiwan CRC incidence CRC incidence and mortality CRC incidence and mortality after polypectomy CRC incidence and mortality after snigle negative screening colonoscopy CRC incidence and mortality in Asia CRC incidence in Canada CRC intrinsic subtypes CRC liver metastases CRC lung metastasis patients CRC prevention CRC prognosis CRC risk CRC risk among survivors CRC risk associated wiht lifetime excess weight CRC risk following polypectomy CRC risk in Lynch syndrome CRC screening in European countries CRC screening program CRC stage at diagnosis before versus during the COVID-19 pandemic CRC stage distribution CRC surgery in older patients CRC survival CRC survivors CRC with asymptomatic synchronous metastases CRC with BRAF V600E mutation CRC with ERBB2 amplification overexpression CRC with G12C-mutation CRC with high tumor mutaional burden CRC-biomarkers CRC-diagnose CRC-PM CRC-PREVENT trial CRC-risico CRC-screening CRCD CRCPM CREATE-studie crenigacestat cretostimogene grenadenorepvec plus nivolumab CRF cribriform groeipatroon CRICKET trial crizotinb crizotinib crizotinib plus chemotherapy crizotinib-resistant ALK-positive NSCLC CRLM CRLX101 CRN crofelemer for CID Crohn’s disease CRONOS study CROSS CROSS trial ten-year outcomes CROSS versus FLOT CROSSFIRE trial crossover or pembrolizumab rechallenge after recurrence CROWN study CROWN Trial CRP CRP flare-response CRP-niveau CRPC CRPC with bone metastases CRS CRS + HIPEC CRS for advanced-stage OC CRS HIPEC CRS plus chemotherapy versus chemotherapy alone CRS plus HIPEC CRS with or without HIPEC CRS-207 CRS-HIPEC CRS-HIPEC cost effectiveness CRS-HIPEC for CRC PMs CRS-HIPEC for CRPM CRT CRT and local excision versus TME for T2-T3ab N0 M0 rectal cancer CRT as alternative for NSCLC surgery with predicted high risk of irradical resection CRT for esophageal cancer CRT for HNC CRT for LA HNC CRT versus CT CRT with cisplatin versus cetuximab CRT with liposomal paclitaxel plus cisplatin CRT with or without metformin CRTCOESC trial cryoablation cryoablation for lung metastases cryoablation with excision cryotherapy CS tumors CS1002 with or without CS1003 CSCC cSCC of head and neck cSCC risk after diagnosis actinic keratosis CSCC-HN CSCCs CSF penetration of anti-PD-1 antibodies CSM CT CT examinations CT lung cancer screening CT radiation exposure before age 22 years CT-based biomarkers CT-guided high-dose-rate interstitial brachytherapy CT-longkankerscreening CT-P10 CT-P6 versus trastuzumab CT-screening longkanker CT041 cT1-2N0 breast cancer cT1T2No OTSCC cTACE CTCAE CTCL CTCs CTCs and early relapse ctDNA ctDNA after NACT ctDNA after neoadjuvant chemotherapy ctDNA alterations ctDNA analysis ctDNA analysis to direct therapy ctDNA analysis to guide adjuvant therapy ctDNA and risk of progression after long-term response ctDNA as a risk stratifying biomarker ctDNA as biomarker of response to palbociclib-fulvestrant ctDNA as marker of MRD ctDNA as response indicator ctDNA dynamics ctDNA for early detection of MRD and risk stratification ctDNA for monitoring disease status ctDNA in CSF and plasma ctDNA markers for early progression ctDNA methylation ctDNA methylation haplotypes ctDNA mutations ctDNA predicts response and prognosis ctDNA profiling ctDNA reflects response and survival ctDNA response ctDNA sequencing ctDNA TMB and response to first-line pembrolizumab ctDNA-guided de-escalation of targeted therapy ctDNA-guided therapy ctHPV DNA ctHPV DNA in saliva ctHPVDNA after surgery for HPV-associated OPSCC ctHPVDNA monitoring in recurrence surveillance CTL019 for pediatric B-ALL CTLA-4 CTLA-4 blokkade CTLC CTONG1104 study CTP CTRCD CTS5 risk score CUDC-907 CUETO cumulative burden of major surgical interventions cumulative burden of psychiatric disorders and self-harm across 26 adult cancers cumulative GRAS score cumulative incidence of CIHL cumulative incidence of CVD cumulative risk of false-positive result CUP CUPISCO study curatie curative intent treatment for bladder cancer curative-intent resection CURB oligoprogression trial current or former smoking cutaan squameus celcarcinoom cutaan squameus celcarcinoom van hoofd en hals cutaan T-cel lymfoom CUTALLO trial cutane bijwerkingen cutaneous adverse events cutaneous BCC cutaneous HNSCC with regional lymph node metastasis cutaneous malignant melanoma cutaneous melanoma cutaneous melanoma survivors cutaneous SCC cutaneous squamous cell carcinoma cutaneous toxicities cutaneous toxicity CUX1-ALK rearrangement CV risk CVD CVD and stroke following cancer in older adults CVD risk CVD risk after GnRH agonists versus GnRH antagonists CVD risk factors CVD risk factors and colorectal cancer CVEs CVSS-studie CX.5 SHAPE trial CXB CXCL8-CXCR1 2 axis CXCR4 expression in lung cancer CXM cycline D1 cyclofosfamide cyclophosphamide cyclophosphamide for prevention of aGVHD cyclophosphamide-bortezomib-dexamethasone cyclophosphamide-free chemotherapy for ovarian protection CYP2D6 genotype CYP3A CYPIDES trial cyproteronacetaat cyramza cystatin-C cystectomie cystectomy versus trimodality therapy cytarabine CYTO-CHIP study CyTOF of peripheral blood cytogenetically defined high-risk multiple myeloma cytogenetisch normaal AML cytokine levels cytokine-induced killer cell therapy cytokines cytology testing cytoreductive surgery Cytosponge-trefoil factor 3 D-2-hydroxyglutaraat D-index-guided early antifugal therapy D-Rd D-Rd versus Rd D-TORCH trial D-VCd D-Vd versus Vd D-VMP D-VTd versus VTd D-VTd versus VTd for newly diagnosed multiple myeloma DA-EPOCH plus InO DA-EPOCH-R versus R-CHOP DAAs DaBlaCa-13 study dabrafenib dabrafenib plus trametinib dabrefenib plus trametinib dacarbazine for metastatic melanoma dacomitinib DADI DAFI daily aspirin daily insulin dose daily sitting time daily step counts dairy intake during adolescence and risk of colorectal adenoma DAISY trial DALLT cohort dalpiciclib Danish Breast Cancer Group Internal Mammary Node study Danish Breast Cancer Group Partial Breast Irradiation Trial Danish cancer patients DAOH DAPHNe trial daratumumab daratumumab for AL amyloidosis daratumumab plus lenalidomide maintenance after transplantation daratumumab-based regimens daratumumab-based treatment daratumumab-bortezomib-dexamethasone darm-microbioom darm-stamcellen darmflora darmkanker darolutamide darolutamide maintenance darolutamide plus ADT DARPin drug candidate MP0250 DART S1609 neuroendocrine cohort DART SWOG 1609 DART SWOG 1609 Cohort 47 DART SWOG S1609 DART-studie dasatinib dasatinib plus blinatumomab dasatinib plus dendritic cell vaccines targeting TBVAs dasatinib versus imatinib DASCERN randomized study DASFREE 5-year analysis DAstop2 trial DATA-studie Dato-DXd Dato-DXd versus docetaxel David A. Karnofsky Memorial Award and Lecture DAVLEC trial davoli DAWN-studie DAWNA-2 trial DAWT DB DBCG 07-READ studie DBCG HYPO trial DBMS DBT versus DM DC-CIK DCCSS-LATER 2 psycho-oncology study DCCSS-LATER 3 DCd with or without P DCE-MRI DCF chemotherapy DCIS DCIS adjacent to IBC DCIS and early stage HR-positive breast cancer DCIS and node-negative breast cancer DCIS before age 50 years DCIS grading DCIS in the male breast DCIS of the breast DCIS risk DCIS size and margin status DCOG-LATER cohort DCOG-LATER cohort study DCOG-LATER studie dd BV plus ICE chemotherapy dd-chemotherapie DDCT DDGP versus SMILE DDLT DDR gene aberrations DDR gene mutations DDR-HRR altered mCRPC de novo HER2-positive metastatic breast cancer de novo metastatic breast cancer de novo metastatic nasopharyngeal carcinoma de novo metastatic prostate cancer de novo mHSPC de novo stage IV breast cancer de novo stage IV HER2-positive MBC de novo stage IV versus distant metastatic recurrent NSCLC De-ESCALaTE HPV study de-escalation of axillary surgery de-escalation of TKIs DEAR study death and dementia risk death from unintentional injury among cancer patients Debio 1143 plus high-dose cisplatin CRT Debio0932 Decipher decision support system decision-making decitabine decitabine plus camrelizumab dedifferentiated chordoma deep learning deep learning model deep molecular response deepening of response after completing therapy defactinib DeFi trial deficient mismatch repair stage III colon cancer definition of positive CRM definitive local therapy definitive radiotherapy definitive RT definitive stereotactic body radiotherapy degarelix DEL delay of cancer surgery delayed CINV in pediatric patients delayed hearing loss delayed immune-related adverse events delayed surgical treatment delirium DeLLphi 300 DeLLphi-301 trial dementia demographic characteristics dendritic cell-based immunotherapy Denemarken denosumab denosumab or zoledronic acid in cancer patients dense breast tissue dentaal trauma dental extractions and ORN risk dental health and lung cancer risk DEP KP80 study depatux-M depressie depression depression and suicidal ideation depth of response dermatofibrosarcoma protuberans DESKTOP III trial desmoïd desmoid tumors DESMOPAZ study DESTINY study DESTINY-Breast01 DESTINY-Breast01 study DESTINY-Breast02 DESTINY-Breast02 trial DESTINY-Breast03 DESTINY-Breast03 subgroup analyses DESTINY-Breast03 trial DESTINY-Breast04 Destiny-Breast06 trial DESTINY-CRC01 trial DESTINY-CRC02 DESTINY-Gastric01 study DESTINY-Lung01 DESTINY-Lung01 trial DESTINY-Lung02 trial DESTINY-PanTumor01 DESTINY-studie detectie Detectie borstkanker detectie colorectaalkanker detecting genomic biomarkers in plasma versus tissue detection advanced neoplasia detection bias detection early-stage OPSCC detection of circulating tumor DNA after surgery for nmCRC detection of colon cancer recurrences detection of CTCs during follow-up detection of germline variants detection of invasion of detrusor muscle detection of microsatellite instability detection of mutations in ctDNA detection of non-index lesions detection of prostate cancer detection of relapse determinants of breast cancer risk determinants of optimal adjuvant therapy determinants of outcomes determinants of survival determinants of tumor cell PD-L1 expression determinants of uptake of active surveillance determinants of xerostomia development of new drugs devimistat in combination with gemcitabine and cisplatin dexamethason dexamethasone dexanethasone dexrazoxane DFCI 11-001 study DFP-10917 DFS DHA DHAP DHL DHL and THL diabetes diabetes and cancer risk diabetes in long-term cancer survivors diabetes mellitus diagnose longcarcinoom diagnosis and treatment diagnostic low-dose ionizing radiation in youth diagnostic scrutiny diagnostic value of FDG PET CT diagnsotic performance of feacal immunochemical test DICER1 pathogenic variants diet and survival diet qualiity diet quality diet quality and risk of prostate cancer grade reclassification during active surveillance dietary carbohydrate quality and human health dietary carbohydrates dietary fat dietary fiber dietary fiber and yogurt dietary intake dietary intake of antioxidants dietary modification and breast cancer mortality dietary polyunsaturated fat dietary sodium restriction dietary supplement use dietary supplement use and documentation dietary supplement use during chemotherapy differences in treatment outcomes different cancer types different types of plant-based dietary patterns and CRC risk differential activity of PARP inhibitors differential response to neoadjuvant endocrine therapy differential ribosome measurements of codon reading differentiated thyroid cancer difficult patients diffuse large B cell lymphoma diffuse large B-cell lymphoma diffuse large B-cell lymphoma-specific mortality Diffuse midline H3K27-altered gliomas in the spinal cord Diffuse optical spectroscopic imaging diffuse type TGCT diffuse-type giant cell tumor diffusion-weighted MRI diffuus grootcellig B-cel lymfoom diffuus intrinsiek ponsglioom difluoromethylornithine maintenance digestive tract cancer digital breast tomosynthesis digital breast tomosythesis digital remote monitoring digital screening mammografie DigniCap digoxine DII DIP DIPG DIPG patients ≥ 10 years of age DIPG-BATS studie direct-acting antivirals direct-to-patient outreach discontinuation imatinib for CML in children discontinuation of anti-PD-1 antibody therapy discontinuation of first-line dasatinib for CML discontinuation of immune suppression discontinuation of TKIs for de novo CP-CML discontinuous SBRT discordance between CA-125 progression and RECIST progression discordance between primary and matched metastatic breast cancer disease burden disease control after radiotherapy disease progression in cancer patients disease trajectories and mortality after breast cancer disease-free survival diseases and deaths in middle-aged adults disontinuation of trastuzumab disparaties in cancer incidence by sexual orientation disparities disparities by race ethnicity and age disparities in access to high-volume pancreatectomy centers disparity between children and AYAs dispositional optimism disruption of FIT-screening programmes distal cholangiocarcinoma distal rectal cancer distale pancreatectomie distant disease-specific survival distant metastasis of salivary gland cancer distant metastatic breast cancer distant recurrence of breast cancer distant versus supraclavicular lymph node metastases DisTinGuish trial distress Distress Thermometer divarasib divarasib plus cetuximab DLBCL DLBCL in elderly frail patients DLBCL in patients aged 18-65 years DLBCL survivors DLBCL-RT DLGG DM DMFS dMMR CC dMMR colon cancer dMMR MSI mCRC dMMR MSI metastatic gastrointestinal cancer dMMR MSI-H PaC dMMR MSI-H solid tumors dMMR PDAC dMMR subgroup analysis DMPM DN DNA damage immune response DNA Damage Immune Response signatrue DNA damage repair mutations DNA damage response targeting treatments DNA next-generation sequencing DNA promoter-hypermethylering DNA repair gene aberrations. platinum-base chemotherapy DNA-methylering DNA-test DNA-thioguanine concentration DNMT3A-mutatie DOACs versus LMWH for prevention of recurrent VTE in cancer patients DOACs versus LMWHs docetaxel docetaxel and trametinib docetaxel-based neoadjuvant chemotherapy and en bloc resection docetaxel-cyclophosphamide for breast cancer docetaxel-PM plus trastuzumab-pkrb documentaire doelgerichte behandeling DOLPHIN phase 2 nonrandomized trial dominant TCR clone donor clonal hematopoiesis donor-derived anti-CD19 CAR T cells donor-derived CD7 CAR T-cells donor-derived expanded NK-cells to prevent relapse DoR dordaviprone (ONC201) DOREMY study dormancy-genen dose dense doxorubicin-cyclophosphamide and-paclitaxel dose optimization dose reduction of preoperative RT dose-adjusted EPOCH-R dose-dense adjuvant chemotherapy plus trastuzumab dose-dense versus standard chemotherapy dose-individualized FP therapy dosisescalatie DOSISPHERE-01 study dostarlimab dostarlimab for endometrial cancer dostarlimab in doublet triplet combinations DOT1L double expressor DLBCL doublet therapy for de novo mCSPC DOVIGIST-studie Down syndrome and ALL in children and AYAs downstaging before liver transplant doxorubicin delivery from ultrasound-triggered liposomes doxorubicin for adolescent and adult HL doxorubicin for sarcoma doxorubicin plus pembrolizumab doxorubicin with or without ICI doxorubicine dPFSors after PD-1 blockade for melanoma or NSCLC DPP-4 inhibition for aGVHD proylaxis DPYD genotyping DPYD*2A variant carrying cancer patients DRAGON IV CAP 05 trial DRD-positive mUC DREAM study DREAMM-2 study DREAMM-2 trial final analysis DREAMM-7 DREAMM-8 trial DREAMseq trial driver-negative advanced non-small cell lung cancer drivers of patients rating of cancer care in Switzerland droge mond droplet digital PCR DRRD DRUG Access Protocol Drug Rediscovery Protocol drug response predictor drug-drug interactions drug-funding reimbursement DRUP trial drye eye syndrome DSMM XI-studie DSRCT DSTP30865 dt-GCT DTC DTCs DTX3 copy number in breast cancer dual PD-1 and HER2 blockade for aGC DUBLIN-3 trial ductaal carcinoom in situ ductal carcinoma in situ DUD dunne-darmadenocarcinoom dunne-darmneoplasie DUO Crossover Extension Study DUO study durability of response to SARS-CoV-2 BNT162b2 vaccine duration of adjuvant trastuzumab duration of ADT with postoperative radiotherapy duration of androgen deprivation therapy added to RT for PCa duration of immunotherapy duration of response DURIGAST trial durvalumab durvalumab after CRT durvalumab and tremelimumab with definitive CCRT durvalumab for NSCLC durvalumab for solid tumors in HIV-1 infected patients durvalumab or placebo after CRT for stage III NSCLC durvalumab plus chemotherapy durvalumab plus CRT durvalumab plus gemcitabine and cisplatin durvalumab plus olaparib durvalumab plus olaparib plus cediranib durvalumab plus radiotherapy durvalumab plus targeted therapy durvalumab plus tremelimumab durvalumab with or without stereotactic body radiotherapy durvalumab with or without tremelimumab durvalumab-cisplatin-pemetrexed DURVAST study dutasteride Dutch Bone Metastasis Study Dutch MINDACT cohort analyis Dutch trends in incidence and prognosis duvelisib duvelisib plus romidepsin DV DYNAMIC study DYNAMIC trial dynamics of ctDNA DYNAMO study DYPD genotyping dysfagie dyslipidemia dyspnea in cancer patients dyspnoe E GEJ cancer e-sigaretten E1609 study E1912 study E1912 updated results E2F8 E3805-studie E3A06 study E3N E3N cohort E4 E5103 study E7389-EF plus nivolumab E75 EA EA2108 study EAA EAC EAC and GEJ adenocarcinoma EADC EAGLE study EAGLES study early and locally advanced breast cancer early AYAs early breast cancer early breast cancer or ductal carcinoma in situ early breast cancer treatment early cancer surveillance early cervical cancer early changes in ctDNA early CRC early CRP kinetics as predictive biomarker early death early detection and monitoring progression of gastric cancer early detection and prognosis prediction early diagnosis early discontinuation of endocrine therapy early donor identification early experience early HER2-positive breast cancer early HR-positive breast cancer early interdisicplinary supportive care early intervention early invasive breast cancer mortality early local therapy early markers for cardiovascular disease early melanoma recurrence despite adjuvant anti-PD-1 therapy early metabolic response early mortality early multinodular HCC early noninvasive detection of response early onset CRC early onset female cancer survivors early palliative care use early phase ICI-trials early prediction of chemoradiotherapy-induced cardiotoxicity early prediction of response early prediction of response or progression early predictors of pathologic complete response to neoadjuvant therapy early rectal cancer early recurrence early recurrence after resection early relapse detection early stage breast cancer early stage breast cancer in older women early stage breast cancer outcome early stage EGFR-mutated NSCLC early stage ER-positive breast cancer early stage ER-positive breast cancer in older women early stage prostate cancer early stage TNBC early stage triple-negative breast cancer early thymic precursor acuut lymfoblastische leukemie early thymic precursor-like phenotype ALL early TNBC early trastuzumab interruption early triple-negative breast cancer early-life alcohol intake early-onset cancers early-onset colorectal cancer early-onset colorectal cancer among women early-onset CRC early-onset familial breast cancer early-onset pancreas cancer early-onset pancreatic cancer early-onset severe infections early-onset versus late-onset CRC early-stage breast cancer early-stage breast cancer in elderly patients early-stage breast cancer in the elderly early-stage breast cancer in young women early-stage breast cancer recurrence early-stage cancers early-stage cervical cancer early-stage cutaneous T-cell lymphoma early-stage endometrial cancer early-stage gastric cancer early-stage hepatocellular carcinoma early-stage HER2-positive breast cancer early-stage Hodgkin lymphoma early-stage HR-positive breast cancer early-stage lung cancer early-stage MCC early-stage melanoma micrometastases early-stage non-small cell lung cancer early-stage non-small lung cancer early-stage NSCLC early-stage or isolated lung parenchymal recurrent node-negative NSCLC early-stage oropharyngeal squamous cell carcinoma early-stage PaC early-stage pediatric HL early-stage primary cutaneous melanoma early-stage TNBC early-stage unfavorable cHL early-stage unfavorable classic Hodgkin lymphoma early-stage unfavorable HL EAST ENERGY trial EBC EBCC-12 postponed EBMT ALWP study EBRT for localized prostate cancer EBRT for prostate cancer EBV EC EC with ERBB2 3 alterations EC with lymph node metastasis EC-CRT-001 ECD Echelon-1 studie ECHELON-1 study ECHELON-1 trial ECHELON-2 study ECHO-202 KEYNOTE-037 ECLIPSE trial ECOG PS ECOG PS 2 ECOG-ACRIN 2511 study ECOG-ACRIN 5508 study ECOG-ACRIN E1412 study ECOG-ACRIN E1609 study analysis ECOG-ACRIN E1912 study ECOG-ACRIN E2211 ECOG-ACRIN E2810 ECOG-ACRIN E3311 trial ECOG-PS economic evaluation ECX) ED ED-SCLC ED-SCLC in elderly patients Edinburgh Pain Assessment and management Tool education level related inequalities in cancer mortality in Europe educational level educational outcomes EE2012 trial één-maands mortaliteit eenarmige versus gerandomiseerde fase 2-studies eerdere kanker EF-14 efbemalenograstim alfa effect modification effect modifiers of low-dose tamoxifen effect of immunotherapy time-of-day infusion effect of racial concordance on patient trust effect on early cancer detection effectivity and safety of BNT162b2 vaccine in patients undergoing treatment for cancer effects of GVHD on long-term outcomes effects of HER2 alterations efficacy of adjuvant chemotherapy efficacy of BNT162b2 mRNA vaccine in patients with CLL efficacy of ICIs efficacy of immunotherapy efficacy of medications for reduction of risk of primary breast cancer in women EFVPTC EGA EGCG for prevention of postoperative RT-induced dermatitis in breast cancer patients EGD for detection of gastric neoplasms EGFR EGFR amplification EGFR amplified glioblastoma EGFR copy number gain EGFR ex20ins-mutant NSCLC EGFR exon 20 insertion-mutated NSCLC EGFR inhibition EGFR inhibition resistance EGFR mutant NSCLC EGFR mutated advanced non-small cell lung cancer EGFR mutated metastatic non-small cell lung cancer EGFR mutated NSCLC EGFR mutation status EGFR mutation-positive advanced NSCLC EGFR mutation-positive MET-amplified NSCLC after EGFR TKIs EGFR mutation-positive NSCLC with leptomeningeal metastases EGFR T790 mutated aNSCLC detected in plasma EGFR T790M EGFR T790M mutant NSCLC EGFR T790M-positive advanced NSCLC with leptomeningeal metastases EGFR T790M-positive NSCLC EGFR T790M-positive NSCLC in elderly patients EGFR therapy resistant NSCLC EGFR wild-type aNSCLC EGFR-amplified GEA EGFR-amplified recurrent glioblastoma EGFR-blokkade EGFR-mutant and MET-amplified NSCLC EGFR-mutant aNSCLC EGFR-mutant lung adenocarcinoma EGFR-mutant lung cancer EGFR-mutant mNSCLC EGFR-mutant non-small cell lung cancer EGFR-mutant NSCLC EGFR-mutant NSCLC with liver metastases EGFR-mutant RET fusion-positive non-small cell lung cancer EGFR-mutated advanced non-small cell lung cancer EGFR-mutated advanced non-small-cell lung cancer EGFR-mutated advanced NSCLC EGFR-mutated aNSCLC EGFR-mutated LA M NSCLC EGFR-mutated lung adenocarcinoma EGFR-mutated non-small cell lung cancer EGFR-mutated nonsquamous NSCLC after EGFR-TKI therapy EGFR-mutated NSCLC EGFR-mutated NSCLC in elderly or frail patients EGFR-mutated NSCLC with brain metastases EGFR-mutated NSCLC with LMs EGFR-mutatie EGFR-mutaties EGFR-TKI EGFR-TKI with or without thoracic radiotherapy EGFR-TKIs EGFR-TKIs for stage IIIB IV EGFR-mutant NSCLC EGFR-variant NSCLC EGFR+ and ALK+ NSCLC EGFRex20ins mutation-positive NSCLC EGFRex20ins-positive mNSCLC EHCC eHealth support eierstokkanker eiwitbiomarkers elacestrant elacestrant (RAD1901) ELCC 2017 elderly cancer patients elderly HR-positive breast cancer patients elderly patients elderly patients with advanced non-small cell lung cancer electric power morcellation electroacupuncture electroacupuncture for postoperative ileus electronic nose electroporated plasmid IL-12 ELEVATE TN study ELEVATE-TN 4-year follow-up elevated CRP elevated platelet count elevated vitamin B12 levels ELIANA study QOL analysis ELIANA trial Eliasof eliminating surgery ELM-2 trial ELOQUENT-3 study ELOQUENT-3 trial elotuzumab elranatamab ELRP ELSA eltrombopag ELTS-score emactuzumab EMBARK trial EMBRACA study EMBRACA-studie EMBRACE-I study EMBRACE-studie embryonale hersentumoren EMD EMERALD trial emergency department use and unplanned hospitalization EMERGING-CTONG 1103 study emesis emetogenic chemotherapy in pediatric patients EMILIA EMN09 study emotionele uitputting EMP of the head and neck EMPIRE-1 study EMPOWER-Cervical 1 trial EMPOWER-Lung 1 EMPOWER-Lung 1 trial EMPOWER-Lung 3 EMPOWER-Lung 3 part 2 EMPOWER-Lung 3 trial EMT EMVI EMZL ENACT trial enasidenib plus azacitidine encorafenib encorafenib plus binimetinib encorafenib-binimetinib-cetuximab ENCORE-601 study end of life use of systemic therapy END versus observation end-of-life care end-of-life quality indicators end-of-life zorg ENDEAVOR-studie ENDOANGEL system endocriene behandeling endocriene effecten endocriene therapie endocrine deficiency endocrine diseases endocrine pathways dysregulation endocrine resistance endocrine therapies endocrine therapy endocrine therapy adherence endocrine therapy for breast cancer endocrine therapy resistance endocrine therapy response endocrine treatment endocrine treatment versus chemotherapy endocrine-resistant ABC endocrine-resistant mBC endocrine-responsive lobular carcinoma of the breast endometrial ancer endometrial cancer endometrial cancer risk endometrial cancer surgery endometrial cancer survival endometrioïd endometriumcarcinoom endometrioïd epitheliaal ovariumcarcinoom endometriosis endometriosis typology and ovarian cancer risk endometrium-adenocarcinoom endometriumcarcinoom endometriumkanker EndoPredict endoprosthetic reconstruction for lower extremity bone tumors endoscopic or open resection endoscopic surgery versus intensity-modulated radiotherapy endoscopist ADR endotheliaal ovariumcarcinoom ENDS ENDURANCE trial ENEC energetic capacity ENESTfreedom ENESTfreedom trial enfortumab vedotin ENGOT-EN5 GOG-3055 SIENDO ENGOT-EN6 GOG-3031 RUBY ENGOT-OV16 NOVA study ENGOT-OV16 NOVA trial ENHANCE 1 study enhanced recovery after surgery enhancer of zeste homolog 2 ENITEC consortium ENKTL ENLIVEN study enobosarm ENOC enocrafnib ensartinib ensartinib versus crizotinib entecavir entecavir with or without interferon-α enteropancreatic neuroendocrine tumors enterovirus enthusiasm hypothesis entinostat with nivolumab and ipilimumab entospletinib ENTRATA trial entrectinib Environmental Quality Index ENZ or ABI for mCRPC ENZ vs AA ENZA-p trial enzalutamide enzalutamide for castration-resistant prostate cancer enzalutamide plus trastuzumab enzalutamide versus bicalutamide ENZAMET study ENZAMET trial enzastaurine EOC EOC in Black women EOC in high income countries EOC stage IC2 IC3 EOCRC EOCRC versus LOCRC EOPC EOPM EORTC EORTC 10995 EORTC 1325 Keynote-054 studie EORTC 1325 KEYNOTE-054 study EORTC 1325 KEYNOTE-054 trial EORTC 1325-MG KEYNOTE-054 EORTC 1325-MG KEYNOTE-054 3-year follow-up EORTC 18071 EORTC 22922 10925 study EORTC 22922 10925-studie EORTC 22952-26001 trial exploratory analysis EORTC 26101 analysis EORTC 26951 EORTC LYSA FIL H10 and NCRI RAPID joint analysis EORTC study 22033-26033 EORTC-62092 EPA epacadostat EpCAM-positieve tumoren EPCORE NHL-1 EPCORE NHL-1 trial epcoritamab EPd versus Pd ependymoom epertinib EPHOS-B EPHOS-B trial long-term results ephrinB2 inhibition plus pembrolizumab EPI-CT cohort study epi-drugs EPIC EPIC and UK Biobank prospective cohort studies EPIC cohort EPIC-analyse EPIC-NL EPICAL trial EPICAP-studie epichaperome-targeted positron emission tomography for tumor imaging epidemiologic trends epidemiological characteristics epidemiology and outcomes epidemiology of primary and metastatic brain tumors in children epidemiology of VTE epidural use epidurale metastasen epigenetic age acceleration epigenetic editing epigenetische stabiliteit epigenetische veranderingen epilepsy risk factors epirubicin epitheliaal ovariumcarcinoom epithelial ovarian cancer epithelial ovarian cancer risk epithelial ovarian cancer survivors epithelial ovarian carcinoma epitinib Epitopes-HPV02 ancillary study Epitopes-HPV02 study EPOC EPOC1706 study. advanced gastric cancer EPOCH study eprenetapopt (APR-246) plus azacitidine eprenetapopt plus azacitidine eprenetapopt-azacitidine maintenance eprenetapopt-venetoclax-azacitidine EPSILoN Epstein Barr virus-specific autologous cytotoxic T lymphocytes Epstein-Barr virus serology-based screening Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte EQoL-MDS EQOL-MDS trial eque-cel ER low-positive breast cancer ER positive breast cancer ER status ER status and breast cancer survival ER- en PR-testen ER-low positive breast cancer ER-low-positive breast cancer ER-negatief mammacarcinoom ER-negatieve borstkanker ER-negatieve tumoren ER-positief HER2-negatief gevorderd mammacarcinoom ER-positief mammacarcinoom ER-positieve borstkanker ER-positive advanced breast cancer ER-positive advanced breast cancer after aromatase inhibitor failure ER-positive BC ER-positive breast cancer ER-positive breast cancer in postmenopausal women ER-positive early-stage breast cancer ER-positive HER2 negative ABC ER-positive HER2 negative breast cancer ER-positive HER2-negative advanced breast cancer ER-positive HER2-negative breast cancer ER-positive HER2-negative breast cancer in elderly patients ER-positive HER2-negative MBC ER-positive HER2-negative primary breast cancer ER-positive node-positive breast cancer in elderly patients with comorbidities ER-targeted PET ER+ HER2- ER+ HER2- BC ER+ HER2- breast cancer ER+ HER2- MBC after failure of AI ERA 223 study era-by-era analysis of survival eRAPID intervention ERAS ERBB2 HER2-positive metastatic breast cancer ERBB2 mRNA expression ERBB2 mutations in solid tumors ERBB2 plasma copy number erdafitinib erdafitinib versus chemotherapy Erdheim-Chester disease erfelijke borst- en eierstokkanker erfelijke syndromen erfelijkheid ERG- and PTEN-defined prostate cancer eribulin eribulin plus cyclophosphamide eribulin plus everolimus eribulin plus gemcitabine eribulin plus pembrolizumab eribulin versus S-1 eribulin with or without pembrolizumab eribuline ErkentNIS erlotinib erlotinib for advanced EGFR-mutated NSCLC erlotinib plus vemurafenib ersatzdroge Erβ1 Erβ2 ES ES SCLC ES-NSCLC ES-SCLC ES-SCLC after platinum-based chemotherapy ES-SCLC in chemo-naïve patients ESAS-scores ESCC ESCC detection by microRNA profiling ESCC in older patients ESCORT study ESCORT-1st study ESD ESGC ESHAP eSMART study ESME trial ESMO ESMO-MCBS H ESO-Shanghai 13 esomeprazole esophageal adenocarcinoma esophageal and esophagogastric junction adenocarcinoma esophageal and gastric cancer esophageal and GEJ adenocarcinoma esophageal cancer esophageal cancer in older patients esophageal cancer surgery esophageal gastroesophageal junction cancer esophageal squamous cell carcinom esophageal squamous cell carcinoma esophagectomy esophagectomy for cancer esophagogastric adenocarcinoma esophagogastric cancer surgery ESPAC-4 secondary analysis ESPAC5 trial ESR1 mutations ESR1 mutations in CTCs and ctDNA ESR1-amplificatie essential thrombocythenia and polycythemia vera estetrol ESTHER cohort study esthesioneuroblastoom esthetische uitkomst ESTIMABL2 trial estimated gained lifetime estimated projection of US cancer incidence and deaths to 2040 estimates of overtreatment with adjuvant systemic therapy estimating risk of pancreatic cancer in the general population estimating survival estimation of risk by HCPs estradiol levels estrogen monotherapy estrogen receptor-positive recurrent endometrial cancer estrogen therapy after breast cancer diagnosis ET ET outcomes ET with or without ribociclib ET with versus without CDK4 6 inhibitors ETD EOD ETER701 trial ethnic disparities in ERBB2 amplification in gastric cancer etirinotecan pegol etnische diversiteit ETP-ALL LBL ETS EU cancer mortality prediction for 2023 EU cancer mortality predictions for 2024 EU-regelgeving EURECCA Euro-E.W.I.N.G.99 Euro-Ski EURO-SKI studie EUROCARE-5 EUROCARE-6 EuroNet-PHL-C1 European cancer mortality European Code against Cancer European Mantle Cell Lymphoma Elderly Trial European trends in NST use for node-positive breast cancer Europese kankermortaliteit EURTAC EUTOS EV-101 study EV-201 study EV-201 trial EV-202 trial EV-301 study EV-302 trial EV-assay EV-pembrolizumab evaluation of adjuvant chemotherapy after neoadjuvant FOLFIRINOX evaluation of hematuria evaluation of systemic treatments EVAN study event order EVEREST trial everolimus everolimus plus ET everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer everolimus plus letrozole and metformin everolimus plus octreotide everolimus plus pazopanib everyday clinical practice EVICT EVIDENCE study evofosfamide EWALL-INO trial Ewing and Ewing-like sarcoma in adults Ewing sarcoma Ewing sarcoom Ewing-2008 ex vivo IFNγ production eXalt3 study exceptional responder exceptional response to RAI excess body weight excess long-term morbidity with modern treatment excision margin size EXCITE-studie exclusive breastfeeding duration exemestaan exemestaan plus everolimus exemestane dose regimens exemestane with or without enzalutaimde exemstaan exercise exercise and nutrition intervention exercise intervention in cancer patients exercise versus usual care exhaled breath tests exogenous estrogen exogenous hormone use exome sequencing-based screening exosomal lncRNA-GC1 exosomen expansie van fase 1-studie PCD4989g expansion of cancer risk profile explaining risk factors Exploratieve analyse MARQUEE-studie exposoom exposure to occupational carcinogens in 195 countries expressie stromagenen in CRC EXPRESSION III-studie expression of biomarkers expression of insulin-like growth factor-1 receptor on CTCs EXTEND phase 2 randomized trial EXTEND trial extended adjuvant letrozole therapy extended endocrine benefit extended follow-up of PALOMA-2 study extended postgastrectomy follow-up EXteNET ExteNET-studie extension of aromatase inhibitor therapy extensive stage extensive stage small cell lung cancer extensive-stage small cell lung cancer extensive-stage small-cell lung cancer extent of resection EXTENTORCH trial external beam radiation therapy external validation of risk calculators extracapsular extension in sentinel node extracorporeal photopheresis extracranial chondrosarcoma extracranial disease control extracranial oligometastasis extracranial oligometastatic breast cancer extrahepatic CCA extrahepatic malignancies extrahepatisch cholangiocarcinoom extrameningeal primary SFT extranodal natural killer T-cell lymphoma extranodale extensie extraocular retinoblastoma extrapleural pneumonectomy extrauterine disease extremity cooling EZH2 EZH2 inhibitor SHR2554 FACE facial nerve function facial-aging app facility patient volume and survival facility volume facilty volume and mortality FACT-HN-RAD factors affecting recurrence and survival factors affecting sentinel node metastasis factors associated with duration of diagnostic interval factors associated with risk of body image-related distress factors associated with risk of progression factors associated with vomiting control factors explaining sex differences factors influencing multidisciplinary tumor board recommendations factors leading to alpelisib discontinuation factors predicting invasive breast cancer recurrence failure to rescue rates FAK inhibition for meningiomas with somatic NF2 mutations FAKTION study FALCON fall and fracture risk false positive FIT familair mammacarcinoom familiaal colorectaalcarcinoom familiaal risico familiaire adenomateuze polyposis familiaire adenomateuze popyposis familial adenomatous polyposis familial and hereditary cancer syndromes familial platelet disorder familiale adenomateuze polyposis familiegeschiedenis familiegeschiedenis prostaatkanker family history family history of breast cancer family history of cancer family history of OC and BC family history of plasma cell disorders family history-based screening famitinib plus camrelizumab and nab-paclitaxel FaMRIsc study FAP-IL2v plus atezolizumab fase 2-studie BOLERO-4 fase 2-studie BOLERO-6 fase 2-studie KEYNOTE-224 Fase 2-studie SWOG S0801 fase 3- studie DREAM fase 3-studie AURA3 fase 3-studie BrighTNess fase 3-studie COLUMBUS Fase 3-studie CRITICS fase 3-studie ETNA fase 3-studie FATA-GIM3 fase 3-studie GEC-ESTRO Fase 3-studie KEYNOTE-045 fase 3-studie METEOR Fase 3-studie MONALEESA-3 fase 3-studie MONALEESA-7 fase 3-studie NETTER-1 Fase 3-studie PERSEPHONE fase 3-studie PRODRIGE 9 Fase 3-studie SAKK 75 08 Fase 3-studie SWOG S9921 fase 3-studie TROG 05.01 fase 3-studies FAST study FAST-Foward noninferiority phase 3 study fasting-mimicking diet FASTRACK II trial fatal ICI-associated toxic effects fatalisme fatigue fatigue in cancer patients favorable histology Wilms tumor favorable-risk AML in patients younger than 60 years FCR FCT FDA approval of novel cancer therapies between 2000 and 2016 FDA oncology drug approvals in 2018 FDA-approved novel oncology drugs FDG PET CT after 1 week predicts response FDG-PET FDG-PET CT FDG-PET scanning feasibility febriele neutropenie fecal and plasma short-chain fatty acdis fecale immunochemische test fedratinib female and male breast cancer. global trends 1990-2017 female breast cancer risk female invasive breast cancer patients female reproductive and hormonal factors female survivors of childhood and adolescent cancer FENIX fentanyl fentanyl sublinguale spray fenylketonurie hyperfenylalaninemie fermented dairy foods fertiliteitspreservatie fertility drugs fertility preservation fertility treatment fertility-sparing surgery FFCD-ANABASE FGFR pathway alterations FGFR2-rearranged ICC FGFR2b-selected gastric or gastro-esophageal junction adenocarcinoma FGFR3 mutation FGFR4 alterations predict efficacy FGFRs FH02 study FHBC FHWT FIA ficlatuzumab with or without cetuximab ficonalkib fifteen-year results FIGHT trial FIGHT-207 trial FIGHTDIGO-studie FIGO score 5 or 6 gestational trophoblastic neoplasia fijne motoriek fijnstof FIL MIRO trial FIL_ReRi trial FIL-HD0801 study final OS analysis Final OS results from SOLO2 study final overall survival analysis of IMpassion130 final results of CheckMate 204 final survival outcomes Finale analyse FIRST-studie finale analyse van GOG 240-studie finale overlevingsresultaten van KEYNOTE-006 financial links financiële toxiciteit finasteride fine-needle biopsy Finland Capecitabine Trial 15-year follow-up finotonlimab FinRSPC study FinXX-studie FIR prostate cancer FIR-studie FIRE-3 FIRE-4.5 trial FIRE-SCLC Cohort Study firefighters FIREFLY-1 trial FIRES first line anlotinib first line therapy first relapse B-ALL in children and AYAs first responders exposed to WTC disaster first- versus second-line CDK4 6 inhibitor first-degree relatives of pancreas cancer patients First-iGAP study first-in-human study of ivuxolimab-utomilumab combination first-line abiraterone or enzalutamide first-line abiraterone-prednisone for mCRPC with bone metastases first-line afatinib combined with anti-EGF vaccination first-line anlotinib plus platinum-etoposide first-line anlotinib plus toripalimab first-line anlotinib-oxaliplatin-capecitabine first-line anti-PD-1 or targeted therapy first-line apatinib plus gefitinib first-line atezolizumab first-line atezolizumab plus bevacizumab first-line atezolizumab plus chemotherapy first-line atezolizumab-bevacizumab versus sunitinib first-line aUC treatment first-line avelumab first-line avelumab for mMCC first-line axi-cel first-line azacitidine plus venetoclax first-line bavacizumab plus trebananib without chemotherapy first-line befotertinib versus icotinib first-line BEMPEG plus NIVO first-line bevacizumab-erlotinib first-line blinatumomab first-line BV plus AVD first-line BV plus nivolumab first-line cabozantib and nivolumab with or without CBM588 first-line cabozantinib first-line cadonilimab plus anlotinib first-line camrelizumab plus famitinib first-line camrelizumab plus RT first-line carboplatin versus cisplatin first-line carboplatin-paclitaxel with or without bevacizumab first-line CCRT first-line cemiplimab first-line chemo-immunotherapy for stage IV NSCLC first-line chemotherapy plus PD-(L)1 blockade first-line chemotherapy with or without bevacizumab first-line chemotherapy with or without immunotherapy first-line chemotherapy with or without pembrolizumab first-line chemotherapy with sugemalimab versus placebo for mNSCLC first-line CHOP or R-CHOP first-line cisplatin-pemetrexed-nivolumab first-line cladribine with concurrent or delayed rituximab first-line CLL treatment first-line combinations of immune checkpoint inhibitors and chemotherapy first-line dacomitinib versus afatinib first-line DADI trial first-line donafenib versus sorafenib first-line dose-dense early postoperative intraperitoneal chemotherapy first-line everolimus plus bevacizumab first-line FOLFIRINOX first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel first-line gemcitabine-trastuzumab-erlotinib combination first-line ibrutinib first-line ibrutinib plus rituximab first-line ibrutinib plus venetoclax first-line ibrutinib-venetoclax versus chlorambucil-obinutuzumab first-line ICI first-line ICI plus chemotherapy versus bevacizumab plus chemotherapy first-line ICIs first-line ICIs for mM first-line ICIs with or without chemotherapy first-line imatinib plus binimetinib first-line immunotherapy for SCLC first-line ipatasertib plus paclitaxel for advanced TNBC first-line lenvatinib first-line lenvatinib plus transarterial chemoembolization first-line lenvatinib versus atezolizumab plus bevacizumab first-line lorlatinib versus crizotinib first-line mCRC first-line mFOLFOX6 plus bevacizumab versus cetuximab first-line nab-paclitaxel plus carboplatin for aNSCLC in clinical practice first-line niraparib plus pembrolizumab first-line nivolumab first-line nivolumab plus cabozantinib for advanced RCC first-line nivolumab plus ipilimumab first-line nivolumab plus ipilimumab and chemotherapy first-line NSCLC treatment first-line obinutuzumab plus lenalidomide first-line options first-line osimertinib first-line osimertinib versus afatinib or erlotinib first-line pazopanib first-line pembrolizumab first-line pembrolizumab for advanced NSCLC with low PD-L1 expression first-line pembrolizumab for NSCLC first-line pembrolizumab monotherapy first-line pembrolizumab plus lenvatinib first-line pembrolizumab plus R-CHOP first-line PLD-IFO first-line PVAB first-line quavonlimab (anti-CTLA-4) plus pembrolizumab first-line R-CHOP plus roflumilast first-line R-CODOX-M R-IVAC chemotherapy first-line R2 versus rituximab-chemotherapy first-line radioembolization plus chemotherapy first-line regorafenib with nivolumab and chemotherapy first-line S-1 versus anthracyclines first-line selinexor plus R-CHOP first-line selpercatinib first-line serplulimab plus chemotherapy first-line sintilimab with pegaspargase-gemcitabine-oxaliplatin first-line SRS versus WBRT first-line sunitinib first-line systemic treatment options first-line systemic treatment strategies first-line tebentafusp versus investigator’s choice first-line tebentafusp versus nivolumab plus ipilimumab first-line therapies first-line therapy first-line tislelizumab plus chemotherapy first-line tislelizumab versus sorafenib first-line TKIs first-line toripalimab plus bevacizumab first-line toripalimab plus chemotherapy first-line TPEx versus EXTREME first-line trastuzumab first-line treatment first-line treatment options first-line Tumor Treating Fields plus chemotherapy first-line vemurafenib plus obinutuzumab first-line venetoclax combinations first-line venetoclax plus 3 + 7 daunorubicin-cytarabine first-line venetoclax plus azacitidine for AML first-line venetoclax-obinutuzumab versus chlorambucil-obinutuzumab first-line versus second line daratumumab first-line zuberitamab plus CHOP first-recurrence GBM first-relapse rhabdomyosarcoma FIRSTANA-studie FIRSTMAPPP study FIRSTMAPPP trial fistula FIT FIT cohort FIT implementation in guaiac-based screening program FIT screening FIT screening and risk of CRC death FIT-detection of advanced colorectal neoplasia FIT-screening fitheid fitness five miRNA-model five versus two years adjuvant zoledronate five-miRNA based classifier five-year analysis five-year follow-up of CPX-351 versus 7+3 cytabine and daunorubicin five-year outcome five-year outcomes five-year outcomes with cobimetinib plus vemurafenib five-year PROs five-year survival outcomes five-year survivors of adolescent and young adult cancer five-year survivors of chldhood cancer fixed duration of venetoclax-rituximab fixed-duration ibrutinib-venetoclax fixed-duration MRD-guided approach FKBPL FL FLAIR trial FLAME trial FLAMES trial FLASH trial FLAURA study FLAURA-studie FLAURA2 trial flavonoïden flexibele sigmoïdoscopie flexibele-sigmoïdoscopie FLIPPER trial Florence Trial long-term results FLOT4 study FLOT4-studie flow cytometry status FLT3-internal tandem duplication mutated AML FLT3-ITD AML FLT3-ITD positive AML FLT3-ITD-positive acute myeloid leukemia FLT3-mutated R R AML fluciclovine versus PSMA PET-CT fludarabine FLUOGLIO-studie fluoropyrimidine fluoropyrimidine therapy fluoropyrimidines fluoroscopie fluorouracil-leucovorin fluzoparib FLYER study FMD FMT plus tislelizumab and fruquintinib FN FN after chemotherapy for breast cancer FNMTC focal adhesion kinase focal boost focal versus extended IRE FOCUS-cohort FOCUS4-C trial FOCUS4-N trial FOENIX-CCA2 Study FOHAIC-1 trial Fol-BRITe study FOLFIRI FOLFIRI plus bevacizumab or aflibercept FOLFIRI plus cetuximab or bevacizumab FOLFIRI plus durvalumab with or without tremelimumab FOLFIRINOX FOLFIRINOX and chemoradiotherapy FOLFIRINOX induction for LAPC FOLFIRINOX salvage treatment FOLFOX FOLFOX hepatic arterial infusion FOLFOX4 FOLFOXIRI FOLFOXIRI plus bevacizumab FOLFOXIRI plus panitumumab FOLFOXIRI-bevacizumab FOLFOXIRI-bevacizumab versus doublets-bevacizumab FOLH1 expression foliumzuur FOLL05-studie folliculair lymfoom follicular and other CD20+ non-Hodgkin lymphoma follicular lymphoma follow-up after discontinuation follow-up after resection follow-up after treatment cessation Follow-up analyse van CheckMate 067-studie follow-up analyse van JFMC34-0601 follow-up of overdue abnormal cancer screening test results follow-up van overlevers food insecurity in cancer survivors forego medical care foritinib formaldehyde FOrMAT-studie FoRT trial FORT-1 trial FORT-2 multinational phase 1b trial FORUM study fosaprepitant fosaprepitant meglumine FosNTP versus FosAPR fotofarmacologie four-factor prognostic model FOXA1-expressie FOXA2 FOXC1 FOxTROT trial FP in BC patients FP with or without oxaliplatin FPD AML FR FRACTION-RCC trial fractionated gamma knife radiosurgery fractionated pre-operative SRS fractionated stereotactic radiosurgery fractionated stereotactic radiotherapy fractionation schedule of CCTRT fracture risk fracture risk prediction in cancer patients fracturen fractures fractuurrisico fragiele ouderen fragiliteit fragmentation of surgery and chemotherapy frailty and neurocognitive decline frailty and survival FRAX FREEDOM2 trial frequency and outcomes frequency and outcomes of brain metastases frequency and quantity of alcohol consumption frequent aspirin use frequent cystoscopy FRESCO study FRESCO-2 fresolimumab front-line fludarabine-cyclophosphamide-rituximab front-line ibrutinib for CLL patient populations not included in RESONATE-2 frontline acalabrutinib plus venetoclax and obinutuzumab frontline dasatinib frontline FCR frontline hyper-CVAD plus ofatumumab frontline hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab frontline ibrutinib-rituximab followed by R-HCVAD frontline low-dose versus standard dose dasatinib frontline ponatinib versus imatinib frontline targeted therapy plus low-intensity chemotherapy frontline therapies frontline therapy for AML in elderly patients frontline treatment for pediatric AML frontline treatments fruit fruit and vegetable consumption fruquintinib fruquintinib in Chinese patients in clinical practice FRUTIGA trial FS118 FSRT FSS versus RS FTD versus HD-MA FTD-TPI FTD-TPI with or without bevacizumab FTL3-mutatie Fudan CUP-001 FUJI cohort fulvestrant fulvestrant plus capivasertib fulvestrant plus palbociclib fulvestrant versus AIs FUMANBA-1 trial functional outcomes FURLONG study FURLONG trial furmonertinib furmonertinib versus gefitinib FUS-ERG and RUNX1-CBFA2T3 fusion gene Fusobacterium nucleatum futibatinib future cancer risk FUTURE-C-PLUS study FUTURE-SUPER trial fuzuloparib maintenance fuzuloparib plus apatinib fysieke activiteit FZOCUS-2 trial G GEJ adenocarcinoma G GEJ cancer G-CSF support G-CSFs g-NETs G84E GAIA CLL13 4-year follow-up gain-of-function mutatie gait speed galactography galblaascarcinoom GALEN study galeterone gallbladder cancer GALLIUM study gallium-68 labelled PSMA-11 PET gallium-68 PET-MRI GALLIUM-studie galunisertib galunisertinib plus neoadjuvant chemoradiotherapy galwegcarcinoom gamma knife radiosurgery GammaTile brachytherapy ganglioside vaccine for high-risk neuroblastoma ganglioside-monosialic acid ganitumab GAP BRAIN phase 3 study GARD garlic GARNET study GARNET trial garsorasib GASTO 1028 study GASTO1003 trial gastric adenocarcinoma gastric and duodenal cancer gastric cancer gastric cancer detection one year after negative endoscopy gastric cancer family history gastric cancer in Helicobacter pylori-infected patients gastric cancer prevention gastric cancer risk gastric cancer surgery gastric cancer with synchronous peritoneal metastases gastric gastroesophageal junction AC gastric gastroesophageal junction adenocarcinoma gastric or esophagastric junction adenocarcinoma gastric or gastric-esophageal junction adenocarcinoma gastric or gastro-esophageal junction cancer gastric or gastroesophageal junction adenocarcinoma gastric or gastroesophageal junction cancer gastric or GEJ adenocarcinoma GASTRIPEC-I trial gastritis gastro-intestinale mucositis gastro-intestinale stromale tumoren gastro-oesofagaal adenomcarcinoom gastroenteropancreatic neuroendocrine tumors gastroesophageal adenocarcinoma gastroesophageal cancer gastroesophageal reflux disease gastrointestinal bleeding gastrointestinal cancer gastrointestinal neuroendocrine carcinoma gastrointestinal stromal tumor gastrointestinal stromal tumors gastroïntestinale kanker gastroïntestinale stromale tumoren Gattelli GAUDI GBC GBCA GBD 2019 GBM GBM in elderly patients gBRCAm HER2-negative mBC GBS GBSM GBV-C GC GC GEJC GC with synchronous PMs GC012F GC1008 GC4419 GCA GCC GCC19 CART GCIG INTERLACE trial GCPM GCT GCTB GCTs GD GD2-CART01 GDP GEA GEC GECCOR-GB study gedatolisib gedatolisib plus paclitaxel and carboplatin gedatolisib plus palbociclb and ET GeDDiS-studie gedifferentieerd schildkliercarcinoom gedissemineerde tumorcellen gefitinib gefitinib alone or with chemotherapy gefitinib and erlotinib gefitinib continuation after progression gefitinib plus chemotherapy GEICAM 2003-11_CIBOMA 2004-01 study GEICAM 2010-04 study GELAD chemotherapy with sandwiched radiotherapy GELATO trial GELLC-7 trial gelokaliseerd prostaatcarcinoom GEM GEM-1402 study GEM20110714 study gemcitabine gemcitabine plus adavosertib gemcitabine plus cisplatin induction chemotherapy gemcitabine plus nab-paclitaxel and ficlatuzumab gemcitabine with or without berzosertib gemcitabine with or without ramucirumab gemcitabine-eribulin combination gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy gemcitabineresistentie gemetastaseerd mammacarcinoom gemetastaseerd melanoom gemetastaseerde borstkanker gemetastaseerde borstkanker; trastuzumab gemetastaseerde colorectaalkanker GEMPAX study GemPred GEMSTONE-201 GEMSTONE-301 trial GEMSTONE-302 GEMSTONE-302 trial gemtuzumab ozogamicin gemtuzumab ozogamicine GEN501 and SIRIUS final results gender differences gene expression markers in peripheral blood gene expression profiles gene expression profiling assay gene expression signature to predict response gene signature for predicting lymph node status gene variants and subsequent neoplasms gene variants associated with increased cancer risk gene-specific prevention strategies for OC and BC geneesmiddelinteracties generalizibilty among different ethnicities Generations Study genetic alterations genetic and clinical predictors genetic factors genetic prognostic and predictive factors genetic risk genetic risk for overall cancer genetic susceptibility genetic testing genetically defined renal tumors genetically determined cutaneous nevi genetically predicted low-density lipoprotein level genetically proxied inhibition of HMG-CoA reductase genexpressie genito-urinaire maligniteiten genmethylering genome sequencing genome-edited donor-derived anti-CD19 CAR T cells for pediatric and adult B- ALL genome-wide association study genome-wide diet-gene interaction genome-wide variants genomic alterations genomic analysis in NRG Oncology RTOG 9802 genomic biomarkers predicting anti-PD-(L)1 response genomic characterization genomic classification and clinical outcome genomic correlates genomic correlates of progression or response genomic determinants of clinical outcomes genomic determinants of early recurrence genomic determinants of outcomes genomic identification of HRD genomic profiling genomic profiling of prostate cancers from met with African and European ancestry genomics and outcomes genotoxic pks E. coli genotyping before first-line therapy genotyping lung adenocarcinoma GENUINE trial genvarianten GEOMETRY mono-1 study GEP-NETs GeparNuevo analysis GeparNuevo study GeparOcto secondary analysis GeparQuattro-studie GeparSepto GeparSepto long-term outcomes GeparSixto trial GeparX trial gepegyleerd liposomaal doxorubicine geptanolimab geptanolimab (GB226) gerandomiseerde fase 2-studie PrE0102 GERD treatment Gerecke geriatirc patients geriatric assessment impairments geriatric comanagement Geriatric Prognostic Indicator germ cell tumors germline BARD1 gene variants germline BRCA PALB2 mutation germline BRCA pathogenic variant germline BRCA PVs and ovarian reserve germline BRCA-mutated metastatic pancreatic cancer germline BRCA-mutated mPaC germline BRCA1 2 mutation germline BRCA1 2 pathogenic variants germline BRCA2 mutations germline CDH1 variants and lifetime cancer risk germline CDH1 variants in HLBC germline genetic testing germline genetic testing after cancer diagnosis germline mutaties germline mutations germline mutations in DNA repair genes germline PALB2 pathogenic variants germline pathogenic variants in 28 genes germline predisposition gene mutations germline PTEN variants in children and adults germline PVs in cancer predisposition genes germline sequencing analysis germline variant status germline variants in DNA repair genes germline variants in natural killer cells germline variations in drug transporters geserreerde poliepen geslachtshormonen gestation and birthweight of offspring gestational trophoblastic neoplasia gestationele trofoblasttumor GETNE-TRASGU study GETUG-AFU 16 study 112-months follow-up gevorderd cervixcarcinoom gevorderd maag-adenocarcinoom gevorderd melanoom gevorderd niercelcarcinoom gevorderde borstkanker gevorderde maagkanker geweichtsverlies gezondheidsutiliteitsindex gFOBT GFPC 08-2015 ENERGY trial GFR GFR; niercelcarcinoom; urotheelcarcinoom GGO lung adenocarcinoma GHSG HD13-15 trials GHSG HD17 study GI adverse events GI cancer GI malignancies GI malignant neoplasms giant-cell tumor of bone gilteritinib gilteritinib as post-transplant maintenance GIMEMA-MMY-3006 trail GIST GISTs GK GK-SRS with or without EGFR-TKIs GKRS GKRS for BMs of non-pulmonary primary tumors GLARIUS-studie glasdegib GLASS study Gleason score 9-10 prostate cancer glembatumumab vedotin glioblastoma glioblastoma in elderly patients glioblastoma in patients aged 80 years and older glioblastoma in poor perfomance status patients glioblastoma multiforme glioblastoma recurrence glioblastoma with methylated MGMT promoter glioblastoom glioma glioma risk glioma with BRAF-V600E mutation gliomas gliomen glioom glitazonen global burden in 2019 global burden of 30 cancers among men in 2022 and projections for 2050 global burden of breast cancer Global Burden of Cancer global burden of cancer attributable ro risk factors global burden of cancer attributable to infections in 2018 global burden of cancer in 2020 attributable to alcohol consumption Global Burden of Disease Study Global Burden of Disease Study 2019 global cancer incidence and mortality from 2010 to 2019 global expanded access program global incidence and mortality for 29 cancer groups in 2019 global incidence and mortality trends global longitudinal strain global pediatric cancer care global retinoblastoma presentation analysis by national income level global trends global variations in incidence by histological subtype glofitamab glofitamab plus GemOx versus rituximab plus GemOx GLORY trial glottic squamous cell carcinoma GLOW study GLOW trial GLP-1RAs glucocorticoid treatment glucocorticoid-refractory cGVHD glucose lowering drugs GLUT- GLUT-14 glutamine glutathion-S-transferase P1 glycaan-gerelateerde genen glypicaan-1 GM-CSF GM1 for OIPN GMMG-CONCEPT trial GMMG-HD7 trial GMMG-MM5 trial GNAS variants in solid tumors GNCC GnHRa GNOS-PV02 plus pembrolizumab GnP or mFFX GnRH-agonist GnRHa GO GO30103 trial GO30140 study GO42144 trial goals of care in last years of life GOG 0212 study GOG 281 LOGS GOG Study 279 GOG-0213 studie GOG-0213 study GOG-0218 final OS-analysis GOG-0218 studie GOG-0277 Golestan Cohort Study golidocitinib gonadotropine Google Translate GORILLA-3004 study GORTEC 2007-01 studie GORTEC 2014-01 TPExtreme study GOSAFE Study gosereline GÖTEBORG-2 ISRCTN study GOYA-studie GP-led versus surgeon-led colon cancer survivorship care GPRC5D-targeted CAR T cells grade 1-2 AEs grade 2 oligodendroglioma grade migration during the last decade graded cardiac response criteria graft failure graft versus host disease graft-versus-host disease graft-versus-host disease prophylaxis grain consumption and dietary fiber intake GRASPA GRAVITAS-301 trial GRCCC cohort study GRECCAR 2-studie GREEN study subgroup analysis GRIFFIN study grijpkrachtverlies grip strength groeicurves naevi groeisnelheid groenten groentenconsumptie GROINSS-V-II grootcellig granulair lymfocytaire leukemie grootcellig neuro-endocrien longcarcinoom grootte van lymfekliermetastasen gross total versus subtotal resection gross-total resection grote-korrel lymfocyten leukemie growth hormone deficiency growth rate of untreated hemangioblastomas growth rates GSK2857916 GT-30 GT90001 plus nivolumab GTN GTT GU-toxiciteit guadecitabine guanylaatcyclase GUIDANCE-03 trial gumarontinib gut microbiota and metabolites GVAX pancreas GVHD GVHD prevention after haploidentical HCT GVHD prophylaxis GWAS GX-188E Gxplore-002 study Gxplore-005 study gynecologic cancers gynecologic oligometastatic and oligoprogressive tumors gynecological brain metastases gynecological cancer gynecologische maligniteiten H-RT versus C-RT H. pylori H. pylori infection status H. pylori screening H3K27M+ diffuse midline glioma HA-WBRT + SIB for brain metastases HA-WBRT + SIB versus conventional WBRT haarverlies hafnium oxide nanoparticle HAI HAI chemotherapy HAI pump chemotherapy plus systemic therapy HAIC HAIC with FOLFOX HAIP floxuridine chemotherapy versus resection hair dye use and prostate cancer risk hair products hairy cell leukemia hairy-cell leukemie hallmarks of cancer HALO 202-studie HALT-D trial Ham-Wasserman lecture Hamilton Fairley Award hand-voet huidreacties hand-voet syndroom hand-voetsyndroom HannaH study final analysis haplo versus UD transplantation haplo-HSCT haplo-HSCT versus chemotherapy haplo-identieke HSCT haplo-SCT haploidentical HSCT haploidentical versus unrelated cord blood transplantation haploidentical versus unrelated SCT haploidentical; sibling; matched unrelated donor HARMONi-A study harms of exercise training HART hartfalen hartfalen na auto-HCT HAS HBOC HBOT for late local toxic effects HBOT in breast cancer patients HBV-related HCC HBV-related HCC risk HBV-vaccinatie HC hcc HCC diagnosis HCC expressing CD147 HCC in children compared to young adults HCC in HBV- or HCV-infected patients HCC mortality HCC overall survival HCC risk HCC risk algorithm HCC risk in patients with HBV and or HCV infection HCC screening in a cohort of at-risk patients HCC surveillance in cirrhosis patients HCC with extrahepatic metastasis HCC with MVI HCC with portal vein tumor thrombus HCL HCMV reactivation during radiochemotherapy HCRN GU16-257 trial HCT HCV HCV-associated indolent NHL HD 0607 trial HD IL-2 HD-MTX for prevention of CNS progression HD12 study HD16 trial HD18-studie HD201 HD21 trial HD9 study HDAC inhibition HDCT plus autoHSCT HDCT plus PBSCT HDL-cholesterol level and risk of hematologic malignancy HDR-brachytherapie head and neck cancer head and neck cancer risk after hematologic cancer head and neck cancer surgery during COVID-19 pandemic head and neck procedures head and neck squamous cell carcinoma head en neck cancer Head Start III health care contact days health care use health consequences health literacy health maintenance practices Health Professionals Follow-up Study health promotion among cancer survivors health-related quality of life healthy eating patterns healthy immigrant effect healthy lifestyle healthy lifestyle and liver cancer risk healthy older adults healthy postpolypectomy lifestyle hearing impairment hearing loss heart failure heart failure risk heavily pretreated HR-positive HER2-negative metastatic breast cancer heavily pretreated MBC heavily pretreated PROC heavy smokers HECTOR model hedgehog inhibitors hedgehog-signaalroute HEI-2010 heldercellig niercelcarcinoom heldercellig ovariumcarcinoom Helicobacter pylori Helicobacter pylori treatment HELIOS study HeLiX randomized clinical trial hematologic cancer patients hematologic cancers and COVID-19 hematologic malignancies hematologic malignancies in older patients hematologic malignant neoplasms hematological cancer hematological disorders hematologische maligniteiten hematopoietic cell transplantation hematopoietic score predicts outcomes hematopoietic stem cell transplantation hematopoietic stem cell transplation hematopoïetische celtransplantatie hemicolectomy versus appendectomy hemispheric-specific clinical presentation hemochromatosis HFE p.C282Y homozygosity hemorrhagic cystitis following allotransplantation hENT1 expression HEPAR PluS study hepatectomy in academic versus community cancer center hepatectomy with or without adjuvant mFOLFOX6 hepatic arterial infusion chemotherapy hepatic artery infusion pump chemotherapy hepatitis B virus infection hepatitis B-virus hepatitis C hepatobiliary cancers hepatocallular carcinoma hepatocellulair carcinoom hepatocellular carcinoma hepatocellular carcinoma and pancreatic ductal adenocarcinoma hepatocellular carcinoma with portal vein invasion hepatocellular carcinoma with preoperative portal vein tumor thrombus hepatospleen T-cel lymfoom hepatotoxiciteit hepatotoxicity HER2 HER2 amplification HER2 exon 20 insertions HER2 exon 20 mutant NSCLC HER2 expressing UCS HER2 expression discordance between primary and metastatic breast cancer HER2 expression testing HER2 gene expression levels HER2 mutated aNSCLC HER2 negative advanced gastric gastroesophageal junction cancer HER2 peptide vaccines for prevention of breast cancer recurrence HER2 pro-oncogene signalering HER2-0 and HER2-low mBC HER2-altered advanced solid tumors HER2-amplified LA M BTC HER2-amplified mCRC HER2-amplified non-breast gastroesophageal tumors HER2-directed therapies HER2-expressie HER2-expressing cancers HER2-expressing mCRC HER2-expressing or mutated advanced solid tumors HER2-expressing prostate cancer HER2-gedreven NSCLC HER2-HER3 dimerization HER2-low HER2-low advanced breast cancer HER2-low breast cancer HER2-low expression HER2-low versus HER2-negative breast cancer HER2-low versus HER2-negative mBC HER2-low versus HER2-null HER2-low versus HER2-zero MBC HER2-low-positive breast cancer HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy HER2-mutant lung cancer HER2-mutant metastatic cervical cancer HER2-mutant mNSCLC HER2-mutant NSCLC HER2-negatief mammacarcinoom HER2-negatieve borstkanker HER2-negatieve MBC HER2-negative HER2-negative advanced G GEJ cancer HER2-negative BC HER2-negative BRCA mutated resectable breast cancer HER2-negative breast cancer HER2-negative early breast cancer HER2-negative MBC HER2-negative metastatic breast cancer HER2-negative node-positive breast cancer HER2-negative tumors HER2-overexpressing breast cancer HER2-overexpressing mGEA HER2-overexpressing mNSCLC HER2-positief mammacarcinoom HER2-positief metastatisch mammacarcinoom HER2-positieve borstkanker HER2-positieve vroege borstkanker HER2-positive ABC HER2-positive ABC MBC HER2-positive aCRC HER2-positive advanced breast cancer HER2-positive advanced G GEJ cancer HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma HER2-positive advanced gastric or gastroesophageal junction cancer HER2-positive advanced solid malignancies HER2-positive and AR-positive advanced breast cancer HER2-positive and biopsy-proven node-positive breast cancer HER2-positive BC with BMs HER2-positive BCBM HER2-positive BCBMs HER2-positive biliary tract cancer HER2-positive breast cancer HER2-positive breast cancer and brain metastases HER2-positive breast cancer brain metastases HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer survivors HER2-positive breast cancer with brain metastases HER2-positive BTC HER2-positive de novo metastatic breast cancer HER2-positive EAC HER2-positive early breast cancer HER2-positive early breast cancer in elderly HER2-positive early-stage breast cancer HER2-positive EBC HER2-positive esophagogastric adenocarcinoma HER2-positive esophagogastric cancer HER2-positive gastric cancer HER2-positive gastro-esophageal adenocarcinoma HER2-positive LA M UC HER2-positive localized breast cancer HER2-positive MBC HER2-positive mBC in Europe HER2-positive mBTC HER2-positive metastatic breast cancer HER2-positive metastatic breast cancer after ≥ 2 HER2-directed regimens HER2-positive non-metastatic breast cancer HER2-positive R MBC HER2-positive salivary duct carcinoma HER2-positive stage II or III breast cancer HER2-scoringsysteem HER2-screening HER2-targeted ADCs HER2-targeted CAR T cell therapy HER2-targeted therapies HER2-targeted therapy HER2+ BC HER2+ breast cancer HER2+ breast cancer brain metastases HER2+ mCRC HER2CLIMB HER2CLIMB brain metastases subgroup analysis HER2CLIMB randomized phase 2 study HER2CLIMB study HER2CLIMB study exploratory analyses HER2DX HER2DX model HER2DX pCR-score HER3 overexpression HER3-DXd HER3-mutant mammacarcinoom HERA HERA trial HERALD EPOC 1806 herb and supplement use HERBY-studie herceptin herceptin-biosimilar herceptine hereditary diffuse gastric cancer Heritage HERIZON-BTC-01 HERO study heropname herpes zoster after autologous stem cell tranplantation hersenmetastasen hersenmetastasen mammacarcinoom hersenmetastasering hersenmicrobloedingen hersentumoren HERTHENA-Lung01 Heterocephalus glaber heterogeneity between SEER counties heterogeneity of IHC HF-WBI HFSRT HGG HGGs HGS OC HGSC at RRSO HGSOC HIDAC versus IDAC consolidation hidden-genome classifier hidradenitis suppurativa HIFU high burden of clonal hematopoiesis high hereditary breast cancer risk high PD-L1 expressing NSCLC high risk early breast cancer high risk locally advanced rectal cancer high risk melanoma high risk of colorectal peritoneal metastasis high RS high sensitivity C reactive protein high TIL and pCR high TMB tumors high versus low dose lenalidomide maintenance after transplantation high- or very high-risk localized prostate cancer in patients ≤ 65 years high-dose carboplatin high-dose chemotherapy high-dose chemotherapy and 3D conformal radiation high-dose cyproterone acetate high-dose folic acid use during pregnancy in epilepsy patients high-dose intensity-modulated chemoradiotherapy high-dose once-daily RT high-dose versus standard-dose twice daily thoracic RT high-dose vitamin D high-dose-rate brachytherapy high-grade and low-grade glioma high-grade brainstem gliomas high-grade breast DCIS high-grade glioma high-grade gliomas in children high-grade gliomas in pediatric patients high-grade mature B-cell NHL in children and adolescents high-grade osteosarcoma of the extremities high-grade ovarian cancer high-grade prostate cancer high-grade UTUC high-intensity focused ultrasound high-intermediate and high risk early stage EC high-mobility group box 1 High-molecular-mass hyaluronan high-PD-L1 expressing NSCLC with brain metastases high-risk ALL in children high-risk AML high-risk AML in remission high-risk asymptomatic bone metastases high-risk B-ALL high-risk biochemically recurrent prostate cancer high-risk breast cancer high-risk cancer surgery high-risk CSPC high-risk DLBLC high-risk early breast cancer high-risk EBC high-risk endometrial cancer high-risk extremity trunk STS high-risk factors and real-world outcomes high-risk features high-risk first-relapse B-ALL in children high-risk HCC high-risk HNC patients high-risk LBCL high-risk localized gastrointestinal stromal tumor high-risk locally advanced rectal cancer high-risk locally advanced squamous cell carcinoma of head and neck high-risk low-grade glioma high-risk luminal breast cancer high-risk lymphoma high-risk mature B-cell non-Hodgkin’s lymphoma in children high-risk medulloblastoma high-risk medulloblastoma in children high-risk melanoma high-risk MIUC high-risk mNSCLC high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia high-risk neuroblastoma high-risk non-muscle-invasive bladder cancer high-risk nonmetastatic breast cancer high-risk oral squamous cell carcinoma high-risk pediatric HL high-risk prostate cancer high-risk resected melanoma high-risk retinoblastoma high-risk rhabdomyosarcoma high-risk SM high-risk smoldering multiple myeloma high-risk smoldering myeloma high-risk soft tissue sarcoma high-risk stage 2 colon cancer high-risk stage II melanoma high-risk uveal melanoma high-volume metastatic hormone-sensitive prostate cancer higher-risk MDS or CMML HIIT HiLo trial hilotherapy versus frozen gloves HIMALAYA study HIMALAYA trial HIPEC HIPEC + CS HIPEC after CRS histologic regression histological biomarkers histologically rare triple-negative breast cancers histologische regressie histology-tailored versus standard neoadjuvant chemotherapy histopathologic features historical 90-day mortality history of atopy history of use of statins and COX-2 inhibitors HIV HIV AIDS HIV infection HIV infection in elderly patients HIV RNA HIV status and survival HIV-associated Kaposi sarcoma HIV-infection HL HL diagnosis during pregnancy HL in elderly patients HL survivors HL with high risk of failure after autoHSCT HL-behandeling HLA antigen mismatch HLA-A*03 and response to immune checkpoint blockade in cancer HLA-matched or alternative donors HLA-matched sibling donor transplantation HLA-mismatched unrelated donor HCT HMA plus venetoclax HMAs for high-risk MDS or AML HMAs plus venetoclax for HR-MDS HMIE versus open esophagectomy hMPV HMR 2.0 HMT for BC HNC HNC risk HNC survivors HNC versus onther cancers HNCs HNMCC HNSCC HNSCC in older patients HNSCC patients HNSCC surgery Hodgkin and non-Hodgkin lymphoma Hodgkin lymfoom Hodgkin lymphoma Hodgkin lymphoma in children and adolescents Hodgkin lymphoma survivors Hodgkin's lymfoom Hodgkin’s lymphoma hofd-hals Merkel celcarcinoom hoge dosering chemotherapie Hokusai VTE-Cancer studie holmium-166 after lutetium-177-dotatate home administration of trastuzumab homeobox B13 homocysteïne homologous recombination deficiency hoofd hals squameus celcarcinoom hoofd halscarcinoom hoofd halskanker hoofd-hals melanoom hoofd-hals squameus celcarcinoom hoofd-halscarcinoom hoofd-halskanker hoofdhuidkoeling hoog-risico B-ALL hoog-risico cervixcarcinoom hoog-risico CML hoog-risico melanoom hooggradig sereus ovariumcarcinoom HOPE trial horizontale transfer hormonal therapy hormonal therapy resistance hormone receptor low positive breast cancer hormone-modulating breast cancer therapy hormone-naïve metastatic prostate cancer hormoonreceptor positieve borstkanker hormoontherapie hospital connectedness hospital frailty risk score hospital variation in treatment and survival in The Netherlands hospital volume hospitalisatie hospitalization hospitalization after adolescent and young adult cancer hospitalizations and ED visits after CAR T-cell therapy hospitalized patients with active cancer hot flashes HOVON 105 ALLG NHL 24 HOVON 105 study Hovon 143 study HOVON-143 trial HOVON124 ECMW-R2 HOVON141 VISION trial How Long studie HP SCC HPC-SFT HPD HPTC HPV HPV ctDNA HPV ctDNA after CRT HPV DNA in penile cancer and intraepithelial neoplasia HPV DNA persistence HPV genotypes HPV infection HPV load and genotype analysis HPV status HPV status and HPV16 viral load HPV types HPV types 16 18 in cervical precancers HPV vaccination HPV vaccination and anal HSIL+ and cancer HPV vaccine HPV-16 18 vaccin HPV-associated epithelial cancers HPV-associated malignancies HPV-associated OPSCC HPV-associated oropharyngeal carcinoma HPV-associated oropharyngeal squamous cell carcinoma HPV-associated SNSCC HPV-FOCAL trial HPV-independent and HPV-associated vulvar SCC HPV-infectie HPV-negative head and neck squamous cell carcinoma HPV-negative HNSCC HPV-orofarynxcarcinoom HPV-positive oropharyngeal cancer HPV-positive oropharyngeal squamous cell cancer HPV-positive oropharyngeal squamous cell carcinoma HPV-related malignancies HPV-related OPSCC HPV-related oropharyngeal cancer and cancer of unknown primary HPV-typen HPV-unrelated locally advanced HNSCC HPV-vaccinatie HPV+ OPC HPV+OPSCC HPV16 18-positive advanced cervical cancer HPV16- and or HPV18-positive recurrent of advanced cervical cancer HPV16-E6 serology test HPV16-related cancerISA101 HR-deficiëntie HR-MDS HR-NB HR-NBL1 SIOPEN study HR-NL81 SIOPEN HR-NMPC HR-positief mammacarcinoom HR-positief metastatisch mammacarcinoom HR-positive advanced breast cancer HR-positive advanced postmenopausal breast cancer HR-positive and HER2-negative T1a bN0M0 breast cancer HR-positive BC HR-positive breast cancer HR-positive breast cancer brain metastases HR-positive breast cancer in young women HR-positive early breast cancer HR-positive early-stage breast cancer HR-positive EBC HR-positive HER2 negative metastatic breast cancer HR-positive HER2-negative aBC HR-positive HER2-negative advanced breast cancer HR-positive HER2-negative advanced or metastatic breast cancer HR-positive HER2-negative breast cancer in older patients HR-positive HER2-negative early breast cancer HR-positive HER2-negative mBC HR-positive HER2-negative metastatic breast cancer HR-positive HER2-negative metastatic breast cancer in older women HR-positive HER2-positive advanced breast cancer HR-positive HER2-positive early-stage breast cancer HR-positive metastatic breast cancer HR-status HR+ HER- ABC HR+ HER- BC HR+ HER2- ABC HR+ HER2- aBC progressing beyond CDK4 6 inhibitor HR+ HER2- breast cancer HR+ HER2- breast cancer in real-world patients HR+ HER2- breast cancer survival HR+ HER2- EBC HR+ HER2- MBC HR+ HER2- vroeg-stadium mammacarcinoom HR+ HER2-ABC HR+ HER2+ breast cancer HR+ MBC HRBOC hrCT HRD HRGI cancers HRP ovarian cancer HRQoL HRQOL impact HRQOL in long-term survivors HRQOL in prostate cancer HRR-deficient metastatic castration-resistant prostate cancer HRT HRT and breast cancer risk HRT versus CRT hs-cTnT HSC HSCT HSCT-bijwerkingen HSCT-TMA in adults Hsp70 HT hTERT-DCs hu14.18K322A hu3F8 huCART19 HUDSON trial huidkanker huidkankerscreening huidmaligniteit huidneoplasmen huisartsenzorg humaan papillomavirus human equilibrative nucleoside transporter 1 human readers versus machine-learning algorithms hyaluronic acid hybrid minimally invasive esophagectomy hyper-CVAD followed by blinatumomab hyperbaric oxygen therapy hypercalcaemia of malignancy hypercalcemie hyperemesis gravidarum hyperfractionated versus standard fractionated IMRT hyperleukocytosis hyperprogression hyperprogressive disease hyperproliferatie van stamcellen hypertensie hypertension hyperthermic intraperitoneal chemotherapy hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery hyperthermische intraperitoneale chemoperfusie hypervascular intracranial tumors HYPO-RT-PC study hypodiploid ALL in children hypofarynxcarcinoom hypofractionated adjuvant radiotherapy hypofractionated breast RT for 1 week versus 3 weeks hypofractionated IMRT hypofractionated postmastectomy radiation therapy hypofractionated postmastectomy radiotherapy hypofractionated preoperative radiotherapy hypofractionated RT hypofractionated SRS hypofractionated SRT to the resection cavity hypofractionated stereotactic radiotherapy hypofractionated stereotactic radiotherapy after surgery for brain metastases hypofractionated versus conventional RT hypofractionated versus conventionally fractionated RT hypofractionated versus conventionally fractionated whole-breast irradiation hypolipidemic drugs hypomethylating agents hyponatremie HYPOR HYPORT-STS HYPRO hysterectomy I CARE study secondary outcome I CARE trial I T DIN GM-CSF I-131 labelled metuximab i-ALCL I-SPY 2 trial I-SPY2 three-year follow-up analysis I-SPY2 trial I+V versus FCR iadademstat plus azacitidine iAMP21 IARC IBC IBC versus SBC IBC with exceptional response to NST IBCSG 23-01 trial IBD iberdomide plus dexamethasone IBI351 IBIS II IBIS-I IBIS-II trial 10 year follow-up IBM Watson IBR ibrutinib ibrutinib –bortezomib ibrutinib discontinuation ibrutinib followed by ofatumumab consolidation ibrutinib for CLL ibrutinib maintenanc ibrutinib monotherapy ibrutinib plus fludarabine ibrutinib plus palbociclib ibrutinib plus rituximab ibrutinib plus venetoclax ibrutinib versus ofatumamab ibrutinib with or without ublituximab ibrutinib-obinutuzumab-venetoclax combination ibrutinib-rituximab versus chemoimmunotherapy ibrutinib-rituximab versus placebo-rituximab ibuprofen ICANS prophylaxis with anakinra ICARIA-MM study ICARIA-MM subgroep analysis ICB ICB for SCLC ICBP SURVMARK-2 study ICC ICC versus STC iCCA ICd versus Id ICE3 trial ICI ICI dosing strategy ICI effectiveness ICI efficacy ICI for aNSCLC ICI for GBM ICI monotherapy ICI plus VEGFR inhibitor therapy for aRCC ICI rechallenge ICI therapy ICI therapy in IBD patients ICI treated mUC ICI treatment ICI use during pregnancy ICI use in real-life practice ICI versus chemotherapy ICI with or without chemotherapy followed by resection of primary tumor ICI with or without SBRT ICI with or without SRS ICI-AKIs ICI-associated irAEs terminology ICI-associated neurotoxicities ICI-induced autoimmunity ICI-naïve A R NSCLC ICI-pretreated stage IV NSCLC ICI-refractory advanced melanoma ICI-related multisystem immune-related adverse events ICI-related myocarditis ICIs ICIs after EGFR TKIs ICIs and chemotherapy ICIs for advanced cSCCs ICIs for advanced gastrointestinal cancers ICIs for advanced non-small cell lung cancer ICIs for advanced NSCLC ICIs for advanced NSCLC in clinical practice ICIs for advanced PLC ICIs for advanced solid tumors ICIs for aGEC ICIs for aNSCLC ICIs for cancer ICIs for cancer in clinical practice ICIs for cancer in patients with autoimmune disease ICIs for HNSCC ICIs for lung cancer or malignant melanoma ICIs for melanoma ICIs for melanoma in patients with preexisting autoimmune disease ICIs for metastatic cancer ICIs for metastatic cancers in solid organ transplant recipients ICIs for metastatic melanoma. early prediction of pseudoprogression ICIs for metastatic renal and urothelial cancer ICIs for mNSCLC ICIs for mRCC ICIs for MSI-H metastatic colorectal cancer ICIs for mUC ICIs for non-small cell lung cancer ICIs for NSCLC ICIs for NSCLC in patients with pre-existing autoimmune disorders ICIs for solid malignancies ICIs for solid tumors ICIs plus anlotinib ICIs plus anti-VEGF therapy with or without TACE ICIs plus bevacizumab ICIs plus chemotherapy ICIs with or without denosumab ICLL-07 FILO trial ICLL07 FILO study ICON6-studie ICON8 study ICON8-studie ICPi ICs ICU-opname idarubicine plus cytarabine plus nivolumab IDC versus ILC iddEPC-studie ide-cel IDEA collaboration IDEA database IDEA-collaboration idecabtagene vicleucel idelalisib identification of patients with high recurrence risk identification of patients with underrecognized symptoms IDH mutant and wildtype LGG IDH mutation IDH mutation status IDH wildtype glioblastoma IDH-mutant CNS WHO grades 2 or 3 astrocytoma IDH-mutant diffuse glioma IDH-mutant lower-grade glioma and glioblastoma IDH-mutated acute myeloid leukemia myelodysplastic syndrome IDH-wildtype GBM IDH-wildtype supratentorial GBM IDH1 2-mutant low-grade glioma IDH1 IDH2-mutant solid tumors IDH1 mutation IDH1-expressie IDH1-mutant glioma IDH1-mutant LGG IDH1-mutant solid tumors IDH1-mutated AML idiopathische membraneuze nefropathie idiopatische MCD IDO PD-L1 targeting peptide vaccine plus nivolumab Idylla IELSG-19 studie IELSG32 trial 7-year results IELSG32-studie ieramilimab with or without spartalizumab IES IFCT-0302 trial IFCT-2104 CAPMATU IFD IFG IFM 2009 IFN-onderhoudsbehandeling IFRT IFTC-1703 R2D2 trial Ig paraproteïn IGBT IGF-1 IGF-1R expressie IGF2-AS IgM MGUS IGT IHC IHCA IHCC IHGV mutational status IHP IHT iIC versus iC IIIA-N2 NSCLC ijzersuppletie IKEMA trial IKFZ1-deletie IKFZ1-deletion IKZF1-deletie IL-12 plasmid transfection IL-6 IL-8 ILC ILC in premenopausal patients illness perception and outcomes in cancer iLLUMINATE study image-guided intensity modulated radiation therapy Imaging imaging surveillance imaging-based prostate cancer screening IMAJEM-studie imatinib imatinib after other multi-kinase inbitors imatinib plus binimetinib iMATRIX study IMbrave 150 study IMbrave050 IMbrave150 IMbrave150 study IMbrave151 IMbrella A trial IMCL-2015 trial IMD IMDC imetelstat IMiDs imiquimod immediate vs deferred cytoreductive nephrectomy IMmotion 151 trial IMmotion 151-studie IMmotion151 trial immune cells in mesothelioma microenvironment immune checkpoint blockade immune checkpoint inbition for cancer immune checkpoint inhibition immune checkpoint inhibition for unresectable HCC Immune Checkpoint Inhibitor immune checkpoint inhibitor associated acute kidney injury immune checkpoint inhibitor for NSCLC immune checkpoint inhibitor induced pituitary dysfunction immune checkpoint inhibitor rechallenge after irAE immune checkpoint inhibitor therapy immune checkpoint inhibitor trials immune checkpoint inhibitor-induced colitis immune checkpoint inhibitor-mediated diarrhea and colitis immune checkpoint inhibitors immune checkpoint inhibitors for AML immune checkpoint inhibitors for metastatic cutaneous melanoma immune effector cell-associated neurotoxity syndrome immune effects of rituximab immune health immune infiltration immune markers of nivolumab response immune microenvironment immune phenotype immune response immune status immune-mediated diarrhea and colitis immune-related adverse events immune-related adverse events and efficacy of avelumab immune-related enteritis immune-related gene expression in osteosarcoma immune-related meningitis immune-related pneumonitis IMMUNED study immunocheckpoint blockade immunochemottherapy immunocompromised cancer patients immunogenicity and safety in patients with solid cancer immunogenicity of metastatic breast cancer immunogenomic biomarker analysis immunoglobuline lichte-keten amyloïdose immunologically quiescent melanoma immunomodulatory TNBC immunophenotyping of TILs and PBLs IMMUNOSARC Immunoscore immunosuppression immunosuppressive therapy for management of MDS immunotherapeutic boost immunotherapy immunotherapy after chemotherapy and radiation for stage III NSCLC immunotherapy after surgery of the primary tumor immunotherapy for advanced cancers immunotherapy for advanced non-small cell lung cancer immunotherapy for advanced stage cancer immunotherapy for EGFR ALK wild-type advanced NSCLC immunotherapy for melanoma immunotherapy for metastatic melanoma immunotherapy for NSCLC immunotherapy initiation at EOL immunotherapy or chemoimmunotherapy immunotherapy plus stereotactic radiotherapy immunotherapy rechallenge immunotherapy versus BSC immunotherapy versus chemotherapy immunotherapy with or without live bacterial supplementation immunotherapy-based TNT immunotherapy-related pruritus immutherapy immuuncheckpointremmers immuunrespons immuunsuppressie immuuntherapie IMPAC IMPACT impact of adjuvant regimes impact of adjuvant therapies on outcomes impact of advances in treatment impact of age impact of age and frailty impact of age at diagnosis on survival impact of age on melanoma response to bevacizumab impact of age on outcomes impact of age on outcomes of dual anti-HER2 therapy impact of alcohol and smoking and FRP impact of ancestry on frequency of actionable alterations impact of antibiotics impact of antiviral therapy for chronic hepatitis C impact of asparaginase discontinuation on outcome impact of attending surgeon impact of baseline body mass index impact of biopsy frequncy on metastasis and mortality impact of BMI impact of body composition factors impact of bone metastases impact of BRAF V600E K mutation status impact of breast cancer treatment on employment impact of breast screening programme on mortality in England impact of calcium channel blocker use impact of cancer on COVID-19 outcomes impact of care fragmentation on outcomes impact of celebrity’s disclosure of leukemia impact of center volume on outcomes of adverse events impact of centralization within hospital systems impact of cisplatin-based chemotherapy on risk of metachronous contralateral disease impact of Combined Positive Score impact of comorbidities on overall survival impact of concomitant antihypertensive medication impact of concomitant PPIs on survival impact of concurrent dexamethasone on clinical benefit impact of conditioning intensity impact of COVID-19 on treatment and short-term mortality impact of COVID-19 pandemic impact of cumulative exposure to premenopausal obesity impact of detailed family history impact of diet impact of disease stage impact of ECD impact of EGFR mutation and ALK rearrangement impact of epigenetics on association of aspirin use with mortality after breast cancer impact of ER status on survival impact of ET adherence impact of experimental molecular-matched therapies on cancer outcomes impact of facility caseload impact of facility surgical caseload volume on survival impact of FIT-screening on CRC incidence and outcomes in The Netherlands impact of follow-up time impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response impact of germline mutations impact of glycemic status impact of high TMB on response rates impact of HIV infection impact of hormone receptor status impact of ILD on outcomes of lung cancer surgery impact of imaging intensity on survival after systemic therapy impact of intratumoral Escherichia impact of low-dose aspirin impact of lower airway dysbiosis on progression impact of metabolic syndrome impact of moderate-to-vigorous intensity physical activity impact of molecular subtype and race impact of molecular subtypes on incidence and prognosis of CNS metastases impact of NST on postoperative complications impact of obesity impact of oophorectomy on breast cancer survival in patients with CHEK2 mutations impact of optimizing diagnostic workup and reducing time to treatment impact of overweight and obesity impact of overweignt and obesity impact of patient age impact of POD24 on survival impact of polypharmacy on AI adherence impact of poverty impact of pre-existing CVD on mortality impact of pregnancy on genomic landscape impact of primary tumor surgery impact of prior CT or RT on efficacy of durvalumab for NSCLC impact of prior or concurrent antibiotic therapy impact of prior ruxolitinib impact of prior therapy impact of prior treatment impact of prior treatments impact of probiotics use impact of race impact of race and age on response to NACT and long-term outcomes impact of race ethnicity impact of race ethnicity on OS impact of race on outcomes impact of race on outcomes of definitive RT impact of radiation facility volume impact of screening impact of screening on OPE diagnosis impact of solid cancer on in-hospital mortality impact of stewardship program impact of subtype on axillary pCR to neoadjuvant therapy impact of subtype on GKS outcomes impact of surveillance impact of T2D impact of the COVID-19 pandemic on new diagnoses of cancers impact of TP53 genomic alterations on CD19 CAR T-cell therapy impact of treatment modality on performance of prognostic factors impact of tumor size and high-risk features on chemotherapy benefit impact on antitumor immunity in cancer patients impact on breast cancer incidence and mortality impact on breast cancer risk impact on cancer risk in men impact on cancer stage at diagnosis impact on COVID-19 survival impact on CRC incidence and mortality impact on CRC screening rate impact on diagnosis and initial treatment of breast cancer in The Netherlands impact on Dutch lung cancer care impact on frequency of biopsy and tumor grade impact on functional age and mortality impact on long-term risk of morbidity impact on memory impact on metastatic behavior and outcome impact on OC risk in African American and White women impact on OS impact on outcome impact on outcomes impact on outcomes of durvalumab for NSCLC impact on patients’ treatment experience and treatment discontinuation impact on recurrence and survival impact on sexual function impact on short-term mortality impact on survival impact on survival and recommended treatment intensity impact on survival of cancer patients impact on survival of patients with cancer impact on treatment and survival of cancer patients impact on treatments for metastatic solid cancer in the USA IMPACT program IMPACT study Impact van timing van adjuvante chemotherapie voor vroeg-stadium mammacarcinoom IMPACT-studie IMPACT2 IMPARTER IMpassion031 trial IMpassion130 study IMpassion130 study updated results IMpassion130 trial IMPATTO study implementation of best practices in pancreatic care implications of minimal residual disease detection IMPORT LOW study IMpower010 IMpower010 study IMpower010 trial IMpower110 study IMpower130 trial IMpower132 trial IMpower133 Study IMpower133 updated analyses IMpower150 final overall survival analyses IMpower150 regimen IMpower150 study IMpower150 trial safety and PROs IMpower150-studie IMPRESS-studie IMPROVE study improvements in survival between 2009 and 2022 improvent over time in posttransplant outcomes improving PCa diagnosis IMPT IMROZ trial IMRT IMRT alone IMRT for HNC IMRT versus 3D-CRT IMRT versus 3DCRT for prostate cancer IMRT versus SBRT IMRT with or without cisplatin IMspire150 IMspire150 second interim analysis IMspire150 study IMspire150 trial IMT IMvigor130 study IMvigor211-studie in situ mammacarcinoom in utero chemotherapy exposure in utero exposure to maternal cancer in utero pembrolizumab exposure in-breast tumor recurrence in-hospital mortality in-transit metastatic melanoma INAVO120 trial inavolisib incidence incidence and mortality in England incidence and mortality of colon and lung and prostate cancer incidence and mortality of second primary cancers incidence and outcomes incidence and outcomes of lung cancer incidence and patterns of cancer incidence and predictors of diabetes mellitus incidence and predictors of SPCs incidence and risk factors incidence and survival among solid organ transplant recipients incidence and survival in the USA 1973-2015 incidence and survival outcomes incidence of adverse events with various therapies incidence of and mortality from malignancies after CIN treatment incidence of cancer incidence of cancer and CVD incidence of cancer diagnoses incidence of hypothyroidism incidence of pneumonitis incidence of recurrence 10-32 years after primary diagnosis incidence of recurrence and time to recurrence in Denmark incidence of relapse incidence of second primary melanoma incidence of subtypes incidence of T790M mutation in cfDNA incidence of thyroid cancer in WTC-exposed rescue workers incidence of vulvar precancerous lesions and cancer incidence of young adult cancers in Canada incidence trends incidence trends in Finland incidence trends of breast cancer molecular subtypes by age and race in the US incident breast cancer incident cancer incident cancer risk incident cardiovascular events incident comorbidities incident type 2 diabetes duration incidental pulmonary embolism in cancer patients incidentally detected lung nodules incidentally found pediatric brain tumors incidentie incidentie mammacarcinoom USA Incidentie van cardiovasculaire gebeurtenissen in ICI-behandelde patiënten incomplete pregnanacy increase since 2017 increased α-fetoprotein increasing dose intensity of chemotherapy INDAR indatuximab ravtansine independence independent roles indeterminate pulmonary nodules index lymph node individual and neighborhood-level SES individual oncogenic HPV types individual patient data meta-analysis individual patient-level analysis individual patient-level data meta-analysis individualised axitinib regimen individualized prognostic model indolent lymfoom indolent mammacarcinoom indolent MCL indoor tanning Indoor tanning industry indoximod indoximod plus pembrolizumab inductie-chemoradiatie inductiechemotherapie induction chemotherapy induction chemotherapy for AML induction chemotherapy for NPC induction CRT with or without sintilimab induction CT followed by CCRT induction CT followed by RT versus CRT induction CT followed by standard CRT induction toripalimab and chemotherapy infant lymphoblastic leukemia infants infectie infertility and risk of breast cancer in men infigratinib inflammatie inflammation inflammation and clinical decline inflammation cascade Inflammatoir mammacarcinoom inflammatoire voeding inflammatory and insulinemic dietary patterns inflammatory biomarkers and survival inflammatory blood markers inflammatory bowel disease inflammatory bowel disease and risk of adenocarcinoma and NETs in the small bowel Inflammatory breast cancer inflammatory markers inflammory tongue conditions and risk of oral tongue cancer in elderly patients infliximab INFLUENCE 2.0 model for improved risk estimations influenza vaccination influenza vaccine effectiveness among cancer patients influenzavaccinatie infradiaphragmatic disease infrared laser moxibustion inhaled corticosteroids INHANCE-consortium iNHL iniparib initial FOLFIRINOX INITIAL-1 trial INITIATE study iNNOVATE iNNOVATE-studie innovations in therapy InnovaTV 201 study innovaTV 204 study innovaTV 205 trial innovaTV 301 ENGOT-cx12 GOG-3057 InO INO-VATE studie inoperable endometrial cancer inoperable pancreatic cancer inoperable pleural mesothelioma immediate versus deferred systemic therapy inoperable stage I NSCLC inotuzumab ozogamicin INOVA trial inpatient care and outcomes inpatient versus outpatient administration INSIGHT 2 trial INSIGHT-studie insomnia inspanning INSPIRE study Institute of Cancer Research insulin resistance insulin-like growth factor insulin-like growth factor -1 insulinemie insulineresistentie intake of dietary fats intake of one-carbon metabolism-related micronutrients intake of whole grains and dietary fiber INTEGRATE INTEGRATE IIa study integrated palliative and oncology care INTELLANCE 2 study intellectual functioning intellectual outcomes INTENS-studie intense androgen deprivation before prostatectomy intensieve chemotherapie intensification of androgen blockade intensity of diagnostic evaluation intensity-modulated proton therapy versus intensity-modulated radiation therapy intensity-modulated radiation therapy intensity-modulated reirriation plus nivolumab intensive chemotherapy versus HMAs intensive therapy inter- and intra-laboratory variation Inter-B-NHL Ritux 2010 trial secondary analysis InterAAct interaction of Helicobacter pylori infection and HR genes interaction of leisure-time physical activity with BMI interaction of sexual orientation with race ethnicity Intergroup Exemestane Study interim OS analysis of MONARCH 2 interim PET interim PET CT predicts PFS intermediate endpoints intermediate endpoints as surrogates for OS intermediate recurrence score intermediate stage recurrent hepatocellular carcinoma intermediate- or high-risk GIST intermediate-risk AML intermediate-risk prostate cancer intermediate-stage hepatocellular carcinoma intermediate-stage uHCC intermittent nivolumab intermittent versus continous PEG-asparaginase intermitterende claudicatie internal mammary and medial supraclavicular irradiation internal mammary node irradiation International Breast Cancer Intervention Study I International Childhood Cancer Cohort Consortium International Male BC Program International Prognostic Index International Prognostic Score international variation in radiation dose international variation in survival internet-steunprogramma's interrupting endocrine therapy to attempt pregnancy after breast cancer interruption of adjuvant endocrine therapy interruption or noncompletion of chemoradiotherapy interstitial lung disease induced by HER2-targeting therapy for MBC interval and screen-detected breast cancers interval breast cancer interval cancers interval CRC incidence interval versus screening-detected breast cancers interval-compressed VDC IE-chemotherapy intervalcarcinomen intervals to diagnosis intra-tumor heterogeniteit intra-tumoral genomic heterogeneity in rectal cancer intracraniaal ependymoom intracranial efficacy of lorlatinib intracranial injection of NK cells engineered with a HER2-targeted CAR intracranial meningioma intracranial metastatic disease intracranial SFTs intractable serous ascites intraductal papillary mucinous neoplasms intraductale papillaire mucineuze neoplasie intraductale papillaire mucineuze neoplasmen intradural spinal hemangioblastoma intrahepatic cholangiocarcinoma intrahepatic cholangiocarcinoma risk intrahepatisch cholangiocarcinoom intraoperative frozen section analysis intraoperative peritoneal lavage intrapatient heterogeneity in enzalutamide response intraperitoneale chemotherapie intrathecal pemetrexed intrathecal trastuzumab intratumoral CD8 intratumoral F. nucleatum intratumoral immune infiltrate and prognosis intratumoral oncolytic herpes virus G47Δ intratumoral PVSRIPO intratumoral V937 plus ipilimumab intratumorale genetische heterogeniteit intratumorale genoomdiversiteit intrauterine devices intravenous and intracranial GD2-CAR T cell therapy intravenous high-dose methotrexate based therapy intravesical BCG vaccine intravitale microscopie INTRIGUE trial intrinsic subtype analysis of BOLERO-2 intrinsiek subtype intrinsieke subtypes intrinsieke subtypes mammacarcinoom INTUITT-NF2 invasieve borstkanker invasive breast cancer invasive breast cancer after non-screen detected DCIS invasive breast cancer risk invasive cervical cancer invasive cSCC risk invasive ductal carcinoma of the breast invasive fungal infections invasive lobular carcinoma of the breast invasive lobular carinoma of the breast invasive melanoma invasve breast cancer and breast cancer mortality after screen-detected DCIS INVICTUS trial invitation letter in language of origin invloed behandelcentrum op overleving involvement of dentists IO IO plus bosutinib iodine 131-refractory DTC iodine-131 apamistamab IOERT for early invasive ductal breast cancer IOHDR-BT IOLite trial IONESCO trial ioniserende straling iontoforese IORT IORT versus adjuvant SRT IOTA5 study IOUS IP IP1-PROSTAGRAM study iparomlimab (QL1604) ipatasertib ipatasertib plus abiraterone and prednisolone IPATential150 trial IPD meta-analysis iPDT IPH4102 ipilimumab ipilimumab and nivolumab ipilimumab every three versus twelve weeks plus nivolumab ipilimumab plus nivolumab ipilimumab plus nivolumab for desmoid tumors ipilimumab versus pembrolizumab ipilimumab with or without anti-PD-1 ipilimumab with or without T-VEC IPMN IPMNs ipsilateral axillary lymph node reactivity on imaging ipsilateral breast event ipsilateral breast tumor recurrence IPSS-M IPTT IR versus FCR irAEs irAEs and survival irAEs with ICIs IRd IRE irinotecan irinotecan dose irinotecan plus cetuximab with or without vemurafenib irinotecan-based nCRT IRIS irradiation for breast cancer iruplinalkib IS in stage III CRC Isa-Kd versus Kd Isa-KRd iSABR phase 2 trial ISARIC-CCP-UK isatuximab isatuximab fixed-volume infusion isatuximab-bortezomib-lenalidomide-dexamethasone isatuximab-VRd ISB ischemic cardiotoxicity iscocitraatdehydrogenase ISM isocitraatdehydrogenaseremmer isocitrate dehydrogenase 1-mutated glioma isocitrate dehydrogenase wild-type glioblastoma in young adults isoflavone intake isolated breast pain isolated synchronous colorectal peritoneal metastases isotretinoin itacitinib Italiaanse cultuur ITCC-050 study ITOMIC-001 studie iuESCC IV versus IP chemotherapy plus bevacizumab IVC filters IVF IVIG for HG IVMs ivonescimab ivonescimab plus etoposide and carboplatin ivosidenib ivosidenib plus azacitidine ivosidenib plus azacitidine versus placebo plus azacitidine IVY study IWDD ixazomib ixazomib maintenance ixazomib of placebo toegevoegd aan lenalidomide-dexamethason J-ALEX studie J-FAPP Study IV JACC-studie JACCRO CC-08 study JACCRO GC-07 study JACKPOT8 Part B JACOB study JAKARTA-2 studie jandus Janus Cohort JASPER study JAVELIN Bladder 100 JAVELIN Bladder 100 study JAVELIN Lung 100 JAVELIN Lung 200 study JAVELIN Merkel 200 study JAVELIN Merkel 200 trial JAVELIN Merkel 200-studie deel B JAVELIN ovarian cancer cohort JAVELIN Renal 100-studie JAVELIN Renal 101 study JAVELIN Renal 101 trial JAVELIN Renal 101 trial second interim analysis JAVELIN Solid Tumor studie JAVELIN Solid Tumor study mUC cohort two-year follow-up JAVELIN Solid Tumor Study NSCLC cohort JAVELIN Solid Tumor trial JAVELIN Solid Tumor trial mesothelioma cohort JCOG0203 trial JCOG0504-studie JCOG0910-studie JCOG0912 study JCOG1001-studie JCOG1007 study JCOG1109 NExT trial JCOG1202 trial JCOG1211 JFMC37-0801 study JGO JIPANG study JLSSG0901 trial JME-001 trial job-exposure matrices jodium-131 joint replacement. B-cell neoplasms JPHC nested case-control study JULIET long-term follow-up JULIET trial JULIET-studie JUPITER-02 JVDL study Kailuan study KAMILLA exploratory analysis kanker kanker bij kinderen kanker-immunotherapie kankerchirurgie kankerincidentie kankermortaliteit kankermortaliteit 2015 kankerpijn kankerrisico kankerrrisico kankersterfte kankersubtypes KARISMA study KARISMA trial KARMA study KATE2 study KATHERINE phase 3 study KATHERINE study katheter KC KCSG-HB19-14 KDD KdD versus Kd keratinocytcarcinoom keratinocyte carcinoma Keratinocyte Carcinoma Chemoprevention Trial keratinocyte carcinomas kerncentrales ketotifen KEYNOTE-001 KEYNOTE-001 (secundaire analyse) KEYNOTE-001 study KEYNOTE-006 KEYNOTE-006 study KEYNOTE-010 KEYNOTE-010 study KEYNOTE-012 KEYNOTE-013 and -170 KEYNOTE-017 study KEYNOTE-020 KEYNOTE-021 KEYNOTE-021 cohort G KEYNOTE-021 study KEYNOTE-022 study KEYNOTE-024 KEYNOTE-024 five-year outcomes KEYNOTE-028 KEYNOTE-028 and -158 KEYNOTE-028 and -158 pooled analysis KEYNOTE-028 and -158 studies KEYNOTE-028 studie KEYNOTE-028 study KEYNOTE-029 KEYNOTE-029 cohort C KEYNOTE-029 Part 1B long-term follow-up KEYNOTE-029 studie KEYNOTE-040 study KEYNOTE-040 study HRQOL analysis KEYNOTE-042 five-year outcomes KEYNOTE-042 study KEYNOTE-045 KEYNOTE-045 and KEYNOTE-052 long-term follow-up KEYNOTE-048 secondary analysis KEYNOTE-048 study KEYNOTE-048 subgroup analyses KEYNOTE-048 trial KEYNOTE-052 long-term oucomes KEYNOTE-052 studie KEYNOTE-055 KEYNOTE-057 KEYNOTE-057 cohort B KEYNOTE-059 studie KEYNOTE-061 exploratory analysis KEYNOTE-061 studie KEYNOTE-062 analysis KEYNOTE-062 phase 3 study KEYNOTE-086 cohort A KEYNOTE-086 cohort B KEYNOTE-087 KEYNOTE-100 study KEYNOTE-119 trial KEYNOTE-146 study KEYNOTE-158 KEYNOTE-158 study KEYNOTE-158 trial KEYNOTE-164 KEYNOTE-164 studie cohort B KEYNOTE-177 health-related quality of life analysis KEYNOTE-177 study KEYNOTE-177 trial final analysis KEYNOTE-180 study KEYNOTE-181 KEYNOTE-181 study KEYNOTE-189 studie KEYNOTE-189 study KEYNOTE-189 study 5-year outcomes KEYNOTE-189 trial final analysis KEYNOTE-199 study KEYNOTE-204 trial KEYNOTE-224 trial cohort 2 KEYNOTE-240 study KEYNOTE-355 KEYNOTE-355 PRO analysis KEYNOTE-355 trial KEYNOTE-361 KEYNOTE-394 KEYNOTE-407 KEYNOTE-407 final analysis KEYNOTE-407 study KEYNOTE-412 KEYNOTE-426 extended follow-up KEYNOTE-426 study KEYNOTE-427 cohort B KEYNOTE-427 study cohort A KEYNOTE-427 study cohort B KEYNOTE-495 KeyImPaCT KEYNOTE-522 study KEYNOTE-522 trial KEYNOTE-564 KEYNOTE-564 30-month follow-up KEYNOTE-564 trial KEYNOTE-567 KEYNOTE-585 KEYNOTE-590 study KEYNOTE-598 KEYNOTE-604 KEYNOTE-629 study KEYNOTE-671 KEYNOTE-716 KEYNOTE-716 DMFS results KEYNOTE-716 trial KEYNOTE-756 KEYNOTE-775 final analysis KEYNOTE-775 trial KEYNOTE-782 KEYNOTE-799 trial KEYNOTE-811 trial KEYNOTE-826 KEYNOTE-826 HRQOL analysis KEYNOTE-826 study KEYNOTE-942 KEYNOTE-966 trial KEYNOTE-A18 KEYNOTE-B10 KEYNOTE-B21 KEYNOTE-B61 Khorana-score Ki-67 Ki-67 labeling index Ki67 kidney cancer kidney disease in long-term survivors kidney function and cancer risk kidney stones and risk of RCC and UTUC kidney transplant recipients kidney transplantation kiemceltumor kiemceltumoren kinaseremmers kinderkanker KIT klachten aromataseremmers KLASS-01 studie KLASS-02-RCT klassiek Hodgkin lymfoom klein lymfocytair lymfoom kleincellig longcarcinoom kleincellig prostaatcarcinoom kleincellige longkanker kliernegatief mammacarcinoom klierpositief mammacarcinoom Klinische uitkomsten en gebruik van gezondheidszorg onder patiënten met Burkitt lymfoom KMT2A-rearranged ALL in infants KMT2A-rearranged or NPM1-mutant leukemia KMT2A-rearranged relapsed or refractory acute leukemia Know Your Tumor registry trial KO-TIP-001 trial koffie koffieconsumptie KOMET-001 trial Koos grade IV VS in young patients kosten behandeling HER2-positief MBC kosten van gezondheidszorg kosteneffectiviteit hematologische middelen kosteneffectiviteit screening KP-BSI KRAS KRAS allelic variants KRAS and BRAF mutations in stage II III colon cancer KRAS G12C mutated NSCLC KRAS G12C mutation KRAS G12C-mutated aNSCLC KRAS G12C-mutated NSCLC KRAS G12C-positive CRC KRAS mutation KRAS mutation positive rNSCLC KRAS p.G12C-mutated advanced pancreatic cancer KRAS variant status KRAS variant subypes KRAS wild-type mCRC KRAS-G12C mutant NSCLC KRAS-G12C mutated NSCLC with untreated CNS metastases KRAS-mutant metastatic colorectal cancer KRAS-mutatie KRAS-mutaties KRASG12C mutated NSCLC KRd versus R maintenance KRd versus VRd for newly diagnosed multiple myeloma KRISTINE study KRISTINE-studie KRYSTAL -1 study KRYSTAL-1 study KRYSTAL-1 trial KS KS with or without HIV infection KSHV-transmissie KTE-X19 CAR T-cell therapy KUNPENG study cohort 1 kwaliteit van leven L-COSY L-MIND study LA BCC LA CC LA dMMR colon cancer LA ESCC LA G GEJ adenocarcinoma LA HCC LA HNSCC LA M CSCC LA M PDAC LA M solid tumors la mUC in cisplatin-ineligible patients LA NPC LA NSCLC LA OSCC LA VSCC LA-CSCC LA-ESCC LA-HNSCC LA-NPC LA-NSCLC laag-moleculairgewicht heparine laag-vet voeding laaggradig glioom laaggradig niet-spierinvasief urotheelcarcinoom laaggradig sereus ovarium- of peritoneaal carcinoom laat recidief coloncarcinoom LABC labeled sodium fluoride PET CT laboratory prognostic scores LACC LACC trial final analysis LACE-Bio studies LACE-Bio-II study LACE-studie LAcSCC LADG LADG versus ODG LADG versus ODG for advanced gastric cancer LAEGSC LAFA-studie LAGC LAGC in elderly patients LAHNC LAM LAM-SA 2007 study LAMIS LAN Lancet Haematology Lange-termijn analyse van SBG 2004-1 studie lange-termijn follow-up van KEYNOTE-001 lange-termijn uitkomsten GeparQuinto langerhanscel histiocytose LAP07 LAPA and BRPA LAPACT study laparascopic versus open hemihepatectomy laparoscopic surgery for CRC laparoscopic versus open distal gastrectomy laparoscopic versus open gastrectomy laparoscopic versus open pancreatoduodenectomy laparoscopic versus open resection laparoscopic versus open surgery laparoscopic versus open total gastrectomy laparoscopie laparoscopische chirurgie laparoscopische hysterectomie laparoscopische ingreep laparoscopische resectie lapatinib LAPC LAPC mPC with associated pain LAPC-1 trial LARC LARC in older patients large B cell lymphoma large B-cell lymphoma large brain metastases large brain metastases from NSCLC large skull base meningiomas larotrectinib laryngectomy laryngectomy outcomes larynxcarcinoom larynxkanker larynxpreservatie Lasker Award LASRE randomized trial late alopecia late bone marrow relapse of B-cell ALL in children late cardiac adverse events late cardiac effects late distant recurrence late health outcomes late lower cranial neuropathy late mortaliteit late mortality in the North American CCSS versus the UK BCCSS late outcomes late radiation toxicity late recurrence late recurrence after liver resection late recurrence and second primary cancers late toxicity of moderately hypofractionated PBT versus IMRT late-onset anorectal disease late-onset cognitive impairment later-line atezolizumab later-line irinotecan and TAS-102 plus bevacizumab later-line nanvuranlat Lateral Node Study LATITUDE study LATITUDE-studie LAUNCH trial LAURA trial LAVC lazertinib lazertinib for CNS metastases LBCL LBCL in autoSCT ineligible patients LC LCH LCL161 LCMC3 study LCNEC LCS-6 KRAS LDCT lung cancer screening LDH response as prognostic biomarker LE LEA-studie lead time to recurrence leaflet versus film impact on understanding of GEP LEANer study LEAP-002 trial LEAP-004 study LEAP-005 study TNBC cohort LEAP-007 trial LEBS leefstijl leefstijl-geassocieerde maligniteit leefstijlfactoren leefstijlinterventies leeftijd left anterior descending coronary artery radiation dose left lung cancer left ventricular global longitudinal strain LEGEND-2 trial leighl leiomyomatose leiomyosarcoma leiomyosarcoom leisure-time physical activity lenalidomide lenalidomide and dexamethasone lenalidomide dose lenalidomide for hematological cancers lenalidomide maintenance lenalidomide maintenance after autologous hematopoietic stem cell transplantation lenalidomide maintenance versus observation lenalidomide plus eltrombopag lenalidomide plus obinutuzumab lenalidomide plus rituximab lenalidomide with or without EPO alfa LENPEM lenvatinib lenvatinib after atezolizumab plus bevacizumab lenvatinib after atezolizumab-bevacizumab lenvatinib after immunotherapy lenvatinib plus PD-1 blockade lenvatinib plus PD-1 inhibitor lenvatinib plus pembrolizumab lenvatinib plus pembrolizumab or everolimus versus sunitinib lenvatinib plus pembrolizumab salvage therapy lenvatinib plus toripalimab and chemotherapy lenvatinib with etoposide plus ifosfamide lenvatinib with or without pembrolizumab lenvatinib-pembrolizumab leptomeningeal disease leptomeningeal disease in metastatic melanoma patients leptomeningeal disease recurrence leptomeningeal metastases leptomeningeal metastases from EGFR-mutant NSCLC leptomeningeal metastases from NSCLC leptomeningeale ziekte letrozol letrozole letrozole compared to exemestane letrozole for early breast cancer letrozole maintenance therapy letrozole plus abemaciclib letrozole with or without bevacizumab letrozole with or without ribociclib leucine-rich repeating G-protein-coupled receptor 5 leukapheresis leukemia leukemia cutis leukemie leukemie in kinderen leukocyt-telomeerlengte leukocytenattractie leukocytosis leumie levensverwachting levercarcinoom levercelcarcinoom levercelkanker leverfunctie leverkanker levermetastasen levofloxacin prophylaxis of infection Leydig cell function LFS LGB AYACS LGG LGG before one year of age LGIN LGSC LGSOC Li-Fraumeni syndrome Li-Fraumeni syndroom liberal versus restrictive thresholds LibraT1 study LIBRETTO-001 long-term follow-up LIBRETTO-001 study LIBRETTO-001 updated results LIBRETTO-431 LIBRETTO-531 lichaamsgewicht lichaamslengte lichaamsomvang lichaamsvet lichaamsvetgehalte lichte keten-geassocieerd Fanconi syndroom lidocaïne lieu lifastuzumab vedotin life expectancy life expectancy free from major chronic diseases life expectancy of adult survivors of childhood cancer diagnosed between 1970 and 1999 lifestyle lifestyle and breast cancer risk lifestyle factors lifestyle factors and risk of MPN lifestyle intervention lifileucel lifirafenib ligating veins first versus arteries first light-chain amyloidosis limited e-Health literacy limited stage small-cell lung cancer limited-stage diffuse large B-cell lymphoma limited-stage plasmablastic lymphoma limited-stage small cell lung cancer LINC00472 lincRNA linked color imaging linperlisib linsitinib linvoseltamab Linxian NIT cohort LIP lip-SCC LIPI lipophilic statin use lipophilic statins liposarcoom liposomal irinotecan liposomal irinotecan versus topotecan lipoxygenases liquid biopsies for detecting MRD liquid biopsy liquid biopsy detected MSI-H liquid biopsy versus tissue biopsy liquid biopt tracking in surveillance liquide biopten liso-cel Listeria expressing mesothelin LITE risk model LITESPARK-004 LITESPARK-005 trial LITESPARK-013 study LITT liver cancer liver cancer mortality Liver Cancer Pooling Project liver cancer risk liver malignancies liver metastasis liver metastatic breast cancer liver or lung oligometastatic CRC liver resection for a cancer-related indication liver resection for malignancy liver resection versus nonsurgical treatments liver surgery for primary liver cancer liver transplant liver transplant for HCC liver transplantation liver transplantation after tumor downstaging liver-directed local therapy liver-only mCRC living alone and cancer mortality living donors living-donor liver transplant LL-mCRC LLPCa LLR versus RFA LM LM from HER2-positive BC LMB-2 LMD LMM LMR LMS-04 trial LN regression after NACT LNC-PATH score lncRNA expression lncRNAs LOAd703 plus chemotherapy lobaplatin versus cisplatin non-inferiority trial lobar versus sublobar resection lobectomie lobectomy lobulair carcinoom in situ lobulair mammacarcinoom lobular breast cancer local and systemic therapy local consolidative therapy local control local failure local recurrence local recurrence after complete resection local recurrence after transanal TME local therapy local treatment-related adverse effects localized bone or soft tissue sarcoma localized breast cancer localized GIST localized high-risk prostate cancer localized low- or intermediate-risk prostate cancer localized myxofibrosarcoma localized OPSCC localized pancreatic cancer localized pancreatic ductal adenocarcinoma localized PCa localized PDAC localized prostate cancer localized recurrent prostate cancer localized renal cell carcinoma localized small bowel adenocarcinoma localized TNBC localized versus advanced stage localizing recurrent prostate cancer locally advaced cervical carcinoma locally advanced adenocarcinoma of stomach or gastroesophageal junction locally advanced BCC locally advanced BCC after HHI locally advanced bladder cancer locally advanced breast cancer locally advanced cancer locally advanced cervical cancer locally advanced colon cancer locally advanced ESCC locally advanced esophageal cancer locally advanced esophageal squamous cell carcinoma locally advanced esophagogastric adenocarcinoma locally advanced G GEJ adenocarcinoma locally advanced gastric adenocarcinoma locally advanced gastric cancer locally advanced gastric or gastroesophageal cancer locally advanced HCC locally advanced head and neck squamous cell cancer locally advanced head and neck squamous cell carcinoma locally advanced HER2-negative breast cancer locally advanced HER2-positive BC locally advanced intrahepatic cholangiocarcinoma locally advanced large cell neuroendocrine carcinoma of the lung locally advanced laryngeal and hypopharyngeal cancer locally advanced laryngeal cancer locally advanced lung cancer locally advanced metastatic ALK-rearranged NSLC locally advanced non-small cell lung cancer locally advanced NSCLC locally advanced NSCLC not progressing after CRT locally advanced operable colon cancer locally advanced or metastatic ALK-positive NSCLC locally advanced or metastatic EGFR mutation-positive NSCLC locally advanced or metastatic ESCC locally advanced or metastatic melanoma locally advanced or metastatic non-squamous NSCLC locally advanced or metastatic nonsquamous NSClC locally advanced or metastatic NSCLC locally advanced or metastatic sarcoma locally advanced or metastatic UC locally advanced or recurrent metastatic cSCC locally advanced pancreatic adenocarcinoma locally advanced pancreatic cancer locally advanced pancreatic cander locally advanced pancreatic neuroendocrine tumors locally advanced prostate cancer locally advanced rectal cancer locally advanced rectal cancer not responding to preoperative CRT locally advanced squamous cell carcinoma of the head and neck locally advanced squamous cell lung cancer locally advanced unresectable hepatocellular carcinoma locally recurrent brain metastases locally recurrent breast cancer locally recurrent endometrial cancer locally recurrent NPC locally recurrent or metastatic HER2-positive breast cancer locally recurrent pancreatic cancer locally recurrent pancreatic cancer after resection locally recurrent PCa locally recurrent STS locally-advanced or metastatic HER2-positive cancers locally-advanced rectal cancer locatie locatie van overlijden LocoMMotion study locoregionaal recidief locoregional progression during neoadjuvant systemic therapy locoregional recurrence locoregional recurrence of breast cancer Locoregional recurrent rhabdomyosarcome locoregional treatment of primary tumor locoregionale behandeling locoregionally advanced HNSCC locoregionally advanced nasopharyngeal carcinoma locoregionally advanced NPC locoregionally advanced resectable CSCC-HN LOGICA trial LOH lokaaal-gevorderd rectumcarcinoom lokaal gevorderd prostaatcarcinoom lokaal gevorderd rectumcarcinoom lokaal recidiverend mammacarcinoom lokaal-gevorderd hoofd-halscarcinoom lokaal-gevorderd metastatisch mammacarcinoom lokaal-gevorderd rectumcarcinoom LOKON001 study LOLE lomustine lomustine plus temozolomide loncastuximab tesirine Long Island Breast Cancer Study Project long term VTE risk long-term adverse effects and complications long-term antiandrogen therapy long-term bone-modifying agents for bone metastases long-term cancer risk long-term cause-specific mortality long-term cerebrovascular changes long-term clinical outcomes long-term consequences long-term CRC risk long-term CRC risk after screen detected adenoma long-term CVD risk and all-cause mortality long-term disease-free breast cancer survivors long-term effects long-term efficacy and toxicity long-term follow-up long-term follow-up BIG 1-98 trial long-term follow-up KEYNOTE-012 long-term follow-up of CASSIOPEIA long-term follow-up of CD19-CAR T-cell therapy long-term follow-up of combination CAR T cell therapy long-term follow-up of FS long-term health outcomes long-term heart function long-term HRQOL long-term hypertension and cardiovascular toxicity long-term IHD risk long-term impact long-term local recurrence long-term mental health service utilization long-term morbidity long-term morbidity and mortality long-term mortality long-term neurocognitive and psychosocial outcomes long-term OPC survivors long-term oropharyngeal cancer survivors long-term outcomes long-term outcomes after first-line NIVO+IPI versus SUN long-term outcomes in Poland long-term outcomes of survivors long-term PROs following primary surgery versus radiotherapy long-term QOL long-term quality of life long-term responders long-term results long-term results OlympiAD study long-term risk of cardiovascular disease mortality long-term risk of CAS long-term risk of endocrine and metabolic diseases long-term risk of hospitalization long-term risk of infections long-term risk of infections associated with hospitalization long-term somatic disease risk long-term survival long-term survival with RT long-term survivors long-term survivors NHL long-term survivors of advanced melanoma treated with checkpoint inhibitor long-term survivors of childhood cancer long-term survivors of cisplatin for testicular cancer long-term survivors of IDH-wildtype glioblastoma long-term survivos of childhood cancer long-term thyroid cancer risk longadenocarcinoom longcarcinoom longer interval between first colonoscopy with negative findings for CRC and repeat colonoscopy longer intervals after negative low-dose CT result longfunctie longitudinal analysis of fatigue and anxiety and quality of life longitudinal analysis of HRQOL longitudinal ctDNA analyses longitudinal impact of surgery on HRQOL longitudinal monitoring of ctDNA longkanker longkanker-screening longkankerchirurgie longkankerscreening longmetastasen LORELEI study lorlatinib lorlatinib after second-generation ALK TKI lorlatinib serum concentrations lorlatinib versus crizotinib loss of CEACAM1-expression loss of HER2-positivity after neoadjuvant therapy loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer loss of heterozygosity 1p and 16q loss of life expectancy LOTIS-2 study LOTUS trial LOTUS-studie low cT3 4 rectal cancer low dose radioiodine ablation low grade and anaplastic glioma low grade glioma low rectal cancer low skeletal muscle mass low- and high-fat dairy intake low- or intermediate MDS low- or intermediate risk prostate cancer low- versus high-dose 5-fluorouracil low-carbohydrate diets low-dose aspirin low-dose aspirin use low-dose bisphosponates or denosumab low-dose dasatinib low-dose erlotinib low-dose immunotherapy low-dose lenvatinb plus anti-PD-1 therapy low-dose metronomic versus conventional chemotherapy low-dose tamoxifen low-dose tamoxifen for mammographic density reduction low-dose versus standard-dose olanzapine low-grade and anaplastic gliomas low-grade glioma low-grade glioma in children low-grade serous OC low-grade upper tract urothelial carcinoma low-intensity chemotherapy low-intensity regimens Low-PV study low-risk BD-IPMNs low-risk breast cancer low-risk cervical cancer low-risk CRC symptoms low-risk early-stage breast cancer low-risk HPVOPC low-risk meningioma low-risk NPC low-risk prostate cancer low-risk PTC low-risk thyroid cancer low-stage low-grade EEC low-tumor burden FL low-volume mHSPC lower extremity lymphedema lower-risk MDS lower-risk myelodysplastic syndromes lowering recommended CRC screening age in Canada LP LPHL LPL LPPG LPS LR-ESHAP LR-HL LR-MDS LR-MDS with thrombocytopenia lraNPC LRBC LRC LRPC LRR LRR after breast cancer treatment LRRs detected at routine and interval visits LS LS SCLC LS SCLC in elderly patients LS-SCLC LSCC LSNNS versus LSG LTL LTLD LTSC trial Lu-177 for metastatic castration-resistant prostate cancer Lu-177-octreotate peptide radionuclide therapy for NETs Lu-PSMA-617 versus cabazitaxel LUAD LUAD with LM LUAD-LM LUME-Meso studie LUMINA trial luminal A breast cancer luminal B luminal B breast cancer luminal B HER2 negative breast cancers LUMINOSITY trial lumpectomy for early breast cancer lumpectomy without RT in elderly women LUN 14-179 study LUNA-studie lung adenocarcinoma lung adenocarcinoma brain metastases lung adenocarcinoma with CNS metastases lung and colorectal cancer lung and gastrointestinal cancers lung ASC lung cancer lung cancer brain metastases lung cancer breath biomarkers lung cancer incidence lung cancer incidence in young women versus young men in 40 coutnries lung cancer mortality lung cancer mortality among never smokers lung cancer patients in France lung cancer patients of Institut Curie lung cancer resection lung cancer risk lung cancer screening lung cancer screening efficacy lung cancer stage at diagnosis lung cancer surgery lung cancer survival lung cancer survivors lung cancer-associated T cell repertoire as biomarker for early detection of stage I lung cancer lung nodule progression to cancer lung oligometastases lung squamous cell carcinoma Lung-MAP S1800A Lung-MAP SWOG S1400 LUNGCA-1 study LungMate 002 trial LUNGSTAR LuPSMA LuPSMA-studie lurbinectedin lurbinectedine LUSC luspatercept luspatercept versus epoetin alfa LUSTRE trial lutathera lutetium-177 PSMA-617 versus cabazitaxel lutetium-177-PSMA-616 lutetium-177-PSMA-617 LUX-Lung 8 trial LUX-Lung3; LUX-Lung6 LV-V5 LVI LY3039478 LY3127804 with or without ramucirumab lycopeen LYM-3002 LYM-3002 study LYMA trial LyMa-101 study lymfadenectomie lymfekliermetastasen lymfeklierpositiviteit lymfoblastisch non-Hodgkin lymfoom lymfocyten lymfocyteninfiltratie lymfoedeem lymfoïde neoplasie lymfoom lymph node burden lymph node irradiation in breast cancer lymph node ITCs in endometrial cancer patients lymph node macrometastases lymph node metastasis lymph node ratio lymphadenectomy lymphatic versus hematogneous dissemination lymphaticovenous anastomosis lymphedema lymphocyte doubling time in CLL lymphoid blast phase of CML lymphoid cancers lymphoma lymphoma patients aged ≥85 years Lymphome Malin de Burkitt chemotherapy lymphopenia lymphoplasmatcytic lymphoma Waldenström macroglobulinemia lymphoscintigraphy Lynch syndrome Lynch syndrome associated cancers lynch syndroom Lynch syndrooom LYRA study M-trap MA.17R MA.17R-studie MA.27 MA.32 randomized clinical trial maag maag-slokdarmovergangkanker maag-slokdarmadenocarcinoom maagadenocarcinoom maagcarcinoom maagkanker MaBC MaBC risk MaBC with positive sentinel nodes MabEase-studie MABLE-studie MACBETH-studie MACE machine learning model to predict undectable minimal residual disease and survival machine-learning risk prediction model for mesothelioma machine-learning-directed clinical evaluation of RT and CRT patients MACRO2 TTD study MAESTRO study Magee Equation 3 MAGIC-studie magnesium magnesiuminname MagnetisMM-1 trial MagnetisMM-3 trial MAGNITUDE trial MAGNITUDE trial second interim analysis Magnolia trial magrolimab plus azacitidine MAIA frailty subgroup analysis MAIA study MAIA trial main-duct intraductal papillary mucinous neoplasms maintenance maintenance pembrolizumab after first-line chemotherapy maintenance rituximab maintenance therapy maintenance treatment maintenance with or without pembrolizumab maitenance chemotherapy MAJA study MAJA-studie MajesTEC-1 trial MAJIC-PV trial major adverse cardiovascular events major head and neck surgery MALDI-MS male BRCA mutation carriers male breast cancer male breast cancer after Hodgkin lymphoma male breast cancer survivors male excess risk of advanced colorectal neoplasms male germ cell cancer treatment male patients male pattern baldness male sex disease-specific mortality MALE study male-pattern baldness malignant glioma malignant gliomas malignant lymphoma malignant melanoma malignant mesothelioma malignant pheochromocytoma and paraganglioma malignant pleural disease malignant pleural effusion malignant pleural mesothelioma maligne ascites maligne glioom maligne pleura mesothelioom maligne pleuraal mesothelioom Malmö Breast Tomosynthesis Screening Trial Malmö Diet and Cancer Study malnutrition in older adults with gastrointestinal malignancies MALT lymfoom MALT-IPI MALT-lymfoom mamacarcinoom mammacarcinoom mammacarcinoom in mannen mammacarcinoom mannen mammacarcinoom; SABCS 2015 mammacarcinoom. lichaamsgewicht mammacarcinoomscreening mammacarcinooom mammacarcionoom mammacarcioon MammaPrint MammaPrint-assay mammografie mammografiescreening mammographic density mammographic microcalcifications and breast cancer risk mammographic surveillance in young women mammography mammography breast cancer screening in high-risk males mammography screening mammograpic screening MAN management and outcomes managing oral complications of oral cavity and oropharyngeal cancer mandibular preservation MANHATTAN trial MANIFEST trial mannen Mannuci mantelcellymfoom mantle cell lymphoma mantle cell lymphoma in younger patients manual therapy MAPPYACTS MAPS IFCT-GFPC-0701 study MAPS2-studie MARCH margetuximab margetuximab plus pembrolizumab margin status and survival outcomes marginaal zone lymfoom marginal zone lymphoma MARIANNE study final results MARIE study MARIE-cohort marihuana marijuana use MARIPOSA trial marital status marizomib marker borstkanker MARQUEE study MARS mutation-adjusted risk score MARTA trial MASAI trial masitinib MasSpec Pen MAST study mastectomie mastectomy for breast cancer in males versus females mastectomy for clinical N0 SLN-positive breast cancer mastectomy versus lumpectomy plus RT mastectomy with IBR mastectomy with immediate breast reconstruction after NACT in young women with breast cancer MASTER trial matched sibling donor transplantation matched sibling transplantation matched therapy MATCHPOINT trial MATE-1 inhibiting TKIs maternal and fetal outcomes maternal breast cancer risk maternal cancer during pregnancy maternal infection during pregnancy maternal obesity during pregnancy MATISSE-studie MATRix induction matrix metalloproteïnase-8 MATRix regimen followed by ASCT or WBRT mature B-cell malignancies MAVORIC study MAVORIC-studie MaxRP MaxRT MAYA trial MBC mBC after endocrine therapy mBC in elderly women mBC in older patients and patients with comorbidities MBC in real-world patients MBC in Swedish patients MBC with high TMB mBC with variable HER2 expression mBCC MBI MBL MBM MBMs MBO in advanced cancer patients mBTC MC1631 trial MCC MCC-Spain follow-up study mccRCC mCDC MCL MCL in older patients MCL in young patients MCL in younger patients MCL Younger trial long-term follow-up mCRC mCRC after failure of FOLFOX-bevacizumab mCRC extremes of survivorship mCRC with KRAS G12C mutation mCRC with response or stable disease with 16 weeks first line treatment mCRPC mCRPC and DRDs mCRPC in DDRmut patients mCRPC in older patients mCRPC taxane after radium-223 mCRPC with or without PTEN-loss mCSCC mCSPC MD MDNA55-05 study MDS MDS and CMML MDS and sAML MDS or AML MDS-EB-1 or EB-2 MDS-RAEB or secondary AML MDT MDTB meat consumption meat intake mebendazol MEC mechanisms of resistance to BRAF-targeted therapy MED10562 MEDALIST study MedCan1-CBD study median 15.7 years follow-up mediating factors mediation analysis of racial disparities medical decision-making capacity medically diagnosed postnatal infection medication interactions medication-associated phthalate exposure and childhood cancer incidence medication-related osteonecrosis of the jaw MEDIOLA study medische marihuana mediterrane voeding MEDITREME trial medium-sized brain metastases medium-throughput drug screening MEDOCC medullair schildkliercarcinoom medullair thyroïdcarcinoom medulloblastoma medulloblastoma subgroups medulloblastoom meeroken mEGA MEI MEK- plus AKT-remming MEK-remmers MEK-remming Mel-Ipi-Rx study melanoma melanoma after SLNB melanoma brain metastases melanoma brain metastasis melanoma CNS metastases melanoma detection melanoma in adolescents and young adults melanoma in children and adolescents melanoma in situ melanoma in-transit metastases melanoma incidence Melanoma Institute Australia nomogram melanoma metastatic to the adrenal gland melanoma of unknown primary melanoma survival melanoma trends in Sweden melanoma with CNS metastases melanoma with LMD melanoma with rare BRAF mutations melanoom melanoom-geassocieerde leucoderma melanoom-mortaliteit melanoomrisico melatonin after lung cancer resection melatonine MelBase French cohort melfalan melflufen plus dexamethasone melkconsumptie MEMMAT MEMOIR study Memorial Sloan Kettering Cancer Center nomogram men with germline BRCA1 and BRCA2 pathogenic variants MEN1 Mendelian randomisation analysis Mendelian randomization study menigioma risk following treatment for childhood cancer meningioma meningioma in patients exposed to progestin drugs meningioma risk factors meningiomas of the confluence of falx and tentorium meningioom menopausal hormone therapy menopausal hormone therapy options menopauzale hormoontherapie mental disorders mental health mental health care utilization mental health disorders mental health disorders and survival mental health of mothers and siblings mental health resource use mental health service users mental health symptoms and chemotherapy toxicity mentale stoornis mepitel film Merkel celcarcinoom Merkel cell carcinoma Merkel cell carcinoma of unknown primary cutaneous lesion Merkelcelcarcinoom MESCC mesenchymal stem cells for cGVHD prophylaxis mesenchymal stromal cells mesothelin-targeted CAR T cells mesothelioma mesothelioom mestcel-neoplasmata MET exon 14 altered lung cancer MET exon 14 skipping in NSCLC MET exon 14-altered NSCLC MET exon 14-mutated or MET-amplified NCSLC MET-amplificatie MET-driven metastatic papillary RCC MET-dysregulated NSCLC MET-mutated aNSCLC meta-analysis meta-analysis of outcomes meta-analysis of studies of immunotherapy for NSCLC metabole gezondheid metabolic and cardiac and bone health testing metabolic dysregulation metabolic health metabolic syndrome metabolic syndrome biomarkers metabolomic biomarkers of cancer metabool syndroom metachronous CLMs after chemotherapy for stage III CRC metachronous contralateral testicular cancer MetaPHER study metastase metastasectomie metastasering metastasevrije overleving metastasis sites metastasis-directed therapy metastasis-free interval metastatic biliary tract cancer metastatic brain tumors metastatic breast cancer metastatic breast cancer in BRCA-mutated patients metastatic breast cancer in geriatric patients metastatic cancer metastatic cancers metastatic cardiophrenic lymph nodes metastatic castration resistant prostate cancer metastatic castration-naïve prostate cancer metastatic castration-resistant prostate cancer metastatic castration-resistant prostate cancer with DNA repair defects metastatic castration-sensitive prostate cancer metastatic clear cell RCC metastatic colorectal cancer metastatic colorectal cancer cetuximab plus FOLFOX-4 metastatic colorectal cancer in older vulnerable patients metastatic CRC and other cancers metastatic CRC and other solid tumors with KRAS G12C mutation metastatic desmoplastic melanoma metastatic disease at diagnosis metastatic EGFR-mutated NSCLC after TKI failure metastatic endometrial cancer metastatic esophagastric cancer metastatic esophageal cancer metastatic esophagogastric adenocarcinoma metastatic esophagogastric cancer metastatic gastric and gastroesophageal junction adenocarcinoma metastatic gastric cancer metastatic gastric or gastroesophageal junction cancer metastatic gastric or junctional adenocarcinoma metastatic gastrointestinal stromal tumors metastatic gastrointestinal tract cancer metastatic HER2-positive breast cancer metastatic hormone sensitive prostate cancer metastatic hormone-sensitive prostate cancer metastatic intracranial lesions metastatic intrahepatic cholangiocarcinoma metastatic lung NEC metastatic lung tumors metastatic melanoma metastatic melanoma after failure anti-PD-1 therapy metastatic melanoma after ICIs and targeted agents metastatic melanoma and NSCLC metastatic melanoma of the heart metastatic Merkel cell carcinoma metastatic MSI-H dMMR CRC metastatic mucosal melanoma metastatic nasopharyngeal carcinoma metastatic non-small cell lung cancer metastatic non-squamous NSCLC metastatic nonseminomatous germ cell tumors metastatic nonsquamous NSCLC metastatic or inoperable locally advanced DDLPS metastatic or persistent or recurrent cervical cancer metastatic osteosarcoma metastatic pancreatic adenocarcinoma metastatic pancreatic cancer metastatic pancreatic ductal adenocarcinoma metastatic papillary renal cell carcinoma metastatic papillary thyroid cancer metastatic prostate cancer metastatic prostate cancer incidence metastatic prostate cancer patients metastatic renal cell carcinoma metastatic seminoma metastatic soft tissue sarcoma in patients aged 60 years or older metastatic soft-tissue sarcoma metastatic solid tumors metastatic spinal canal compression metastatic squamous cell carcinoma of head and neck metastatic squamous cell carcinoma of the anal canal metastatic squamous non-small cell lung cancer metastatic squamous NSCLC metastatic thyroid cancer metastatic triple-negative breast cancer metastatic unresectable STS metastatic urothelial carcinoma metastatic urothelial carcinoma in cisplatin-unfit patients metastatic uterine leiomyosarcoma metastatic uveal melanoma metastatisch castratieresistent prostaatcarcinoom metastatisch cervixcarcinoom metastatisch colorectaalcarcinoom metastatisch colorectaalkanker metastatisch colorrectaalcarcinoom metastatisch heldercellig niercelcarcinoom metastatisch maagcarcinoom metastatisch mammacarcinoom metastatisch melanoom metastatisch niercelcarcinoom metastatisch niet-castratieresistent prostaatcarcinoom metastatisch pancreas ductaal adenocarcinoom metastatisch pancreascarcinoom metastatisch PDAC metastatisch potentieel metastatisch prostaatcarcinoom metastatisch squameus celcarcinoom van hoofd en hals metastatische borstkanker metastatische botziekte metastatische castratieresistente prostaatkanker metastatische colorectaalkanker metastatische niet-kleincellige longkanker metastatische prostaatkanker metastatische triple-negative borstkanker metastic castration-sensitive prostate cancer metastic melanoma progressing on anti-PD-1 METEOR METEOR trial analysis METEOR-studie METEORA-II trial METex14-positive pulmonary sarcomatoid carcinomas and other NSCLC-subtypes metformin metformin plus CRT metformin plus irinotecan metformin use metformine methionine methotrexate methotrexate neurotoxicity metronome chemotherapie metronomic chemotherapy metronomic chemotherapy plus toripalimab metronomic cyclophosphamide-methotrexate with or without bevacizumab metronomic eribulin metronomic methotrexate-celecoxib-erlotinib metronomic oral vinorelbine plus trastuzumab MetroPancreas model to predict futility of upfront resection for PDAC METROS study MetS MetS scores trajectory patterns mezigdomide plus dexamethasone MF mFOLFOX6 MFS mGC mGCT mGEA after progression on ICI MGMT promoter methylation mGPS MGPT MGUS MHD mHNSCC mHSPC MHSs MHT MHT and ovarian and endometrial cancer risk MIA calculator for predicting RFS and OS MIBC MIC-1 microductectomy microRNA-203 microRNA-371a-3p test microRNA-classifier microRNAs microRNAs as biomarkers and radiosensitivity modifiers microsatelliet-instabiele kanker microsatellite instability microsatellite instability-high advanced endometrial cancer microsatellite instability-high gastric or gastroesphageal junction cancer microsatellite instability-high mCRC microsatellite instability-high mismatch repair deficient tumors microsatellite instability-high mismatch repair-deficient mCRC microsatellite instability-high solid tumors microsatellite-instability-high advanced CRC microsatellite-stable mismatch repair-proficient mCRC microvascular invasion microwave ablation mIDC middel-heupomtrekverhouding middelomtrek middelomvang middle low rectum versus left-sided colon middle-aged and older adults midgut NETs midline low-grade gliomas of early childhood migraine migratie naar hersenparenchym mILC MILD trial MILES-3 MILES-4 Miller-Payne score million women study MILO ENGOT-ov11 study MILS MIMOSA-1 study MINDACT MINDACT trial MINDACT trial post-hoc analysis mindfulness mindfulness-based cognitive therapy mini-mental state examination minimal access breast surgery versus conventional breast surgery minimal invasive secondary cytoreduction minimal invasive versus open liver resection minimal residual disease minimal residual disease status minimally invasive robotic surgery minimally invasive surgery minimally invasive versus open radical hysterectomy minimally invasive versus open surgery minoxidil MIPS versus OPS mipsagargin MIPSS70 miR-126 miR-190b miR-34 miR-345 miR-506 MIRACLE trial MIRAGE trial MIRASOL trial mirdametinib mirdametinib (PD-0325901) miRNA miRNA as independent prognostic marker miRNA signature miRNA-based signature for early detection of gastric cancer miRNAs MIRO trial MIRO-studie MIRV mirvetuximab soravtansine mismatch repair deficient small bowel adenocarcinoma mismatch repair genes pathogenic variants mismatch repair status mismatch repair-deficient LARC MiST2 trial mitazalimab plus mFOLFIRINOX Mitchell MITCI study MITCI-studie MITNEC-A1 trial MITO END-3 MITO-8 studie MITO-9 study mitochondrially targeted tamoxifen mitomycin C mitosesnelheid mitotische activiteitsindex mitoxantrone MIUC mivebresib with or without venetoclax MK-2206 MK-3475 MK-4166 with or without pembrolizumab MK-6482 MK-6482-004 trial ML MLBO MM MM and AL amyloidosis MM before age 41 years MM in octogenarians MM-302 mMCC mMGMT MMR MMR-D noncolorectal cancers MMR-deficiency MMR-deficient or hypermutated gynecological cancer MMR-deficiëntie MMRd MMRP EC MMS vs WLE MMSE mNPC mNSCLC mNSCLC after ICI and chemotherapy mNSCLC in patients aged 80 years and over mNSCLC with atypical EGFR mutations mNSCLC with high expression PD-L1+ mNSCLC with PD-L1 TPS≥50% mNSCLC with PD-L1 tumor proportion score ≥1% mNSCLC with uncommon EGFR mutations mNSCLCwith PD-L1 tumor proportion score ≥ 50% mnsqNSCLC with high TMB MNTX mobility program for hospitalized patients with cancer mobocertinib mode of detection mode of progression model for predicting acute complications after surgery for breast cancer model for predicting individualized outcomes modelling study of cost-effectiveness of various mammography screening strategies moderately hypofractionated helical IMRT moderately hypofractionated IMRT modern chemotherapy modern treatments for newly diagnosed lymphoma Moderna vaccine in patients receiving systemic therapy for solid tumors modifiable risk factors for early ET discontinuation mogamulizumab Mohs micrographic surgery for T1a-T2a invasive melanoma Mohs surgery versus wide margin excision moleculaire subtypen moleculaire tumormarkers molecular analysis molecular classification molecular classification and recurrence risk molecular expression assays molecular features and outcomes Molecular International Prognostic Scoring System for Myelodysplastic Syndromes molecular markers of prognosis molecular markers of recurrence molecular pahtological subtypes and pathways molecular predictors of response to neoadjuvant therapy molecular profiling molecular profiling for assessment of distant metastasis risk molecular recurrence molecular relapse detection molecular residual disease molecular risk stratification molecular subtype molecular subtypes molecular subtypes of breast cancer molecularly-defined diffuse glioma types Molina MOLTO trial momelotinib MOMENTUM trial MONALEESA studies exploratory analysis MONALEESA-2 MONALEESA-2 OS analysis MONALEESA-2 studie MONALEESA-3 OS analysis MONALEESA-3 overall survival analysis MONALEESA-7 studie MONALEESA-7 trial MONALEESA-7 update monalizumab plus durvalumab MONARCH 1 MONARCH 1-studie MONARCH 2 study MONARCH 2 trial premenopausal subgroup analysis MONARCH 2-studie MONARCH 3 trial MONARCH 3-studie monarchE study monarchE trial monarchE trial analysis monarcHER trial mondholte squameus celcarcinoom mondholtecarcinoom mondhygiëne mondkanker monitoring of ctDNA in CSF monoclonal antibody combined with induction chemotherapy monoklonale B-cel lymfocytose montelukast and rupatadine premedication Moore-criteria MOR202 morbidity and mortality morcellatie morphomics and survival mortaliteit mortaliteit colorectaalcarcinoom mortaliteit na kankerdiagnose mortality mortality after breast cancer mortality after late recurrence mortality after PCa diagnosis mortality and chronic health conditions mortality and overall survival trends mortality as function of age mortality due to cancer treatment delay mortality from unrelated causes mortality prediction by Oncotype DX mortality rates mortality risk mortality trends mortality trends in multiple myeloma after introduction of novel therapies in the USA mortalteit MOSAIC MOSAIC trial post hoc analysis mosunetuzumab MOTION trial moxetumomab pasudotox mPaC mPanNET mPC mPCa mPDAC MplBC MPM mpMRI MPN MPNs MPNs treated during pregnancy MPPGs MPR mPRC mPTC MR analysis mRCC mRCC histologic varants MRCLS MRD MRD and clinical outcomes MRD at EOC MRD dynamics MRD response and prognosis MRD response-adapted Dara-KRd therapy MRD status MRD-guided stop and start of venetoclax plus ibrutinib MRD-negative ALL in adult patients MRD-status MRD-stratified treatment MRE11 expression and mortality mRECIST objecte response MRg-A-SBRT MRI MRI background parenchymal enhancement MRI of ultrasonography for prostate concer screening MRI plus targeted biopsy versus systematic biopsy alone MRI staging of breast camcer MRI surveillance and breast cancer mortality MRI versus conventional endoscopy MRI- versus CT-guided SBRT MRI-based versus PSA-based PCa screening MRI-detected additional lesions MRI-FIRST study MRI-guided adaptive brachytherapy MRI-guided biopsy to verify pCR MRI-guided focused ultrasound focal therapy MRI-guided or standard biopsy MRI-guided salvage focal cryoablation MRI-screening MRI-screening mammacarcinoom MRI-targeted versus systematic versus combined biopsy MRLN region sparing RT mRNA-4157 vaccine plus pembrolizumab MRONJ MS2010 study MSC MSCC mSCLC MSE MSG-carcinomen MSI MSI dMMR mCRC MSI mCRC MSI-CRC MSI-H dMMR CRC MSI-H dMMR gastrointestinal tumors MSI-H dMMR mCRC MSI-H mCRPC MSLCs MSLT-II studie msRCC MSS and MGMT-silenced mCRC MSS colorectal cancer and pancreatic ductal adenocarcinoma mss CRC MSS CRC after chemotherapy MSS LARC MSS mCRC MSS metastatic colorectal cancer MT-GCT MTC mtDNA mtDNAfb mtFIT versus FIT MTH1-remmers MTL-CEBPA mTNBC mTOR-remmer mTOR-remmers mUC mUC after platinum-based chemotherapy mUC and other genitourinary tumors mUC in patients with renal insufficiency or mixed variant histology mUC progressing after chemotherapy and ICIs MUC16 mutations mucosa-associated lymphoid tissue lymphoma mucosaal melanoom mucosal melanoma mucosalaesies mucositis mucositispijn MUIC mulitpel myeloom Müllerian carcinoom multi-antigen targeted T cells multi-cancer detection and localization multi-cancer early detection test multi-gen panel testing HBOC multi-organ irAEs multicenter randomized phase 2 NeoTrio trial multidisciplinary salvage treatment multidrugresistentie Multiethnic Cohort Multiethnic Cohort Study multifocal iCCA multigene testing for all patients multikinase inhibitors multimodal therapy multimodal treatment multimodality management multimodality therapy multimorbidity multinational post registration study of nivolumab multipel myeloom multipel myeloom. KTd multipele endocriene neoplasie multiple brain metastases multiple foci of microinvasion multiple myeloma multiple myeloma refractory to CD38 MoABs multiple myeloma survival multiple primary melanoma multiple primary melanoma incidence multiple sclerosis multitarget stool RNA test for screening MULTOMAB study mUM MUP MURANO study MURANO study 4-year results MURANO-studie muscle mass muscle radiodensity muscle-invasive bladder cancer musculoskeletal burden mutatiescreening mutatievolgorde mutation burden mutation clearance mutation profiling mutation status and prognosis mutation-enhanced prognostic system mutational profile mutational signature changes mutational signature in colorectal cancer mutations associated with high-grade irAEs mutations in cancer-associated genes mutations in cancer-related genes mutations in homologous recombination-related genes mutp53 proteins muziektherapie MVAC MVD and MCD MVI MVPA MWA versus LR MYC MYC deregulated cancers MYC rearrangement and translocation partner Myc-remming MyCARe model MYCN mycobacterial infections mycosis fungoides mycosis fungoides and Sézary syndrome mycosis fungoides cutaneous T-cell lymphoma myelodysplasie myelodysplastic syndrome myelodysplastic syndromes myelodysplastic syndromes and chronic myelomonocytic leukemia myelodysplastic syndromes refractory to hypomethylating agents myelodysplastisch syndroom myelodysplastisch syndroom myeloproliferatieve neoplasmen myelodysplastische syndromen myelofibrose myelofibrosis myelofibrosis patients with anemia myeloid cancers myeloid malignancies myeloid neoplasms after allogeneic versus autologous HCT myeloïde neoplasie myeloma Myeloma X trial Myeloma XI study Myeloma XI trial myeloom myelopreservation with trilaciclib myeloproliferatieve neoplasmen myelosuppression with chemotherapy for extensive-stage SCLC MYL-14010 myocarditis myomectomie MyPathway MyPathway study MyPathway-studie MYSTIC study myxofibrosarcoma myxoid liposarcoma MZL MZL-IPI n-3 fatty acids N-cadherine N-terminal-pro-B-type natriuretic peptide N107C CEC.3 trial N1087-studie N2-3 breast cancer N2-3 NPC N3 stage IIIB NSCLC in elderly patients N3C NA-PHER2 studie Naakte molrat nab-paclitaxel nab-paclitaxel after taxanes nab-paclitaxel plus gemcitabine nab-paclitaxel plus gemcitabine dose-reduction strategy nab-paclitaxel plus gemcitabine plus cisplatin nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine nab-paclitaxel versus paclitaxel nab-sirolimus nabiximols oromucosal spray NABON Breast Cancer Audit NABPLAGEM NAC NAC for BC NAC for breast cancer NACATRINE trial nachtarbeid NACI study NACRT versus NACT NACT NACT and IDS with or without HIPEC NACT versus PCS NACT-induced immune microenvironment changes NADIM II trial NADIM study NADIM trial nadofaragene firadenovec nadunolimab plus chemotherapy naevi NAG naI-IRI plus FU and LV naive T-cell depletion NALA study NALA study health-related quality of life analysis NALA trial naldemedine NALIRIFOX naming of cancers needs to change nanoparticle-assisted axillary staging after NAC for pretreatment node-positive breast cancer nanoparticles nanotechnologie nanvuranlat NAPOLI 3 trial NAPOLI-1 study naporafenib plus trametinib narsoplimab NAS nasofarynxcarcinoom nasopharyngeal cancer nasopharyngeal carcinoma nasopharyngeal carcinoma early detection NAST in geriatric breast cancer patients NATALEE trial Natalie Trial NATION-1907 trial National Breast and Cervical Cancer Early Detection Program National Cancer Data Base National Cancer Database analysis national health expenditure National Institute for Health and Care Excellence National Lung Cancer Screening Trial secondary analysis natriumthiosulfaat natural history and prognostic factors natural killer natural killer T-cel lymfoom natural killer T-cell lymphoma navicixizumab plus paclitaxel NAVIGATOR trial NBTXR3 NC NC-6004 NCCN-richtlijnen NCDB analysis NCDB analysis of immunotherapy in resected stage III melanoma NCDB analysis of treatment utilization and outcomes NCDB analysis of use of mastectomy for DCIS in young women NCGA NCGC NCI 8628 NCI Protocol 10250 NCI trial 9984 NCI-CONNECT NCI-Maryland Case Control Study NCI-MATCH ECOG-ACRIN trial subprotocol E NCI-MATCH study NCI-MATCH subprotocol EAY131-Y NCI-MATCH Subprotocol J NCI-MATCH subprotocol Z1F NCI-MATCH trial NCI-Match Trial E131-Y NCI-MATCH trial subprotocol H NCI9673 NCIC CTG MA.27-studie nCIT versus nCT NCM NCRI AML18 trial nCRT NCSLC NCT03931291 trial NCTN study S1001 ND AML in patients aged 16-60 years ND Ph- B-ALL in older patients ND- or R R-AML NDMM NDMM in transplant-ineligible patients near real-time intraoperative brain tumor diagnosis NEC study NECC necitumumab nectin-4-positive solid tumors nedaplatin- versus cisplatin-based CCRT negative colonoscopy negative for intraepithelial lesions or maligancy negative thyroid biopsy neighborhood deprivation and breast cancer mortality among Black and White women neighborhood opportunity neighborhood-level household income NEJ009 study NEJ047 nelarabine nelfinavir plus chemoradiotherapy nelfinavir with concurrent chemoradiotherapy NELM NELSON study NELSON-studie NEMO NENs NENs of the breast NEO trial neo-adjuvant-adjuvant versus neoadjuvant-only PD-(L)1 inhibition Neo-CRAG trial NEO-GAP trial Neo-PATH phase 2 trial Neo-Pre-IC trial neoadjuvant adebrelimab neoadjuvant and adjuvant chemotherapy neoadjuvant and adjuvant nivolumab plus lirilumab neoadjuvant and adjuvant pembrolizumab neoadjuvant and adjuvant toripalimab neoadjuvant anlotinib plus chemotherapy neoadjuvant anti-HER2 therapy for HER2-positive breast cancer neoadjuvant apatinib plus chemotherapy neoadjuvant aspirine neoadjuvant atezolizumab neoadjuvant atezolizumab plus chemotherapy neoadjuvant atezolizumab plus gemcitabine and cisplatin neoadjuvant atzolizumab plus chemotherapy neoadjuvant bevacizumab neoadjuvant breast cancer treatment neoadjuvant cabozantinib plus nivolumab neoadjuvant camrelizumab plus apatinib neoadjuvant camrelizumab plus chemotherapy neoadjuvant camrelizumab plus chemotherapy and apatinib neoadjuvant camrelizumab plus CT neoadjuvant CAPOX plus radiotherapy neoadjuvant carboplatin neoadjuvant carboplatin plus docetaxel neoadjuvant carboplatin with or without anthracycline neoadjuvant cemiplimab neoadjuvant cemiplimab and surgery neoadjuvant chemo-immunotherapy neoadjuvant chemoimmunotherapy neoadjuvant chemoradiation neoadjuvant chemoradiotherapy neoadjuvant chemotherapie neoadjuvant chemotherapy neoadjuvant chemotherapy followed by excision and observation neoadjuvant chemotherapy for breast cancer neoadjuvant chemotherapy for early breast cancer neoadjuvant chemotherapy for ovarian cancer neoadjuvant chemotherapy for TNBC neoadjuvant chemotherapy or chemoradiation neoadjuvant chemotherapy plus durvalumab neoadjuvant chemotherapy plus nivolumab neoadjuvant chemotherapy versus upfront surgery neoadjuvant chemotherapy with or without PD-1 inhibitor neoadjuvant CRT neoadjuvant CRT for rectal cancer neoadjuvant CRT plus atezolizumab neoadjuvant CRT versus CT neoadjuvant CRT versus upfront surgery neoadjuvant CRT with UGT1A1 status guided irinotecan dose neoadjuvant dabrafenib plus trametinib neoadjuvant dual checkpoint blockade neoadjuvant durvalumab neoadjuvant durvalumab plus chemotherapy neoadjuvant endocrine therapy neoadjuvant endocrine versus chemotherapy neoadjuvant enoblituzumab neoadjuvant erlotinib neoadjuvant exercise therapy neoadjuvant FOLFIRINOX neoadjuvant FOLFIRINOX followed by CRT neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel neoadjuvant FOLFOX versus CRT neoadjuvant gemcitabine plus cisplatin neoadjuvant gemcitabine plus S-1 neoadjuvant gemcitabine-cisplatin plus tislelizumab neoadjuvant gemcitabine-cisplatin-nab-paclitaxel neoadjuvant gemcitabine-cisplatin-pembrolizumab before radical cystectomy neoadjuvant ICI neoadjuvant ICI for stage III melanoma neoadjuvant ICIs neoadjuvant ICIs plus chemotherapy neoadjuvant immune checkpoint blockade neoadjuvant immunoradiotherapy neoadjuvant immunotherapy neoadjuvant immunotherapy and chemotherapy neoadjuvant immunotherapy plus chemotherapy neoadjuvant immunotherapy plus chemotherapy for NSCLC neoadjuvant intensity-modulated radiotherapy neoadjuvant ipilimumab plus nivolumab neoadjuvant K522 chemoimmunotherapy for TNBC neoadjuvant lapatinib plus trastuzumab without chemotherapy neoadjuvant larotrectinib neoadjuvant mFOLFIRINOX and postoperative gemcitabine neoadjuvant mFOLFIRINOX with or without HFRT neoadjuvant nab-paclitaxel neoadjuvant niraparib neoadjuvant nivolumab neoadjuvant nivolumab for NSCLC neoadjuvant nivolumab plus chemotherapy neoadjuvant nivolumab plus ipilimumab neoadjuvant nivolumab plus relatlimab neoadjuvant nivolumab with or without ipilimumab neoadjuvant nivolumab with or without relatlimab neoadjuvant nivolumab with or without tadalafil neoadjuvant osimertinib neoadjuvant paclitaxel plus platinum neoadjuvant PD-(L)1 inhibitors neoadjuvant pegylated liposomal doxorubicin neoadjuvant pembrolizumab neoadjuvant pembrolizumab plus HDI neoadjuvant pembrolizumab plus ramucirumab neoadjuvant pembrolizumab-carboplatin-docetaxel neoadjuvant pertuzumab neoadjuvant plus adjuvant durvalumab-based treatment neoadjuvant plus adjuvant erlotinib neoadjuvant radiotherapy neoadjuvant relatlimab plus nivolumab neoadjuvant ribociclib-letrozole versus chemotherapy neoadjuvant SABRT neoadjuvant SBRT after CT neoadjuvant SBRT plus single-dose durvalumab neoadjuvant SG neoadjuvant single or dual HER2 blockade neoadjuvant sintilimab neoadjuvant sintilimab for NSCLC neoadjuvant sintilimab plus chemotherapy neoadjuvant stereotactic radiotherapy for brain metastases neoadjuvant systemic therapy neoadjuvant systemic therapy for breast cancer neoadjuvant T-DM1 neoadjuvant T-DM1 plus lapatinib plus paclitaxel neoadjuvant talazoparib neoadjuvant talimogene laherparepvec neoadjuvant targeted therapy neoadjuvant TCHP neoadjuvant therapy neoadjuvant therapy before metastasectomy neoadjuvant therapy for breast cancer neoadjuvant therapy for NSCLC neoadjuvant toripalimab neoadjuvant toripalimab plus axitinib neoadjuvant toripalimab plus chemotherapy neoadjuvant trastuzumab emtansine plus pertuzumab neoadjuvant trastuzumab plus pertuzumab neoadjuvant trastuzumab plus pyrotinib neoadjuvant treatment neoadjuvant tucidinostat plus exemestane neoadjuvant zoledronic acid neoadjuvant-treated breast cancer neoadjuvante chemotherapie neoadjuvante CRT neoadjvuant systemic therapy neoALTAL trial NeoALTTO neoantigen T-cell receptor gene therapy NEOCAP study NeoCF NeoCF+D NeoCF+RT NeoCombi study NeoCombi trial NEOCRTEC-1601 NEOCRTEC1901 trial neodjuvant studies of early stage breast cancer neonatal inflammatory markers neonatal phototherapy NEONIPIGA phase 2 study NeoPACT phase 2 clinical trial NeoPAL study NeoPalAna neoplasm detection in upper gastrintestinal tract neoplasm risk NEOpredict-Lung trial neopterine NEOS trial NEOSTAR trial NeoSTOP study NEOSUMMIT-01 trial NeoTENNIS trial Neotorch randomized trial NEOZOTAC trial nephrectomy nephrotoxicity NEPTUN study neratinib neratinib for HER2-positive breast cancer neratinib plus trastuzumab emtansine nercelcarcinoom NET NET liver metastases NET versus NACT NETs NETTER-1 study network meta-analysis network meta-analysis of first-line treatments network meta-analysis of long-term efficacy of interventions network meta-analysis of regimens network meta-analysis of treatments neurale invasie neuro-endocrien carcinoom neuro-endocriene neoplasmen neuro-endocriene tumoren neuroblastoma neuroblastoom NeuroCARE neurocognitie neurocognition neurocognitive function neurocognitive problems neurodegenerative outcomes neuroendocrine carcinoma neuroendocrine prostate cancer neuroendocrine tumors neuroeondocriene tumoren neurofibromatose neurofibromatose 1 neurofibromatosis type 1 neurofibromatosis type 1-related plexiform neurofibromas neurologic adverse events neurologic disorders neuropathie neuropsychiatric functioning neuropsychological outcomes neurosurgical resection neutrofiel lymfocyt-ratio neutrofiel-lymfocyt ratio neutropenie neutrophil to lymphocyte ratio neutrophilia never-smoker lung adenocarcinoma patients new cancer diagnoses before and during the COVID-19 pandemic new cancer diagnosis over a ten-year period New EPOC trial new long-term opioid use after lung cancer surgery new treatment options new-generation BCR-ABL TKIs versus imatinib for CML new-onset NAFLD age newly diagnosed acute myeloid leukemia newly diagnosed AML newly diagnosed AML in elderly patients newly diagnosed AML in older patients newly diagnosed AML or high-risk MDS newly diagnosed AML with IDH1 mutation newly diagnosed AML with IDH1-mutation in elderly patients newly diagnosed and relapsed or refractory FLT3-mutated AML newly diagnosed APL newly diagnosed average-risk medulloblastoma in children newly diagnosed cancer patients newly diagnosed CD22+ Ph- B-cell precursor acute lymphoblastic leukemia newly diagnosed cHL in children and AYAs newly diagnosed CML newly diagnosed CP CML newly diagnosed DLBCL newly diagnosed early NK T cell lymphoma newly diagnosed endometrial cancer newly diagnosed glioblastoma newly diagnosed high-risk neuroblastoma in children newly diagnosed low-burden metastatic prostate cancer newly diagnosed metastatic colorectal cancer newly diagnosed metastatic nasopharyngeal cancer newly diagnosed multipel myeloma newly diagnosed multiple myeloma newly diagnosed multiple myeloma in frail patients newly diagnosed multiple myeloma in transplant-ineligible patients newly diagnosed mutant IDH2 AML newly diagnosed OPC newly diagnosed or relapsed multiple myeloma newly diagnosed Ph-negative B-cell ALL newly diagnosed Ph+ALL newly diagnosed stage II-IVa esophageal squamous cell carcinoma newly diagnosed stage III IV ovarian cancer in vulnerable patients newly diagnosed stage IV squamous cell lung cancer newly diagnosed T-ALL newly diagnosed transplant-ineligible multiple myeloma newly-diagnosed glioblastoma newly-diagnosed multiple myeloma newly-diagnosed transplant-eligible multiple myeloma newly-diagnosed triple-negative breast cancer Next Generation Trial next-generation BRAF inhibitor PLX8394 next-generation flow cytometry for assessing measurable residual disease next-generation sequencing next-generation sequencing detected MET amplification next-generation sequencing of ctDNA NEXUS-1 trial NF1 NF1 mutations NF1-PNs NF1-related PNs NF106 trial NF2 NF2-SWN NFD related donor Nfl levels NFSI after new cancer diagnosis NFκB nGBM NGS NHANES III analysis NHB versus NHW CCSs nHL NHL in AYAs NHL risk NHL subtypes NHL subtypes in Sweden 2000-2016 NHL-001 study NHS NIBIT-MESO-1 studie nice-or-naughty theorie NICHE study NICHE-2 study NICHE-2 trial NICHE-3 study nicotine NICT niercarcinoom niercelcarcinoom niercelkanker nierfunctie niet-cervicale anogenitale maligniteit niet-chirurgische behandeling niet-invasief prenataal testen niet-kelincellig longcarcinoom niet-kleincellg longcarcinoom niet-kleincellig longcarcinoom niet-kleincellige longkanker niet-melanoom huidkanker niet-seminomateus testiscarcinoom niet-squameus niet-kleincellig longcarcinoom nieuw logo Nieuw-Zeeland NIFTP NIFTY trial night shift work NIH-AARP NIH-AARP cohort NIH-AARP Diet and Health study NIH-AARP Diet and Health Study prospective cohort NIH-AARP Diet and Health Study; alcohol consumption Nijmegen breakage syndrome NILM NiloPeg nilotinib nimotuzumab nimotuzumab plus concurrent CRT nine weeks versus one year trastuzumab nintedanib nipple-sparing mastectomy NIPPON DATA 80 niraparib niraparib after response to chemotherapy niraparib and abiraterone acetate niraparib maintenance niraparib maintenance therapy niraparib plus anlotinib niraparib plus pembrolizumab nirogacestat nitraat nitriet NIVAHL trial NIVO nivo + ipi NIVO or IPI nivo+ipi vs sun nivolumab nivolumab and AVD nivolumab combination therapy nivolumab for advanced cancer nivolumab for mccRCC nivolumab for metastatic renal cell carcinoma nivolumab for NSCLC nivolumab for recurrent or metastatic head and neck squamous cell carcinoma nivolumab maintenance after ir AEs on nivolumab plus ipilimumab nivolumab plus AVD nivolumab plus cabozantinib nivolumab plus cabozantinib versus sunitib nivolumab plus chemotherapy nivolumab plus gemcitabine and cisplatin nivolumab plus ipilimumab nivolumab plus ipilimumab and radiotherapy nivolumab plus ipilimumab for NSCLC with brain metastases nivolumab plus ipilimumab versus sunitinib nivolumab plus ipilimumab with or without local therapy nivolumab plus relatlimab nivolumab plus rucaparib nivolumab plus SBRT nivolumab plus sunitinib nivolumab plus temozolomide nivolumab versus bevacizumab nivolumab versus docetaxel nivolumab versus nivolumab plus ipilimumab nivolumab versus sorafenib nivolumab with chemotherapy with or without relatlimab nivolumab with or without docetaxel nivolumab with or without ipilimumab nivolumab with or without relatlimab nivolumab-ipilimumab vs nivolumab for advanced cancers other than melanoma nivolumab-ipilimumab with or without stereotactic body radiation therapy NIVOREN study NIVOREN trial NK NKTCL NLCS NLPHL NLR NLR after SBRT for early-stage NSCLC NLR and survival outcomes NLR as prognostic factor NMA of treatment options NMBC in women aged ≥ 70 years nmCPRC nmCRC nmCRPC NMIBC nmMIBC nmPaC nmPrC nmPrCa NMR nmRCC NMSC NMSC-ASE NMSIs NNAL no AST versus ET no evidence of increased breast cancer risk NO16968 NO2 NOA-07 studie NOA-08 study NOCCA study nociplastic pain nodal PTCL nodal-positve breast cancer node-negative TNBC in older women node-positive breast cancer node-positive HER2-positive breast cancer node-positive HR-positive HER2-negative breast cancer node-positive melanoma node-positive vulvar cancer node-postive HR+ HER2-breast cancer with RS≤25 nodulair lymfocyt-predominant Hodgkin lymfoom nodular desmoplastic medulloblastoma in young children NOM nomogram for individualized prediction of survival nomogram for predicting mortality nomogram for predicting pathological respons to neoadjuvant treatment nomogram to estimate individualized overall survival nomogram to predict postoperative outcome nomograms for overall and cancer-specific survival nomograms to predict outcomes Non Core Binding Factor AML non-adherence to aromatase inhibitors non-alcoholic fatty liver disease non-alcoholic fatty liver disease-related HCC non-engineered multi-antigen specific T cells non-erosive GERD non-germinal center B-cell DLBCL non-germinal center B-cell like diffuus grootcellig B-cel lymfoom non-HAS non-Hispanic black versus non-Hispanic white AYAs non-Hodgkin lymfoom non-Hodgkin lymphoma non-inferioriteits fase 3-studie AXEPT non-initiation and non-persistence of adjuvant ET non-melanoma skin cancer non-metastatic castration-resistant prostate cancer non-metastatic castration-resistant prostate cancer in older men non-metastatic central nervous system germinoma non-metastatic esophageal cancer non-metastatic esophagogastric cancer non-metastatic SCCA non-muscle invasive bladder cancer non-muscle-invasive bladder cancer non-muscle-invasive bladder cancer unresponsive to BCG non-relapse mortaliteit non-remission AML non-rhabdomyosarcoma STS non-RMS soft tissue sarcoma in patients younger than 30 years non-seminoom testikelkanker non-small cell lung cancer non-small cell lung cancer brain metastases non-small cell lung cancer surgery non-small cell lung cancer with MET exon 14 skipping mutations non-specific symptoms and signs of cancer non-squamous metastatic non-small cell lung cancer non-squamous non-small cell lung cancer non-squamous NSCLC with BMs non-squamous NSCLC with high PD-L1 expression non-V600 BRAF mutations nonadherence nonadherence to cancer screening nonalcoholic fatty liver disease nonaspirin NSAIDs noncancer mortality noncolorectal dMMR MSI-H cancers noncutaneous and cutaneous cancer risk nonelderly adult cancer survivors nonepithelioid pleural mesothelioma nonfatal self-injury after a cancer diagnosis nonfunctional adrenal tumors nonfunctioning pituitary adenomas in elderly patients nongerminomatous malignant germ cell tumors nonhereditary breast cancer noninferiority phase 3 study HYPO-RT-PC noninvasive prediction of occult peritoneal metastasis nonkeratinocyte skin cancer nonkeratinocyte skin cancer risk nonmelanoma skin cancer nonmetastatic breast cancer nonmetastatic castration-resistant prostate cancer nonmetastatic head and neck cancer nonmetastatic NPC nonmetastatic prostate cancer nonmetastatic retroperitoneal sarcoma nonmetastatic unfavorable-risk prostate cancer nonmetastic castration-resistant prostate cancer nonoperative management in older women nonoropharyngeal squamous cell carcinoma nonpancreatic neuroendocrine tumors nonrelapse mortality nonsquamous non-small cell lung cancer with high PD-L1 expression nonsquamous NSCLC nonsteroidal aromatase inhibitor with or without abemaciclib nonverbale communicatie Noorwegen NOP10 NOPHO ALL2008 protocol NOPHO ALL2008 study NORA overall survival results NORCCAP-studie Nordic BRCA2 mutation carriers Nordic Lymphoma Group NORDIC9 study NORPACT-1 trial not previously treated mNSCLC not transplant-eligilbe MM NOTABLE study notifying GPs regarding nonadherence to FIT screening novel prognostic staging system novel regrouping novel treatment sequences for transplant-ineligible MM patients NOx NPC NPC mortality NPC risk NPM1-gemuteerde AML NPM1-mutated AML NPY methylated ctDNA NRAS-mutant melanoma NRAS-mutated NSCLC NRAS-mutatie NRAS-mutaties NRF2 expression NRG Oncology CC001 trial NRG Oncology NSABP R-04 study NRG Oncology RTOG 0617 study NRG Oncology RTOG 0926 NRG Oncology RTOG 1203 NRG Oncology RTOG studie 0621 NRG-BN002 NRG-GU003 trial NRG-GY003 NS7CAR T cells NSABP B-28 studie NSABP B-31 study NSABP B-40 NSABP B-41 neoadjuvant trial NSABP B-42 NSABP B-42 study NSABP FB-10 trial NSAID NSAID use NSAID-gebruik NSAIDs NSCLC NSCLC after EGFR TKI NSCLC after PD-1 PD-L1 blockade NSCLC BMs NSCLC brain metastases NSCLC brain metastasis NSCLC in older adults NSCLC in older patients NSCLC in patients with interstitial lung disease NSCLC in performance status 2 patients NSCLC in postmenopausal women NSCLC patients receiving immunotherapy NSCLC progressing on various EGFR TKIs NSCLC refractory to second-generation ALK inhibitor NSCLC survivors NSCLC with ALK or ROS1-rearrangement NSCLC with BMs NSCLC with bone metastases NSCLC with brain metastases NSCLC with common or uncommon EGFR mutation NSCLC with EGFR variant NSCLC with G12C mutation NSCLC with HER2 exon 20 mutations NSCLC with HER2ex20ins NSCLC with high PD-L1 expression NSCLC with MET exon 14 skipping mutations NSCLC with RET fusion NSCLC with RET fusions NSCLC with TPS ≥ 1% NSCLC with uncommon EGFR mutations NSCLC; linifanib NSGCT NSM nsq NSCLC nsq-NSCLC NSQIP nsqNSCLC NST for HER2-positive IBC NTD-Haplo versus SUCBT NTP nucleaire installaties nuclear ZEB2 expression number of doses number of lines of NAC NURE-Combo trial Nurses' Health Study Nurses’ Health Studies Nurses’ Health Study Nurses’ Health Study I and II Nurses’ Health Study II nursing home residents nut consumption nutrient intake NutriNet-Santé cohort NutriNet-Santé prospective cohort NutriNet-Santé studie NutriNet-Santé study nutrition interventions for improved cancer outcomes nutritional status NVALT19 trial NWAS NWTS 3-5 NWTS-5 O E incidence ratios of second malignant neoplasms OA-MCL OAC OAC for AF OACs OAK OAK and POPLAR trials OAK-studie obesitas obesitasparadox obesity obesity paradox obesity-related cancer trends obinutuzumab obinutuzumab plus DHAP obinutuzumab plus lenalidomide obinutuzumab versus rituximab observation versus SABR Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk obstetric and maternal outcomes obstetric outcomes obstetrical and perinatal outcomes OCC OCCC occult breast cancer occulte kanker occupational environment occupational variation OCEAN study OCOG-ALMERA trial OCSCC OCT versus punch biopsy octagenarians compared to younger patients OCTOVA trial ocular toxicity ocular toxicity of bortezomib OCUM study ODM-201 ODM-208 odontoom odronextamab ODXRS oedeem oesofagaal squameus celcarcinoom oesofagastrische tumoren oesofagectomie oesofagogastrisch adenocarcinoom oesofagus squameus celcarcinoom oesofagusadenocarcinoom oesofaguscarcinoom oesofaguskanker oesophageal cancer oesophageal squmous cell carcinoma oestradiol oestrogeengebruik oestrogeenreceptor oestrogeensuppressie OFA versus OBA ofatumumab offspring donors versus HLA-matched siblings offspring of survivors of childhood or adolescent CNS tumors ofranergene obadenovec OGC OHERA study OIPN Okayama Lung Cancer Study Group Trial 1404 olanzapine olaparib olaparib and temozolomide olaparib maintenance olaparib monotherapy olaparib plus abiraterone olaparib plus bevacizumab first-line maintenance olaparib plus bevacizumab maintenance olaparib plus cetuximab and IMRT olaparib plus durvalumab olaparib plus temozolomide combination olaparib with or without cediranib olaparib without ADT olaratumab older adults receiving cancer chemotherapy older adults undergoing cancer surgery older adults with blood cancer older adults with cancer older adults with GI cancers older breast cancer patients with high recurrence scores older breast cancer survivors older breast cancer survivors with and without prior chemotherapy older cancer patients older cancer survivors older MSDs versus younger MUDs olfactorisch neuroblastoom oligo-organ mNSCLC oligo-residual EGFR-mutant NSCLC oligometastase oligometastatic breast cancer oligometastatic cancer oligometastatic cancers oligometastatic CRPC oligometastatic EGFR-mutated NSCLC oligometastatic non-small cell lung cancer oligometastatic NSCLC oligometastatic oesophageal squamous cell carcinoma oligometastatic oligoprogressive NSCLC oligometastatic prostate cancer oligometastatic RCC OLIVIA olmutinib olutasidenib Olvi-Vec OlympiA study OlympiA trial OlympiaD subgroup analyses OlympiAD-studie OLYMPUS study OM OM-CRC omacetaxine mepesuccinate omalizumab omega 3-vetzuren OMEGA offspring cohort omission of adjuvant RT in breast cancer omission of dexamethasone omission of radioiodine after thyroidectomy omitting axillary dissection omitting RT after BCS Ommaya reservoir on-target adverse events on-target ALK resistance mutations ONC201 once weekly selinexor-bortezomib-dexamethasone once-weekly XVd OncoCast-MPM oncogenic drivers of NSCLC oncologic and reproductive outcomes oncolytic adenoviral therapy oncolytic coxsackievirus A21 oncolytic DNX-2401 virotherapy plus pembrolizumab oncolytic DNX-2401 virus for pediatric DIPG oncolytic HSV-1 G207 immunovirotherapy oncolytic T-VEC therapy plus neoadjuvant chemotherapy oncolytic virotherapy oncolytisch adenovirus oncolytische virustherapie oncoplastische mammoplastie ONCOS-102 ONCOS-102 plus pembrolizumab Oncoscience Oncotype Oncotype DX Oncotype DX DCIS-score OnCovid study ondergewicht onderhoudstherapie ondervoeding onderzoeksfraude one versus two doses of Pfizer-BioNTech vaccine for patients with cancer one week off one-off low-dose CT ONJ ONKOTEV risk prediction model for VTE online predictor of short-term postoperative outcomes online preview AACR Annual Meeting online videos about prostate cancer ONO-4538-52 TASUKI-52 ONT-380 Ontario Lung Cancer Screening Pilot ontstaan colorectaalkanker ontwikkeling resistentie onvansertib oogmelanoom oophorectomy Oost-Afrika OP-TIL OpACIN and OpACIN-neo trials OPAL research platform OPAS-1 study OPC open resectie open versus laparoscopic surgery open versus minimally invasive surgery open versus robot-assisted radical cystectomy operability and post-treatment mortality operable bladder cancer operable oral and oropharyngeal cT1-T2N0 cancer operable stage I-IIIA NSCLC operable TNBC opioid use opioid use among older cancer survivors opioid use and toxicity among cancer survivors opioid-associated mortality in cancer survivors versus general population opioid-induced constipation opleidingsniveau OPN opportuniby costs of receiving palliative chemotherapy opportunistic salpingectomy for ovarian cancer prevention opportunities to achieve 50% reduction of mortality by 2047 OPRA trial long-term results OPSCC opsoclonus-myoclonus ataxie syndroom OPTICAL trial OPTIMA II trial OPTIMA Prelim optimal adjuvant trearment time Optimal Breast Cancer Chemotherapy Dosing Study optimal duration of adjuvant AI therapy optimal duration of adjuvant endocrine therapy optimal imaging surveillance interval optimal neoadjuvant sequence of anthracyclines and taxanes optimal RT regime optimal RT strategy after breast-conserving surgery optimal sequence of enzalutamide and abiraterone acetate plus prednisone optimal time interval between breast cancer diagnosis and surgery optimal timing of chemoradiotherap optimal treatment duration of adjuvant bevacizumab OPTIMISMM study OPTIMIZE-1 trial optimizing chemotherapy optimizing patient selection for cytoreductive nephrectomy OPTION-studie Opto-RTKs oraal carcinoom oraal oncogeen HPV ORACLE study oral agents oral androgen signaling inhiibitos oral antibiotic use oral arsenic trioxide oral azacitidine oral azacitidine maintenance oral cancer oral cavity cancer outcomes oral cavity or oropharyngeal squamous cell carcinoma oral cavity squamous cell carcinoma oral contraceptive use oral decitabine plus cedazuridine and venetoclax oral endocrine therapy oral health oral hydration after cisplatin oral microbiome and subsequent HNSCC risk oral mucositis oral mucositis after chemoradiotherapy for OCC OPCC oral mucositis after hematopoietic stem cell transplantation oral mucositis with high-dose chemotherapy and transplanation oral paclitaxel plus encequidar versus intravenous paclitaxel oral S-1 oral selinexor oral squamous cell carcinoma ORAL Surveillance trial orale anticonceptiva orale contraceptiva ORALEV study ORANGE II PLUS trial ORATOR study ORATOR2 trial orbital indolent BCL orbital metastases ORCA-010 ORCHARRD orelabrutinib orgaantransplantatie organ preservation organ preservation trends Organ transplant recipients organ-sparing chemo-immunotherapy organ-sparing transanal endoscopic microsurgery organic food consumption organische oplosmiddelen organoids from colorectal peritoneal metastases orgnnoïdencultures ORIENT-1 study ORIENT-11 study ORIENT-11 trial ORIENT-12 study ORIENT-15 ORIENT-15 trial ORIENT-16 trial ORIENT-31 second interim analysis ORIENT-31 study ORIENT-31 trial ORIENT-32 study ORIOLE trial orofaryngeaal squameus celcarcinoom orofarynx squameus celcarcinoom orofarynxcarcinoom oropharyngeal cancer oropharyngeal carcinoma in older patients oropharyngeal HPV infections oropharyngeal squamous cell carcinoma ORR and six months PFS as surrogate endpoints for OS orthopedische oncologie OS OS impact of pembrolizumab treatment duration OS impact of surgical margins larger than 1 cm OS with CDK4 6-inhibitors OS with ivosidenib OS2006 Sarcome-09 study OSCC OSCC survivors OSI-FACT-EP osimertinib osimertinib 160 mg osimertinib after CRT osimertinib combination therapy osimertinib for advanced T790M-positive and -negative NSCLC osimertinib for NSCLC osimertinib plus local treatment versus osimertinib alone osimertinib plus navitoclax osimertinib plus savolitinib osimertinib plus selpercatinib OSJ Oslo 1-studie OSLO-COMET study osteonecrose van de kaak osteopenie osteopontin osteoporosis osteosarcoma osteosarcoma with cell-cycle and fibroblast growth factor mutations osteosarcoom ototoxiciteit van chemotherapie ototoxicity OTX015 outcome of patients with ultralow-risk 70-gene signature outcomes outcomes after allogeneic hematopoietic cell transplantation outcomes after CD19-CAR outcomes after contemporary first-line treatment outcomes after nonrespons and relapse post-tisagenlecleucel outcomes after surgery outcomes after various types of radiotherapy outcomes by prior treatment at first relapse outcomes in AYAs compared with children outcomes in cancer patients outcomes in pregnant individuals and newborns outcomes of AML outcomes of CRT outcomes of different breast cancer screening strategies outcomes of first therapy after CD19-CAR-T treatment failure outcomes of melanoma in smokers outcomes of patients treated with CAR T-cell therapy admitted to intensive care outcomes of primary endocrine therapy outcomes of rechallenge after high-grade heaptitis outcomes of risk-reducing total gastrectomy outcomes of surgery outcomes of transgender cancer patients in the USA outcomes of various RIC-NMAC conditioning regimes outcomes outside clinical studies outcomes with care in high- versus low-volume centers outcomes with chemotherapy outcomes with delayed surgery outcomes with ICIs outcomes without locoregional treatment outpatient medication errors among children with leukemia and lymphoma outpatient versus inpatient neutropenia management outpatients with cancer OV21 PETROC ovarian cancer ovarian cancer and borderline tumors ovarian cancer in women aged 65 years and older ovarian cancer risk ovarian cancer survival ovarian cancer survivors ovarian carcinoma with BRCA-like genomic aberrations ovarian clear cell carcinoma ovarian function ovarian function suppression ovarian or endometrial cancer ovarian removal at or after benign hysterectomy ovarian stimulation ovarian suppression ovarian tumors ovariëctomie ovariumcacrinoom ovariumcarcinoom ovariumfunctie ovariumfunctie-suppressie ovariumfunctiesuppressie ovariumkanker ovariumtumoren ovariumvolume OVC overall and specific cancer risks overall mortality in men versus women overall survival overall survival after treatment failure for rectal cancer overall survival trend from 2000 to 2019 overall survival-analyse van fase 3-studie ARCHER 1050 overdiagnose overdiagnosis overgewicht overhospitalisatie overlevers overlevers jeugdkanker overlevers kinderkanker overleving overleving borstkanker overleving CRC overleving in Europa overleving melanoom overleving oudere patiënten overtreatment among men with limited longevity overweight OVHIPEC-1 final analysis oviductcarcinoom oxaliplatin oxaliplatin hepatic artery infusion oxaliplatin-based adjuvant chemotherapy oxaliplatine oxybutynin P LP germline TP53 variants P LP variants P R M CC p16 Ki-67 dual stain and HPV16 18 genotyping p16+ locally advanced OPC p16ink4A-deficient mesothelioma p53 PABC PABC versus non-PABC PaC PACE study PACE-B study PACE-B trial PACE-MDS study PACE-studie pachymeningeal seeding PACIFIC study PACIFIC study post-hoc analysis PACIFIC trial PACIFIC trial update PACIFIC-studie paclitaxel paclitaxel for breast cancer paclitaxel- and oxaliplatin-induced peripheral neuropathy PACMEL trial pacmilimab for advanced or recurrent solid tumors PACT trial PACT-15 studie PACT-19 study PADA-1 trial PADT pain and pain interference pain control for SNL radiotracer injections in breast cancer patients pain in advanced cancer pain in older survivors pain monitoring app painful bone metastases painful hepatic cancer painful spinal metastases Painyanitikul PAKT trial PALB2 germline mutations PALB2-mutatie PALB2-mutaties palbociclib palbociclib and fulvestrant palbociclib combination therapy for advanced or metastatic breast cancer palbociclib for advanced breast cancer palbociclib monotherapy palbociclib plus endocrine therapy palbociclib plus fulvestrant palbociclib rechallenge PALLAS trial final analysis palliatie palliatieve radiotherapie palliative care referral Palliative Prognostic Index palliative radiotherapy PALOMA-1 TRIO-18 PALOMA-2 analyse PALOMA-2 and PALOMA-3 pooled analysis PALOMA-3 PALOMA-3 analysis PALOMA-3 study palonosetron PAM50 signature PAMELA PAMELA-studie pamiparib pamiparib plus tislelizumab pAML pan-cancer analysis of postdiagnosis exercise and mortality pan-cancer noninvasive detection of MSI and high TMB pan-RAF remmers pan-tumor retrospective analysis PANACEA study PANAMA trial PanCarSurFup study pancreas pancreas cancer pancreas ductaal adenocarcinoom pancreas-adenocarcinoom pancreas-ductaaladenocarcinoom pancreas-MCNs pancreasadenocarcinoom pancreascarcinoom pancreaskanker pancreatectomie pancreatic adenocarcinoma pancreatic adenocarcinoma in patients older than 79 years pancreatic cancer pancreatic cancer incidence and mortality pancreatic cancer risk pancreatic cancer with vascular involvement pancreatic cystic neoplasms pancreatic ductal adenocarcinoma pancreatic fistula pancreatic head adenocarcinoma pancreatic NETs pancreatic neuroendocrine tumors pancreatic or periampullary tumors pancreatic-colorectal-stomach cancer pancreaticobiliary malignancies ctDNA from plasma or bile pancreaticoduodenectomie pancreaticoduodenectomy pancreaticoduodenectomy for pancreatic cancer pancreatoduodenectomy for pancreatic and periampullary cancers PANDA trial PANFIRE PANFIRE-2 study PANIB trial PanIN lesions in healthy individuals panitumumab panitumumab maintenance panitumumab rechallenge panitumumab versus bevacizumab panitumumab versus cetuximab after bevacizumab panNEC panobinostat PANOPTIMOX-PRODIGE 35 trial PANORAMA 3 study PANTHER trial PANTHER trial end-of-study results Panther trial long-term HRQOL PANVAC PAOLA-1 ENGOT-ov25 PAOLA-1 ENGOT-ov25 trial PAOLA-1 secondary analysis PAOLA-1 study PAOLA-1 trial PAPAGEMO trial papillair craniofaryngioom papillair metastatisch niercelcarcinoom papillair schildkliercarcinoom papillary craniopharyngioma papillary neoplasms of the breast papillary thyroid cancer risk papillary thyroid carcinoma aggressive variants PAPILLON trial paraganglioma paraneoplastisch neurologisch syndroom parasagittal meningioma PARCER trial parenthood rates and use of assisted reproductive techniques parents of children with cancer parity Parkinson PARP inhibitor maintenance PARP inhibitor maintenance therapy PARP inhibitor treatment PARP-remmer PARP1-expressie parsaclisib partial hepatectomy versus TACE partial nephrectomy for RCC partial prostate treatment partial versus whole breast irradiation particle radiation therapy particpating in randomized breast cancer study ParvOryx PAs passief roken PASSION trial PASSOS Heart studie PATCH trial program paternity after treatment for testicular germ cell cancer PATHFINDER study PATHFINDER study interim analysis pathogenic germline variants pathogenic variants in less familiar cancer susceptibily genes pathogenic variants in RAD51C and RAD51D pathologic fractures pathologic response pathologic response and survival pathologic stage II nonseminomatous ger cel tumors pathological complete response pathological nipple discharge pathological response to neoadjuvant chemotherapy pathological stage I-IIIA NSCLC pathologically node-negative neck Pathways Heart Study patient age and progression patient and diagnostic intervals of sarcoma survivors patient enrollment to industry-sponsored versus federally sponsored cancer trials patient factors and ratio of basal cell to cutaneous squamous cell carcinoma patient factors associated with prognosis patient mortality after surgery on surgeon’s birthday patient portal messaging before mailing FIT kit patient reported outcome patient reported outcomes patient reported symptoms patient volume of oncologist patient with cancer and cryptogenic stroke patient withdrawal of consent patient- and clinican-reported patient- and clinician-reported symptoms during standard RT or IMRT patient- and hospital-level risk factors patient-collected versus clinician-collected samples patient-derived xenograft engraftment patiënt-gerapporteerde uitkomsten patient-reported functional impairment patient-reported outcome measures patient-reported outcomes patient-reported outcomes with first-line EV w wo P patient-reported symptom burden patient-specific measurable residual disease markers patiëntnavigatie patients aged 40 years or younger patients on active anticancer treatment patients receiving CAR T-cell therapy in the USA patients with 4-15 brain metastases patients with advanced cancer and their family caregivers patients with BRCA1 2-wt and mutations in other HR pathway genes patients with breast cancer harboring TP53 germline variants patients with cancer and acute deep venous thrombosis patients with cancer and DPYD variant alleles patients with COVID-19 and solid tumors patients with hematologic malignancy and other independent cancer patients with melanoma considering adjuvant immunotherapy patients with myelofibrosis and anemia patients with non specific symptoms patients younger than 50 years patterns and survival patterns in incidence 2010 to 2019 patterns of invasive recurrence patterns of locoregional recurrence patterns of practice patterns of recurrence patterns of relapse patterns of relapse after neoadjuvant chemotherapy in clinical practice patterns of treatment and outcome in The Netherlands PAVO study pazopanib pazopanib plus cetuximab pazopanib versus doxorubicin pazopanib with or without gemcitabine PBC PBDEs PBI or IORT versus WBI PBI versus WBI PBL PBRT PBSO PBT PBT versus IMRT PBT versus TACE PBTs PC PC epidemiology PCa PCa diagnosis PCCRC risk PCD PCF after laryngectomy PCI PCI versus HA-PCI PCLO PCM PCNSL PCNSL in fit older patients PCNSL in patients aged 60 years or younger PCNSL SCNSL PCOS pCR pCR after NAC for gastric cancer pCR after NACT pCR and outcomes by intrinsic subtypes of breast cancer pCR of DCIS component pCR to NACT pCR to pertuzumab and trastuzumab PCS with or without HIPEC PCSM PCSM with AS PCSNL PCT for aPSCC PCYC-1123-CA study PD PD-(L)1 blockade for NSCLC PD-(L)1 blockers for advanced NSCLC PD-(L)1 immune checkpoint inhibitors PD-(L)1 inhibitors PD-(L)1 inhibitors plus chemotherapy for aNSCLC PD-(L)1 targeting therapy PD-(L)1-based combination therapies PD-(L)1-blockade PD-1 PD-1 Ab PD-1 and PD-L1 checkpoint inhibitors PD-1 and PD-L1 expression in breast cancer PD-1 and PD-L1 inhibitos PD-1 blockade PD-1 blockade for melanoma PD-1 inhibition PD-1 inhibition plus antiangiogenic therapy PD-1 inhibitor PD-1 inhibitors for metastatic melanoma PD-1 inhibitors for mNSCLC PD-1 or PD-L1 blockade refractory metastatic melanoma PD-1 PD-L1 inhibitors PD-1 PD-L1 targeting PD-1 VEGF bispecific antibody PD-1-inhibitor therapy PD-L1 PD-L1 blockade plus carboplatin PD-L1 combined positive score PD-L1 expression PD-L1 expression as predictive biomarker PD-L1 expression as predictive biomarker for EGFR TKIs PD-L1 expression on immune cells PD-L1 inhibitor-based combination therapy PD-L1 negative NSCLC PD-L1 positive mUC in cisplatin ineligible patients PD-L1 positive NSCLC PD-L1-inhibitor LY3300054 PD-L1-positive advanced NSCLC PD-L1-positive mTNBC PD-L1-positive recurrent or metastatic cervical cancer PD1 inhitiors for NSCLC PD1-based immunotherapy for melanoma PDAC PDAC in the real world PDAC patients undergoing PD with vascular resection PDAC PMs PDAC surveillance and survival of high-risk individuals PDAC survival PDGFRA D842V-mutated GIST PDR and postcolonoscopy colorectal cancer risk PDS PDT PDX engraftment PEA versus PEAT for ES-SCLC PEACE randomized trial PEAK study PEARLS KEYNOTE-091 trial PEComa pediatric acute leukemia pediatric ALK-positive malignancies pediatric ALL pediatric AML pediatric and adolescent HL patients pediatric and adolescent melanocytic lesions pediatric and youg adult cancer surivors pediatric and young adult DS-ALL pediatric and young adult EWS pediatric and young adult R R B-ALL pediatric APL pediatric B-NHL pediatric BRAF V600E-mutated glioma pediatric BRAFV600-mutant LGG pediatric brain tumor survivors pediatric brain tumors pediatric cancer pediatric cancer patients pediatric cancer patients with febrile neutropenia pediatric cerebral microbleeds pediatric CNS and head-and-neck cancer pediatric cranial SRS pediatric craniopharygioma pediatric CT-related radiation exposure pediatric ependymoma pediatric germ cell tumors pediatric hepatoblastoma pediatric high-grade gliomas pediatric high-grade malignancies pediatric high-risk HL pediatric high-risk medulloblastoma pediatric inflammatory bowel disease pediatric locally advanced TRK fusion sarcomas pediatric low-grade glioma pediatric medulloblastoma pediatric neuro-oncology pediatric neuroblastoma pediatric NPC pediatric or adolescent NHL pediatric patients treated for optic pathway gliomas pediatric Ph+ ALL pediatric Ph+ CML-CP pediatric posterior fossa tumors pediatric R R ALL pediatric recurrent ependymoma pediatric recurrent or refractory CNS tumors pediatric relapsed HRNB pediatric relapsing high-risk ALL pediatric spinal cord low-grade glioma pediatric thyroid cancer pediatric thyroid cancer incidence and mortality trends pediatric-style chemotherapy versus alloHCT pediatrisch ALL pediatrisch AML pediatrisch ependymoom pediatrisch sarcoom pediatrische AML pediatrische CNS-tumoren pediatrische hersentumoren pediatrische leukemie pediatrische NETs pediatrische patiënt-gerapporteerde uitkomsten pediatrische stamceltransplantatie PEG PEG-IFN pegaspargase versus calaspargase PEGASUS PEGASUS-D trial pegfilgastrim pegfilgrastim-profylaxe pegilodecakin peginterferon alpha-2b pegteograstim PEH with cancer pelabresib plus ruxolutinib pelareorep pelvic exenteration pelvic fractures and changes in bone mineral density pelvic radiotherapy pelvic RT versus IMRT pembolizumab pembolizumab plus ipilimumab pembolizumab with bevacizumab and oral metronomic cyclophosphamide PEMBRO-RT study pembrolizmab pembrolizumab pembrolizumab activity pembrolizumab after concurrent CRT pembrolizumab after locally ablative therapy pembrolizumab and concurrent CRT pembrolizumab for advanced melanoma pembrolizumab for advanced NSCLC pembrolizumab for advanced prostate adenocarcinoma pembrolizumab for mUC pembrolizumab for non-small cell lung cancer pembrolizumab for NSCLC pembrolizumab for previously treated mTNBC pembrolizumab for previously treated PD-L1 positive advanced NSCLC pembrolizumab for previously untreated pembrolizumab for solid tumors pembrolizumab monotherapy pembrolizumab monotherapy for aNSCLC pembrolizumab plus axitinib pembrolizumab plus axitinib versus sunitinib pembrolizumab plus bevacizumab pembrolizumab plus bevacizumab and oral cyclophosphamide pembrolizumab plus cabozantinib pembrolizumab plus cetuximab pembrolizumab plus chemotherapy pembrolizumab plus concurrent chemoradiation pembrolizumab plus CRT pembrolizumab plus doxorubicin pembrolizumab plus enzalutamide pembrolizumab plus GX-188E DNA vaccine pembrolizumab plus ipilimumab pembrolizumab plus lenvatinib pembrolizumab plus nab-paclitaxel salvage pembrolizumab plus NACT pembrolizumab plus olaratumab pembrolizumab plus RT after induction chemotherapy pembrolizumab plus single-fraction RT pembrolizumab plus T-DM1 pembrolizumab plus trastuzumab pembrolizumab versus best supportive care for advanced HCC pembrolizumab versus brentuximab vedotin pembrolizumab versus chemotherapy pembrolizumab versus ipilimumab pembrolizumab with or without chemotherapy pembrolizumab with or without LAT pembrolizumab with or without mRNA-4157 pembrolizumab with or without RT pembrolizumab-chemotherapy pembrolizumab-etoposide-platinum PEMBROSARC trial pemetrexed and platinum pemetrexed for lung cancer pemetrexed plus carboplatin pemetrexed plus cisplatine pemigatinib PEMMELA trial penpulimab penta-refractory MM PEPI pepinemab plus avelumab peptide receptor radionuclide therapy percent ctDNA percentage dense area perception of cancer risk perceptions and practice regarding patient request to record clinical visits perceptions of telehealth in real-world oncological care percutaneous ablation percutaneous cryoablation percutaneous image-guided ablation percutaneous IRE PerELISA neoadjuvant study PERFECT trial perfluarinated alkylated substances in serum performance of liquid biopsy for diagnosis and surveillance performance status performance status ratings in pediatric cancer pericardial disease perifeer T-cel lymfoom perifere neuropathie perinatal and postnatal exposures perinatal exposures perinatal outcomes periodontale ziekte perioperative adebrelimab plus chemotherapy perioperative anti-HER2 therapy perioperative beta-blocker supply perioperative camrelizumab plus apatinib perioperative cell-free DNA dynamics perioperative chemotherapy perioperative chemotherapy plus ICB perioperative chemotherapy plus nivolumab perioperative chemotherapy with without ramucirumab perioperative COX2 and β-adrenergic blockade perioperative ctDNA as prognostic marker perioperative ctDNA-based molecular residual disease detection perioperative dexamethasone perioperative durvalumab perioperative durvalumab and tremelimumab perioperative dynamic changes in ctDNA perioperative FLOT versus ECF ECX perioperative ghrelin administration perioperative LP002 plus chemotherapy perioperative mFOLFIRINOX perioperative nivolumab perioperative nivolumab and chemotherapy perioperative pembrolizumab plus chemotherapy perioperative radiotherapy perioperative SOX versus FOLFOX perioperative toripalimab plus chemotherapy perioperative trastuzumab plus FLOT perioperative versus adjuvant SOX peripheral blood derived neutrophil-to-lymphocyte ratio peripheral neuropathy peripheral stage IA NSCLC peripheral T-cell lymphoma peripheral T-cell lymphoma in elderly patients perirectal hydrogel spacer peritoneal mesothelioma peritoneal metastases from gastric cancer peritoneal sarcomatosis peritoneale carcinomatose index peritoneale metastasen PERLS PERMEATE trial PERSEPHONE trial PERSEUS trial PeRSIA study PERSIST-1 PERSIST-2 studie PERSIST-5 trial persistence of ctDNA persistence of F. nucleatum persistent acromegaly persistent febrile neutropenia persistent or recurrent or metastatic cervical cancer persistent peripheral neuropathy persistent postchemotherapy alopecia persistent PSA after radical prostatectomy persistent radiation-induced alopecia in cancer patients persistente pijn personalised versus standard dosimetry personalized ctDNA as predictive biomarker personalized ctDNA profiling personalized mRNA neoantigen vaccine personalized neoantigen vaccine monotherapy personalized radioimmunotherapy personalized selection of experimental treatment PERTAIN study pertuzumab pertuzumab plus trastuzumab pertuzumab plus trastuzumab and chemotherapy pertuzumab plus trastuzumab with or without chemotherapy peru PERUSE study pesticide exposure PET PET CT PET CT for predicting PD-L1 expression PET-adapted regimen for advanced HL PET-adapted therapy PET-CT PET-CT staged localized follicular lymphoma PET-CT versus conventional staging PET-guided BrECADD versus eBEACOPP PET-guided neoadjuvant chemotherapy de-escalation PET-guided omission of radiotherapy PET-guided risk adapted treatment PET-guided therapy PET-guided treatment PETAL study PETAL-studie PETHEMA GEM2012 study PETra trial peulvruchten pevonedistat pexidartinib PF-05280014 PFAS in serum PFS PFS on ET before or after CT PFT PGA PGC-1α PGF PGHD PGINKTL PGT PGV frequency PH Ph- ALL Ph-ALL Ph-like ALL Ph-negative ALL in adults Ph-negative ALL in AYAs in first CR Ph-negative ALL in older patients Ph-negative B-ALL Ph-negative CD20-positive B-cell ALL Ph-positive ALL Ph-positive ALL in adults Ph-positive CML Ph+ ALL Ph+ ALL in adult patients Ph+ALL in first CMR PhALLCON trial pharmacological ovarian suppression phase 1 oncology trials phase 1-2 MajesTEC-1 trial phase 1b COSMIC-021 trial expansion cohorts phase 2 ACCRU study phase 2 adaptively randomized I-SPY2 trial phase 2 AMPECT trial phase 2 BENEFIT trial phase 2 COAST study phase 2 CONTROL trial phase 2 DESTINY-Gastric02 study phase 2 FAKTION trial phase 2 GALAHAD study phase 2 GEMCAD 1402 study phase 2 GEOMETRY mono-1 trial phase 2 HORIZON trial phase 2 IMPemBra trial phase 2 METALLICA trial phase 2 MOUNTAINEER trial phase 2 NeoATP study phase 2 PEANUT study interim results phase 2 PETREMAC study phase 2 RIGHT Choice trial phase 2 STOMP trial phase 2 study JULIET phase 2 TRAIN-3 study phase 2 TUXEDO-1 trial phase 2 VIRO-15 trial phase 2-3 DANTE trial phase 2b NIFTY study phase 3 ADAURA trial phase 3 AEGEAN trial phase 3 ANCHOR study phase 3 APHINITY trial phase 3 CAIRO5 trial phase 3 CASTOR study phase 3 COSMIC-311 trial phase 3 EA1131 study phase 3 ESCORT-NEO NCCES01 trial phase 3 FIRE-3 study phase 3 GLOW study phase 3 IMpassion050 trial phase 3 IPSOS study phase 3 JAVELIN Gastric 100 study phase 3 KCSG CO09-07 trial phase 3 KEYNOTE-062 study phase 3 KEYNOTE-522 trial phase 3 LUNAR trial phase 3 MAIA study phase 3 MOMENTUM trial update phase 3 monarchE study phase 3 monarchE trial 5-year follow-up phase 3 NEJ026 study phase 3 NIAGARA trial phase 3 NRG RTOG 9804 study long-term outcomes phase 3 OlympiA trial phase 3 PRODIGY study phase 3 PUFFIN trial phase 3 RESOLVE trial phase 3 RESORT study phase 3 STELLAR trial phase 3 studies supporting FDA approval of cancer drugs phase 3 study AML08 phase 3 study COMBI-AD phase 3 study TRAIN-2 phase 3 study TRIBE 2 phase 3 trial RADAR phase 3 VESPER trial phase 3b-4 CheckMate 920 trial phase 4 BYOND trial phase I trials in hematologic malignancy phase III APROMISS study phase III IMpower131 study phase III iNNOVATE study phase III POLO trial phase III SUCCESS-A trial Phc pheochrmocytoma pheochromocytoma pheochromocytoma and paraganglioma PHEREXA-studie PHERGain trial Philadelphia chromosome-negative ALL Philadelphia-negative B-cell ALL PHILEMON-studie PHL86 NCI#9322 study phlebotomy with or without ropeginterferon α-2b PHOEBE trial PHOENIX study photobiomodulation photodynamic therapy PHP-Mel physical activity physical activity and mortality physical activity during adolescence physical activity during adolescence and early adulthood physical health and neurocognitive outcomes physican workforce requirements physician adenoma detection rate physicians’ perspectives physiotherapy regimens in esophagectomy and gastrectomy PI-RADS 3 lesions PI3K inhibitors PI3K mTOR-remming PI3K-signalering PI3Kδ PIB PICN pictilisib PICTURE trial PID pigmented skin lesion classification pIIIA-N2 NSCLC pijnlijke botmetastasen PIK3CA PIK3CA mutation PIK3CA mutation and survival outcomes PIK3CA mutation status PIK3CA mutations PIK3CA-activated stage III colon cancer PIK3CA-altered HNSCC PIK3CA-mutated aBC PIK3CA-mutated HR+ ABC PIK3CA-mutated HR+ HER2- advanced breast cancer PIK3CA-mutaties pilaralisib pilocarpine pilocytic astrocytoma and optic pathway glioma PILOT trial pimasertib versus dacarbazine pimecrolimus PimTo-MF trial pink SWAN study pioglitazon PIONEER trial pirtobrutinib pirtobrutinib after a covalent BTK inhibitor pituitary and cavernous sinus metastases pituitary macroadenomas pituitary metastasis PIV pivekimab sunirine PIVOT-02 study PIVOT-studie pixatimod plus nivolumab PK-guided pembrolizumab administration PL placebo adverse events in cancer trials PLACOL-studie plant-based diet and survival plant-based diets plant-based diets and disease progression plaque radiotherapy for uveal melanoma plasma and saliva HPV DNA testing plasma circulating tumor DNA fraction plasma EBV DNA plasma Epstein-Barr virus DNA plasma exosomal miRNAs plasma metabolomic signatures PLASMA study plasma tumor gene conversions after one cycle of abiraterone acetate plasma-based genotyping plasma-biomarkers plasmacarotenoïden plasmaMATCH trial platinum exposure platinum ineligibilty and survival platinum versus capecitabine platinum-based chemotherapy platinum-pemetrexed platinum-refractory aUC platinum-refractory early failure oral cancer platinum-refractory mUC platinum-resistant grade 2-3 ovarian cancer platinum-resistant high-grade serous ovarian cancer platinum-resistant or platinum-refractory ovarian cancer platinum-resistant ovarian cancer platinum-resistant recurrent ovarian cancer platinum-resistente ovariumkanker platinum-sensitive advanced pancreatic cancer platinum-sensitive recurrent ovarian cancer platinum-sensitive recurrent ovarian carcinoma platinum-sensitive relapsed ovarian cancer platinum-sensitive relapsed ovarian cancer in gBRCA1 2 mutated patients PLATO study plaveiselcelcarcinoom PLCO cancer screening trial PLCO RCT secondary analysis PLCO trial PLD PLD with or without apatinib pleiomorf lobulair mammacarcinoom pleister pleural mesothelioma pleurectomie pleurectomy decortication PLGA PLGG plinabulin plus docetaxel versus docetaxel plinabulin versus pegfilgrastim for CIN prevention plinabulin vs pegfilgrastim ploegendienst PLP PLR PLRG Observational Study PM PM from CRC PMBCL PMBT caregivers PMF PMRT PMs from GC PN pN1 prostate cancer pnacreascarcinoom pNEN pNET PNET HR+5 trial PNETs pneumonitis pneumonitis after CRT for LA SNSCLC PNS PO-IMRT versus PPLN-IMRT POAF in cancer patients POD24 POEMS final analysis POHIM-CCRT trial Pola-G-Len Poland POLAR POLAR signature POLARIS trial POLARIS-02 trial POLARIS-03 study POLARIX study polatuzumab vedotin POLE-mutaties POLLUX and CASTOR studies POLLUX trial POLLUX-studie POLO study POLO trial OS results polo-like kinaseremmer poly-G repeats polycyclische aromatische koolwaterstoffen polycystic ovary syndrome and breast cancer risk polycystische nierziekte polycythemia vera polyfarmacie polygenic breast cancer risk scores polymerase theta polymicrobial bloodstream infections in oncohematological patients polymorfismen polyp subtype polypectomie polypharmacy polypose pom-dex pomalidomide pomalidomide-dexamethasone-daratumumab ponatinib ponatinib plus blinatumomab ponatinib versus imatinib Ponatinib-FLAG-IDA ponsegromab pooled analysis poor dental health and risk of pancreatic cancer poor KPS poor prognosis breast cancer POP-RT study population diversity population-based study of immunotherapy-related toxicities population-based treatment patterns and survival population-level cure patterns of cancer patients population-level survival PORT PORT after mandibulectomy PORT for residual TNBC after neoadjuvant chemotherapy PORT-C trial PORTEC trials cohort PORTEC-3 PORTEC-3 analysis PORTOS POSEIDON trial POSH-studie positive initial margins positive margins POSITIVE trial posoleucel possible synergy of enzalutamide and Lu-PSMA 617 radioligand therapy post hoc analyse ASPIRE-studie post hoc analyse FIRST-studie post hoc analyse KEYNOTE-001 studie Post hoc analysis PACIFIC study post hoc exploratieve analyse RAISE-studie post-CDK 4 6 inhibitor survival post-diagnostic beta blocker use and breast cancer-specific mortality post-diagnostic statin use post-hoc analyse PETACC-8 studie post-hoc analyse REACH-studie post-hoc analysis of CheckMate 227 post-induction ctDNA analysis post-mastectomie radiotherapie post-nephrectomy adjuvant pembrolizumab post-progression outcomes post-SRS recurrent brain metastases post-transplant cyclophosphamide post-transplantation cyclophosphamide post-transplantation cyclophosphamide-based GVHD prophylaxis post-transplantation ICIs post-transplantie lymfoproliferatieve ziekte post-treatment inflammation biomarkers and survival postcolonoscopy colorectal cancer postdiagnosis BMI and weight change postdiagnosis smoking cessation postdiagnostic calcium intake postdiagnostic coffee and tea consumption postdiagnostic metformin use postdiagnostic multivitamin supplement use postembolization syndrome postmastectomy implant reconstruction postmastectomy proton radiotherapy postmastectomy radiotherapy postmenopausal advanced HR-positive breast cancer postmenopausal bleeding postmenopausal breast cancer postmenopausal breast cancer risk postmenopausal breast cancer. oncogenic drivers of late distant recurrence postmenopausal cancer postmenopausal CRC risk postmenopausal early-stage breast cancer postmenopausal EBC postmenopausal endometrial cancer screening postmenopausal ER-positive DCIS postmenopausal HER2-positive HR-positive MBC postmenopausal HR+ HER2- metastatic breast cancer postmenopausal women postmenopauzaal mammacarcinoom postmenopauzaal mammarcinoom postmenopauzal HR+ HER2- breast cancer postmenopauzale borstkanker postmenopauzale hormoontherapie postmenopauzale vrouwen postoperatieve mortaliteit postoperative [11C]-methionine accumulation postoperative complications postoperative cough postoperative follow-up postoperative hypofractionated IMRT plus chemotherapy postoperative mortality postoperative outcomes postoperative outcomes of CRC postoperative pathology postoperative radiation field postoperative radiation therapy postoperative radiotherapy postoperative seizures postoperative SRS postoperative SRS with or without immunotherapy postoperative surveillance postpartum breast cancer and survival postprostatectomy HYPORT versus COPORT postprostatectomy salvage radiotherapy postradiation versus sporadic OCSCC posttransplantation maintenance with IRd versus Rd posttraumatische stressstoornis POTENT trial potential cost implications potential of genetics in identifying women at lower risk of breast cancer potential years of life lost due to cancer potentially modifiable risk factors potentially preventable emergency department visits among cancer patients potentially resectable stage III NSCLC potentially resectable stage IIIA B NSCLC POUT trial power morcellation poziotinib PPAR-gamma PPBC pPCL PPGL during pregnancy PPI use PPIs PPM PPTIDs PR status PR-status PR1 PRACTICAL-studie pralsetinib pralsetinib for RET fusion-positive NSCLC praluzatamab ravtansine PrC in the UK PrCa PRCC pre- and post-diagnosis leisure time physical activty pre- and post-diagnosis obesity pre- and post-diagnosis smoking pre-BCS MRI pre-diagnosis dietary patterns and survival pre-diagnosis tea and coffee consumption pre-existing autoimmune disease pre-existing cardiometabolic disease pre-existing mental illness pre-existing thyroid autoimmunity pre-GKRS leucocyt ratios pre-leukemisch pre-operative MRI imaging pre-transplant cytoreductive therapy PrE0505 study precancerous lesions that progress to cancer PRECIS study precisie-oncologie precisietherapie precision medicine PRECISION-studie PRecur model precursor stages of multiple myeloma PREDATOR trial prediabetes prediagnositc frailty prediagnostic alterations in circulating bile acid profiles prediagnostic bile acid levels prediagnostic immune cell profiles and breast cancer risk prediagnostic PSA level prediagnostic signs and symptoms prediagnostic telomere length PREDICT predicted versus observed metastasis-free survival predicting 90-day mortality after concurrent chemoradiotherapy predicting cardiac events predicting chemotherapy benefit predicting outcomes of various interventions for DCIS predicting pCR predicting response on ICIs predicting RFS and DSS predicting severe toxicity from chemotherapy for early-stage breast cancer in older patients prediction for 2020 prediction model prediction model for risk stratification prediction of AML risk in healthy individuals prediction of early progression prediction of invasive cervical cancer prediction of MSI prediction of Oncotype DX risk category prediction of outcome prediction of outcomes prediction of outcomes of ibrutinib for CLL prediction of progression prediction of recurrence in early-stage LUAD prediction of recurrence risk in endometrial cancer prediction of response to anti-PD-1 therapy prediction of response to neoadjuvant chemotherapy plus bevacizumab prediction of risk for myeloid malignancy prediction of severe fatigue after breast cancer diagnosis prediction of toxicity of systemic therapy for mCRPC in older men predictions for 2019 predictive and prognostic role of HO-1 expression predictive factors predictive role of frameshift mutations predictive role of tumor infiltrate predictive score for VCF predictive value of combined biomarkers predictive value of ctDNA predictive value of ECOG performance status ≥ 2 predictive value of pretreatment circulating tumor DNA predictive value of SNP-signature for recurrence predictive value of TMB for pembrolizumab efficacy predictor of outcomes with first-line endocrine therapy predictors of dacomitinib response predictors of early relapse predictors of efficacy of neoadjuvant therapy predictors of outcome and irAEs predictors of outcome of HCT predictors of recurrence predictors of recurrence after laparoscopic radical hysterectomy predictors of reponse to immune checkpoint inhibitors predictors of response and survival predictors of response to anti-PD-1 PD-L1 therapy predictors of single-agent resistance predictors of survival predictors of unplanned hospitalization predictors of uptake of CPM PREDIX HER2 trial preëclampsie preemptive local ablative therapy to residual oligometastases preexisting antibodies preexisting pain PREF ALL PREFERABLE-EFFECT trial pregabalin pregnancy pregnancy after breast cancer pregnancy after cancer diagnosis pregnancy duration pregnancy outcomes pregnancy-associated breast cancer pregnancy-associated cancer pregnancy-associated hematological malignancies pregnancy-related risk factors prehabilitatie prehabilitation preïmplantatie-genetische diagnose premalignant gastric cardia lesions premature aging premature ET discontinuation premature menopauze premenopausal aggressive HR+ HER2- ABC premenopausal avanced breast cancer premenopausal breast cancer premenopausal breast cancer patients premenopausal breast cancer risk premenopausal early breast cancer premenopausal ER-positive EBC premenopausal HR-positive HER2-negative advanced breast cancer premenopausal HR-positive HER2-negative metastatic breast cancer PREMER multicenter phase 3 trial prenatale blootstelling prenatale carcinogenenblootstelling PREOPANC study PREOPANC trial long-term results preoperatieve chemotherapie preoperatieve MRI preoperatieve radiotherapie preoperatieve radiotherapie voor rectumkanker preoperative adverse event risk index for head and neck cancer surgery preoperative anemia preoperative CA 19-9 preoperative CA19-9 and CEA preoperative chemotherapy preoperative chemotherapy or radiotherapy preoperative CONUT score preoperative CRT preoperative CRT plus nivolumab preoperative CRT with or without pazopanib preoperative detection of KRAS G12D mutation in ctDNA preoperative dietary fiber intake preoperative elevated tumor markers preoperative embolization preoperative features and clinical beneficial pathology preoperative identification of pathologic tumor invasion preoperative letrozole preoperative mFOLFOX6 plus cetuximab preoperative MRI preoperative nomogram predictive for early recurrence after pancreatectomy preoperative oral antibiotics preoperative patient-related prognostic factors preoperative PBI preoperative PET CT preoperative radiotherapy for retroperitoneal primary sarcoma preoperative risk evaluation preoperative therapy Preoperative-Palbociclib studie presalvage radiotherapy PSA level prescription opioid use presentation and characteristics presentation and outcomes PRESSING panel mutations PRESTO trial presurgical peritumoral lidocaine infiltration preterm birth preterm birth and risk of childhood cancer pretransplant DNA sequencing to detect residual disease pretreated advanced biliary tumors pretreated advanced endometrial cancer pretreated ALK-rearranged mNSCLC pretreated ALL pretreated aSCLC pretreated grade 3 or 4 glioma pretreated HER2+ metastatic breast cancer pretreated LA M NSCLC with EGFR exon 20 insertion pretreated multiple myeloma pretreated NSCLC pretreated RAS wild-type metastatic colorectal cancer pretreated STS pretreatment metastatic growth rate pretreatment NLR pretreatment vitamin D deficiency pretretreated EGFR-mutant NSCLC PREVAIL-studie prevalence and drivers in Ontario prevalence and prognostic implications of accelerated aging prevalence and risk factors prevalence and risk factors for multifocality prevalence of altered body image prevalence of clinical diagnosis of ADHD prevalence of functional disability among US cancer survivors prevalence of HBV prevalence of targetable genomic alterations prevalence of thromboembolic events prevalence of US cancer survivors preventable harm preventie preventie cervixkanker preventie mammacarcinoom prevention of cGVHD prevention of early menopause prevention with polaprezinc preventive drugs in the last year of life previously diagnosed primary malignancies in Swedish breast cancer patients previously treated advanced cervical cancer previously treated advanced gastric cancer previously treated advanced hepatocellular carcinoma previously treated advanced KRAS-mutated NSCLC previously treated advanced melanoma previously treated advanced non-squamous NSCLC previously treated advanced NSCLC previously treated advanced urothelial carcinoma previously treated aGBC previously treated ALK-positive advanced NSCLC previously treated aNSCLC previously treated cholangiocarcinoma previously treated CLL previously treated CML previously treated EGFR-mutated NSCLC previously treated FL and MCL previously treated HR+ HER2+ breast cancer previously treated mEGA previously treated MM previously treated mUC previously treated NSCLC previously treated NSCLC harboring KRAS G12C mutation previously treated NSCLC with KRAS G12C mutation previously treated NSCLC with KRAS p.G12C mutation previously treated PD-L1 expressing advanced NSCLC previously treated recurrent or metastatic cervical cancer previously treated SCLC previously treated small-cell lung cancer previously treated solid tumors in children and young adults previously treated sqNSCLC previously treated WM previously untreated advanced CRC previously untreated advanced solid tumors previously untreated AML previously untreated CLL previously untreated high-risk AML previously untreated locally recurrent or metastatic TNBC previously untreated MPM prijzen medicatie PRIMA study primair CNS-lymfoom primair melanoom primair urethracarcinoom primaire borstkanker primaire plasmacelleukemie primary and secondary CNS lymphoma primary brain tumor patients primary breast cancer treatment primary care clinic appointment time primary care intervention primary care presentation with fatigue primary care use primary care use and 90-day mortality primary central nervous system DLBCL primary central nervous system lymphoma primary central nervous system lymphoma in elderly patients primary CNS embryonal rhabdomyosarcoma with PAX3-NCOA2 fusion primary CNS lymphoma primary cutaneous melanoma primary debulking surgery primary definitve CRT versus upfront surgery primary dural lymphoma primary HPV testing with cytology versus cytology alone primary liver cancer primary liver resection for HCC primary mediastinal large B-cell lymphoma primary or interval CRS primary surgery primary surgery for OCSCC primary surgery versus CRT primary tumor location primary tumor resection primary tumor sidedness primary versus acquired T790M mutatiion PRIME study PRINCIPAL study prior ICI treatment prior or concurrent antibiotic use PRISM trial PRO-CTCAE PRO-IMPACT studie PROACCT score probability of live births among female survivors of childhood cancer ProBio trial PROC PROC with high FRα expression ProCAID study procarbazine-CCNU-vincristine procarbazine-lomustine-vincristine PROCAS Study PROCLAIM-CX-072 study PRODIGE 20-studie PRODIGE 24 trial PRODIGE 41-BEVANEC trial PRODIGE 9 trial analysis PRODIGE-24 CCTG PA6 trial PRODIGY trial PRODRIGE18 study PROFILE 1001 study ProfiLER-studie PROFILES registry PROfoud Trial OS analysis PROfound study PROfound trial PROfound trial post-hoc analysis profylactic salpingo-oophorectomy profylactische mastectomie prognose prognose luminal A prognosis prognosis after treatment for testicular cancer prognosis in women with endometriosis or adenomyosis prognosis of screen-detected versus interval breast cancers prognostic and predictive relevance of CMSs prognostic and predictive value prognostic and predictive value of HER2 expression in DCIS prognostic and predictive value of Immunoscore prognostic biomarkers for salvage chemotherapy following nivolumab prognostic case volume thresholds prognostic effect of nodal status prognostic effects of aspirin prognostic factors prognostic factors and outcomes after progression prognostic factors for relapse prognostic impact of ETS and DoR prognostic impact of HR subtypes prognostic impact of inflammation prognostic impact of mismatch repair status prognostic impact of myosteatosis prognostic impact of number of induction courses to attain CR prognostic impact of obesity prognostic impact of TP53 mutations prognostic implication of body composition change during primary treatment prognostic implications prognostic index prognostic model prognostic nomogram prognostic parameters in lobular versus nonlobular disease prognostic protein-based signature prognostic relevance prognostic relevance of 21-gene recurrence score prognostic risk score prognostic role in lung cancer prognostic role of circulating cell-free DNA prognostic role of hypoxia and angiogenesis prognostic role of PD-L1 expression on circulating tumor cells prognostic role of pre-diagnosis health-related quality of life prognostic role of TILs prognostic score prognostic score after neoadjuvant therapy and resection prognostic signature based on DNA repair genes prognostic significance prognostic significance of early detection of KRAS-mutation in cfDNA prognostic significance of metastatic pattern prognostic significance of microsatellites prognostic significance of NLR prognostic significance of survivin expression prognostic significance of TILs prognostic value prognostic value of chemotherapy-induced neutropenia prognostic value of CTCs prognostic value of ctDNA after resection for mCRC prognostic value of depth of response prognostic value of EndoPredict prognostic value of HER2-status of CTCs prognostic value of histopathological subtyping prognostic value of KRAS sequence variation prognostic value of MPS prognostic value of MVI prognostic value of PSA at 6 months after RT prognostic value of teratoma in primary tumor and postchemotherapy lymph nodes prognostic value of TILs prognostic value of VA-FI prognostic variables in patients achieving CR on initial therapy prognostication prognosticators prognostische biomarker prognostische discordantie prognostische test prognostische tools mammacarcinoom progress in cancer survival and incidence progressievrije overleving progressievrije overleving na 24 maanden progressing DD-LPS progression –free survival 2 progression and mortality progression following durvalumab consolidation progression of frailty progression risk in black and white men progression risk stratification progression within 24 months of frontline chemoimmunotherapy progressive and symptomatic medullary thyroid cancer progressive glioblastoma progressive mACC progressive metastatic breast cancer progressive MPM proguanil atovaquone projections until 2030 projections until 2039 prolaris prolonged infusion of low dose gemcitabine prolonged-duration chemoprophylaxis of venous thromboembolism PROLUNG study PROMIS-studie PROMISE-GIM6 trial PROMISE-studie promotie promoting physical activity after lung cancer surgery prone versus supine breast radiotherapy PRONOPALL-studie propanolol plus pembrolizumab PROpel phase 3 trial PROpel trial PROPHECY study prophylactic antibiotics prophylactic chestwall irradiation prophylactic contralateral breast irradiation prophylactic cranial irradiation prophylactic heparin in ambulatory patients with solid tumors prophylactic hyperthermic intraperitoneal chemotherapy prophylactic intravitreal bevacizumab prophylactic RT versus standard of care prophylactic use of compression sleeves proportion of patients receiving ultimately approved treatments proposed diagnostic criteria PROREPAIR-B study PROs PROs after BCT versus mastectomy with reconstruction PROs with olaparib or placebo plus abiraterone PROSELICA-studie Prosigna Prosigna risk of recurrence score Prosigna test in breast cancer PROSINT trial PROSPECT trial prospective analysis prospective genotyping prospective IDEA trial prospective precision oncology prospective study of association of lever function and CRC risk prospective study of mid-term neurotoxicity prospective validation Gail Model PROSPER study PROSPER study final OS analysis prostaatcarcinoom prostaatcarcinoom. androgeendeprivatietherapie prostaatkanke prostaatkanker prostaatkankermortaliteit Prostaid prostate cancer prostate cancer aggressiveness prostate cancer among Black men in Canada prostate cancer diagnosis prostate cancer in Black and White men prostate cancer in transgender women prostate cancer incidence and mortality prostate cancer incidence in men with PSA below 3 ng ml prostate cancer long-course versus short-course ADT with PORT prostate cancer mortality prostate cancer outcomes prostate cancer outcomes following solid-organ transplantation prostate cancer probability in Black and non-Hispanic White men prostate cancer prognosis prostate cancer progression prostate cancer risk prostate cancer risk and mortality prostate cancer screening prostate cancer treatment prostate cancer treatments prostate cancer; long-term follow up NRG RTOG 9413 study prostate MRI prostate radiotherapy with adjuvant versus neoadjuvant androgen deprivation prostate tumors from African American and European American men prostate-only versus whole-pelvic RT prostatectomie proteasome inhibitor proteasoomremmer ProtecT ProtecT study PROTECT-1 en -2 studies PROTECT-studie PROTECTIVE-1 study Proteus Donna study protocol waivers proton beam radiation therapy proton beam radiotherapy proton beam therapy proton craniospinal irradiation proton pump inhibitor use proton radiotherapy proton therapy proton therapy and photon therapy proton therapy reirradiation proton versus photon radiation proton versus photon radiotherapy protonradiotherapie protontherapie PROUD-PV and CONTINUATION-PV studies proximal colon serrated neoplasia proximal versus distal detection PRROC PRRT PRRT versus chemotherapy or targeted therapy PRT PRT and CIRT pruritus related to ICIs and anti-HER2 therapies PS PSA PSA bounce PSA levels in men aged 55-60 PSA screening PSA screening and 15-year prostate cancer mortality PSA screening and PCSM in NHB and NHW veterans PSA screening in older males PSA-based EFS as surrogate for OS PSA-recidief PSA-screening PSAD PSAV PSCCB pSCI versus IFRT PSMA PET-CT versus conventional imaging PSMA-PET imaging pSmad2 PSN PSO after resection of breast cancer in BRCA1 2 variant carriers psoriasis psoriasis and psoriatic arthritis psoriasis risk PSPDR PSROC psychiatric disorders in cancer patients psychiatric utilisation prior to cancer diagnosis psycho-oncology psychologic distress psychological distress psychological outcomes psychosocial health and lifestyle pT1 node-negative TNBC pT1-2N0M0 OTSCC PTBP1 PTC PTCL pten PTEN loss predicts poor prognosis PTEN promoter methylation and prognosis PTEN-verlies PTGS2 PTH PTR PTSD pubertal timing and breast cancer risk pulmonaire metastasen pulmonary adenocarcinoma pulmonary embolism pulmonary fibrosis pulmonary large cell neuroendocrine carcinoma pulmonary oligometastases pulmonary oligorecurrence after radical resection of NSCLC purchase of antidepressants PURE study PURE-01 PURE-01 study PUVA therapy PV PVI PVRL PVs in hereditary cancer genes PWH PWH with cancer pyrotinib pyrotinib plus capecitabine pyrotinib plus metronomic etoposide pyrotinib-trastuzumab-chemotherapy Q-122 Q-koorts QNBC QoL QOL analysis QOL and physical functoning QOL and psychosocial well-being in young survivors QOL in CARD study QOL in older adults after major cancer surgery QOLIXANE trial QSkin Study QSkin-studie QUADRA study quadrivalent HPV vacinnation quality of breast cancer care in The Netherlands and Norway quality of life quality of life after lung resection quality of life after surgery quality of life and mortality quality of life in survivors of adolescent and young adult cancer quality of surgery quality-adjusted time without symptoms of progression or toxicity quantification of contribution of risk factors QuANTUM-First trial QuANTUM-R study QUAZAR AML-001 Maintenance Trial QUAZAR AML-001 trial QUINTETT trial secondary analysis QuiRedex quitting smoking after NSCLC diagnosis quitting smoking at or around diagnose lung cancer quizartinib R M ACC R M CC R M cervical cancer R M cervical carcinoma R M cervical SCC R M head and neck cancer R M HNC R M HNSCC R M MCC R M NPC R M SDC R M TNBC R R ALCL R R ALL R R ALL in CAR-naive and CAR-exposed children and young adults R R AML R R AML in children R R AML in patients not eligible for intensive therapy R R AML MDS R R B-ALL R R B-ALL in adults R R B-ALL in children and adolescents R R B-ALL in young children R R B-ALLafter allogeneic HSCT R R B-cel lymphoma R R B-cell lymphoma R R B-cell non-Hodgkin lymphoma R R B-NHL R R BCP-ALL R R BRAF V600-mutant pHGG R R cHL R R CLL R R CLL or SLL R R CLL SLL R R CNSL R R diffuse large B-cell lymphoma ibrutinib-lenalidomide-rituximab R R DLBCL R R extranodal natural killer T-cell lymphoma R R FL R R FLT3-mutated AML R R folliculair B-cell lymphoma R R FTL3-mutated AML R R high-risk CLL R R high-risk neuroblastoma R R HL R R indolent NHL R R large B-cell lymphoma R R LBCL R R lymphoma R R mature lymphoid neoplasms R R MCL R R MDS R R MF or SS R R MF SS R R MM R R MSS mCRC R R multiple myeloma R R myelofibrosis R R MZL R R neuroblastoma R R NHL R R OC R R osteosarcoma R R PCNSL R R PCNSL or SCNSL R R peripheral T-cell lymphoma R R PMBCL R R PTCL R R T-ALL R R TCL R R WM r r-AML R-cadherine R-CHOP R-CHOP 14 versus 21 studie R-CHOP-14 R-HAD with or without bortezomib R-M HNSCC R2-CHOP RAAS race and ethnicity-adjusted age recommendation race and outcomes race and PN risk race and risk of subsequent aggressive breast cancer race and survival race ethnicity-associated differences in stage at diagnosis and survival among leading cancer types race-based differences in survival race-dependent differences in risk of MGUS progression race-specific differences race-specific outcomes in equal access health care setting racial and ethnic differences racial and ethnic differences in germline pathogenic variants racial and ethnic disparities racial disparities racial disparities in frailty and function limitations racial disparities in stage at diagnosis and survival racial disparity in biomarker-directed therapy racial disparity in distant recurrence-free survival racial disparity in survival racial ethnic disparities racial ethnic disparities in outcomes RAD51 test radcial cystectomy RADIANT-2 RADIANT-4 radiation and androgen deprivation for Pca radiation and chemotherapy radiation and chemotherapy for CNS and pediatric head-and-neck tumors radiation dermatitis in breast cancer radiation dose radiation doses to organs at risk radiation exposure from CT examinations radiation facility volume radiation for localized prostate cancer radiation pneumonitis radiation segmentectomy radiation therapy facility patient volume radiation therapy for cancer radiation therapy for head and neck cancer radiation therapy for medulloblastoma radiation therapy plus ICI therapy radiation to hypothalamus and pituitary radiation-associated intracranial malignancy radiation-associated ototoxicity radiation-associated trismus after head and neck cancer radiation-induced cardiac toxicity radiation-induced cystitis radiation-induced meningioma radiation-induced oral mucositis and dermatitis radiation-related CV risk radical cystectomy radical hemi-thoracic radiotherapy radical hysterectomy radical prostatectomy versus watchful waiting RADICALS-HD trial RADiChol-studie radioactief jodium radioactive iodine-refractory differentiated thyroid cancer radiodermatitis radiodermatitis in breast cancer patients radioembolisatie radiofrequency localization radiofrequentie-ablatie radiogenomics radioiodine-refractory differentiated thyroid cancer radiojodium-refractair gedifferentieerd schildkliercarcinoom radiologic complete response radiomica radiomics radionecrosis radiosensitivity radiosurgery radiotherapeutic efficacy radiotherapie radiotherapy radiotherapy after BCS radiotherapy for breast cancer radiotherapy for childhood cancer radiotherapy for esophageal cancer radiotherapy for gynecologic cancers radiotherapy for oropharyngeal cancer radiotherapy for prostate cancer radiotherapy for rectal cancer radiotherapy or autologous SCT radiotherapy or temozolomide radiotherapy plus docetaxel radiotherapy plus ipilimumab radiotherapy to regional nodes in early breast cancer radiotherapy versus surgical resection radiotherapy versus temozolomide radiotherapy vs surgery radiotherapy with or without S-1 chemotherapy radiotherapy-induced OM radiotherapy-related heuropathic pain radium 223 radium-223 radon radotinib RAGNAR trial RAI for differentiated thyroid cancer in children and young adults RAI for hyperthyroidism RAI-R DTC RAINBOW-studie RAINFALL study RAIR-DTC RAL versus LAL ralimetinib raloxifeen RAMES study RAMOSE trial ramucirumab ramucirumab beyond progression plus TAS-102 ramucirumab plus atezolizumab ramucirumab plus chemotherapy ramucirumab plus osimertinib ramucirumab plus paclitaxel ramucirumab plus pembrolizumab ramucirumab plus pembrolizumab after failure of immunotherapy ramucirumab-irinotecan-cisplatin randomized phase 2 MAINTAIN trial randomized phase 2 NEONAX trial randomized phase 2 SALV-ENZA trial randomized trials of cancer screening RANGE study RANGE-studie RAP trial rapid binding off-rate CD19 CAR-T therapy RAPID trial rapidly proliferating glioblastoma RAPIDO trial RARC with IUD versus ORC rare cancers rare CNS tumors rare sarcomas rare T cell lymphomas rare versus common genetic variants RARECAREnet RAS alterations RAS BRAF wild-type metastatic colorectal cancer RAS BRAF-wt metastatic colorectal cancer RAS mutant unresectable CLM RAS mutated MGMT methylated mCRC RAS wild-type left-sided metastatic colorectal cancer RAS wild-type metastatic colorectal cancer RAS wildtype metastatic colorectal cancer Ras-gebonden associaties tussen obesitas en early-onset mammacarcinoom en specifieke moleculaire subtypen RAS-mutant pancreas adenocarcinoma RAS-mutated metastatic colorectal cancer RAS-mutaties RASER study RASTEN-studie rate of memory change rate of occult contralateral nodal disease rate of secondary sarcoma rates of brain metastase of breast cancer subtypes rates of cancer and all-cause mortality RATHL trial RATIONALE 302 study RATIONALE 304 study RATIONALE-301 trial RATIONALE-302 study RATIONALE-306 RB1 mutation status RC48 plus toripalimab RCB after NACT RCC RCC after ICI treatment RCC at intermediate or high risk of relapse RCC brain metastases RCC in VHL RCC incidence and mortality RCM RD RDC plus blinatumomab RDD re-biopsy after first-line treatment re-excisie RE-ExPEL trial re-irradiation plus BV and TMZ re-RT re-testing predictive biomarkers in surgical specimens REACH-2 study REACH2 trial REACH3 study REACH5 study REACHIN study ReACT study readministration of anti-PD-1 or anti-PD-L1 after irAE readmission readmission risk scoring system real world effectiveness of nivolumab after systemic therapy real world evidence real world outcomes real world outcomes of pertuzumab and T-DM1 real-life experience real-life outcomes real-life outcomes with pazopanib real-life results of CAR T-cell therapy real-world analysis real-world breast cancer screening with DBT versus 2D mammography real-world cardiovascular outcomes with degarelix versus leuprolide real-world clinical outcomes with avelumab real-world comparison of tisa-cel and axi-cel real-world data real-world data model real-world effectiveness against cervical cancer real-world effectiveness of second-line ICI versus chemotherapy real-world effectiveness study real-world effectivenss for prevemtion of high-grade vulvovaginal lesions real-world evaluation real-world experience real-world experience in the UK real-world incidence of cardiotoxicity real-world mutation-tailored treatment selection real-world OS real-world outcomes real-world outcomes after definitive radiation therapy real-world outcomes of first-line immunotherapy real-world outcomes of ICIs for cancer real-world outcomes of neoadjuvant endocrine therapy real-world outcomes with brigatinib real-world outcomes with first-line treatments real-world outcomes with ICIs real-world outcomes with ICIs in cohorts underrepresented in clinical trials real-world outcomes with second or later line lurbinectedin real-world overall survival real-world pooled analysis real-world QOL with first-line nab-paclitaxel and gemcitabine for mPaC real-world survival real-world survival of early-stage breast cancer patients real-world treatment and survival real-world treatment drop-off real-world treatment patterns and survival in Germany real-world use real-world use of EGFR TKIs REALISE phase 2 study REALITY trial REASSURE study rebiopsy rEC recent weight loss receptor conversion in breast cancer metastases receptor discordance between primary tumor and brain metastases receptor expression discordance between primary and recurrent breast cancer receptor status receptor status conversion following neoadjuvant chemotherapy receptorstatusverandering recidief recidiefrisico recidiefrisico ER-positief mammacarcinoom recidiverend multipel myeloom recidiverend of refractair ALL recidiverend of refractair mantelcellymfoom recidiverend of refractair multipel myeloom recidiverend refractair mantelcellymfoom recidiverend refractair multipel myeloom recidiverend refractair PCNSL recidiverende beroerte recidiverende ER-positieve borstkanker RECIST recombinant erythropoietin-refractory anemia recombinant human granulocyte colony-stimulating factor recombinant poliovirus for recurrent glioblastoma recombinant zoster vaccine recommended definition RECORD-2 recovery of gonadal function recovery of HRQoL of patients and parents recovery of ovarian function rectal adenocarcinoma rectal cancer rectal cancer in elderly patients rectumcarcinoom rectumccarcinoom rectumkanker recurrence recurrence after complete response to HAE or DEB-TACE recurrence after incomplete resection recurrence after nephrectomy for RCC recurrence in nipple-areola complex recurrence of breast cancer recurrence or oligometastases in gynecologic malignancies recurrence patterns recurrence patterns after RT for brain metastases recurrence predictive model recurrence risk recurrent aCRC recurrent acute myeloid leukemia recurrent advanced urothelial cancer recurrent and or metastatic HNSCC recurrent and or metastatic HNSCC with HRAS mutations recurrent APTs and PCs recurrent cervical cancer recurrent CT scans for early gastric cancer recurrent endometrial cancer recurrent EOC recurrent GBM recurrent glioblastoma recurrent glioma recurrent H3 K27M-mutant diffuse midline glioma recurrent head and neck squamous cell carcinoma recurrent hepatocellular carcinoma recurrent HGG recurrent high grade glioma recurrent high-grade serous ovarian cancer recurrent HNSCC recurrent intermediate-stage HCC recurrent LA NPC recurrent low-grade serous ovarian cancer recurrent malignancies in children and adolescents recurrent medulloblastoma recurrent melanoma after adjuvant immunotherapy recurrent meningioma recurrent metastatic breast cancer recurrent metastatic head and neck squamous-cell carcinoma recurrent metastatic HRAS-mutant salivary gland cancer recurrent nonmuscle invasive bladder cancer recurrent of refractory soldi tumors in children and adolescents recurrent or advanced endometrial cancer recurrent or advanced mismatch repair-deficient EC recurrent or metastatic ASPS recurrent or metastatic cervical cancer recurrent or metastatic CSCC recurrent or metastatic endometrial cancer recurrent or metastatic head and neck squamous cell carcinoma recurrent or metastatic HNSCC recurrent or metastatic mucosal HNSCC recurrent or metastatic nasopharyngeal carcinoma recurrent or metastatic NPC recurrent or metastatic triple-negative or BRCA1 2-associated breast cancer recurrent or persistent gynecologic malignancies recurrent or persistent ovarian cancer recurrent or second primary HNSCC recurrent ovarian and endometrial cancer recurrent ovarian cancer recurrent platinum-resistant ovarian carcinoma recurrent platinum-sensitive ovarian cancer recurrent prostate cancer recurrent uterine serous carcinoma recurrent women’s cancers recurring advanced melanoma recurring endometrial cancer red blood cell transfusion red flag signs and symptoms red or processed meat intake and risk of red recurrence and mortality ReDOS study REDUCE trial reduced intensity alloHCT reduced LVEF reduced-dose capecitabine plus cetuximab maintenance reduced-dose fluoropyrimidine therapy reduced-dose radiation therapy reducing early discontinuation adjuvant aromatase inhibitor therapy refractory B cell malignancies refractory B-cell lymphoma refractory cancers refractory central nervous system leukemia refractory colorectal cancer refractory EGFR-mutated NSCLC refractory EGFR-T790M-positive NSCLC with CNS metastases refractory esophageal cancer refractory large B cell lymphoma refractory large B-cell lymphoma refractory mCRC refractory mCRPC refractory metastatic colorectal cancer refractory MM refractory or relapsed hairy-cell leukemia refractory RAS wt mCRC refractory relapsed B-cell malignancies refractory soft tissue sarcomas refractory solid tumor refractory solid tumors harboring CCNE1 amplification refractory solid tumors in children refractory viral infections after allo-HCT refusal of conventional cancer therapy refusal of surgery REGARDS cohort study REGARDS study regional inequalities of tumor size at diagnosis regional lymph node irradiation regional nodal irradiation regional versus general anesthesia regionale lymfeklierbestraling REGN5459 REGOBONE study REGOMA study REGOMUNE trial REGONIVO REGONIVO study regorafenib regorafenib plus avelumab regorafenib plus nivolumab regorafenib-ipilimumab-nivolumab REGOSARC reintroduction of chemotherapy reintroduction of ICIs rejection of systemic therapy relacorilant plus nab-paclitaxel relapse relapse after adjuvant BEP relapse after allogeneic stem-cell transplantation relapse after alloHCT relapse after autoSCT relapse detection by routine CT scan versus symptoms relapse of ALL in children and young adults relapse rate ReLApsE trial relapsed aggressive B-cell non-Hodgkin lymphoma relapsed AL amyloidosis relapsed AML in children relapsed and or refractory multiple myeloma relapsed BRCA1 or 2 mutated ovarian cancer relapsed CLL relapsed CLL SLL relapsed early-stage favorable HL relapsed EGFRvIII-expressing glioblastoma relapsed Ewing sarcoma relapsed follicular lymphoma relapsed glioblastoma relapsed indolent non-Hodgkin lymphoma relapsed metastatic germ cell tumors relapsed MM relapsed multiple myeloma relapsed of refractory solid tumors or lymphoma relapsed or refractory ALL in children and young adults relapsed or refractory AML relapsed or refractory AML in children relapsed or refractory B-ALL relapsed or refractory B-cell ALL in children and young adults relapsed or refractory B-cell malignancies relapsed or refractory bone tumors relapsed or refractory cHL relapsed or refractory chronic lymphocytic leukemia relapsed or refractory classic Hodgkin lymphoma relapsed or refractory classical Hodgkin lymphoma relapsed or refractory diffuse large B cell lymphoma relapsed or refractory diffuse large B-cell lymphoma relapsed or refractory DLBCL relapsed or refractory ENKTL relapsed or refractory follicular lymphoma relapsed or refractory Hodgkin lymphoma relapsed or refractory Hodgkin lymphoma. BV plus bendamustine as first salvage therapy relapsed or refractory indolent lymphoma relapsed or refractory large B-cell lymphoma relapsed or refractory lymphoma relapsed or refractory MCL relapsed or refractory multiple myeloma relapsed or refractory neuroblastoma relapsed or refractory non-Hodgkin lymphoma relapsed or refractory primary CNS or introcular lymphoma relapsed or refractory rhabdomyosarcoma relapsed or refractory Sézary syndrome relapsed or refractory solid tumors relapsed or refractory WM relapsed or relapsed and refractory multiple myeloma relapsed or untreated MCL relapsed ovarian cancer relapsed PCNSL relapsed Ph+ ALL after allogeneic hematopoietic cell transplantation relapsed platinum-sensitive ovarian cancer relapsed refractory AML relapsed refractory diffuse large B cell lymphoma relapsed refractory Hodgkin lymphoma relapsed refractory multiple myeloma relapsed refractory multiple myeloma. subcutaneous daratumumab relapsed refractory NHL relapsed refractory Ph+ ALL relapsed refractory systemic light-chain amyloidosis relapsed SCLC relative dose intensity relative lymphocyte count relative SMN risk in adult cancer patients relative survival RELATIVITY-020 trial RELATIVITY-047 and CheckMate 067 RELATIVITY-047 trial relatlimab RELAY study RELAZA2 study RELEVANCE study RELEVANCE trial RELEVENT trial religieuze overtuigingen relmacabtagene autoleucel relugolix for ADT REMAGUS02 study remaining life expectancy REMARC study remming CD95-route remming hedgehog-signaalroute remnant liver ischemia REMORA study REMOTUX trial renal cancer risk renal cell carcinoma renal function renal impairment ReNeu trial RENMIN-215 trial RENO study RENOBATE trial reovirus repeat hepatectomy vs percutaneous radiofrequency ablation repeat radiosurgery repeat SRS repeated CTC enumeration for early treatment monitoring repeated prostate cancer screening with PSA testing and MRI repotrectinib reproduction outcomes after breast cancer reproductive factors reproductive factors and endometrial cancer risk in East Asian women reproductive history and molecular subtype of breast cancer diagnosed before age 51 years RERISE long-term follow-up RERISE-studie resctable NSCLC resectable and borderline resectable pancreatic cancer resectable CLM resectable colorectal cancer resectable colorectal cancer liver metastases resectable esophageal adenocarcinoma resectable gallbladder cancer resectable gastric cancer resectable HCC resectable head and neck squamous cell carcinoma resectable HPV-unrelated head and neck cancer resectable LAHPC resectable locally advanced HNSCC resectable locally advanced rectal cancer resectable lung SCC resectable malignant pleural mesothelioma resectable melanoma resectable MIBC resectable mucosal melanoma resectable NSCLC resectable pancreatic cancer resectable pancreatic head cancer resectable PD-L1 negative NSCLC resectable PDAC resectable regionally advanced melanoma resectable stage IB-IIIA NSCLC resectable stage III melanoma resectable synchronous CLM resected ampullary carcinoma resected biliary tract cancer resected brain metastases resected colon cancer resected colorectal liver metastases resected early-stage NSCLC resected esophageal of gastroesophageal junction cancer resected glioblastoma resected high-risk melanoma resected lung adenocarcinoma resected NSCLC BMs resected pancreatic cancer resected PDAC resected RPS resected stage 3 and oligometastatic stage 4 melanoma resected stage IB-IIIA NSCLC resected stage II-IIIA NSCLC resected stage III colon cancer resected stage III IV melanoma resected stage III melanoma resected stage IV melanoma resectie laaggradig glioom resection resection before immunotherapy resection of brain metastases resection of primary tumor residual cancer burden residual cancer burden index residual HER2-positive breast cancer residual or recurrent glioblastoma residual risk of breast cancer after bariatric surgery residual TNBC after neoadjuvant chemotherapy RESILIENT resiquimod resistance alterations resistant starch resistentie RESONANCE trial RESONATE study RESONATE-17 respiratory morbidity respiratory outcomes Response Assessment in Neuro-Oncology werkgroep response of localized prostate cancer to definitive RT RESPONSE study 5-year follow-up response to anti-EGFR therapy response to HER2-targeted therapy response to ICI response to ICIs response to immunotherapy response to lung cancer immunochemotherapy response to neoadjuvant treatment response to nivolumab plus ipilimumab response to preoperative CRT response to stereotactic radiosurgery response to third dose of BNT162b2 vaccine in actively treated cancer patients RESPONSE-2 RESPONSE-2 trial 5-year follow-up response-adapted low dose radiotherapy response-adapted treatment following radiotherapy response-based radiotherapy responses to retreatment RESQ study restarting durvalumab after stopping without disease progression RESTORE Restoring Invisible and Abandoned Trials results in North America resumption of immune checkpoint inhibitor therapy Ret RET fusion-positive advanced non-small cell lung cancer RET fusion-positive NSCLC RET fusion-positive solid tumors RET TKIs for cancer RET-activated thyroid cancer RET-altered thyroid cancers RET-fusion positive NSCLC RET-MAP trial RET-rearranged lung cancer retinoblastoma retinoblastoma patients retinoblastoom retinol retroperitoneaal sarcoom retroperitoneal liposarcoma retroperitoneal lymph node dissection retroperitoneal sarcoma retrospectieve analyse PETACC-3 studie retrospective study of W&S vs TMZ vs RT reumatoïde artritis REVERCE study reverse gene expression profiling reversions in BRCA and PARP revised STARS trial REVIVE Trial revumenib rezvilutamide (SHR3680) RFA RFA after TACE plus sorafenib RFA with or without toripalimab RFS rGBM rhabdomyosarcoma rhabdomyosarcoom rHCC rHGG rHNSCC rHR-NB ribociclib ribociclib plus ET vs combination therapy ribociclib plus fulvestrant ribociclib plus letrozole riboflavine RIC alloHSCT rich TILs RICH-ART study Richter syndrome Richter transformation RICMAC-studie ridaforolimus RIGHT Choice trial right-sided colon cancer rilotumumab RILT rindopepimut ripretinib ripretinib versus sunitinib for gastrointestinal stromal tumor risedronaat risico borstkanker risicoscore risicostratificatie rising ctDNA as early biomarker of progression risk and outcomes of COVID-19 in cancer patients risk factor for low RDI risk factors risk factors and outcomes risk factors and prognostic implications risk factors and racial or ethnic disparities risk factors associated with second primary lung cancer risk factors for breast cancer risk factors for cardiovascular disease risk factors for clinically significant prostate cancer risk factors for depression and anxiety risk factors for development of bullous pemphigoid risk factors for early mortality risk factors for first and second primary melanoma risk factors for immune-related adverse events risk factors for keratinocyte carcinoma risk factors for primary bone cancer risk factors for primary resistance to immunotherapy risk factors for progression risk factors for recurrence risk factors for recurrence and death risk factors for short-term PSA recurrence risk factors for small adult height risk factors for voice and speech symptoms risk factors of late distant recurrence risk model risk of adverse events with RT in patients receiving immunotherapy risk of aggressive breast cancer subtype risk of all cancer types risk of Alzheimers disease in survivors risk of bladder cancer risk of breast cancer risk of breast cancer after breast radiation and anthracycline use risk of breast cancer by intrinsic subtypes risk of breast SCC risk of cancer risk of cancer in regular and low meat-eaters and vegetarians risk of cardiac diseasse risk of cardiac events risk of cardiovascular disease mortality risk of cardiovascular hospitalization risk of cerebrovascular disease risk of chemotherapy-related amenorrhoea in early stage breast cancer patients risk of childhood cancer risk of childhood cancers risk of chronic health conditions risk of colorectal adenoma risk of congenital malformation risk of contralateral breast cancer risk of death from breast cancer risk of developing ipsilateral BC post-treatment risk of developing or dying of cancer risk of digestive tract cancers risk of early-onset cancer risk of early-onset colorectal cancer risk of elevated intraocular pressure risk of endometrial cancer risk of esophageal and gastric cancer risk of future new cancer risk of gastric and oesophageal cancer risk of gastrointestinal cancer risk of genitourinary diseases risk of glioma risk of hematologic cancer risk of hematological malignancies risk of herpes zoster risk of IBTR and CBC risk of in situ and invasive lesions after primary DCIS risk of incident and fatal breast cancer risk of infections risk of infectious complications risk of internal malignancies risk of interstitial lung disease risk of late-onset breast cancer in genetically predisposed women risk of lethal prostate cancer risk of lifestyle-related cancers risk of liver cancer risk of lung risk of lung cancer histological subtypes risk of major psychiatric disorders risk of malignancy risk of malignant neoplasms risk of MDS and AML risk of mental health problems risk of MM risk of obesity-related cancers risk of ocular adverse events risk of ovarian and breast camcer risk of PaC risk of pancreatic cancer risk of peritoneal disease risk of pneumonitis risk of preterm birth risk of primary lung cancer after treatment for breast cancer risk of primary urological and genital cancers after breast cancer risk of progression risk of psychiatric disorders risk of QTc prolongation risk of RCC risk of recurrence risk of recurrence and mortality risk of recurrence and pregnancy outcomes risk of second brain tumor risk of second cancer risk of second event after DCIS risk of second malignancies risk of second non-breast primaries risk of second primary breast cancer risk of second primary cancer risk of secondary malignancies risk of simultaneous of subsequent cancers risk of SMNs after treatment for testicular germ cell cancer risk of somatic diseases in offspring risk of SPC after breast cancer risk of SPCs risk of SPMs risk of stroke risk of subsequent cancers risk of subsequent primary cancers risk of subsequent primary neoplasms risk of suicidal self-directed violence risk of suicide risk of suicide after cancer diagnosis risk of testicular germ cell tumors risk of thoracic vertebral fracture risk of uterine cancer in breast cancer survivors risk of uterine diseases risk of venous thromboembolism risk of VTE and ATE risk of VTE and ATE with KRd or VRd risk of young-onset breast cancer risk prediction calculator for sentinel node positivity risk prediction model risk stratification risk stratification of EO-CRC risk-adapted chemoimmunotherapy risk-adapted maintenance therapy risk-adapted omission of nCRT risk-adapted therapy for pediatric Hodgkin lymphoma risk-adapted tocilizumab to prevent CRS risk-based treatment strategy risk-based treatment stratgy risk-directed thromboprophylaxis risk-reducing salpingo-oophorectomy risks and benefits of anticancer drugs risks of subsequent primary cancers according to HR status risks of watch-and-wait approach RIST-rNB-2011 trial rituximab rituximab maintenance rituximab plus lenalidomide rituximab SC of IV rituximab-associated infusion reactions rivaroxaban RLI before chemotherapy RLR versus OLR RM- NPC RM-NPC RMHNSCC RMM RMP RMS RMS 2005 study RNA next-generation sequencing RNA-disruptie rNPC RNU RNU2-1f ROAR basket study ROAR basket trial ROAR study robot-assisted partial nephrectomy robot-assisted trachelectomy robot-assisted versus laparoscopic versus open radical prostatectomy robot-assisted versus open or laparoscopic surgery robot-geassisteerde prostatectomie robotic versus laparoscopic hepatectomy robotic versus open pancreaticoduodenectomy robotic-assisted versus laparoscopic liver surgery ROC’N’ROLL trial rociletinib rogaratinib roken rolapitant ROLARR-studie role of adrenalectomy role of diet in colorectal cancer incidence role of perioperative radiotherapy role of therapy ROMANA 3-studie romidepsin and lenalidomide based regimens romidepsine romiplostim ROMULUS study romyelocel-L to reduce infection during induction chemotherapy rookloze tabaksproducten ropeg ropeginterferon alfa-2b ROR1 ROS-1 rearranged NSCLC ROS1 fusion-positive NSCLC ROS1-positive aNSCLC ROS1-positive NSCLC ROS1-rearranged advanced NSLCL ROS1-rearranged aNSCLC ROS1-rearranged NSCLC ROS1+ NSCLC ROSE TRIO-012 Ross rotating night shift work ROTOR Rotterdam Study routine splenectomy specimens Rova-T roxadustat RP vs IMRT plus ADT RP-LPS RPD vs OPD rPFS rPFS and cPFS as surrogates for OS RPLMS RPLND RPS RR CLL SLL RR DLBCL RR multiple myeloma after lenalidomide RR PTCL RR versus MR strategy RRFL RRFL after two or more prior lines of therapy rrHL RRM RRM in high-risk patients RRMM rrPMBCL RRSO RRSO in BRCA1 2 mutation carriers RRx-001 RS rs4143094 RSClin risk calculator RT RT after BCS RT after complete response to ABVD RT and trastuzumab for HER2-positive breast cancer RT dose escalation RT for BC RT for cancer in adolescent and young adults RT for HNC RT for oligometastatic prostate cancer RT for pituitary adenoma or craniopharyngeoma RT in CLL RT omission after BCS RT plus immunotherapy RT plus XRT RT versus IFL RT versus sequential DDGP and RT RT versus surgery RT versus TOS RT versus transoral robotic surgery RT with or without cisplatin RT with or without icotinib RT with or without trastuzumab after lumpectomy for HER2-positive DCIS RT-associated secondary cancer RT-induced mucocutaneous side effects RT-naïve CNS metastases from EGFR-mutated NSCLC RT1 trial RTOG 0126-studie RTOG 0214 study RTOG 0415 RTOG 0521 study RTOG 0539 trial RTOG 0617 RTOG 0617 trial RTOG 0813 trial RTOG 1014 study RTOG 1016 study RTOG 1203 trial RTOG 9402 RTOG 9408 secondary analysis RTOG-0129 risk groups RTOG1205 RTSG-SIOP RTW RUBY trial rucaparib rucaparib maintenance rucaparib versus placebo maintenance followin chemotherapy rusfertide for control of erythrocytosis ruxolitinib ruxolitinib plus azacytidine ruxolitinib plus etanercept ruxolitinib versus BAT after HC failure RVD induction RVd with or without daratumumab RVd with or without isatuximab RxPONDER study S-1 S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin S-1 plus oxiplatin S-1 versus S-1 plus oxaliplatin versus S-1 plus oxaliplatin plus RT S-1-based CRT S-CRC S-PORT S-TRAC trial S. aureus colonisation S1416 S1500 trial S1512 trial S1826 trial S1P-antagonisme SA SABCS 2015 SABR SABR for patients with early non-small cell lung cancer and interstitial lung disease SABR for up to 5 oligometastases in patients with cancer SABR to intrapulmonary lesions SABR versus IRE SABR-5 trial SABR-COMET study SABR-COMET trial long-term results SABRINA-studie SABRT sacher sacituzumab govitecan sacituzumab govitecan versus chemotherapy sacituzumab govitecan-hziy sacral chordoma SACURA trial SADAL study SADAL study survival results Safe PBM study SAFE trial SAFE-HEaRt study safety and patient-reported outcomes safety and survival impact safety implications safety of AA with glucocorticoids safety of acalabrutinib monotherapy safety of CRS HIPEC safety of discontinuing maintenance pulse therapy beyond one year safety of first-line nivolumab plus ipilimumab safety of hormone replacement therapy in breast cancer survivors safety of repeat BCS safety outcomes SAFFRON-103 SAFRON II SAFRON II study SaGa SAKK 01 10 trial SAKK 06 17 phase 2 trial SAKK 08 16 SAKK 16 14 study SAKK 17 16 trial SAKK 35 10 trial SAKK 75 08 trial exploratory analysis sALCL salivary MECs salpingectomie SALTO-studie salvage chemotherapy after immunotherapy salvage chirurgie salvage ipilimumab plus nivolumab after prior anti-PD-1 anti-PD-L1 therapy salvage PARPi salvage re-irradiation salvage reirradiation salvage repeat breast conservation with re-irradiation salvage resection plus cesium-131 brachytherapy salvage surgery after first-line alectinib salvage surgery after TKI treatment salvage treatment salvage treatment after BCMA-specific CAR-T salvage treatments SALVO trial SAMBA 101 SAMCO-PRODIGE 54 trial sAML sAML versus dnAML SANET-p study sapanisertib plus ziv-aflibercept saracatinib SARAH-studie SARC024 study SARC028 trial SARC028-studie sarcoma sarcoma survivors sarcoma-associated immune infiltrate sarcomatoid HCC sarcoom sarcopenia sarcopenia measures before and after cancer diagnosis in older adults sarcopenic obesity and outcomes of solid cancers sarcopenic patients SARS-CoV-2 infection SARS-CoV-2 infection in cancer patients SARS-CoV-2 infection in children and adolescents with cancer SARS-COV-2 pandemic SARS-COV2 antibody production in cancer patients sASCT SAVOIR study savolitinib savolitinib plus durvalumab sAxl SBA SBM SBRT SBRT for spinal metastases SBRT plus ipilimumab versus SBRT plus pembrolizumab SBRT plus nivolumab with or without ipilimumab SBRT plus pembrolizumab and trametinib SBRT schedule SBRT versus cEBRT SBRT versus CIRT SBRT versus CRT SC SC.23 scalp cooling scalp cooling for prevention of alopecia scalpmelanoom Scandinavian HYPO-RT-PC study SCANDIUM trial SCARCE C17-02 PRODIGE 60 SCC SCCA SCCAC SCCHN SCCOT SCCS SCCUP sCD23 schade kleine hersenvaten schildkliercarcinoom schildklierkanker schildkliertumoren schildwachtklier schildwachtklierbiopsie schildwachtlymfeklierbiopsie schwannomatosis SCIENTIFIC-studie scIL2 SCLC SCLC BMs SCLC with CTFI ≥ 30 days and without CNS metastases sclerotic cGVHD SCORAD III-studie SCORAD randomized trial SCORAD trial scoring system to predict prognosis SCORPION trial SCOT post hoc analysis SCOT-studie screen-detected and interval breast cancers screen-detected vs non-screen-detected screening screening cervixcarcinoom screening colorectaalcarcinoom screening contralateraal mammacarcinoom screening CRC tumors for Lynch syndrome screening digital mammography screening for dental infections screening for lung cancer screening for multiple cancers during one visit screening for pancreatic cancer screening longcarcinoom screening mammacarcinoom screening mammography screening mammography among women aged 70 years and older screening ordering and completion screening status ScreenTrustCAD trial SCRT-TNT SCSHN SDF1 SDOH SDOHs and cancer mortality SEAFOOD Polyp Prevention Trial SEAL SEAL study SEARCH cohort sebaceous carcinoma SECOMBIT trial second allo-HCT versus donor lymphocyte infusion second cancer risk after 3DCRT versus IMRT versus PBRT for primary cancer second cancers after radical treatment second CD19-targeted CAR T-cell infusion second gynecological malignant neoplasms second ipsilateral breast event; salvage mastectmy versus second BCS plus brachytherapy second line FOLFIRI plus ramucirumab second line options second lumpectomy and reirradiation second or later line anlotinib plus camrelizumab second or later line immunotherapy for aNSCLC second primary cancer second primary cancers second primary invasive melanoma second primary NSCLC after HNC second recurrences of retroperitoneal sarcoma second solid cancer outcomes second-generation antiandrogens second-generation ARIs second-line afatinib versus erlotinib second-line avelumab second-line avelumab plus gemcitabine second-line balstilimab plus zalifrelimab second-line bevacizumab plus FOLFIRI second-line bevacizumab plus irinotecan with or without GKS second-line binimetinib plus capecitabine second-line camrelizumab-apatinib second-line CAPTEM versus FOLFIRI second-line carboplatin plus etoposide versus topotecan second-line docetaxel plus ramucirumab second-line FOLFIRI w wo bevacizumab second-line FOLFOX second-line Gem-Nab or Gem second-line HX008 plus irinotecan second-line liposomal irinotecan second-line lurbinectedin second-line lurbinectedin for SCLC after chemotherapy-free interval at least 180 days second-line lurbinectedin versus topotecan second-line nivolumab plus paclitaxel and ramucirumab second-line options second-line osimertinib for EGFR-mutated NSCLC second-line PD-1 inhibitors versus chemotherapy second-line pembrolizumab second-line pembrolizumab-gemcitabine-vinorelbine-liposomal doxorubicin second-line platinum doublet chemotherapy second-line ramucirumab-avelumab-paclitaxel second-line XELIRI versus irinotecan monotherapy second-look surgery plus HIPEC versus surveillance secondary analysis CONVERT study secondary analysis of CheckMate 141 secondary analysis of SWOG-1216 secondary cytoreduction secondary cytoreductive surgery secondary hematological dysplasia secondary MDS AML secondary solid tumor malignancies secondary surgical cytoreduction secondhand smoking secundaire analyse ATAC-studie secundaire analyse AZURE-studie secundaire analyse BIG 1-98 studie secundaire analyse GOG-0218 studie secundaire analyse GOG-210 studie secundaire analyse LUX-Lung 8-studie Secundaire analyse NSABP B-30 Secundaire analyse REVEL-studie secundaire analyse van CANTOS-studie Secundaire analyse van EF-14 secundaire analyse van EORTC 22952-26001 secundaire analyse van FAPEST-studie secundaire analyse van GeparSixto secundaire analyse van GOG-0218 studie secundaire analyse van RTOG 9704-studie secundaire analyse van STO-3 studie Secundaire analyse van SWOG S0221 sedentaire tijd sedentary behavior SEER analysis SEER database analysis SEER database analysis of survival of primary spinal chordoma SEER registry analysis SEER-Medicare analysis of treatments and outcomes segmentectomie segmentectomy versus lobectomy SEHIB-studie SEIPLUS study seksueel functioneren seksuele toxiciteit SELECT trial SELECT-1 studie SELECT-D studie selecteren van moleculair-geleide therapie selectieve interne radiotherapie seleen SELENIB trial selenium Selenium and Celecoxib Trial self-compression versus standard compression SELHEM selinexor selinexor for R R DLBCL selinexor maintenance selinexor plus ibrutinib selinexor-dexamethasone selpercatinib selpercatinib for RET fusion-positive NSCLC selumetinib seminoom SEMS SEMS trial senaparib maintenance SENIOR study SENOMAC trial sensitive relapsed SCLC sensitive-relapsed SCLC sensitization to subsequent therapy SenSzi study SenTa study sentinel sentinel lymph node biopsy sentinel lymph node detection sentinel node biopsy sentinel node biopsy and radiotherapy sentinel-node micrometastases sepantronium bromide sEpCAM sepsis surveillance sequelae among adult survivors sequence of RT and chemotherapie sequencing of ADT and external-beam radiotherapy sequencing plasma cell-free DNA sequential antiresorptive drugs sequential CD19 and CD22 CAR T-cell therapy sequential CD7 CAR T-cell therapy and alloHSCT without GVHD prophylaxis sequential FOLFIRINOX and SBRT sequential ICI and crizotinib sequential or concomitant schedule sequential PD-(L)1 blockade and osimertinib sequential PD-(L)1 inhibitors and EGFR TKIs sequential radiotherapy and chemotherapy sequential versus concomitant nabP and gemcitabine SEQUOIA trial SERENA-2 sereus ovariumcarcinoom serial ctDNA analysis serial ctDNA detection serial imaging serial molecular annotation serial postoperative ctDNA analysis SERM serological markers of response serous ovarian cancer serplulimab Sertoli-Leydig serum amyloid A levels serum assessment of non-adherence serum exosomal PD-L1 serum hormones serum levels of soluble B and T lymphocyte attenuator serum metabolomic signature serum methionine-related metabolites serum periostin levels serum protein classifier associated with benefit from ICIs serum proteomics serum thiol levels serum VEGF serum vitamin E serum-metaboloomprofiel serum-microRNAs serumlipidem serumlipiden SES SES and OS among Danish patients with hematological malignancies severe COVID-19 in vaccinated patients with hematologic cancers in the VHA severe hepatopathy severe neutropenia severe sepsis during treatment for childhood leukemia sex sex and adverse events of adjuvant chemotherapy for colon cancer sex as a prognostic factor in glioma sex cord-stromal tumors sex difference sex differences in prognosis sex differences in severe adverse events sex disparities in incidence of 21 cancer types sex disparity sex-based heterogeneity sex-linked differences sex-related differences in cancer incidence sex-specific neurocognitive impairment sexually transmitted infections Sézary syndrome Sézary syndroom SFA SG SG for mTNBC SG for TNBC SG plus pembrolizumab SGC SGM patients SGNTUC-019 shape of breast cancers shared decision making SHCC SHIELD-RT SHINE trial short regimen of rituximab plus lenalidomide short-course neoadjuvant therapies Short-HER study short-term mortality after starting chemotherapy short-term outcomes of surgery for breast cancer short-term RT plus CT versus long-term CRT ShortHER trial SHR-1210 SHR-A1811 SI-NETs SIA side effects after 15 years side effects of low-dose tamoxifen in healthy women sidedness sidedness-depedent prognosis SIENDO study SIERRA trial sigaren siglec siglec15 expression sigmoidoscopy screening significance of PD-L1 status significant hearing loss signifor SII SILIUS trial siltuximab silver jk simian virus 40 SIMONAL study simple versus radical hysterectomy SIMPLICITY-studie Simplified Early Relapse in MM score simplified risk stratification model SIMPLIFY study SIMPLIFY-1 and SIMPLIFY-2 SIMPLIFY-1 studie simulation of chemotherapy effects simultaneous versus delayed resection of liver metastases SINDAS trial siNET Singapore Chinese Health Study single center longitudinal experience single dose HDR brachytherapy single hormone receptor-positive breast cancer single versus multiple primary melanomas single-agent atezolizumab for pediatric tumors single-agent chemotherapy single-fraction SBRT vs multifraction conventional RT single-fraction versus hypofractionated SRS single-fraction versus multifraction RT single-fraction versus multifraction SABRT sinonasaal adenocarcinoom sinonasaal carcinoom sinonasaal melanoom sinonasal mucosal melanoma sintilimab sintilimab plus anlotinib sintilimab plus anlotinib in second or later line sintilimab plus bevacizumab sintilimab plus chemotherapy sintilimab plus IBI305 sintilimab plus platinum and gemcitabine SintraREV trial sipuleucel –T with or without radium-223 sirolimus sirolimus versus prednisone SIRT for LA-HCC SIRveNIB-studie Sister Study Sisters Study site-specific therapy versus empiricial chemotherapy sites and sequence of metastases sitravatinib plus tislelizumab six month efficacy and toxicity of BNT162b2 vaccine in solid cancer patients six R-CHOP cycles versus four CHOP cycles plus six doses rituximab six versus 12 months adjuvant capecitabine skelet-gerelateerde gebeurtenissen skeletal adverse events skeletal metastases skeletal muscle loss skeletal muscle loss after esophagectomy skin cancer skin cancer incidence skin cancer prevention skin cancer rates by transplanted organ type skin cancer risk skin microbiome skin reaction skin toxicity skip N2 metastasis skipping ALND skull base chordomas skull base osteosarcoma skull-base chondrosarcoma skull-based meningioma slaapduur sleep and cancer recurrence and survival sleep characteristics sleep medication use and risk of fractures SLFN11 SLL SLN mapping versus lymphadenectomy SLN-biopsie SLN-status SLNB SLNB after NACT for selective axillary approach in node-positive breast cancer SLNB in stage II endometrial cancer SLNB versus ALND slokdarm adenocarcinoom slokdarm squameus celcarcinoom slokdarmadenocarcinoom slokdarmcarcinoom slokdarmkanker slokdarmkanker; chemoradiotherapie SM SMAD4 loss small bowel adenocarcinoma small bowel neuroendocrine tumors small cell carcinoma of the cervix small cell lung cancer brain metastases small ground-glass-dominant lung cancer small HR-positive HER2-positive node-negative breast cancer small ipsilateral breast cancer recurrence after BCS small lymphocytic lymphoma small NF-PanNETs small node-negative HER2-positive breast cancer small- or medium-sized VS small-cell lung cancer small-sized peripheral NSCLC SMART Smart Start trial smeulend multipel myeloom SMM SMN SMNs smoking smoking behaviors and prognosis smoking cessation smoking history and overall survival smoking or alcohol consumption and risk of bladder cancer smoking status and survival smoldering multiple myeloma SMT SN biopsy versus neck lymph node dissection SNIPP study snoRNAs SNP SNPs SNPs correlated with sunitinib benefit SNSCC SNTI SNUC SOAR-studie SOC-1 trial socazolimab sociaal-economische status Sociaaleconomische status social and economic challenges social characterics and endocrine therapy adherence sociale media socioeconomic deprivation socioeconomic inequalities socioeconomic status SoFEA and EFECT trials analysis SOFT 12-year follow-up SOFT and TEXT combined analysis soft tissue sarcoma SOFT- en TEXT-studies soft-tissue sarcoma soft-tissue sarcoma expressing NY-ESO-1 sojaconsumptie SOLAR study solar UV radiation SOLAR-1 OS analysis SOLAR-1 overall survival results SOLAR-1 study SOLD randomized trial long-term follow-up SOLD-studie SOLE-studie solid cancer diagnosis solid cancers solid organ transplant solid organ transplant recipients solid tumor LM solid tumors solid tumors and hematologic cancers solid tumors wit KRAS G12C mutation solid tumors with activating HER2 mutations solid-organ transplant solide maligniteiten solide tumoren solitair intrathyroïdaal papillair schildkliercarcinoom solitary breast cancer brain metastastasis solitary fibrous tumor solitary pulmonary nodules SOLO1 GOG 3004 five-year follow-up SOLO1 study SOLO1 trial subgroups SOLO2 ENGOT-Ov21 final analysis SOLO2 ENGOT-Ov21 studie SOLO2 trial post-hoc analysis SOLO3 study SOLSTICE phase 3 study SOLSTICE study SOLTI-1402 CORALLEEN study soluble immune checkpoint-related proteins somatic and germline genomic alterations somatic mutations predicting thromboembolic risk in patients with solid tumors somatische variatie somatostatin analogues somatostatine-analogen SONABRE registry SOPHIA trial SOR-TACE versus TACE sorafenib sorafenib combined with conventional treatments sorafenib for advanced HCC sorafenib for HCC sorafenib maintenance sorafenib maintenance after alloHSCT sorafenib plus OME sorafnib maintenance after allo-transplantion SORAML SORAML trial long-term follow-up SORAYA study SORCE trial SORMAIN study SORMAIN Trial SOS study SOS-studie sotatercept sotigalimab (APX005M) sotigalimab plus nivolumab sotorasib SOTR SOTRs South Korean lung cancer screening program SOX2 soy-based dietary supplements SPARC spartalizumab SPARTAN final survival results SPARTAN trial secondary analysis SPARTAN-studie spatial location of local recurrences after mastectomy SPC SPC risk SPCG-4 SPEARHEAD-1 study SPEARHEAD-1 trial special section of Supportive Care in Cancer specific cardiovascular diseases specific type of ovarian cancer SPECT versus PET-CT for detection of skeletal metastases spectroscopie SPECTRUM study sperm count sperm-associated antigen 5 expression Spierinvasief blaascarcinoom spinaal myxopapillair ependymoom spinal metastases spinal metastases from prostate cancer spinal metastatic disease spinale epidurale metastase spinale metastase spinale SRS spine metastases from hepatobiliary malignancy SPIONs SPIRIT trial spirituality and religiosity spirometry at diagnosis splanchnische veneuze trombose splenisch DLBCL splenomegaly splicing factor SPM risk SPM risk after high-dose chemotherapy and autoHSCT for lymphoma SPM risk among cancer survivors SPMN SPMs spontane abortus sporadic colorectal cancer sporadic versus familial microsatellite instable metastatic colorectal cancer SPOTLIGHT retrospective study SPOTLIGHT trial spouses of cancer patients SPPORT trial spread through air spaces SPRING trial SPS sputum miRNA sqCLC sqNSCLC squameus celcarcinoom squameus celcarcinoom van de mondholte squameus celcarcinoom van de orofarynx squameus celcarcinoom van hoofd en hals squameus-celcarcinoom squamous cell carcinoma squamous cell carcinoma bladder cancer squamous cell carcinoma of head and neck squamous cell carcinoma of the base of the tongue squamous cell carcinoma of the breast squamous cell carcinoma with HRAS mutations squamous NSCLC squamous NSCLC in elderly patients SQUIRE-studie SR-cGVHD after alloHSCT SRA737 plus low-dose gemcitabine SRCC SRE SREs SRS SRS for atypical meningioma SRS for BMs SRS for intracranial metastases SRS versus active surveillance SRS versus WBRT for resected brain metastasis SRS with immune checkpoint inhibiton or targeted therapy SRT SRT versus ART SS SS MF SS or MRCLS SSA SSIs SsK12 SSTR2 St Jude Lifetime Cohort Study St Jude Total Therapy Study 16 St. Jude Lifertime Cohort St. Jude Lifetime Cohort St. Jude Lifetime Cohort Study stadium IV colorectaalcarcinoom stadium IV-NSCLC stage 0 to II breast cancer stage 1 and 2 melanoma stage 1 nonseminomatous GCTs stage 1 NSCLC stage 1 pT1N0 HER2+ breast cancer stage 1 RCC stage 1A or 1B gastric cancer stage 1A RCC stage 1A uterine papillary serous cancers stage 2 colorectal cancer stage 3 colon cancer stage 4 high-risk neuroblastoma stage and grade I endometrioid endometrial cancer stage at cancer diagnosis stage at lung cancer diagnosis stage I breast cancer in women 65 years and over stage I CRC stage I ER+ HER2 breast cancer stage I HCC stage I II HCC stage I lung cancer stage I non-small cell lung cancer with spread through air spaces stage I NSCLC stage I NSCLC in patients aged 80 years or older stage I NSCLC with sensitive EGFR mutations stage I to III colorectal cancer stage I to III CRC stage I triple-negative breast cancer stage I-II cutaneous melanoma stage I-IIA cHL stage I-III breast cancer in elderly women stage I-III CRC stage I-III HR-positive breast cancer in men stage I-III HR-positive HER2-negative BC stage I-III NSCLC stage I-IIIA breast cancer stage IA NSCLC stage IA part-solid lungadenocarcinoma stage IA PDAC stage IB NSCLC stage IB-IIIA EGFR-mutated NSCLC stage IB-IIIA NSCLC stage IE IIE natural killer T-cell lymphoma stage II and III cutaneous melanoma stage II and III esophageal cancer stage II colon cancer stage II CRC in patients aged ≥ 75 years stage II endometrial cancer stage II III CRC stage II III gastric cancer stage II III rectal cancer stage II melanoma stage II or III gastric cancer stage II or III gastric cancer in older patients stage II or III rectal adenocarcinoma stage II or III resectable gastric cancer stage II or III TNBC stage II to IVB NPC stage II-III colorectal cancer stage II-III CRC stage II-III NSCLC stage II-IIIA (N1-N2) NSCLC stage II-IIIA EGFR-mutant NSCLC stage II-IIIA NSCLC stage II-IV CRC stage IIA and B seminoma stage IIA node-negative NSCLC > 5 cm stage IIa-IIIB NSCLC stage IIB C melanoma stage IIB or IIC melanoma stage III and IV melanoma stage III and IV Wilms tumor stage III CC stage III colon cance stage III colon cancer stage III colon cancer in older patients stage III CRC stage III EGFR-mutated NSCLC stage III epithelial ovarian cancer stage III gastric cancer stage III inflammatory breast cancer stage III IV melanoma stage III MCC stage III melanoma stage III NSCLC stage III or IV HL stage III ovarian cancer stage III-IV melanoma stage III-IVB nasopharyngeal carcinoma stage IIIA EGFR-positive NSCLC stage IIIA non-small cell lung cancer stage IIIA NSCLC stage IIIA or IIIB non-small cell lung cancer stage IIIA-N2 EGFR mutation-positive NSCLC stage IIIA(N2) NSCLC stage IIIB and IIIC melanoma stage IIIB-C and IV melanoma stage IIIB-C BRAF-V600 mutated melanoma stage IV ALK rearranged NSCLC stage IV breast cancer stage IV breast cancer at diagnosis stage IV EGFR-mutated NSCLC stage IV lung adenocarcinoma stage IV lung cancer stage IV male breast cancer stage IV melanoma stage IV NSCLC stage IV PABC stage IV TNBC stage IV uterine cancer stage of breast cancer diagnosis stage-specific survival staged stereotactic radiosurgery staging staging of melanoma stamceltransplantatie STAMPEDE STAMPEDE study STAMPEDE trial standard therapies standard-dose versus low-dose standard-of care axi-cel standard-risk medulloblastoma standard-risk NDMM standardized uptake value stappenteller STAR trial STARGLO trial STARS trial START START-FIT phase 2 trial STATICE trial statin use statin use and incidence of CRC expressing SMAD4 statin use and liver cancer risk among heart failure patients statin use and survival statines statins statins and lethal prostate cancer statistieken 2012 statistische genezing STEAM study STELLAR study stem cell transplantation stemmingsaandoeningen stereotactic ablative body radiotherapy for oligometastatic cancers stereotactic ablative radiotherapy stereotactic ablative radiotherapy for oligometastasis stereotactic body radiation therapy stereotactic body radiation therapy plus systemic therapy stereotactic body radiotherapy stereotactic body radiotherapy versus conventional palliative radiotherapy stereotactic or conformal radiotherapy stereotactic radiation stereotactic radiosurgery stereotactic radiosurgery before resection of brain metastases stereotactic radiosurgery versus whole-brain radiation therapy stereotactic reirradiation and temozolomide stereotactic RT versus WBRT for cystic or solid brain metastases stereotactic versus external beam radiotherapy stereotactische lichaamsradiotherapie stereotactische radiochirurgie stereotactische radiotherapie sterfte aan kanker steroid refractory GVHD in children steroid-refractory acute graft-versus-host disease steroid-refractory immune-related hepatitis steroid-refractory or steroid-dependent chronic GVHD steroid-refractory PD-(L)1 pneumonitis steroid-refractory resistant ICI related pneumonitis steroid-resistant acute graft-versus-host disease STHLM3 study STHLM3-MRI trial STHLM3AS study STIC CTC study sTILs STO-3 trial long-term follow-up STO-5 trial Stockholm III Stockholm Tamoxifen Randomized Clinical Trial secondary follow-up stoma stomach and esophagus cancer stomach cancer pooling project stomatitis stool butyrate Stop & Go study STOP IMAPED study STOP trial stopping imatinib Stopping of TKIs for CML STORM study STORM Study part 2 straling stratification by cytology and HPV genotype stratification of risk of distant metastasis and death STREAM-studie STRESS-LUNG study cohort 1 stroke at young age stroma-gerichte therapie stromal tumor-infiltrating lymphocytes stromale tumor-infiltrerende lymfocyten strongly HR-positive and HER2-negative breast cancer STS STS in chemotherapy-ineligible patients STS liver metastases STS of extremity STS of the extremities STSs Studie-uitval Study 111 KEYNOTE-146 Study 120 Study 19 Study G200802 study using electronic health records Sturgeon STYLE trial STZ 5-FU SU2C-SARC032 subcutaan trastuzumab subcutaneous administration of daratumumab subcutaneous trastuzumab subcutaneous versus intravenous daratumumab subcutaneous versus intravenous PF-06801591 subcutaneous versus intravenous trastuzumab subependymal giant cell astrocytoma subgroep-analyse van METEOR-studie subgroepanalyse ALEX-studie subgroepanalyse GREEN study subgroepanalyse MONALEESA-2 studie subgroepanalyse van FIRE-3 studie subgroepanalyses LUX-Lung studies subgroepenanalyses CAIRO3 subgroup analyses of ASPIRE and ENDEAVOR studies sublobar resection subsequent cancer diagnoses subsequent female breast cancer subsequent malignant neoplasms subsequent neoplasms subsequent neoplasms after a primary tumor subsequent primary lymphoma subsequent primary neoplasms subsequent risk of cervical cancer subsequent risk of CSCC subsequent risk of DM subsequent therapies after olaparib maintenance substance use and mental health burden in HNC survivors substratification substudie ALTTO substudie van TRYPHAENA subtotal resection subtype subtype-based first-line treatment subtype-specific CBC subtypen subtypen HER2-positieve borstkanker subtypes subtypes maagcarcinoom subtypes mammacarcinoom SUCCESS A SUCCESS A study SUCCESS A trial SUCCESS-C study sugar-sweetened beverage intake sugary drink consumption and risk of cancer sugemalimab suicidality among adult survivors of childhood cancer suïcide suicide attempts and suicide deaths suicide risk and mortality among patients with cancer suicide risk following a new cancer diagnosis in veterans receiving VHA care sulfur microbial diet SUMMIT basket trial sun exposure suncreen use sunitinib sunitinib dose and schedule optimization sunitinib for RCC SUNLIGHT trial SUNSHINE trial sunvozertinib superficial basal-cell carcinoma superior vena cava syndrome supplemental CEM screening in women with elevated breast cancer risk supplemental MRI supplemental surgery suppressie ovariumfunctie supraglottische-larynxcarcinoom SUPREMO trial surgeon-patient sex concordance surgery surgery and PRT surgery for AA surgery for cancer surgery for cancer in older adults surgery for CRC in geriatric patients surgery for head and neck cancer surgery for LAPC in The Netherlands surgery for malignant pleural mesothelioma after radiotherapy surgery for non-palpable breast lesions surgery for prostate cancer surgery versus active surveillance surgery versus chemotherapy surgery versus radiotherapy surgery versus SBRT surgical and oncologic outcomes surgical complications surgical delay and pathological outcomes surgical excision surgical excision margin surgical QMs adherence surgical removal of tonsils and adenoids surgical resection of bone and soft tissue sarcoma of the extremities surgical resection versus biopsy surgical skill and perioperative outcomes surgical treatment surgical utilization and outcomes surgical-site infections surgically treated ACC surgically treated brain metastases surgically treated intrahepatic cholangiocarcinoma surival surivors of childhood AML SURPASSe01 study surrogate end points SURTIME trial surufatinib SurVaxM surveillance surveillance after resection of breast cancer surveillance as alternative to prophylactic surgery surveillance colonoscopy after advanced adenoma removal surveillance endoscopy surveillance for relapse survival survival adjusted for comorbidity and socioeconomic status survival after BCT vs mastectomy in breast cancer patients with or without the BRCA1 2 variant survival after cancer diagnosis survival after development of contralateral breast cancer survival after laparoscopic versus open surgery for rectal cancer survival after radical prostatectomy survival after radiotherapy survival after recurrence survival after resection survival after treatment according to ESMO recommendations survival and cardiovascular outcomes survival and new prognosticator survival before and after CDK4 6-inhibitors survival benefit associated with participation in clinical trials of anticancer drugs survival benefit of increasing number of active drugs survival benefit with primary tumor surgery survival by age survival by race ethinicity survival during the COVID-19 pandemic survival impact survival impact of anti-GD2 antibody response survival impact of number of adjuvant chemotherapy cycles for GC survival impact of obesity survival impact of physical activity before and after diagnosis survival impact of sex survival impact of time to diagnosis and time to treatment survival impact of type and sequencing of therapies survival in breast cancer survival in breast cancer patients survival in male breast cancer survival less than 90 days survival of advanced NSCLC survival of breast cancer survival of childhood cancer survival of early-onset CRC survival of lung cancer survival of lymphoid neoplasms survival of multiple myeloma and AL amyloidosis survival of ovarian cancer survival of patients with brain metastases survival outcomes survival outcomes for cancer in adolescents and young adults survival outcomes with CPM survival past five years survival patterns survival trend survival trend in The Netherlands survival trends survival trends in The Netherlands survival with chemotherapy survival with HCC screening in patients with cirrhosis after HCC cure with DAA therapies survival with new systemic therapies survival with nivolumab for previously treated aNSCLC survivin dendritic cell vaccine survivin-expressie survivors AYA cancer survivors childhood ALL survivors childhood and AYA cancer survivors of adolescent and young adult cancer survivors of adult-onset cancers survivors of breast cancer survivors of breast or prostate or colorectal cancer survivors of childhood and adolescent cancer survivors of childhood and AYA cancer survivors of childhood cancer survivors of childhood Hodgkin lymphoma survivors of childhood or adolescence CNS tumors survivors of colorectal cancer survivors of early-adolescent and young adult cancers survivors of HPV-associated cancers survivors of NB diagnosed in infancy survivors of non-central nervous system tumors in childhood survivors of pediatric CNS tumors survivors of testicular cancer SurvMark-2 study SURVSARC study susceptibility gene mutations sustained minimal residual disease negativity sustained weight loss SVCS SVT SWAN-studie Swedish Breast Cancer Group 91 Radiotherapy studie Swedish children treated for acute lymphoblastic leukemia Swedish Multicenter Cohort Study Swedish Obese Subjects study Swedish pediatric ALL patients sweetened beverages SWISH-studie SWITCH switch maintenance endocrine therapy switch-maintenance switching pembrolizumab from 200 mg Q3W to 400 mg Q6W SWOG 0777 SWOG 1200-studie SWOG 1318 SWOG 1406 SWOG 1500 study SWOG 1609 cohort 48 SWOG 80405 SWOG 9313 trial SWOG S0120 SWOG S0221 study SWOG S0337-studie SWOG S0518 SWOG S0622 SWOG S0800 SWOG S0905 SWOG S1105 study SWOG S1202-studie SWOG S1403 analysis SWOG S1406 study SWOG S1616 SWOG-S0016 SWORD-studie Sym004 SYMPATICO study symptomatic breast cancer patients symptomatic osteonecrosis symptomatic skeletal-related events symptoms of children undergoing cancer treatment SYNCHRONOUS and CCRe-IV pooled analysis synchronous and lifetime brain metastases synchronous bilateral breast cancer synchronous bilateral breast cancer in young women synchronous brain metastasis synchronous metastatic colorectal cancer synchronous neoplasia synchronous oligometastatic NSCLC synchronous or metachronous metastases synchronous stage IV anal canal squamous cell carcinoma synoviaal sarcoom synovial sarcoma synovial sarcoma in children and AYAs synoviosarcoom systematic review systemic anticoagulation systemic chemotherapy systemic light chain amyloidosis systemic mastocytosis systemic therapy systemic therapy after resection systemic therapy with or without local treatment systemic treatment systemic treatment options systemic treatment versus PTR followed by systemic treatment systemische lupus erythematosus systemische mastocytose SystHER study T Cell Project T-ALL T-ALL and T-LL t-APL T-cadherin T-cel acute lymfoblastische leukemie T-cel lymfoom T-cell acute lymphoblastic leukemia or lymphoma T-cell ALL T-cell expression profiles T-cell lymphoblastic lymphoma T-cell lymphomas T-cell-replete haploidentical transplantation for ALL T-cellymfoom T-DM1 T-DM1 for HER2-positive MBC with brain metastases T-DM1 plus neratinib T-DM1 versus TH T-Duo T-DXd T-DXd for mBC with active brain metastases T-DXd versus chemotherapy T-DXd versus T-DM1 t-MNs after aPBSCT for HL NHL T-SAR trial T-SCLC T-VEC T-VEC for melanoma T-VEC plus imiquimod T-VEC plus pembrolizumab T1 bladder cancer T1-T2 OPSCC T1-T2 OSCC T1-T2 RCC T1a melanoma at critical structures T1a-bN0M0 NSCLC T1D T1N0M0 TNBC T2212 study T2D T2D risk T2DM T790M-positive NSCLC after failure of first-line EGFR-TKI T790M-positive NSCLC refractory to osimertinib TAA-Ts TABAsCO trial TABEA TAC TACE TACE followed by pembrolizumab TACE plus RFA as initial treatment TACE plus sunitinib versus sunitinib alone TACT study TACTOPS study TAD after NST tafasitamab plus lenalidomide tagraxofusp TAGS study TAILOR trial tailored immunotherapy approach TAILORx analysis TAILORx secondary analysis TAILORx study TAILORx-studie Taiwanese breast cancer patients TALAPRO-1 study TALAPRO-2 trial talazoparib talazoparib plus avelumab talazoparib plus enzalutamide TALENT trial taletrectinib talk-pleurodesie tall cell papillary thyroid cancer talquetamab TAM-01 trial 10-year follow-up tamilogene laherparepvec tAML tamoxifen tamoxifen for premenopausal breast cancer tandem autologous stem cell transplant tandem CD19 CD20 CAR T cell therapy TAPS TAPUR phase 2 basket trial TAPUR study TAPUR trial TARDOX study TARE combined with second-line chemotherapy TARGET-TP trial targeted agents targeted alpha therapy targeted BRAF inhibion targeted exome next-generation sequencing targeted immunotherapy for pediatric high-risk neuroblastoma targeted intraoperative molecular imaging targeted intraoperative radiotherapy targeted therapies targeted therapy targeted therapy and survival in clinical practice targeted therapy for advanced melanoma targeted versus nontargeted therapy targeting long-term non-attenders TARGIT-A trial tarlatamab TAS-102 TAS-102 Gastric Study subgroup analysis TAS-102 plus ramucirumab TAS-114 taselisib taste function TASUKI-52 study TATTON study tattoos TAUTEM study Taxaan resistentie taxane chemotherapy taxane with versus without anthracycline taxane-based chemotherapy taxane-based chemotherapy for breast cancer taxane-induced nail changes and peripheral neuropathy taxane-related patient-reported outcomes taxanes taxanes maintenance TAXIS study TAXYNERGY-studie TAZ tazemetostat TBCRC 002 study TBCRC 022 study TBCRC 043 trial TBCRC023 study TBCRC026 study TBCRC026 trial TBCRC041 TBI after blood or marrow transplantation TBI versus chemotherapy conditioning TBI- versus CT-based myeloablative condition; impact on outcomes of transplantation for AML TBISI TC TCF3-HLF positief ALL TCH TCIs for atopic dermatitis TCP plus ATRA TCR gene rearrangement TD-FOREKNOW trial TDs TDT TE or GEJ cancer tea intake TEAL study TEAM IIB TEAM-studie TEAMM study tebentafusp tebotelimab TEC TECHNO and PREPARE trials technology-enabled monitoring of toxic effects linked to ICIs for GU cancers teclistamab Teenage and Young Adult Cancer Survivor Study TEKT4 germline variations telaglenastat plus azacytidine telaglenastat plus everolimus tele-oncologie telemedicine telephone counseling televisiekijken telisotuzumab vedotin telisotuzumab vedotin plus erlotinib TELMA trial telomeerlengte telomeerziekten telomerase-activiteit telomerase-positive CTCs temozolomide temozolomide-based CRT temporal changes temporal changes in cause-specific death temporal changes in incidence of relapse and outcome after relapse temporal changes in survival temporal glioblastoma surgery temporal muscle thickness temporal trend temporal trends temporal trends in ALL outcomes in the USA temporal trends in overall survival from 2000-2020 temporal trends in survival temporal trends in testing and treatment temporary cessation versus continuation of first-line TKI temsirolimus ten-year distant-recurrence risk ten-year follow-up of FAST ten-year incidence of mood disorder ten-year outcomes ten-year results ten-year update ten-year update of CALGB 49907 tenofovir tenofovir versus entecavir after resection tenosynovial giant cell tumor tenosynovial giant-cell tumor tepotinib teratoma TERAVOLT registry terbinafine teriparatide TERRA-studie TERT-mutatie tertiary lymphoid structures tesetaxel plus reduced dose of capecitabine testicular cancer testicular cancer in children and young adults testicular cancer in the cisplatin era testicular germ cell tumors testikelkanker testing for EGFR variants in pleural and pericardial effusion cfDNA testing of PVs in BC susceptibility genes testiscarcinoom testosterone therapy TETs textbook outcomes of curative-intent resection textbook surgical outcomes TFAP2C TFHL tFL TFS with first-line ICI therapies TG01 vaccine TG4010 TGCT TGF-βRII TGM95 study TH-302 TH3RESA thalidomide The Multiethnic Cohort thee TheraP TheraP study therapeutic options therapeutic value of SLNB therapeutische vaccins therapietrouw orale hormonale behandelingen therapy-related AML therapy-related cardiac risk thermal ablation thermal ablation versus nephrectomy thermale ablatie thick melanoma thin cutaneous melanoma Thinking and Living With Cancer Study thiopurine thiotepa-busulfan-fludarabine conditioning third or later line apatinib plus vinorelbine third-line irinotecan plus cetuximab rechallenge third-party BKV-HC THOR Cohort 1 trial thorax-radiotherapie three versus six months of adjuvant CAPOX or FOLFOX three versus six months oxaliplatin-based adjuvant chemotherapy three-year follow-up three-year follow-up of TRAIN-2 trial thrombocytosis and cancer risk thromboembolism thromboprofylaxis thrombosis thrombotic events THRα2 thymic carcinoma thymogolublin thymoom thymus removal in adults thymuscarcinoom thyorid cancer surgery thyroid cancer thyroid cancer detection in childhood cancer and BMT survivors thyroid cancer risk thyroid immune related adverse events thyroid nodules Tian TIC TIL therapy TIL therapy versus ipilimumab TIL versus ipilimumab TILs time between positive gFOBT and colonoscopy time for CRC surgery and start of adjuvant chemotherapy time from diagnosis to treatment time from neoadjuvant chemotherapy to surgery time interval between NAT and resection time interval to biochemical failure time series analysis time to death time to first distant recurrence time to first treatment time to metastasis time to surgery time to systemic treatment time to treatment failure time trends time trends and predictors of survival time trends in survival time trends of invasive recurrence time without symptoms or toxicity time-to-surgery timing of adjuvant chemotherapy timing of adjuvant hormone therapy timing of adjuvant radiotherapy timing of adjuvant therapy timing of aspirin use timing of corticosteroid initiation timing of HPV16-E6 antibody seroconversion timing of initiation of adjuvant chemotherapy timing of local therapy timing of MRD-negativity timing of onset of irAEs timing of palliative care timing of postoperative radiotherapy timing of postoperative SRS timing of presentation and outcomes timing of stereotactic radiosurgery and immunotherapy timing of surgery timing of surgery after neoadjuvant chemotherapy timing of trastuzumab tinzaparine TIP tipifarnib TIPN tirabrutinib tiragolumab plus atezolizumab tiragolumab with or without atezolizumab tirbanibulin ointment tirlateraal retinoblastoom tisagenlecleucel tislelizumab tislelizumab plus chemotherapy tislelizumab plus zanubrutinib tisotumab vedotin TITAN and SPARTAN studies TITAN study TITAN-RCC trial TITAN-studie TITAN-TCC study TITAN-TCC trial TIVO-3 study tivozanib TJMUCH-GI-001 trial TKI TKI discontinuation TKI dose reduction without loss of MMR TKI-refractory LUAD TKIs TKIs for cancer TKIs for EGFR-mutant aNSCLC TKIs for NSCLC TKIs with versus without metformin TL TLP trial TLSs TMB TMB and outcomes TMB and response to CPI TMC tMDS TMNs TMW TMZ TMZ plus RT versus RT alone TMZ with or without capecitabine TN or HER2-positive ILC TN-ILC tnAcity-studie TNBC TNBC in older women TNBC in postmenopausal women TNBC risk genes TNBC with residual disease after neoadjuvant chemotherapy TNFi TNFα-remmers TNT TNT-studie TOAD-studie TOCILAM study tociluzimab tolerability tolerability and efficacy of palbociclib tomaten tomosynthese tomosynthesi tomotherapy tongbasiscarcinomen tonsil SCC tonsilcarcinoom tonsillaire tonsillar cancer TOPARP-B trial TOPAZ-1 phase 3 trial TOPAZ-1 trial TOPCS topical calcitriol topical diclofenac topical histone deacytelase inhibition topical hypericin photodynamic therapy topical imiquimod versus surgery topical pimecrolimus topical remetinostat gel topical submicron particle paclitaxel topical TCA for CIN topisch fluorouracil topotecan with or without berzosertib TORCH TORCH trial TORCHLIGHT trial TORG160 trial toripalimab toripalimab plus axitinib toripalimab plus chemoradiotherapy toripalimab plus definitive CRT toripalimab plus HBM4003 toripalimab plus IMRT toripalimab plus nab-paclitaxel TORS TOSCA trial subgroup analysis totaal lichaamsbestraling totaal-vet total neoadjuvant therapy total neoadjuvant therapy vs standard therapy total nodal basin total versus cortical-sparing adenalectomy totale lichaamsbestraling totale mesorectale excisie totale mortaliteit totale overleving TOTEM study TOURMALINE-MM3 study TOURMALINE-MM4 trial tovorafenib toxic effects and survival toxiciteiten van oncologische behandelingen toxicities toxicities of immune checkpoint inhibition toxicity toxicity of chemotherapy toxicity of PBT versus IMRT toxicity profiles of systemic therapies toxicity-related chemotherapy modifcation Toxoplasma gondii infection TP53 TP53 and KEAP1 mutations TP53 genomic abnormalities TP53 GOF and non-GOF mutations TP53 mutation status TP53- and RAS-mutant metastatic colorectal cancer TP53-mutant AML MDS TP53-mutant MDS TP53-mutated acute myeloid leukemia TP53-mutated AML TP53-mutated MDS and AML TP53-mutaties TP53-veranderingen TP53wt EC TPK cohort TPP TQB2450 traankliertumoren trabectedin trabectedin plus doxorubicin trabectedin plus radiotherapy trabectedine plus durvalumab for pretreated advanced STS and OC TRACERx traditional Chinese medicine plus chemotherapy TRAEs trajectories of alcohol consumption during life trametinib trametinib plus neoadjuvant chemoradiation trametinib with or without dabrafenib TRAMUNE study tranexamic acid tranplantation-ineligible MCL patients transarterial chemoembolization transarterial hepatic chemoembolization transarterial radioembolization transarteriële chemo-embolisatie TRANSCEND CLL 004 trial TRANSCEND NHL 001 study transcriptomic signature predicts adjuvant gemcitabine sensitivity transcriptomic signatures transdermaal fentanyl transdermal estradiol transdermale toediening TRANSFORM trial transformation transformation to SCLC TRANSFORMER study transfusion dependent lower-risk myelodysplastic syndromes transgender people transgenders TransMet trial TransMYME trial transoral robotic surgery transoral surgery and low-dose IMRT transorale robotische chirurgie transplant-associated immunosuppression transplant-eligible MCL transplant-eligible MCL patients transplant-ineligible multiple myeloma transplantation for myeloid malignancies transplantation for older leukemia patients transplantation from unrelated donors transplantation-eligible NDMM transverse colon cancer TRAP study TRASTS study trastuzumab trastuzumab deruxtecan trastuzumab deruxtecan versus physician’s choice trastuzumab deruxtecan versus trastuzumab emtansine trastuzumab duocarmazine trastuzumab emtansine trastuzumab emtansine with or without atezolizumab trastuzumab for breast cancer trastuzumab plus FOLFOX trastuzumab plus gemcitabine and cisplatin trastuzumab plus paclitaxel trastuzumab-pertuzumab-docetaxel trastuzumab-related cardiotoxicity trastuzumab-resistant HER2-positive ABC trastuzumab-resistant HER2-positive breast cancer TRBC1-directed CAR T cell therapy TRC102 plus TMZ treatment treatment adherence and outcomes treatment and outcome in Germany treatment and outcomes treatment at specialized cancer centers treatment benefit treatment beyond progression treatment characteristics and outcomes Treatment Efficacy Score treatment facility characteristics and OS treatment failure treatment in Europe treatment interruption treatment modalities for breast cancer treatment of anal HSILs to prevent anal cancer treatment outcomes and clinical characteritics treatment patterns treatment patterns and outcomes treatment patterns and survival treatment recommendations treatment response treatment selection treatment-emergent small-cell neuroendocrine prostate cancer treatment-free remission treatment-free remission after nilotinib for chronic phase CML treatment-free survival treatment-naïve metastatic uveal melanoma treatment-related adverse events treatment-related cardiotoxicity treatment-related incidence of diseases of the circulatory system treatment-related side effects treatment-related thoracic STS treatment-related toxicity treatments treatments after progression on osimertinib treatments after T-DXd treatments and outcomes after progression on crizotinib treatments for advanced NSCLC treatments for cancer of abdomen or pelvis treatments for MaBC trebananib TREM study tremelimumab tremelimumab after platinum tremelimumab and durvalumab tremelimumab plus durvalumab trend in outcomes 1998-2009 trend of toxicity and response in phase 1 trials for solid tumors over time TREnd-studie trends trends 2005-2015 trends 2008-2014 trends and projections trends and projections of incidence in The Netherlands trends and variations in treatment in The Netherlands trends from 1935 to 2015 trends in cancer incidence and mortality in the UK trends in cancer incidence by socioeconomic deprivation trends in cardiac events trends in epidemiology in the US trends in grade 5 toxicity and response trends in incdence and outcomes trends in incidence trends in incidence among US adults trends in incidence and survival trends in incidence in the US trends in late mortality trends in late mortality and life expectancy trends in morbidity and mortality in survivors of childhood ALL trends in omission of ALND trends in OS since 2011 trends in outcomes from 2000 to 2019 trends in primary treatment and survival trends in second primary cancers in survivors of metastatic melanoma trends in subtype-specific mortality trends in survival rates in South Korea trends in use and perceptions in The Netherlands trends of cancer in children and adolescents trends over five decades in Sweden treosulfan-fludarabine conditioning trial effect TRIANGLE trial TRIAS study TRIBE TRIBE and TRIBE2 pooled analysis TRIBE2 study TRICIN trial TRICOLORE-studie TRICOTEL study TRIDENT-1 trifluridine tipiracil plus bevacizumab trifluridine tipiracil with or without bevacizumab trifluridine-tipiracil with or without bevacizumab trilaciclib trimodal therapy trimodality therapy for MIBC trimodality therapy for stage 2-3 rectal cancer TRINITI-1 study TRINOVA-1 triple negatieve borstkanker triple negative and luminal breast cancer triple negative borstkanker triple negative breast cancer triple negative mammacarcinoom triple-class exposed patients with relapse or refractory multiple myeloma triple-class refractory multiple myeloma triple-negatief mammacarcinoom triple-negative borstkanker triple-negative breast cancer triple-negative breast cancer. TNBC-DX genomic test triple-negative mammacarcinoom TripletBev Triplex vaccine triptorelin TRITON3 trial TRK fusion sarcomas TRK fusion-positive lung cancer TRK fusion-positive primary CNS tumors TRK fusion-positive solid tumors TRK inhibitor therapy TROG 03.01-studie TROG 99.03 study TROIKA study trombo-embolie trombocyt lymfocyt ratio TROPHIMMUN trial TROPHY-U-01 TROPHY-U-01 Cohort 2 TROPHY-U-01 cohort 3 TROPHY-U-01 study TROPiCS-02 OS analysis TROPiCS-03 advanced endometrial cancer cohort TROPION-Breast01 trial TROPION-Lung01 study TROPION-PanTumor01 TROPION-PanTumor01 Study TRT TRUST-I study tryptophan-kynurenine pathway metabolites TSC TSCC Tsjernobyl TSP-1 TSR TSR predicts survival TT TTAC TTC TTC after T-DXd TTD of QOL or PF as a surrogate of OS TTF TTFields TTI-621 TTP tubaligatie Tubo-ovarian high-grade serous carcinoma tubulysines tucatinib tucatinib plus trastuzumab tucidinostat TULIP trial tumor budding tumor burden tumor cell heterogeneity tumor characteristics tumor deposits in non-metastatic CRC tumor expression of HGF and CXCL12 tumor genomic profiling in rare cancers tumor hypoxia in FMISO PET tumor inflitraing lymphocytes therapy tumor mutation burden tumor mutational burden tumor mutational burdne tumor necrosis tumor organoids tumor PD-L1 expression tumor phenotype and concordance tumor regrowth between surgery and radiotherapy tumor response dynamics during first-line pembrolizumab therapy tumor spread through air spaces tumor stroma-immune interactions tumor subtypes and survival tumor suppressor tumor treating fields therapy tumor-DNA tumor-geassocieerde neutrofielen tumor-immuuntolerantie tumor-infiltrating lymphocytes tumor-only genomic profiling tumor-stroma ratio tumor-to-breast volume ratio TUMORAPA study tumorgraad tumorgrootte tumorinfiltrerende lymfocyten tumoronderdrukkers tumorpredispositiesyndroom tumorsubtypen TUXEDO-1 trial TV tv kijken TV versus TLD TVU tweede kanker tweede maligne neoplasmen tweede maligniteit tweede mammacarcinoom tweede primaire maligniteit tweejaaars-overleving tweevoudige HER2-blokkade twelve-year trend of textbook outcomes twice versus once daily radiotherapy for SCLC twice-daily thoracic radiotherapy two cycles carboplatin-olaparib followed by olaparib monotherapy two weeks on two-step versus three-step approach of the WHO analgesic ladder in cancer patients TXA type 1-diabetes type 2 diabetes type 2 diabetes and glycemic control type and timing of menopausal hormone therapy type of ADT type of breast cancer surgery type of first-line therapy tyrosine kinase inhibitors tyrosinekinaseremmers tyrosyl-DNA fosfodiësterase 1 U M HCC U.S. papillary thyroid cancer incidence trends UADT-carcinomen UATD-kanker UBC UC UC-CRC UCB UCC UDCA for gallstone prevention after gastectomy for gastric cancer UDON UGN-101 UGT1A! genotype dependent dosed gFOLFIRINOX UGT1A1 genotype uHCC UIP-ADC UK ANZ DCIS randomized trial analysis UK Biobank UK Flexible Sigmoidoscopy Screening Trial UK IMPORT LOW studie UK Million Women Study UK MRC OE05-studie UK RAPID trial UK Sloane Project UK TRACC Part B UKALL14 trial ulocuplumab ultra-deep genomic testing ultra-fast CNS tumor classification during surgery ultra-processed food consumption ultra-processed foods ULTRAPANC study ultraprocessed food ultrasonografie ultrasonography ultrasonography findings ultrasound ultrasound versus palpation UM liver metastases umbralisib umbrella protocol umbrella review of meta-analyses UMRD uncommon histology advanced non-small cell lung cancer underestimation of invasive breast cancer undetectable MRD as treatment endpoint in high-risk MM undifferentiated pleomorphic sarcoma undifferentiated pruritus unesbulin plus dacarbazine unexpected uterine cancer unexpected weight loss in primary care unfavorable-risk prostate cancer UNICANCER-PRODIGE 23 UNICANCER-PRODIGE 23 trial UNICIT trial UNICORN trial unilateral retinoblastoma unilateral RT unilateral TNBC United Kingdom Women’s Cohort Study UNITY-NHL study UNITY-NHL trial universal genetic testing versus guideline-based testing universal germline genetic testing universal screening for hereditary colorectal cancer UNIVERSAL trial unknown primary lesions unmet needs unnecerssary adjuvant chemotherapy in breast cancer unplanned 30-day readmission unplanned reoperation unrelated donor hematopoietic cell transplant unrelated donor hematopoïetische celtransplantatie unresectable advanced RCC unresectable advanced STS unresectable CLM unresectable colorectal liver metastases unresectable CSCC unresectable early stage HCC unresectable esophageal squamous cell carcinoma in older adults unresectable gastric or gastroesophageal junction cancer unresectable HCC unresectable hepatocellular carcinoma unresectable intrahepatic cholangiocarcinoma unresectable locally advanced ESCC unresectable malignant pleural mesothelioma unresectable metastatic colorectal cancer unresectable NRAS-mutated cutaneous melanoma unresectable or metastatic BTC unresectable or metastatic hepatocellular carcinoma unresectable or metastatic HER2-positive breast cancer unresectable or recurrent craniopharyngioma unresectable pleural mesothelioma unresectable refractory melanoma unresectable stage 3 NSCLC unresectable stage III non-small cell lung cancer unresectable stage III NSCLC unresectable stage IIIA B NSCLC unresectable stage IIIC or IV melanoma unresectable TC unselected TNBC untreated advanced melanoma untreated AML in patients unfit for intensive chemotherapy untreated Burkitt lymphoma untreated CIN2 untreated CLL SLL untreated early unfavorable and advanced stage classical Hodgkin lymphoma untreated mCRC in intensive therapy-ineligible patients untreated multiple myeloma untreated stage IIIB IV NSCLC uPAR update MONALEESA-2 Update WECARE-studie updated analysis KEYNOTE-024 updated GPA updated results updated survival outcomes upfront bortezomib upfront doxorubicin-dcarbazine-nivolumab upfront radiosurgery versus wait-and-scan upper gastrointestinal cancer mortality upper tract urothelial cancer upper tract urothelial carcinoma upper-tract urothelial carcinoma uptake of and survival with ICIs uptake of FIT-screening urbanisatiegraad uribiome-based metagenomic signature urinaire bijwerkingen urinary biomarkers urinary cytokine profile to predict response urinary protein signature urinary tract infections urine DNA hypermethylation signatures urine tumor DNA urinetest urineweginfectie UROCCR Study 82 urotheelcarcinoom urotheelcarcinoom van de blaas urotheliaal blaascarcinoom urotheliaal carcinoom urothelial bladder carcinoma urothelial cancer diagnosis urothelial carcinoma urothelial carcinoma of the upper urinary tract URS US cancer patients US CRC mortality trends US Medicare population aged 65 years and older US men and women aged 15-39 years US patients with metastatic cancer US prostate cancer incidence after UPSTF recomeendations against screening US skin cancer survivors US trends 1996-2019 USC use of BRCA-testing use of cancer-directed therapy use of cannabis use of fertility drugs use of new prostate cancer risk stratification technologies use of oral complementary and alternative medication use of social media for recuitment of patients for cancer trials USPSTF recommendation uterine brachytherapy uterine cancer uterine cancer with distant organ metastasis uterine corpus cancer incidence and survival trends uterine leiomyosarcoma uterine sarcoma uterine-confined and node-negative cervical cancer uteruscarcinoom utidelone plus capecitabine utilization and outcomes utomilumab plus rituximab UTUC UV radiation exposure UVEA-Brig study uveaal melanoom uveaalmelanoom uveal melanoma uveal melanoma and metastases uveal melanoma with liver metastasis V-REX trial V600E V600K BRAF-mutant melanoma V600E-BRAF mutated metastatic colorectal cancer VA Health Care System VA patients with cancer vaccin vaccin mammacarcinoom vaccinatie vaginal brachytherapy plus chemotherapy vaginal laser treatment VAIN Val600 BRAF-mutant melanoom VALDAC trial valemetostat VALENTINE-PTCL01 valganciclovir validation validation of RTOG-0129 identified risk groups validation study validity as surrogate trial end point for OS VALOR-studie valproaat valproate and retinoic acid in combination with decitabine vals positieve uitslag value of 21-gene RS value of eHealth interventions value of OR as predictor of OS value of pCR as surrogate end point value of screening lower endoscopy in adults older than 75 years value of systemic chemotherapy Van Nuys Prognostic Index VANCE trial VANDA-blinatumomab vandetanib variables associated with benefit variant allele frequency in circulating tumor DNA variant histology VARIANZ study variation in surgery for DTC varicella zoster virus vaccine various BRCA mutation types various first-line chemotherapies various treatments for localized prostate cancer various types of advanced solid tumors varying test positivity thresholds Vasaloppet vascular aging vasectomie vasectomy vasomotor symptoms VATS L-MLND VATS versus open resection VCE VE-BASKET study vebreltinib vedolizumab compared with infliximab veeleisende patiënten vegetarische voeding VEGF VEGF-behandeling VEGFR-remmer VEGFR-TKI VEGFR-TKIs VEGFRI-induced hypertension VELIA GOG-3005 study veliparib veliparib plus CRT veliparib with carboplatin and paclitaxel VELO trial VELVET VELVET cohort 2 vemurafenib vemurafenib and cometinib for BRAF-mutant melanoma vemurafenib plus everolimus vemurafenib plus rituximab vemurafenib priming before T-cell therapy Ven-Obi versus Clb-Obi for previously untreated CLL venetoclax venetoclax plus azacitidine venetoclax plus cytarabine with or without idarubicin venetoclax plus FLAG-IDA venetoclax plus gilteritinib venetoclax plus intensive chemotherapy venetoclax plus intensive induction chemotherapy venetoclax plus LDAC venetoclax plus low dose cytarabin venetoclax plus low-dose cytarabine venetoclax plus rituximab venetoclax plus rituximab continuous or limited-duration therapy venetoclax-azacitidine-homoharringtonine venetoclax-BR venetoclax-daratumumab-dexamethasone with or without bortezomib venetoxlax plus ibrutinib veneuze trombo-embolie VENICE-1 venous and arterial thrombosis venous thromboembolism ventrico-peritoneal shunt related ascites verbal memory verf verhoogd bloedglucose VeriStrat test vermoeidheid verpleegkundigen vertebral fractures verteerbaar koolhydraat vertrouwen very early recurrence after liver resection very high-risk prostate cancer verzadigd vet vessel co-option vestibular dysfunction and survival vestibular schwannoma vestibular schwannomas Veterans Affairs System vetinname vetrijke voeding vetzuren VGX-3100 VHL disease-associated pancreatic lesions VIALE-A study VIALE-A trial VICTOR-6 study VICTORIA trial VidazaAllo Study video-assisted thoracoscopic surgery Vigil maintenance Vigil vaccine maintenance vimseltinib VIN vincristine vincristine-irinotecan with or without temozolomide vinorelbine VIOLA study VIOLET trial virotherapy virtual prostatectomy virtual reality for symptom control and well-being in oncology virtual reality videos viscerale adipositas visconsumptie VISION study VISION trial vismodegib plus RT vistusertib plus anastrozole visual outcome VITAL study VITAL-studie vitamin A vitamin and garlic supplementation vitamin C intake vitamin D vitamin D binding protein vitamin D deficiency vitamin D intake vitamin D level vitamin D levels vitamin D supplement use vitamin D supplementation vitamin D to attenuate bone loss vitamin D3 vitamin D3 supplements and advanced cancer vitamin E vitamin K antagonists vitamin supplements vitamine B3 vitamine B6 vitamine D vitamine D-spiegel vitamine-inname vitamins vitiligo Vivio VIVROVAIRE I study VLADI-studie Vlagtwegge-Vlaardingen cohort vlees vleesconsumptie vliegend personeel VLL vluchtige organische verbindingen VMS VOCs voeding voeding tijdens zwangerschap voedingsgewoonten voedingskwaliteit voedingssupplementen voedingsvezel voice abnormalities volasertib volatile organic compounds VOLFI study VOLFI-studie Volume Pledge criteria volume-based CT screening von gunten von hippel-lindau Von Hippel-Lindau syndrome-associated CNS hemangioblastoma Von Willebrand Disease voorspelling recidief voorspelling ziektevrije overleving vorasidenib vorasidenib or ivosidenib voriconazole in lung transplant recipients vosaroxine VR consolidation VRD as induction prior to autoSCT vroeg mammacarcinoom vroege detectie vroege detectie MBC vroege menopauze vroege resultaten COMPASS-studie VS VS in patients aged 70 years or older VSCC VTD versus TD VTE VTE risk VTE risk despite thromboprofylaxis VTEs vulvacarcinoom vulvaire intra-epitheliale neoplasie vulvaire intraepitheliale neoplasie vulvaire lichen sclerosus vulvar cancer with SN metastases vulvar cancers cohort vulvar high-grade intraepithelial lesions vulvar squamous cell carcinoma vulvovaginal atrophy in breast cancer patients VWF W&W wachttijd Waldenström macroglobulinemia Waldenstrom's macroglobulinemie Waldenström’s macroglobulinemie warfarine WARMTH Act study warren watch and wait watch-and-wait watchful waiting WBI WBM WBRT WBRT with hippocampal avoidance WBRT with or without Rh-endostatin WBV WD DDLS WDTC wearable device-based intervention web-based symptom monitoring vs routine surveillance WECARE-studie weefseltype-agnostische gerichte therapie weekend effect weekly carboplatin and paclitaxel weekly cisplatin weekly dose-dense chemotherapy weekly KMP weekly paclitaxel weekly paclitaxel with or without alisertib weight change weight cycling weight loss weight stability can mask sarcopenia or myosteatosis weight tracking as prognostic marker after pancreatectomy weight trajectories wekedelensarcoom wekedelensarcoom. STS well-being of cancer survivors werkloosheid werkzaamheid placebo Werkzaamheid van tweede- of laterelijns immuuncheckpointremmer voor sarcomatoïd carcinoom van de long WES Western dietary pattern wetenschappelijk wangedrag WGS as an alternative to cytogenetic analysis WHI WHI randomized clinical trials WHI randomized trial long-term follow up WHI-CaD studie WHI-DM WHO grade 2-3 meningioma WHO grade II-III meningioma whole brain radiation whole brain radiotherapy whole genome sequencing whole grains whole-body MRI whole-brain radiation therapy whole-genome sequencing WHR WID-EC test wigresectie wild-type advanced NSCLC wildfire exposure while recovering from lung cancer surgery Wilms tumor Wilms tumor survivors Wilms' tumor Wilms’ tumor WINDOW-1 trial withdrawal of antiepileptics WM women with BRCA1 2 PVs women's health initiative Women's Health Initiative-Observational Study Women’s Health Initiative Women’s Health Initiative Observational Study Women’s Health Initiative randomized trials worldwide trends in survival of young leukemia patients WP-RT versus BO-RT WPRT WSG-ADAPT studie WSG-ADAPT-HR+ HER2- trial WSG-TP-II trial WT WTB-HRM WTC rescue and recovery workers WTC-responders WU-KONG6 trial WW XELAVIRI study XELOX FOLFOX vs LV 5-FU xerostomia xevinapant XRT plus ADT Y90 plus durvalumab Y90-radioembolization followed by nivolumab YACPRIME study YAP YKL-40 YM155 yoga yogurt consumption young adult ALL patients young adult body mass index young adult survivors of pediatric cancer young breast cancer survivors young children with relapsed medulloblastoma after initial CSI-sparing approaches young Norwegian breast cancer patients Young Women’s Breast Cancer Study Young Women’s Health History Study young-adult childhood cancer survivors young-onset cholangiocarcinoma young-onset digestive tract cancers young-onset esophageal adenocarcinoma young-onset mCRC younger versus older adults yttrium-90 conjugated mAb for solid tumors YY-20394 zandelisib plus zanubrutinib zanidatamab zanubrutinib zanubrutinib versus ibrutinib ZAP-studie zegelringcelcarcinoom zelf-gerapporteerde vermoeidheid zelf-onderzoek huid zelf-test ZENITH20 study cohort 2 ZENITH20-4 ZETA trial ziekenhuisvolume Ziekte van Castleman Ziektevrije-overlevingsanalyse van ABCSG-18 studie ziftomenib zilovertamab plus paclitaxel zilovertamab vedotin zinc-α2-glycoprotein zipalertinib zittende leefstijl ziv-aflibercept zolbetuximab zoledronic acid for bone metastases zoledroninezuur zonlicht ZUMA-1 studie ZUMA-1 trial ZUMA-12 trial ZUMA-5 study ZUMA-5 trial ZUMA-7 trial ZUMA-studie ZW25 zwangerschap zwangerschaps-geassocieerd mammacarcinoom zwangerschapsuitkomsten α-FAtE γ-glutamyltransferase